	Curator	Spot-check	curation_date	cohort	age_min	age_max	age_units	number_subjects	tissue_type	tissue_type_term_id	method	response_component	is_model	response_behavior_type	response_behavior	comparison	baseline_time_event	time_point	time_point_units	exposure_material	exposure_material_id	exposure_process	disease_name	disease_stage	publication_reference_id	publication_date	publication_reference_url	signature_source	signature_source_url	comments	curator_comments
subject										cell_subset		(will be added by processing script)									pathogen										
evidence			label	label	label	label	label	label	label		label		label	label	label	label	label	label	label	label		label	label	label	label	label	url	label	label	label	label
role			background	observed	observed	observed	observed	observed	background	tissue	background	(will be added by processing script)	background	background	measured	background	background	observed	observed	observed	pathogen	background	background	observed	background	background	reference	background	background	background	observed
mime_type																															
numeric_units																															
descriptive text on Dashboard			curation date (YYYY-MM-DD)	cohort - any characteristics of the population(s) studied, besides age	age of youngest subject including both cases and controls	age of oldest subject including both case and controls	age units	number of subjects - count of case plus control subjects used in the measurement.	tissue type (as reported)	Cell Ontology ID of tissue	primary experimental method used to measure the response	response component - genes, proteins, cell types etc. are the entities whose change with infection is being measured	is model - signature is derived from a computational model	response behavior type	response behavior (direction, correlation type etc.)	comparison (affected vs control, correlated variable, time vs baseline event)	baseline time event	time relative to baseline event at which response was measured	time point units	exposure material - e.g. pathogen causing disease	exposure material id, e.g. NCBI taxonomy ID	exposure process - method by which immune exposure occurred	disease name	disease stage - reported disease stage(s) of affected subjects	publication reference (PMID, bioRxiv etc)	publication date (YYYY-MM-DD)	publication URL	signature source - figure, table or text section 	signature source URL	comments and additional details	curator comments
vocabulary, separator			YYYY-MM-DD	free text	number	number	choose from list	number	As reported. Only one entry allowed.	Choose from list or lookup Cell Ontology code	Choose from list. Only one entry expected. You can add new methods.	Gene or protein symbols can be separted with commas, spaces, or semicolons. Cell types or other names must be separated using semicolons. 		Choose from list. Only one entry allowed. 	Choose from list. Only one entry allowed. Add new behaviors if required.	Free text. Use "vs" rather than a dash to separate comparison terms (A vs B).  Separate multiple comparison entries with semicolons (A vs B; C vs D).	Free text. Use "none" if no time was reported.	Number. Use "none" if no time was reported.	Choose from list	NCBI taxonomy term name, or free text	NCBI Taxonomy ID. Choose from list.	Choose from list. Enter new process if needed.	free text	free text	type:id	YYYY-MM-DD	The URL only, not any associated display text	Free text. Up to two entries, separated by semicolons	The URL only, not any associated display text. Up to two entries, separated by semicolon	Free text, limit of 255 characters	Free text, no limit
Additional information for curators			Date this submission was prepared	Any characteristics of the population(s) studied, besides age. Example:  Hong Kong, Atlanta. Also report if the result was limited to a subgroup of the tested cohort, e.g.  - subjects suffering adverse events  - particular threshold levels of antibody titer level - based on a receiving a particular treatment	include both case/affected and control subjects	include both case/affected and control subjects	Hours, days, months, years	Often differs by signature within a publication. If number of subjects for a particular signature is not clear in text, use total for cohort.	The parent tissue of the response components. Report multiple tissues in different rows. For cell-type results, the tissue is often PBMCs. For gene expression, the tissue might be a particular cell-type.	If there is no matching cell type in the pulldown list, the curator can try to look up a matching term in the  Cell Ontology.	The primary experimental method used to measure the response, e.g.  RNA-seq, CyTOF, CITE-seq. 	Please copy symbols and names exactly as reported in the publication - except spell out greek letters. For cell types, this includes all markers.  Examples for a signature with three cell types: T cells CD3+/CD4+/Ki67+; T cells CD3+/CD8+/Ki67+ CD86+ myeloid dendritic cell (DC); CD86+ monocyte	Were the response components chosen using a classification or other model-building strategy?	The type of change being measured, e.g. gene expression, cell-type frequency.	Common values in the pulldown list: - up, down - positively correlated, negatively correlated, correlated - positively predictive, negatively predictive, predictive	Comparisons are typically between two groups, or may reflect a correlation of the response component with some other measured variable. Only report significant results. Examples: - severe COVID-19 cases vs healthy - moderate COVID-19 cases vs healthy; severe COVID-19 cases vs healthy - interferon-stimulated genes in COVID-19 vs healthy - bacterial DNA levels across COVID-19 and healthy subjects Include time comparison if relevant, e.g. 7d vs 0d, where the times are relative to the baseline reference event time (0d). Times before baseline event can be entered as negative numbers, e.g. days before vaccination (7d vs -1d). **Please be concise.**	The reference event from which the time of the experimental response is measured, e.g. hospital admission, onset of symptoms	Time point when response was measured, if available. 	Days, months etc.	Enter the pathogen or vaccine underlying the immune exposure as reported in the publication	NCBI Taxonomy ID of pathogen causing disease. Use format id_type:id, e.g. ncbi_taxid:2697049	Method by which exposure to pathogen occurred		Reported disease stage(s) of affected subjects in all comparisons entered in row (not including control subjects). We will not attempt to match these directly with the comparisons.	Enter an official identifier for the article curated, using format type:id	Use zeros for unavailable month or day	URL of the article curated. Primary source publication (e.g. Cell, Nature) preferred over PMC	Figure, table number etc. where the signature was found, usually original primary publication rather than PMC	Link to figure, table number etc. where the signature was found, usually the original primary publication rather than PMC. Please enter the URL directly, not as a hyperlinked name.	Details clarifying any aspect of the signature not captured in other fields	Questions or notes for further examination from curator. Will not appear in Dashboard
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	NK cell phenotyping	Natural Killer cells; CD56dim Natural Killer cells		cell type frequency	down	moderate COVID-19 patients vs healthy patients 	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	2020-08-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	33	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	NK cell phenotyping	Natural Killer cells; CD56bright Natural Killer cells; CD56dim Natural Killer cells		cell type frequency	down	severe COVID-19 patients vs healthy patients 	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	2020-08-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	43	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	flow cytometry	Ki-67+ CD56bright Natural Killer cells; HLA-DR+ CD56bright Natural Killer cells; CD69+ CD56bright Natural Killer cells		cell activation state	up	COVID-19 patients vs healthy	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	2020-08-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	flow cytometry	Ki-67+ CD56dim Natural Killer cells; CD69+ CD56dim Natural Killer cells		cell activation state	up	moderate COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	2020-08-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	33	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	flow cytometry	Ki-67+ CD56dim Natural Killer cells; HLA-DR+ CD56dim Natural Killer cells; CD69+ CD56dim Natural Killer cells		cell activation state	up	severe COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	26	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	flow cytometry	Ki-67+ NKG2A+ CD56dim Natural Killer cells; HLA-DR+ NKG2A+ CD56dim Natural Killer cells; CD69+ NKG2A+ CD56dim Natural Killer cells		cell activation state	up	NKG2A+ CD56dim NK cells vs NKG2A- CD56dim NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	26	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	flow cytometry	HLA-DR+ CD57- CD56dim Natural Killer cells		cell activation state	up	moderate & severe COVID-19 patients: CD57- CD56dim NK cells vs CD57+ CD56dim NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	26	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	flow cytometry	Ki-67+ CD62L+ CD56dim Natural Killer cells; HLA-DR+ CD62L+ CD56dim Natural Killer cells		cell activation state	up	moderate & severe COVID-19 patients: CD62L+ CD56dim NK cells vs CD62L- CD56dim NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	26	Peripheral Blood Mononuclear Cells (PBMCs)	CL:2000001	flow cytometry	CD69+ CD62L- CD56dim Natural Killer cells		cell activation state	up	moderate & severe COVID-19 patients: CD62L- CD56dim NK cells vs CD62L+ CD56dim NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		directly ex vivo flow cytometry; MFI & percentage	perofrin CD56bright Natural Killer cells; MIP-1beta CD56bright Natural Killer cells; CD98 CD56bright Natural Killer cells; Tim-3 CD56bright Natural Killer cells; Granzyme B CD56bright Natural Killer cells		protein/cytokine levels	up	moderate COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78		32	Peripheral Blood Mononuclear Cells (PBMCs)		directly ex vivo flow cytometry; MFI & percentage	perofrin CD56bright Natural Killer Cells; MIP-1beta CD56bright Natural Killer cells; CD98 CD56bright Natural Killer cells; Tim-3 CD56bright Natural Killer cells; Granzyme B CD56bright Natural Killer cells; Ksp37 CD56bright Natural Killer cells		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78		27	Peripheral Blood Mononuclear Cells (PBMCs)		directly ex vivo flow cytometry; MFI & percentage	CD98 CD56dim natural killer cells; Tim-3 CD56dim natural killer cells		protein/cytokine levels	up	moderate COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78		33	Peripheral Blood Mononuclear Cells (PBMCs)		directly ex vivo flow cytometry; MFI & percentage	CD98 CD56dim natural killer cells; Tim-3 CD56dim natural killer cells		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	12	BAL NK Cells		gene set enrichment analysis; DEGs	GZMA, GZMB, PRF1, HAVCR2, CCL3, CCL4, CCL5		gene expression	up	COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 2K; paragraph before section "Impact of KIR expression..."	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/#__sec2title 	correlated with alphabeta T cells (percent (%) of total Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs))	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	12	NK Cells		gene set enrichment analysis; DEGs	LAG3		gene expression	up	moderate & severe COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 2K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	9	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry	NKG2C+ CD57+ CD56dim Natural Killer cells		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients 	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	6	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry	NKG2C- CD57- CD56dim Natural Killer cells		cell type frequency	down	moderate COVID-19 patients vs healthy patients	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	9	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry	NKG2C- CD57- CD56dim Natural Killer cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-02-14)	COVID-19 patients in Stockholm, Sweden	18	78	years	26	Peripheral Blood Mononuclear Cells (PBMCs)		"phenotypic assessment of CD56bright and CD56dim NK cells in the COVID-19 patients"	COVID-19 Patients: Ki67+ NKG2C- CD57- CD56dim Natural Killer cells		protein/cytokine levels	up	COVID-19 patients: Ki67+ NKG2C- CD57- CD56dim NK cells vs Ki67+ NKG2C+ CD57+CD56dim NK cells	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		scRNA-seq	HLA-E Natural Killer cells; HLA-E B cells; HLA-E epithelial cells; HLA-E mDCs; HLA-E T cells; HLA-E macrophages		protein/cytokine levels	up	moderate COVID-19 patients vs healthy	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	17	Peripheral Blood Mononuclear Cells (PBMCs)		scRNA-seq	HLA-E Natural Killer cells; HLA-E B cells;, HLA-E epithelial cells; HLA-E T cells; HLA-E macrophages		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		scRNA-seq	HLA-E Natural Killer cells; HLA-E B cells; HLA-E epithelial cells; HLA-E mDCs; HLA-E T cells; HLA-E macrophages		protein/cytokine levels	up	severe COVID-19 patientsvs healthy	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-08-24)	COVID-19 patients in Stockholm, Sweden	18	78	years	34	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; NPX	NKG2C+CD57+ CD56dim NK cells		cell type frequency	positively correlated	correlated with soluble factor AREG	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-08-24)	COVID-19 patients in Stockholm, Sweden	18	78	years	34	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; NPX	NKG2C+CD57+ CD56dim NK cells		cell type frequency	negatively correlated	correlated with soluble factors: LTalpha, IFNgamma, IL-12beta 	time of admission	0 to 5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 3L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	24	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; NPX	perforin CD56bright natural killer Cells; Granzyme B CD56bright natural killer Cells		protein/cytokine levels	positively correlated	correlated with IL-6 (NPX) levels	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	CD56bright NK cell		Spearman's correlations; MFI & percentage	perforin		protein/cytokine levels	positively correlated	correlated with SOFA and SOFA-R scores	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	CD56bright NK cell		Spearman's correlations; MFI 	perforin		protein/cytokine levels	positively correlated	correlated with neutrophils (x10E9/L)	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	25	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; MFI & percentage	granzyme B CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; perforin CD56bright natural killer Cells		protein/cytokine levels	positively correlated	correlated with perforin (MFI) expression on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Perforin expression measured as MFI positively correlated with CD25 MFI and % expression and perforin expression measured as %. 	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	25	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; MFI	CD56bright natural killer cells		cell type frequency	positively correlated	correlated with granzyme B (MFI) expression on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	25	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; MFI	peforin CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; Ksp37 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; Granzyme B CD56bright natural killer Cells		protein/cytokine levels	positively correlated	correlated with granzyme B (MFI) expression on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Granzyme B expression measured as MFI positively correlated with CD25 MFI and % expression and granzyme B expression measured as %. 	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	25	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; MFI	perforin CD56dim natural killer Cells		protein/cytokine levels	positively correlated	correlated with perforin (MFI) expression on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Perforin expression (MFI) on CD56bright NK cells positively correlated with perforin expression (MFI) on CD56dim NK cells. 	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	25	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; MFI	granzyme B CD56dim natural killer cells; CD25 CD56dim natural killer cells		protein/cytokine levels	positively correlated	correlated with granzyme B (MFI) expression on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Granzyme B expression (MFI) on CD56bright NK cells positively correlated with granzyme B expression (MFI) & CD25 (%) expression on CD56dim NK cells. 	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	25	Peripheral Blood Mononuclear Cells (PBMCs)		Spearman's correlations; MFI	TIGIT CD56dim natural killer Cells		protein/cytokine levels	negatively correlated	correlated with perforin (MFI) expression on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Perforin expression (MFI) on CD56bright NK cells negatively correlated with TIGIT expression (MFI) on CD56dim NK cells. 	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry	TIGIT CD56bright natural killer Cells; CD38 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells		protein/cytokine levels	up	moderate COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S2C	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	32	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry	TIGIT CD56bright natural killer Cells; CD38 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S2C	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry; hierarchical clustering	KIR2DL1 CD56dim Natural Killer Cells		protein/cytokine levels	down	moderate COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry; hierarchical clustering	CD38 CD56dim natural killer cells; MIP-1beta CD56dim natural killer cells; CD62L CD56dim natural killer cells		protein/cytokine levels	up	moderate COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	33	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry; hierarchical clustering	CD38 CD56dim natural killer cells; MIP-1beta CD56dim natural killer cells; CD62L CD56dim natural killer cells; NKG2C CD56dim natural killer cells		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	26	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry; hierarchical clustering	NKG2C CD56dim natural killer cells		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients 	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1		
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	33	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry	Ki67+ NKG2C+ CD57+ CD56dim natural killer cells		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S4H & 4J	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Measurements in % (S4H) & absolute (from NK cell counts/mL) (S4J).	
	Amani 	Simranpreet	(2021-02-14)	Stockholm, Sweden	18	78	years	26	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry	Ki67+ NKG2C+ CD57+ CD56dim natural killer cells		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients 	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S4H	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	26	NK Cells		NK cell phenotyping 	C-Reactive Protein (CRP)		protein/cytokine levels	up	SARS-CoV-2 viremic COVID-19 patients vs non-viremic COVID-19 patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7A.	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	26	responding CD56bright NK Cells		NK cell phenotyping; percentage	perforin 		protein/cytokine levels	up	SARS-CoV-2 viremic COVID-19 patients vs non-viremic COVID-19 patients	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7A.	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	responding CD56bright NK Cells		NK cell phenotyping; percentage & MFI; Spearman's correlation	CD25 CD56bright NK cells; perforin CD56bright NK cells; perforin CD56dim NK cells; Granzyme B CD56bright NK cells		cell type frequency	positively correlated	each correlated with perforin (MFI) on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7B	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	responding CD56bright NK Cells		NK cell phenotyping; MFI; Spearman's correlation	TIGIT CD56dim NK cells		cell type frequency	negatively correlated	correlated with perforin (MFI) on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7B	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	CD56bright NK Cells		NK cell phenotyping; MFI; Spearman's correlation	Granzyme B CD56dim NK cells; CD25 CD56dim NK cells; Granzyme B CD56bright NK cells; CD25 CD56bright NK cells; Ksp37 CD56bright NK cells		cell type frequency	positively correlated	each correlated with Granzyme B (MFI) on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7C	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	CD56bright NK Cells		NK cell phenotyping; MFI; NPX; Spearman's correlation	KRT19, MCP-3, HGF, PXN, CAPG, CKAP4, NUCB2		protein/cytokine levels	positively correlated	each correlated with perforin (MFI) on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	CD56bright NK Cells		NK cell phenotyping; MFI; NPX; Spearman's correlation	TRIM 5		protein/cytokine levels	negatively correlated	correlated with perforin (MFI) on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	25	CD56bright NK Cells		NK cell phenotyping; MFI; NPX; Spearman's correlation	CKAP4		protein/cytokine levels	positively correlated	correlated with Granzyme B (MFI) on CD56bright NK cells	time of admission	0 to 8	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Fig S7E	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry 	C-Reactive Protein (CRP); D-dimer; lactate dehydrogenase; bilirubin; prothrombin complex, INR; troponin T; myoglobin		protein/cytokine levels	up	severe/critical COVID-19 patients vs moderate COVID-19 patients	before study sampling	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Table S2	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry 	lymphocytes, lowest		cell type frequency	down	severe/critical COVID-19 patients vs moderate COVID-19 patients	before study sampling	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Table S2	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry 	lymphocytes, lowest		cell type frequency	down	severe/critical COVID-19 patients vs moderate COVID-19 patients	before study sampling	1	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Table S2	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry 	D-dimer; lactate dehydrogenase; bilirubin; troponin T; myoglobin; albumin, lowest		protein/cytokine levels	up	severe/critical COVID-19 patients vs moderate COVID-19 patients	at study sampling	1	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Table S2	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry 	leukocytes, highest; leukocytes, lowest; neutrophils, highest		cell type frequency	up	severe/critical COVID-19 patients vs moderate COVID-19 patients	at study sampling	1	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Table S2	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 		(2021-02-14)	Stockholm, Sweden	18	78	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry 	interleukin-6		protein/cytokine levels	up	severe/critical COVID-19 patients vs moderate COVID-19 patients	at study sampling	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32826343	(2020-08-21)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/	Table S2	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC2		
	Amani 	Simranpreet	(2021-02-19)	Basal & Liestal, Switzerland	53	104	years	26	formalin-fixed and paraffin-embedded (FFPE) lung tissue		DEGs of OIRRA gene expression assay 	DMBT1, TDO2, IFI6, KIAA0101, MELK, BUB1, ISG15, IFI27, PSMB9, OAS3, CDK1, HLA-G, SLAMF8, CDKN3, OAS1, OAS2, CXCL11, IDO1, FOXM1, LAMP3, IFIT3, MAD2L1, CD38, CCR1, GZMB, LAG3, IFI44L, TOP2A, MX1, CXCL9, CD276, STAT1, IFI35, IFIH1, CCL18, GBP1, IFIT2, PDCD1LG2, CXCL10, IFIT1, C1QB, CXCL13, CCNB2, BRCA2, MKI67, DDX58, SNAI2, POU2AF1, XAGE1B, C1QA, CCR5, HERC6, BST2, CMKLR1, ISG20, TNFSF18, CD163, CYBB, IFITM1, IRF4, IL21, FCGR1A, SLAMF7, GZMA, IL10, TNFRSF17, KRT5, KRT7		gene expression	up	Autopsies of COVID-19 patients vs healthy patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 1a; Suppl Table 3.	https://www.nature.com/articles/s41467-020-18854-2#Sec24 ; https://www.nature.com/articles/s41467-020-18854-2/figures/1 	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig1/	
	Amani 	Simranpreet	(2021-02-19)	Basal & Liestal, Switzerland	53	104	years	26	formalin-fixed and paraffin-embedded (FFPE) lung tissue		DEGs of OIRRA gene expression assay 	JAML, IRS1, MLANA, IGF1R, TCF7, KLF2, KLRB1, CXCR4, CEACAM8, BCL6, CD69, PTGS2, CD226, BCL2, KLRG1, PTPRC, CCL17, CD1C, MPO, CD83, CRTAM, HLA-DQB2, RORC, TNFRSF9, IL2, CCR6, ARG1, MAGEC2, CXCR5, GAGE10		gene expression	down	Autopsies of COVID-19 patients vs healthy patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 1a; Suppl Table 3.	https://www.nature.com/articles/s41467-020-18854-2#Sec24 ; https://www.nature.com/articles/s41467-020-18854-2/figures/2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig1/	
	Amani 	Simranpreet	(2021-02-19)	Basal, Switzerland	53	96	years	14	formalin-fixed and paraffin-embedded (FFPE) lung tissue		DEGs of OIRRA gene expression assay; k-means clustering	Interferon-stimulated genes (ISG) signature		gene expression	up	cluster 1 (ISG high) vs cluster 2 (ISG low)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 1d	https://www.nature.com/articles/s41467-020-18854-2/figures/1	"Clusters 1 (50% of samples) and 2 (41%) contained COVID-19 samples". "Cluster 1 or 2 were assigned ISG activation label ISGhigh and ISGlow, respectively"	
	Amani 	Simranpreet	(2021-02-19)	Basal & Liestal, Switzerland	53	104	years	33	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses 	CD3+ T cells; CD68+ monocytes; CD163+ monocytes		cell type frequency	up	cluster 2 (ISG low) vs healthy				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 3c	https://www.nature.com/articles/s41467-020-18854-2/figures/3		
	Amani 	Simranpreet	(2021-02-19)	Basal, Switzerland	53	96	years	33	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses 	CD3+ T cells; CD68+ monocytes; CD163+ monocytes; CD8+ T cells		cell type frequency	up	cluster 2 (ISG low) vs cluster 1 (ISG high)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 3c	https://www.nature.com/articles/s41467-020-18854-2/figures/3		
	Amani 	Simranpreet	(2021-02-19)	Basal, Switzerland	53	96	years	33	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses; computational image analysis	CD4+ T cells; CD20+ B cells; CD8+ PD1+ T cells		cell type frequency	up	cluster 2 (ISG low) vs cluster 1 (ISG high)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 4a	https://www.nature.com/articles/s41467-020-18854-2/figures/4		
	Amani 	Simranpreet	(2021-02-19)	Basal, Switzerland	53	96	years	31	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses	TNF, IL-1B, IL6, IFNA17, IFNB1, CCL2, CXCL9, CXCL10, CXCL11		protein/cytokine levels	up	cluster 1 (ISG high) vs cluster 2 (ISG low)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 5a	https://www.nature.com/articles/s41467-020-18854-2/figures/5		
	Amani 	Simranpreet	(2021-02-19)	COVID-19 autopsy cluster 1 (ISG high) in Basal, Switzerland	53	96	years	31	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses; Pearson's correlation	CD38; GZMA; GZMB; CCR5 (activated CD8+ T cell signature)		cell activation state	negatively correlated	correlated with viral load in COVID-19 autopsy cluster 1 (ISG high)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 5b	https://www.nature.com/articles/s41467-020-18854-2/figures/5		
	Amani 	Simranpreet	(2021-02-19)	COVID-19 autopsy cluster 1 (ISG high) in Basal, Switzerland	53	96	years	31	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses; Pearson's correlation	CD38 CD8+ T cell; GZMA CD8+ T cell; GZMB CD8+ T cell; CCR5 CD8+ T cell		protein/cytokine levels	negatively correlated	correlated with viral load in COVID-19 autopsy cluster 1 (ISG high)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 5b	https://www.nature.com/articles/s41467-020-18854-2/figures/5		
	Amani 	Simranpreet	(2021-02-19)	Basal, Switzerland	53	96	years	31	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses	C1QA, C1QB		gene expression	up	cluster 2 (ISG low) vs cluster 1 (ISG high)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 6b	https://www.nature.com/articles/s41467-020-18854-2/figures/6		
	Amani 	Simranpreet	(2021-02-19)	Basal, Switzerland	53	96	years	31	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses	Ki67, p53		protein/cytokine levels	up	cluster 2 (ISG low) vs cluster 1 (ISG high)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 6a; 1st paragraph in Results section "The ISG low lung profile shows..."	https://www.nature.com/articles/s41467-020-18854-2/figures/6 ; https://www.nature.com/articles/s41467-020-18854-2#Fig6 	-also 2nd sentence under "The ISGlow lung profile shows..."  "ISGlow lung samples expressed elevated p53 and Ki67"	
	Amani 		(2021-02-19)	Basal, Switzerland	53	96	years	31	formalin-fixed and paraffin-embedded (FFPE) lung tissue		Immunohistochemical analyses; Pearson's correlation	ISGs		protein/cytokine levels	positively correlated	correlated with pulmonary viral load in autopsies of COVID-19 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33033248	(2020-10-08)	https://www.nature.com/articles/s41467-020-18854-2	Fig 3a	https://www.nature.com/articles/s41467-020-18854-2/figures/3	"expression of ISGs was positively correlated with pulmonary viral load (Fig. 3a)"	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	140	Peripheral Blood Mononuclear Cells (PBMCs)		mass cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 infected patients vs healthy patients	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	140	plasmacytoid dendritic cells (pDCs)		mass cytometry	CD45 cells		cell type frequency	down	COVID-19 infected patients vs healthy patients	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 1c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	140	plasmacytoid dendritic cells (pDCs)		phospho-CyTOF; pS6 staining	pS6 (mTOR) 		protein/cytokine levels	down	COVID-19 infected patients vs healthy patients	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 1d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	140	myeloid dendritic cells (mDCs)		phospho-CyTOF; IB staining	IKBalpha		protein/cytokine levels	down	COVID-19 infected patients vs healthy patients	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 1e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	31	plasmacytoid dendritic cells (pDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IFN-alpha, TNF-alpha, IFN-alpha + TNF-alpha 		protein/cytokine levels	down	COVID-19 infected donors in response to viral cocktail (polyIC + R848) vs healthy donors in response to viral cocktail (polyIC + R848)	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 2a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	31	myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IL-6, TNF-alpha, IL-6 + TNF-alpha		protein/cytokine levels	down	COVID-19 infected without stimulation vs healthy without stimulation	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	31	myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IL-6, TNF-alpha, IL-6 + TNF-alpha		protein/cytokine levels	down	COVID-19 infected donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin) vs healthy donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin)	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	31	myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IL-6, TNF-alpha, IL-6 + TNF-alpha		protein/cytokine levels	down	COVID-19 infected donors in response to viral cocktail (polyIC + R848) vs healthy donors in response to viral cocktail (polyIC + R848)	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	31	myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; NF-kB p65 (Ser529) staining; GeoMFI	p65 (Ser529)		protein/cytokine levels	down	COVID-19 infected donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin) vs healthy donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin)	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	52	plasma		Olink multiplex inflammation panel	IL-6, TNF-alpha, OSM, TNFSF14		protein/cytokine levels	up	moderate COVID-19 patients vs healthy patients	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	52	plasma		Olink multiplex inflammation panel	OSM, TNFSF14, EN-RAGE		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	52	plasma		Olink multiplex inflammation panel	OSM, IL-6		protein/cytokine levels	up	ICU COVID-19 patients vs severe COVID-19 patients  	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	52	plasma		Olink multiplex inflammation panel	OSM, IL-6, TNFSF14, EN-RAGE, MCP-3		protein/cytokine levels	up	ICU COVID-19 patients vs moderate COVID-19 patients   	time of clinical onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	IL7R, LTB, TRAC, LDHB, CD3E, CD3D, NOSIP, TCF7, MAL, TRBC2, CD3G, PIK3IP1, TRBC1, RCAN3, TRAT1, LEF1, CCR7, CD69, SARAF, EEF1B2, TPT1, ETS1, NOP53, EEF1A1, IL32, BCL2, CD27, LEPROTL1, OXNAD1, NPM1, TOMM7, AQP3, TRABD2A, CAMK4, C12orf57, INPP4B, BTG1, SPOCK2, TSHZ2, LCK, EIF3E, GIMAP7, BCL11B, DNAJB1, PBXIP1, JUNB, FOXP1, SH3YL1, CD2, ARID5B, MYC, SNHG8, EEF1D, AES, RACK1		gene expression	up	cluster 0 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	CAPNS1, MOB1A, REL, PIK3AP1, LGALS9, XAF1, GNAI2, ZYX, BID, ITGAX, RTN3, OAS1, IFNGR1, CNPY3, FOSB, DUSP1, SEC61B, RHOB, ARF1, AGTRAP, ETFA, CMC1, CMIP, CD83, CD300A, AKIRIN2, PRKCB, AHNAK, IFI27L2, OGFRL1, CD99, WARS, RAB31, ALDH2, LY86, JAML, HSBP1, BST2, KCTD12, RRBP1, RAB11A, RGS10, GNAS, ABHD17A, GPX4		gene expression	down	cluster 0 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	GNLY, NKG7, PRF1, FGFBP2, SPON2, CCL4, KLRF1, KLRD1, GZMA, CD247, GZMB, KLRB1, CTSW, CLIC3, HOPX, PTGDS, CD7, TRDC, GZMM, IL2RB, MATK, ABHD17A, CST7, IGFBP7, GZMH, CD160, ADGRG1, AKR1C3, PYHIN1, SAMD3, EFHD2, HCST, TTC38, CMC1, APMAP, NCR3, KLRC1, PTGDR, ARL4C, FCGR3A, PRSS23, RARRES3, TXK, APOBEC3G, CX3CR1, CEP78, XCL2, JAK1, GNPTAB, RUNX3, MYBL1, TBX21, CCL5, S1PR5, C1orf21, PTPN4, GNG2, CHST2, FCRL6, SYNE1, ZAP70, IFITM2, LITAF, ARPC5L, METRNL, DHRS7, CD81, EVL, ARHGAP9, ITGB2, CCL3, SKAP1, DDIT4, MBP, CHST12, SYNE2, CALM1, GIMAP7, PLAC8, PLEKHF1, PRKCH, TXNIP, SEPT.7, DENND2D, ASCL2, TBC1D10C, SH2D1B, CXXC5, IL2RG, STK17A, RAC2, RASSF1, OSTF1, SYTL3, TFDP2, AES, CD300A, ID2, SLFN5, CD63		gene expression	up	cluster 1 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	GZMH, IL32, TRGC2, NKG7, CD3D, GZMK, CCL5, GZMA, CD3G, CD8A, KLRG1, CD8B, CD3E, CD2, FGFBP2, GZMM, GNLY, TRAC, TRBC2, CCL4, LYAR, DUSP2, HOPX, KLRD1, HCST, LCK, CTSW, LINC01871, PPP2R5C, CD52, TRBC1, SAMD3, CMC1, RARRES3, SYNE2, HLA-C, CD81, RORA, APOBEC3G, CLEC2D, FCRL6, MYBL1, ARL4C, CALM1, CST7, PRF1, LITAF, ABHD17A, IL2RG, MATK, PYHIN1, SKAP1, B2M, ANXA6, PAXX, ADGRG1, SYNE1, MALAT1, AES, CD6, C1orf21, IL7R		gene expression	up	cluster 2 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	AC007952.4, H2AFY, TNFSF10, SYK, SELL, C1orf162, HCK, CD55, LMO2, GPR183, CTSH, CTSB, HLA-DMB, MAR.1, FOS, RAB11FIP1, FKBP1A, BLVRB, CLEC12A, DAPP1, PECAM1, JAML, NFKBIZ, CAPG, LYL1, RNF130, POU2F2, CAPZA2, GSTO1, SNAP23, VIM, LAMTOR1, HLA-DRB5, ARPC1B, S100A11, CALM3, NT5C3A, VCL		gene expression	down	cluster 2 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	LYZ, VCAN, S100A9, CXCL8, FCN1, S100A8, CD14, MNDA, CTSS, S100A12, NEAT1, MS4A6A, IL1B, AC020656.1, LGALS2, CSTA, CEBPD, ATP2B1-AS1, TKT, CYBB, TSPO, TYROBP, IER3, CSF3R, FGL2, RGS2, KLF4, S100A6, NCF2, NCF1, FOS, NAMPT, AIF1, BRI3, TYMP, CD36, APLP2, DUSP6, CFD, CCL3, S100A11, GRN, PLBD1, LGALS3, FTL, G0S2, CLEC7A, FOSB, EREG, NFKBIA, BLVRB, AP1S2, RBP7, PSAP, KCTD12, MPEG1, CLEC12A, FCGRT, TNFAIP2, FPR1, DUSP1, CPVL, SERPINA1, AC007952.4, SLC11A1, MCL1, PLAUR, IGSF6, ANXA1, TNFSF13B, TMEM176B, CDA, NUP214, CST3, GCA, LRRK2, JAML, VIM, DMXL2, RNF130, S100A10, EGR1, CFP, KLF6, S100A4, SDCBP, TREM1, PYCARD, ASGR1, AC020916.1, C5AR1, MEGF9, LGALS1, SPI1, CLEC4E, CD302, OGFRL1, RETN, NLRP3, IER2		gene expression	up	cluster 3 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA			years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	CDKN1C, LST1, FCGR3A, MS4A7, AIF1, CFD, SMIM25, LYPD2, SERPINA1, COTL1, SAT1, FCER1G, PSAP, LYN, FTL, TCF7L2, CTSS, TNFRSF1B, SPI1, NFKBIZ, CSF1R, C1QA, PECAM1, LILRB2, PILRA, LRRC25, MAFB, S100A11, WARS, TYROBP, MARCKS, C5AR1, POU2F2, HMOX1, FTH1, NEAT1, RHOC, FGL2, BCL2A1, BRI3, CEBPB, HCK, HES4, NAMPT, CD68, BID, RRAS, CST3, LYST, CSTB, SIGLEC10, IFI30, STXBP2, VASP, IFITM2, SLC7A7, S100A4, NPC2, CYBB, MBD2, LMO2, CLEC7A, VSIR, LILRA5, CFP, ATP2B1-AS1, TYMP, APOBEC3A, S100A6, ASAH1, PTPN6, TKT, LILRB1, LGALS3, CLEC12A, ANXA5, PYCARD, CPPED1, SLC2A6, ZFAND5, CTSL, DUSP6, FCN1, TMEM176B, FGR, NAAA, PRELID1, C19orf38, GPBAR1, KLF4, DUSP1, RNASET2, CKB, RGS19, ABI3, CASP1, G0S2, HLA-DPA1, ADGRE2, PLAUR		gene expression	up	cluster 4 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	FCER1A, HLA-DRA, HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DQB1, HLA-DRB1, HLA-DRB5, CLEC10A, CD74, CST3, CD1C, HLA-DMA, HLA-DQA2, CPVL, GPR183, LGALS2, HLA-DMB, ENHO, PHACTR1, LYZ, VIM, ANXA2, ALDH2, RGS1, CTSZ, JAML, IGSF6, GSTP1, S100A10, CAPG, CFP, CTSH, ID2, MS4A6A, CEBPD, BASP1, KLF4, LY86, LMNA, FCGRT, LGALS1, COTL1, C1orf162, AREG, SAMHD1, CCDC88A, H2AFY, AP1S2, GRN, SPI1, PAK1, IFI30, GADD45B, CIITA, ANXA1, NR4A2, IL13RA1, MNDA, CSTA, FOS, RNH1, PPA1, SLC25A5, FGL2, ANXA5, RNF130, CD33, CHMP1B, GDI2, IL1B, CSTB, CLEC4A, MAP3K8, NDRG2, IL18, CD1D, GAPDH, ID1, BHLHE40, EIF3L, TIPARP, LSP1, GSN, TMEM14C, SLC25A6, ACTG1, TYMP, CASP1, TUBA1A, AC020656.1, GLIPR1, GRASP, SGK1, LGALS3, OGFRL1, PRCP, PGLS, RBPJ, PYCARD		gene expression	up	cluster 5 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	NRGN, PPBP, CAVIN2, PF4, HIST1H2AC, TUBB1, GNG11, TSC22D1, RGS18, CLU, GP9, MYL9, ACRBP, CMTM5, MAP3K7CL, TREML1, PTCRA, TUBA4A, SPARC, TMEM40, RUFY1, LIMS1, C2orf88, RGS10, HIST1H3H, NCOA4, PGRMC1, CD9, PRKAR2B, HIST1H2BJ, MMD, F13A1, MPP1, GRAP2, TPM4, ODC1, CTSA, BEX3, TLN1, VCL, 02-Mar, FERMT3, CLDN5, TMEM140, KIF2A, CLEC1B, TAGLN2, TGFB1, NT5C3A, YWHAH, CALM3, OAZ1, OST4, TIMP1, RAB27B, AP003068.2, CTTN, AP001189.1, ESAM, PDLIM1, ITGA2B, MAX, NEXN, TPM1, RAP1B, CCL5, RAB32, GSTO1, ILK, PARVB, GPX4, PRDX6, SMIM5, IFI27, DAB2, SMOX, SNN, MYLK, MPIG6B, GMPR, RSU1, CDKN2D, SNCA, ENKUR, PTGS1, SNAP23, ACTN1, ITM2B, ARHGAP18, H3F3A, LAMTOR1, PKM, PDZK1IP1, TLK1, GAS2L1, SLC40A1, AC147651.1, EIF2AK1, DAPP1, SH3BGRL3		gene expression	up	cluster 6 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		phospho-CyTOF panel	CD79A, MS4A1, IGHD, IGHM, CD79B, RALGPS2, BANK1, TCL1A, CD37, LINC00926, TNFRSF13C, CD74, VPREB3, HLA-DQA1, HLA-DQB1, HLA-DRB1, FCER2, MEF2C, HLA-DRA, CD22, AFF3, SWAP70, P2RX5, BLK, FCRL1, LTB, BIRC3, HVCN1, ADAM28, PLPP5, CD69, CXCR4, IL4R, HLA-DPB1, CD24, HLA-DMB, FCRLA, HLA-DMA, TSC22D3, ARHGAP24, CD40, STRBP, FAM129C, IFT57, BCL11A, BTG1, PAX5, FCMR, HLA-DPA1, HLA-DOB, FAM30A, CD72, STX7, SNX2, 01-Mar, TXNIP, SPIB, EZR, FCRL5, CYB561A3, FCRL2, ZCCHC7, FOXP1, CXXC5, ISG20, CD19, BCL7A, TMEM156, LINC02397, CD52, EAF2, GNG7, CDCA7L, TPD52, COBLL1, PPM1K, IRF8, CLEC2D, CAMK2D, PRDM2, NFKBID, IKZF3, REL, SEC62, NCF1, BLNK, SMIM14, LAPTM5, TCF4, QRSL1, SMAP2, ARID5B, BASP1, ADK, GAPT, GABPB1-AS1, CD83, JUND, KLF2, RHOB		gene expression	up	cluster 7 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	LYZ, IGHG1, S100A9, S100A8, IGKC, CTSS, FCN1, AC020656.1, VCAN, NEAT1, MNDA, AIF1, IGHA1, PSAP, KLF4, EHBP1L1, SPI1, S100A12, SAT1, SERPINA1, LCP1, TKT, PARP14, TYMP, LST1, FGL2, SLC38A2, CFD, NAMPT, CYBB, S100A11		gene expression	up	cluster 9 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	ARL4C, CD3E, CCL5, OST4, TGFB1, KIF2A, RGS10, BTG1, CD52, TUBA4A, LTB, CD7, TRBC2, TAGLN2, NT5C3A, TRAC, CTSW, YWHAH, CST7, TLN1, LIMS1, MARCH2, RUFY1, IGLC3, NKG7, TRBC1, IL7R, IL32		gene expression	down	cluster 9 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	TCF4, IRF8, PPP1R14B, IRF7, CCDC50, PTGDS, ITM2C, PLD4, TPM2, LILRA4, UGCG, SERPINF1, GZMB, IL3RA, TCL1A, BCL11A, ALOX5AP, SPIB, TSPAN13, TXN, SMPD3, CYB561A3, SEC61B, SCT, PLAC8, CLEC4C, APP, GPR183, DNASE1L3, SOX4, C12orf75, STMN1, NPC2, MAPKAPK2, GAPT, CLIC3, RNASE6, SPCS1, CD74, IRF4, SELENOS, HERPUD1, DERL3, CCDC88A, RGS1, FAM129C, LAMP5, LINC00996, VEGFB, PLP2, TRAF4, RUNX2, UNC93B1, CCDC186, CD2AP, FCHSD2, ZFAT, SLC15A4, OFD1, AC119428.2, RNASET2, TGFBI, MZB1, LILRB4, IDH3A, LGMN, MYBL2, COBLL1, NUCB2, GAS6, BLNK, P2RY14, MAP1A, RRBP1, MPEG1, CD4, JCHAIN, CIB2, ERP29, C12orf45, HIGD1A, RGS2, VAMP8, CTSZ, ZDHHC17, PHB, ST6GALNAC4, RAB11FIP1, PARK7, CTSC, PACSIN1, HLA-DMA, SCARB2, PPM1K, RASD1, CLN8, PTMS, PTPRE, SMC6, B4GALT1		gene expression	up	cluster 10 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI27, S100A8, S100A12, S100A9, IFITM3, PLBD1, RNASE2, IFI6, CD14, ISG15, VCAN, APOBEC3A, RETN, MNDA, TYMP, IFI44L, AC020656.1, CTSD, GRN, APLP2, MX1, LYZ, S100A11, FCN1, FPR1, SERPINA1, PLAC8, NAMPT, MX2, IFIT1, LY6E, LGALS1, TNFSF13B, IFIT3, CTSB, S100A6, CTSS, ACSL1, PLSCR1, NCF2, IFI44, SELL, XAF1, TNFSF10, CYBB, CEBPD, BLVRB, MAFB, FTL, IFITM2, CYP1B1, EPSTI1, LILRB2, OAS1, LILRA5, RSAD2, TYROBP, S100A10, MGST1, AIF1, CD163, KCTD12, SPI1, ANXA2, OAS3, GCA, FGL2, CREG1, MEGF9, MS4A4A, OAS2, GLUL, ITGB2, NEAT1, IGSF6, CEBPB, NAIP, SIGLEC1, BLVRA, C5AR1, FCGR1A, CD63, SLC11A1, TSPO, CAPG, S100A4, CSTA, 01-Mar, CLEC12A, SULT1A1, SPTLC2, CD36, SRGN, PSAP, LAP3, CR1, LGALS9, SERPINB1, DUSP6, CDA		gene expression	up	cluster 11 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	SYNE2, MALAT1, RNF213, SYNE1, MACF1, NKTR, XIST, SLFN12L, PRRC2C, UTRN, RORA, ZAP70, DDX17, ATM, ANKRD11, RBM39, PTPRC, SRRM2, ARGLU1, ATRX, ETS1, GOLGA4, SMCHD1, ARAP2, AAK1, CLEC2D, PCSK7, ASH1L, IKZF3, PLCG2, ANKRD12, DIP2A, AHNAK, HNRNPH1, SAMD3, PRPF4B, AKNA, PRF1, TUT4, PNISR, AKAP13, MYO1F, ACAP1, AKAP9, PPP2R5C, ZNF292, EVL, CCNL1, BPTF, TCF25, N4BP2L2, ZFP36L2, OGA, DDX24, MBNL1, LUC7L3, FUS, SMG1, SRSF11, KLRD1, DDX3X, RSRP1, EML4, PNN, SON, ARL4C, IKZF1, KMT2A, PCM1, ATF7IP, ITGAL, ANKRD44, KIAA1551, USP34, SLFN5, VPS13C, NEMF, BDP1, POLR2J3.1, CDK13, EPB41, SNRNP70, GOLGB1, OGT, YIPF4, INTS6, AFF4, PARP8, SREK1, GPBP1, SP100, YME1L1, RBM26, CASP8, ZNF207, HECTD1, TNRC6B, IRF3, TRA2B, USP15		gene expression	up	cluster 12 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IGLC2, IGHA1, IGLC3, IGKC, JCHAIN, IGHG1, IGHG3, MZB1, IGHG4, IGHA2, IGHG2, HSP90B1, SEC11C, ITM2C, PPIB, TNFRSF17, MYDGF, XBP1, FKBP11, CD38, LMAN1, DERL3, PDIA4, HSPA5, SSR3, RRBP1, PDIA6, SPCS3, SUB1, CD27, SDF2L1, SSR4, ISG20, SPCS2, IGHGP, ERLEC1, RPN2, UBE2J1, CALR, PRDX4, MAN1A1, ELL2, TXNDC11, MANF, POU2AF1, FKBP2, NCOA3, SEC61B, P4HB, EAF2, HM13, SELENOS, SEL1L3, SPCS1, DDOST, TENT5C, HDLBP, AQP3, RABAC1, CRELD2, LMAN2, KDELR2, SEC61G, TP53INP1, ZBP1, PIM2, TNFRSF13B, OSTC, SLAMF7, PRDM1, TMED10, TMED9, TMEM258, DERL1, TPD52, FNDC3B, DNAJB11, RPN1, PLPP5, GOLGB1, SPATS2, CPEB4, CANX, SEC61A1, CD79A, TMEM208, TRAM1, FCRL5, COBLL1, HERPUD1, NUCB2, MLEC, IDH2, FAM30A, TXNDC15, SRPRB, ALG5, ARF4, SSR1, IGHM		gene expression	up	cluster 13 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	HBG2, ITGA2B, PPBP, PF4, CLEC1B, PRKAR2B, GNG11, CLU, TREML1, TUBB1, YWHAH, GP9, TLN1, CST7, NRGN, MYL9, RGS18, RUFY1, SNCA, HIST1H2AC, PDLIM1, ACRBP, BEX3, 02-Mar, F13A1, E2F1, PGRMC1, CTSA, TPM4, VCL, CMTM5, GAS2L1, CAVIN2, CD9, MPP1, MMD, TSC22D1, TMEM40, SPARC, TIMP1, CA2, TPM1, TAGLN2, TGFB1, FLNA, OAZ1, RSU1, EIF2AK1, ETFA, RGS10, KIF2A, TUBA4A, RAB32, ARHGAP18, NAP1L1, GRAP2, MPIG6B, FERMT3, OST4, MMRN1, GPX4, ACTN1, ARPC1B, SOD2, MGLL, LIMS1, SELP, PTGS1, STOM, LCN2, ILK, ANKRD9, TSPAN33, CALM3, CTTN, MYL6, GMPR, NCOA4, SH3BGRL2, PRKAR1B, H3F3A, FAXDC2, MGAT4B, PTCRA, PKM, ITM2B, ANO6, ITGB3, ENDOD1, NT5M, WDR1, PROS1, AC147651.1, LAMTOR1, ITGB1, ARHGAP6, TFPI, NORAD, RAB11A, DAP		gene expression	up	cluster 14 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IGHG1, IGKC, IGLC3, IGLC2, IGHA1, JCHAIN, MZB1, IGHG4, IGHG3, HSP90B1, IGHA2, SEC11C, IGHG2, PPIB, MYDGF, LMAN1, XBP1, HSPA5, TNFRSF17, SSR3, SUB1, PDIA6, FKBP11, SDF2L1, PDIA4, ITM2C, HIST1H1B, CD38, SPCS3, CALR, MANF, RRBP1, SPCS2, MKI67, DERL3, UBE2J1, ELL2, SEC61B, POU2AF1, KDELR2, P4HB, HIST1H1D, SEC61G, RPN2, ERLEC1, SMC4, RRM2, PRDX4, TMEM258, MAN1A1, TXNDC11, ISG20, HDLBP, AQP3, HSPD1, FKBP2, EAF2, OSTC, CRELD2, CD27, CCND2, HM13, CANX, SSR4, LMAN2, MYBL2, TMED9, IGHGP, SRM, SELENOS, MLEC, DERL1, SSR1, SPCS1, CENPF, TYMS, PTTG1, DNAJB11, RPN1, HIST1H2AH, PCLAF, FABP5, HIST1H3G, TMED10, LRRC59, SEC61A1, ASPM, PSME2, TMEM208, TOP2A, PIM2, TNFRSF13B, PRDX1, DDOST, NCOA3, H2AFZ, HMGB2, HIST1H1E, HIST1H4C, IGHM		gene expression	up	cluster 15 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	S100A9, LYZ, VCAN, FCN1, S100A8, CXCL8, CD14, MNDA, CTSS, AC020656.1, LGALS2, NEAT1, S100A12, MS4A6A, TSPO, CSTA, CEBPD, ATP2B1-AS1, CCL3, CSF3R, TKT, DUSP6, NCF1, S100A6, FOSB, RGS2, FGL2, NCF2, CYBB, KLF4, AC007952.4, FPR1, RBP7, IER3, CD36, APLP2, RETN, LGALS3, NAMPT, AIF1, BLVRB, PLBD1, SLC11A1, CFD, GRN, KCTD12, CLEC7A, GCA, TYMP, TYROBP, FOS, FTL, S100A11, ZFP36L1, MCL1, DUSP1, IL1B, S100A4, KLF6, IER2, NFKBIA		gene expression	up	cluster 15 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	NRGN, RGS18, CST7, MPP1, IGKC, CCL5, JCHAIN, IGLC3, IGLC2, CLU, VCL, LIMS1, TPM4, PPDPF, TGFB1, IGHA1, TLN1, MARCH2, RGS10, RUFY1		gene expression	down	cluster 16 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	EPB41, RBM38, BAG1, UBB, HAGH, HBB, HBA2, HBA1, HBD, HBM, SLC25A37, ALAS2, AHSP, SLC25A39, SNCA, GYPC, CA1, YBX3, FAM210B, GUK1, BNIP3L, MXI1, SLC4A1, DCAF12, SELENBP1, FBXO7, FKBP8, RNF10, BPGM, ADIPOR1, HBQ1, STRADB, KRT1, FECH, HEMGN, BCL2L1, SMIM1, EPB42, MARCH8, DMTN, MYL4, GYPB, TRIM58, NFIX, IFI27, GSPT1, MKRN1, GLRX5, TENT5C, BLVRB		gene expression	up	cluster 17 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	EIF3J, RASSF1, NCOA3, PTPRA, SEMA4D, KLF10, PARP8, ARL4A, ANXA7, RAB4A, CPNE1, CAMLG, TMED5, TMEM14C, PRDM2, PABPC4, XPO1, DYNLT1, ANKRD13D, USP8, HOOK3, IL16, SSH2, ZC3H13, IDI1, CEBPZ, CCDC107, MAP3K1, CTDSP1, HELZ, INTS6, TSC22D4, UBE2R2, SLIRP, EIF6, SNF8, NDUFS2, PSMB7, CYBC1, ETFB, LSM10, KDELR1, SAT2, PRMT1, CNOT2, RBBP4, PABPN1, SHKBP1, ARHGAP4, IFNAR1		gene expression	down	cluster 18 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	ZFP36L2, SMCHD1, TRBC1, SAMD9, ARID5B, GIMAP7, CLEC2D, NOSIP, IL7R, IFI44L, ISG15, LTB, TRAC, XAF1, MX1, CD3E, IFIT3, LEF1, CD3G, CD3D, TCF7, IL32, MYC, RCAN3, ETS1, CCR7, IFITM1, IFI6, SARAF, TRAT1, PIK3IP1, EIF2AK2, MALAT1, RSAD2, CAMK4, ISG20, CD69, MAL, LDHB, IFIT1, SOCS3, LY6E, ITK, HERC5, TRBC2, TXNIP, BCL2, MX2, CD2, OXNAD1, SPOCK2, SP100, TMEM123, CDC14A, EPSTI1, EIF4A2, LCK, STAT1, DGKA, IFI44, ITM2A, SELL, DDX60, PIM1, PDE3B, LEPROTL1, AAK1		gene expression	up	cluster 18 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	MARCH1, CYBA, SKAP2, ACTG1, PTPRE, MAP3K8, HLA-DMB, MYO1F, CTSH, AP2S1, SERF2, PTPN12, GLUL, TNFSF13B, ARPC5, POU2F2, FCGRT, RAC1, CTSB, TNFRSF1B, TUBA1B, PTPN18, FKBP1A, SERPINB1, PLEKHO1, TPST2, ATP2B1-AS1, ILK, C12orf75, IFI27, GPX4, PKM, NAP1L1		gene expression	down	cluster 18 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	SOX4, LMO4, AREG, JUND, SPINK2, CDK6, AC084033.3, FAM30A, PRSS57, ZFAS1, NPM1, STMN1, SNHG7, ANKRD28, CYTL1, HSP90AB1, LAPTM4B, EBPL, NUCB2, NRIP1, HNRNPA1, MSI2, EGFL7, SMIM24, DDAH2, CRHBP, CD34, MYB, IMPDH2, NPR3, HMGA1, RACK1, GATA2, FAM117A, IGFBP7, BTF3, ARMH1, MDK, IL18, SYPL1, SSBP2, AL157895.1, BEX2, CLEC11A, ALDH1A1, PDZD8, ATP8B4, FHL1, HPGDS, HEMGN, PTMS, TCEAL4, MYL6B, MSRB3, EREG, TFDP2, H1F0, HINT1, EIF3E, H2AFY, SNHG8, EPB41L4A-AS1, APEX1, ANP32B, LDHB, TXN, SERPINB1, C6orf48, CAT, EEF1B2, EEF2, HIST1H1E, HSPD1, ST13, HIST1H1D, PNN, TUBA1A, YBX3, ID1		gene expression	up	cluster 19 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	FAM107B, UPP1, TXNIP, MARCH1, REEP5, KLF2, CAST, AGTRAP, SMAP2, LITAF, MYO1F, PTP4A2, VSIR, GADD45B, CEBPB, GPR183, CLEC2D, IFI27L2, WDR1, SYNE1, HLA-DRB1		gene expression	down	cluster 19 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	STMN1, HMGB2, MKI67, TUBA1B, TYMS, HIST1H1B, TUBB, PCNA, DUT, H2AFZ, PCLAF, HMGN2, CENPF, TOP2A, SMC4, GZMA, NUSAP1, MCM7, NASP, RRM2, RAN, CLSPN, FABP5, DEK, TK1, PTTG1, HMGB1, H2AFV, HELLS, ASPM, RANBP1, ANP32E, SMC2, HSP90AA1, ATAD2, MCM5, CENPM, BIRC5, DNMT1, TPX2, NUCKS1, MCM4, MCM3, RPA3, CENPU, CARHSP1, SNRPB, DNAJC9, HNRNPAB, LMNB1, GINS2, PRF1, CKS1B, SLBP, DDX39A, ZWINT, DHFR, UBE2C, HNRNPA2B1, FEN1, EBP, NUDT1, CDKN3, USP1, EZH2, ATAD5, PTMA, RRM1, CCDC167, HIST1H2AH, PPIA, SNRPD1, SMC3, PFN1, ANP32B, GAPDH, CACYBP, LDHA, HIST1H1D, TMPO, HIST1H4C, JPT1, ENO1, SNRPG, PA2G4, UBE2S, PSME2, HNRNPF, SLC25A5, HOPX, GZMB, NKG7, HIST1H1E, HSPD1, GNLY, CTSW, HSPA8, HSPE1, HIST1H1C, IL32		gene expression	up	cluster 20 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	STMN1, HMGB2, MKI67, TUBA1B, TYMS, HIST1H1B, TUBB, PCNA, DUT, H2AFZ, PCLAF, HMGN2, CENPF, TOP2A, SMC4, GZMA, NUSAP1, MCM7, NASP, RRM2, RAN, CLSPN, FABP5, DEK, TK1, PTTG1, HMGB1, H2AFV, HELLS, ASPM, RANBP1, ANP32E, SMC2, HSP90AA1, ATAD2, MCM5, CENPM, BIRC5, DNMT1, TPX2, NUCKS1, MCM4, MCM3, RPA3, CENPU, CARHSP1, SNRPB, DNAJC9, HNRNPAB, LMNB1, GINS2, PRF1, CKS1B, SLBP, DDX39A, ZWINT, DHFR, UBE2C, HNRNPA2B1, FEN1, EBP, NUDT1, CDKN3, USP1, EZH2, ATAD5, PTMA, RRM1, CCDC167, HIST1H2AH, PPIA, SNRPD1, SMC3, PFN1, ANP32B, GAPDH, CACYBP, LDHA, HIST1H1D, TMPO, HIST1H4C, JPT1, ENO1, SNRPG, PA2G4, UBE2S, PSME2, HNRNPF, SLC25A5, HOPX, GZMB, NKG7, HIST1H1E, HSPD1, GNLY, CTSW, HSPA8, HSPE1, HIST1H1C, IL32		gene expression	up	cluster 21 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	MZB1, IGKC, IGHG3, IGLC3, IGLC2, JCHAIN, IGHG1, ITM2B, SH3BGRL3, RUFY1, IGHA1, VCL, NCOA4		gene expression	down	cluster 21 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	S100A8, S100A12, S100A9, RETN, AC020656.1, LYZ, LGALS1, CD14, RNASE2, CXCL8, NAMPT, VCAN, CTSD, PLBD1, CD36, TSPO, MNDA, FPR1, MAFB, ACSL1, HIF1A, PTAFR, CSTA, AGFG1, CTSB, APLP2, MS4A6A, SLC2A3, LTA4H, MCEMP1, SLC11A1, NAIP, THBS1, CKAP4, BCL2A1, CYP1B1, AHR, SAMSN1, SGK1, GPCPD1, CAPG, PGD, ETS2, ANKRD28, KCTD12, MGST1, GCA, CD163, MEGF9, ASGR2, RBM47, EAF1, BCL6, ITGAM, CD93, CCR1, IL17RA, CLEC7A, SERPINB1, S100A6, SERPINA1, PLAUR, CD63, NCF2, DUSP6, GRN, CEBPD, BRI3, CDC42EP3, CD55, VIM, CYBB, ATP2B1, METTL9, ENO1, S100A10, CTNNB1, SPI1, GAPDH, FCN1, MCL1, CXCL2, ANXA2, CD44, SRGN, IQGAP1, PGAM1, MYADM, ATP6V0B, RAB11FIP1, ANXA1, NEAT1, S100A4, ZEB2, G0S2, TKT, ACTR2, CTSS, EREG, HMGN2, 		gene expression	up	cluster 22 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IL7R, GZMA, NKG7, GZMH, GNLY, CD3G, IL32, CD3E, CAVIN2, PPBP, PF4, TUBB1, GNG11, MYL9, SPARC, TREML1, CMTM5, NRGN, CLU, MAP3K7CL, PRKAR2B, CD9, F13A1, RGS18, CCL5, TUBA4A, LIMS1, NCOA4, ODC1, CD3D		gene expression	up	cluster 23 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	HLA-DRA, TSPO, S100A10, COTL1, LYN, LGALS1, BLVRB, FOS, NPC2, APLP2, S100A11, MCL1, HLA-DPB1, ATP2B1-AS1, ANXA5, PSAP, S100A8, NEAT1, S100A6, FGL2, LYZ, FCGRT, KLF4, NAMPT, HLA-DPA1, NCF1, CFP, CCDC88A, BRI3, HLA-DMB, RGS2, CTSB, CAPG, POU2F2, TKT, TNFSF13B, HLA-DRB5, JAML, CEBPD, TYROBP, LGALS3, TYMP, HLA-DQA1, RAB11FIP1, VIM, S100A9, ANXA2, CYBB, CD74, HLA-DRB1, MNDA, SPI1, CTSZ, 01-Mar, LST1, CTSS, FCN1, MPEG1, NCF2, HLA-DQB1, GRN, IGSF6, HLA-DMA, CTSH, RNF130, AIF1, PYCARD, SERPINA1, CFD		gene expression	down	cluster 23 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	CPVL, C1orf54, CLEC9A, IRF8, BASP1, IDO1, WDFY4, SHTN1, DNASE1L3, BATF3, CLNK, FLT3, CADM1, NDRG2, CCND1, CCSER1, HLA-DOB, XCR1, DST, SERPINF1, ADAM28, TLR10, NET1, CLIC2, HLA-DQA1, REPIN1, HLA-DQB1, CPNE3, CAMK2D, CSRP1, HDAC9, LGALS2, KCNK6, SLAMF7, HSDL2, HLA-DPA1, HLA-DRA, HLA-DPB1, HLA-DMA, CD74, HLA-DRB1, CST3, CIITA, C20orf27, HLA-DMB, HMGA1, SNX3, GSTP1, PPT1, CSF2RA, RAB32, HLA-DQA2, CTSZ, PPA1, ALDH2, S100B, ASAP1, FABP5, LY86, CCDC88A, VIM, RGCC, DPYSL2, CCDC6, FCGRT, S100A10, FGL2, ID2, ACTG1, FNBP1, PTPRE, HLA-DRB5, C1orf162, PPP1R14B, MARCKSL1, H2AFY, RNH1, NAAA, ACTB, RGS1, NDUFV2, LSM6, GDI2, BID, COX5A, C1QBP, SUB1, SPI1, CD83, LYZ, SLC25A6, EEF1B2, GRN, SLC25A3, LSP1, UCP2, SLC25A5, PGLS, SAMHD1, TXN		gene expression	up	cluster 24 (from COVID-19 patients) vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	RETN IFITM3 LY6E IFI6 NKG7 MT-DN2 LINC00937 SMIM5 CD226 LINC00877 RAP1B LDLRAP1 TPT1 RPL26 CALM3 ZNF185 A1BG, BTG1 SSX2IP, PLA2G12A, JUNB, IFIH1, BRK1, ALOX5AP, SPATS2L, ALDH1A1, CENPT, LAMTOR1, RPL35A, SVIP, PIK3AP1, MGST1, ENDOD1, GM2A, TST, FPR1, S100A12, PPP1R14A, HIST1H3H, AC020916.1, FERMT3, PFDN5, B2M, DDX60, JUN, CCL4, COX6C, RPS12, RPS23, TMSB10, HLA-C, CYBA, RNF11, TMEM140, FLNA, AL360012.1, VCAN, NFKBIZ, ANXA4, ENO1, MNDA, HLA-DPB1, TUBA1C, RPL21, LRBA, MT-CYB, RPL18, DOK2, C12orf57, PTBP3, MGST3, CFL1, SAMSN1, TOMM7, TUBB4B, MAFB, CDKN2D, ZCCHC17, HLA-DQB1, RPL5, IFNGR2, 01-Mar, DDX60L, CD164, RAB32, RPL19, SDHD, SNN, RPA1, HSPA6, C12orf75, EEF1A1, NAIP, TTC39C, LARP7, DDX58, PPIB, AC020656.1, CNIH4, RPS11, SP110, PSMB3, ACTR2, ANP32A, SULF2, LUCAT1, LMNB1, SNX2, TMEM91, DDOST, NMI, TNF, RAB5IF, CHMP5, GBP1, ZCCHC2, AP000547.3, ATOX1, PTPRC, LILRB2, TMED9, PTGS2, RPL15, ST14, IRF1, POMP, UBE2L6, PSMA4, TMBIM6, ABTB1, IFIT2, RDH11, FAM110A, ZDHHC1, VPS29, DAB2, AGPAT1, H1FX, ERV3-1, HMOX1, YPEL5, YWHAH, LAMP2, EEF2, RPS7, ABCC3, S100A6, SMAP2, RPL7A, PIM1, PML, TCN2, ARHGAP18, UBB, SHTN1, ATF3, STAT2, MCUR1, H2AFJ, STK17B, LAP3, PSMA3, ACTN1, DRAP1, VIM-AS1, B4GALT5, FRMD4B, F5, BCL2L1, PSMA7, CAMTA1, LGALS3BP, DDX3X, SUSD3, TAGAP, PSMB6, ERO1A, SAP30, HIST1H1C, UNC93B1, NR4A2, ARF6, TXN, VNN1, WBP2, EEF1D, PTEN, SERPING1, SLFN5, SAMD4A, HLX, RPL23, ANO6, CD4, EIF1B, RPS29, HNMT, LMAN2, SRI, ARHGAP21, EZR, PRDX3, GIMAP4, DUSP2, ITGB1, HLA-DMB, SAMHD1, HELZ2, SH3GLB1, CALR, GNS, MYL12A, CTSL, TNFSF10, FLT3, MT-ATP6, ITGB7, RRBP1, NT5C2, CD163, EGR1, PGAM1, KDM6B, UTY, ROMO1, C9orf16, MRPS18C, MTPN, RPLP0, AQP9, AC007952.4, HLA-E, ORAI1, KLF6, THAP2, NDUFA12, LAPTM4A, ANXA5, POLR2L, HSP90AA1, CAPN2, NDUFB3, BAD, NCKAP1L, MAP2K1, FAM20A, PRDX6, ANXA6, DECR1, RPN2, VDAC3, RGS2, LITAF, COX7B, PAG1, RPL7, EIF5A, MEF2A, IFNGR1, EFHD2, MYL12B, TNFSF13B, HLA-DPA1, RRAGA, PDIA6, FCGR1A, SPI1, CCR1, ITGA1, CCDC92, TNFAIP2, VEGFA, CAPG, PLEKHO1, KIAA1958, ATP5F1C, GSTP1, ZNF638, SMIM15, TPST2, SERPINA1, BTG2, SCN1B, METTL7B, FLVCR2, MYOF, ZFP36L2, TCF4, PDE4B, ACSL4, SWI5, GUSB, PSMC2, CES1, CR1, SCPEP1, GMPR, ATP5MF, WAS, RPL3, FDFT1, ATP5PD, KCNE1, STAB1, IDH1, PAK2, CCDC88A, IMPA2, TRIM14, VPS28, BLVRB, SNRPB2, HP, DAPP1, UPP1, STAC3, ETFB, DYSF, SOCS3, CNST, HACD4, NUDT16, RNASE1, SEC61G, TLR8, FABP5, MAP2K6, CD37, EEF1B2, HMGN2, CASP1, CYB5R3, LLPH, PEPD, SIGLEC14, ANKFY1, TMEM107, PRDX1, ORAI2, ASGR2, MAP4, SENCR, RPL35, RAC2, MT-CO2, TMEM126B, FGD4, NRIP1, MSRB1, APBB1IP, LEPROTL1, AREG, SEM1, PANK2, P4HB, UBL4A, MAP3K8, SAV1, RPL4, MTRNR2L8, SLIRP, AP1S2, ADM, NDUFA3, RB1, SCAF11, INF2, SF3B6, HCAR3, OGFRL1, ARID5B, LY96, RUNX1, TMEM165, LAIR1, CXCL2, RHOG, DDAH2, CAPZA1, SMCHD1, ISCU, UBE2E3, FGD2, LRPAP1, ZNFX1, RIN2, NDUFB9, PSME2, FES, MYD88, ID2, MBNL1, IVNS1ABP, IFIT5, SLC16A7, SCARB2, CTNNA1, PIP4K2A, LTA4H, KLF9, CPNE8, CCNL1, CD300A, SASH3, MT-ATP8, ASPH, FBXO6, CBX6, CD58, COX8A, UQCR10, CPT1A, IQGAP1, CDC40, MDH1, BRI3, EMC3, ATP5MD, KTN1, CTSZ, KLF10, DNAJC13, GSR, NENF, PTPN6, ERP44, C3AR1, CCNY, SPNS1, AC245014.3, GLIPR2, SLC25A36, CARHSP1, RGCC, UBE2L3, RPS2, TRMT6, CLEC12A, CST7, CPVL, SLC39A3, SQLE, USF2, URI1, MT1X, RTCB, MYO1G, EHD4, PSMA1, PLXNC1, MTHFD2, TMEM14C, N4BP1, FKBP15, XRN1, SPINT2, RRP7A, SQOR, SLC9A3R1, UBE2M, TLR4, JMJD1C, CD14, ZDHHC20, PATL1, MTFR1L, FKBP1A, THBS1, RAB4A, RAB8B, RAB10, VAMP5, MAP2K2, LILRB3, SMIM3, SPPL2A, MEGF9, MOB2, TLE3, CRYL1, AMD1, TACC3, ABCF1, RBM3, EMC7, G0S2, HSH2D, GLA, PCGF5, EIF3F, MS4A6A, TMPO, RHOQ, TLK1, YWHAZ, JOSD2, CFP, TNFAIP3, SELENOF, CATSPER1, SDHB, PPP4C, PSMB2, TMA7, BACH1, WIPF1, PPIA, PSMB1, HSPA8, NQO2, NLRP3, ZNF148, LILRA6, FPR2, KLF7, PLD3, CAT, SKAP2, SLC25A5, MACF1, DCTN2, CCDC6, SORL1, SRRM1, MIR29B2CHG, CCNG1, TMEM33, HEXB, ANP32E, PPDPF, CSTB, YPEL3, LILRB1, PMAIP1, ARPC5L, ITGAM, PLEKHB2, RASA3, ADIPOR1, UBAC2, ZBTB43, CTSA, NAPRT, EIF4E, TBK1, CD44, BIN2, CSF3R, APOL6, TSPAN14, HSP90B1, DPYD, SYNGR2, ANAPC5, SLA, TCF7L2, GYPC, LYL1, TALDO1, ALDH2, ITGA4, NDUFC2, RAB11A, DENND3, EIF3L, FCGRT, KCTD20, NORAD, EIF4B, U2SURP, CAPN1, FCAR, IRAK3, BASP1, STX11, PRNP, METTL7A, MDM1, CD79B, PRRC2C, CKAP4, VDAC1, CCDC186, EIF2AK1, AGTPBP1, C1orf162, POU2F2, FKBP8, SNRPB, KIDINS220, DNASE2, IL17RA, COQ7, PPIP5K2, HSPA1A, MFSD1, UBXN11, ZNF281, VMP1, CDV3, SLC25A37, OGFR, STEAP4, LINC01003, AP2S1, PDIA3, ID1, DNAJB6, MAPK14, ST8SIA4, NFKB2, SPG11, AKR7A2, TBPL1, MDM2, STK24, WDR74, ETS2, FAM198B, GLUL, UCP2, CDC37, LYPLAL1, PYCR2, GADD45A, CYP1B1, CARD19, DGAT1, RBM38, PGP, TMEM170B, CLEC4A, AC103591.3, PLEK, ATP2C1, ARHGAP45, SOS2, EVL, NDUFAF3, ATP2A3, CMPK1, MAP2K3, RPS27L, MPST, VNN2, CYTOR, H1F0, XPNPEP1, NFE2, PGLS, LEPROT, PCMTD1, CDKN1A, WDR1, MAPRE2, NDE1, DNAJC4, PTPN18, MKRN1, ETFA, EMD, IL13RA1, STOM, UBE2H, AKIRIN2, FFAR2, EREG, GSTO1, RHOB, SIN3B, NEXN, FAM118A, HDAC5, TIMP1, GOLGA2, DAAM1, BLOC1S6, SMARCA2, , TSPOAP1-AS1, TMEM176B, PABPC1, GAS2L1, MLH3, MPP1, SNAP23, NFKBIA, TMSB4X, IER2, SOD2, CD151, PTGS1, ESAM, ODC1, CCL3, FOS, PGRMC1, NAP1L1, TGFB1, FOSB, CTDSPL, H3F3A, GNAS, NRGN, RPS14, LAT, NT5M, KLF4, PNRC1, GPX4, RPS3A, DUSP1, SLC40A1, DYNLL1, RPL6, , RPS4X, , FAXDC2, PPP1R15A, RPL10, NCOA4, F13A1, RPS27A, SNRPN, RAB37, RPL13, ATP2B1-AS1, OAZ1, , RGS1, , RPS8, , MAX, , MGLL, SMOX, Z93241.1, INAFM2, RPLP1, ILK, CDIP1, , CYP27A1, , MGAT4B, , CD83, TPM4, , TLN1, , TAGLN2, FTH1, MT-ND1, LIMS1, SNCA, MARCH2, , EGFL7, IL1B, RUFY1, KIF2A, , VCL, MT-ND3, MAP3K7CL, RGS18, CXCL8, MMD, STON2, TSC22D1, HIST1H2AC, MT-CO3, MT-CO1, HIST1H2BJ, RGS10, ANKRD9, TPM1, OST4, CD9, SLA2, EIF1, NCK2, LTBP1, PARVB, MEIS1, ITGB5, TUBA4A, PDLIM1, FHL1, JUND, C19orf33, GUCY1B1, SYTL4, TRIM58, SELP, IER3, MYLK, AC147651.1, PDZK1IP1, CALD1, CLDN5, TREML1, MPIG6B, HGD, GP9, TUBB1, AP001189.1, HLA-DRB5, PTCRA, CTTN, TMEM40, CAVIN2, GNAZ, C2orf88, CMTM5, MFAP3L, AQP10, GRAP2, GNG11, ITGA2B, MMRN1, AC090409.1, LGALSL, RAB27B, TMEM158, CCL5, PF4, MYL9, TSPAN33, PPBP, SH3BGRL2, CLEC1B, DMTN, TNFSF4, XIST, GP1BA, CA2, AP003068.2, PRKAR2B, ASAP2, GFI1B, MTURN, DNM3, PDE5A, ITGB3, ENKUR, ARHGAP6, SPARC, TNNC2, TAL1, ACRBP, PDGFA, TGFB1I1, ELOVL7, BEX3, KLF2, ITM2B, , IFI35, USP18, TNNT1, H2AFY, CSGALNACT2, RPS26, RPS4Y1, ISG20, PLIN2, SP100, PHF11, DBI, STAT1, CTSB, BLOC1S1, NOP10, AGFG1, HLA-A, LILRA5, , MS4A4A, HMGB2, APOBEC3A, ADAR, IRF7, SAMD9, S100A11, S100A10, ACSL1, S100A9, CREG1, HERC5, HIST1H1D, SULT1A1, IFITM1, S100A8, APLP2, PARP14, LILRB4, SHISA5, DDIT4, PPA1, LDHA, LGALS9, SSB, DTX3L, PARP9, CUL1, BLVRA, , PLAC8, IFI44L, IFITM2, ISG15, MX1, IFI27, SELL, XAF1, EPSTI1, MX2, IFI44, IFIT3, OAS2, RNASE2, LGALS1, OAS3, HIST1H1E, EIF2AK2, BST2, CD63, IFIT1, PLSCR1, TYMP, SIGLEC1, PLBD1, MT2A, CTSD, IFI16, RSAD2, FKBP5, OASL, OAS1, JCHAIN, CMPK2, HLA-B, SPTLC2, TRIM22, LCP1, ANXA2, GRN, ITGB2, SAMD9L, TMEM123, CD53, RNF213		gene expression	enriched	C MONO_IFN cluster/cluster 11 from COVID-19 patients vs healthy   	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI27, IFITM3, JCHAIN, MT-CYB, IFI6, IFI44L, MT-CO1, MT-CO2, JUND, MT-ATP6, MT-ND3, KLF2, DUSP1, MT-CO3, MT-ND1, S100A8, JUN, FOS, MT-ND4, IER2, NCOA4, TXNIP, RPS14, PDZK1IP1, IER5, JUNB, EIF2AK2, TIMP1, SERTAD1, ISG15, ARL4C, NR4A2, RPL3, XAF1, MX1, AC147651.1, FOSB, NFKBIA, S100A9, LY6E, EPSTI1, IFI44, ITM2B, HOPX, NCR3, HBG2, ETS1, MIR4435-2HG, IRF7, ACTG1, RGCC, SIVA1, HBB, HMGA1, HLA-E, SP100, GNAS, TSPAN33, CST3, OAZ1, DYNLL1, IRF1, MATK, LYPLAL1, RPL28, CD81, STAT1, ATP5MPL, ATP2A3, HSPA8, CST7, CD247, PLSCR1, SOCS3, RPL10, HIST1H2AC, DDX6, ANO6, RPL36, TNFAIP3, HTATIP2, N4BP2L1, VIM-AS1, MX2, C4orf48, TMEM123, RPS21, RPS3A, RPL13A, SELL, MYC, CLIC3, KLF13, ISG20, GRK2, ATM, CYTOR, FCGR3A, UQCR11, SAMD9, ANKRD44, TRA2B, MORF4L1, PPM1K, RARRES3, BEX3, SAMHD1, DNAJC4, FGFBP2, MYADM, TAGLN2, CD5, KLRB1, NPM1, HSP90AB1, RPS26, HMGB2, USP16, AP001189.1, AIF1, MAL, ARHGAP9, SP110, CD3D, RNF145, ATF7IP2, CD3G, CCL5, ITGB2, ATP5MD, SMAP2, NKG7, PAG1, SLC40A1, CYLD, BAZ1A, RPL36A, DOK2, SRRM2, HIST1H1C, HIST1H3H, RBMX, DDX21, SETX, PTGS1, CYTIP, CELF2, PCM1, MSL3, FTH1, PFDN1, KLF6, TMEM91, FYN, HSP90B1, APP, DDX60, CD300A, BCL2, TRAT1, JAM3, MAZ, STAT3, NDUFA3, NOP58, IDS, RRAS, HDDC2, CRYBG1, CBX5, TUBA1B, OGA, CMC1, OXNAD1, MTDH, CREBRF, KLF9, ANP32E, TOMM5, NUB1, YPEL5, IL32, FCER1G, CCL4, HCLS1, SLC9A3R1, IL7R, GADD45B, MYCBP2, PPP1R10, TBX21, PRDM1, PPP1R15A, CD3E, NT5C, APMAP, ITGA2B, TUBB4B, MED30, EFHD2, DTX3L, TUBA4A, PAXX, FNBP4, EZR, ITGA6, FGR, CITED2, GZMA, GTF3A, IFI16, IL2RB, TREML1, ASH1L, PPP1R12A, TSHZ2, FKBP11, MT2A, YPEL3, SSR2, SAMD9L, ANP32A, IL6ST, ARID5B, ZFP36, GPRIN3, STK17B, TRDC, ERV3-1, UTRN, BLOC1S1, RSU1, FLNA, MMD, SPON2, TYROBP, SWI5, EIF2AK1, PDE3B, RNPEPL1, CAVIN2, RNF126, MAPRE2, MYBL1, GCC2, DUSP2, CCSER2, CTSW, HNRNPM, TPM1, PDLIM1, UBE2S, TYMP, RNMT, TRIM22, MGAT4B, HLA-DRB1, LEF1, EXOSC6, CCR7, NUMA1, EIF3A, ITGB5, GYPC, SUPT5H, SELP, HSPD1, TUBA1C, POLR2J3.1, R3HDM2, MGAT4A, BOD1L1, ADAR, UIMC1, IFITM1, MSI2, CXCR4, ODC1, AC044849.1, PARP9, BLOC1S6, SERPINB1, SLC4A7, OSTF1, TMEM140, PIK3IP1, DMTN, NDUFB7, HIST1H1D, HIST1H1E, PYHIN1, SEC62, CWF19L2		gene expression	enriched	T cluster/cluster 23 from COVID-19 patients vs healthy   	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI44L, IFI27, XAF1, HLA-DRB5, MT-ND3, LY6E, EPSTI1, MT-ND1, IFI44, MX1, RPS11, RPS14, RPL27A, ISG15, SELL, EIF2AK2, RPL13A, IFI6, HIST1H1E, HLA-A, RPS20, MT-ND2, CDKN1C, HLA-DQA2, TOMM7, RPL23, RPS18, FCGR3A, RSAD2, MBD2, ISG20, PLSCR1, SP100, MS4A7, NR4A2, TMEM123, ADAR, TRA2B, IFIT1, IFITM1, HIST1H1C, SAMD9L, MT2A, LST1, H1FX, TXNIP, IER5, NDUFA3, EIF5A, HLA-DPB1, RNF213, HERC5, HLA-DPA1, JCHAIN, STAT1, SMIM25, SAMD9, FOSB, CSF1R, TRIM22, IFI16, HIST1H1D, SOD2, CD63, MX2, HLA-DRB1, OAS2, FTH1, IFI35, BST2, TNFRSF1B, CXCL8, SAT1, IRF7, HMGB2, PPA1, IL1B, IFITM3, IER3, PARP9, TCF7L2, AIF1, PIM3, NAP1L1, TMEM156, IFIT3, IER2, PRPF4B, NPC2, BRI3, HIF1A, CCND3, FGL2, FCHSD2, CFD, FCER1G, FKBP5, COTL1, PECAM1, IL32, LDHB, FTL, DDIT4, ARID5B, PLAC8, HSPA5, CD3G, AC020656.1, BASP1, CD3D, IL2RG, CCL4, ETS1, LGMN, CTSD, CD3E, MTRNR2L8, IL4R, PPP1R14B, TYMP, LILRB4, LGALS1, APOBEC3A		gene expression	enriched	Cl21 cluster/cluster 21 from COVID-19 patients vs healthy   	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	TYROBP, RPL10, IFI44L, RPS14, MX1, IFITM3, HIST1H1E, LY6E, IFI6, XAF1, RPL19, RPL3, BST2, EPSTI1, HIST1H1D, RPS3A, RPL36, ANXA5, JUND, ISG15, HIST1H1C, EIF2AK2, IFI44, YBX3, PLSCR1, RPS11, SAMD9L, PARP9, RPS10, PRKG1, FOSB, IFIT1, HLA-DRB1, AVP, AREG, IFIT3, RPL13A, RSAD2, OAS1, MSRB3, IFI16, SP100, RPL36A, EEF1B2, GNAS, ATP8B4, IFIH1, TPM4, TYMP, JCHAIN, TCEAL4, FOS, H1F0, YWHAE, DDX60, CEBPZ, EGFL7, PROM1, HSPB1, STAT1, MAP2K2, TFPI, IRF7, ZFP36, STOM, MMRN1, APP, ATP5ME, MTRNR2L12, MDK, NUCB2, SNHG25, MT2A, OAS2, HBB, ADAR, NPDC1, RNF213, SPTLC2, HNRNPDL, TRIM22, MIR181A1HG, S100A8, MX2, SELL, ANKRD28, HLA-A, HLA-B, SAMD9, CD44, APLP2, IER5, LAPTM4B, RGS1, PTMS, MT-ND4L, KTN1, RPS17, ZFP36L2, MSI2, S100A9, PPP1R15A, POLR2J3.1, HSP90B1, DUSP1, KIF2A, CD99, MAZ, PPDPF, H3F3B, MLLT3, GLIPR1, SERTAD1, IQGAP2, CLU, H1FX, CDK6, CST7, FHL1, SOD2, CD9, CNRIP1, HSPD1, SOCS2, PRSS57, HIST1H2AC, IER2, HLA-DQB1, BCL11A, NCOA7, MGST1, NEAT1, SEC11A, NR4A2, CD7, PRDX1, PIM1, NPR3, MTURN, BTG1, IRF1, JUNB, CXCL8, EREG, GADD45B, BEX1, NFKBIA, CEBPB, HPGDS, YPEL5, EVL, ARL4C, TIPARP, HPGD, LTB, CRHBP, TNFAIP3, FCER1G, LST1, AC044849.1, VIM		gene expression	enriched	HSC cluster/cluster 19 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	RNF213, IFI6, MTRNR2L12, XRN1, DDX24, MX1, ENTPD1, TXNDC11, IRF7, TXNDC15, ISG15, TRAM1, TP53INP1, CSDE1, GOLGA4, ATRX, ADAR, SMCHD1, PTPN2, NCOA3, ANKRD12, SIL1, SAMD9L, HNRNPH1, YWHAE, IFI35, SRP54, PRDM1, ROMO1, RFC1, MAN1A1, CPEB4, SCARB2, AKAP9, OGT, SEC14L1, SEC13, MIF, SLAMF7, FNDC3A, CLINT1, ARGLU1, FCRL5, CNPY2, MIR4435-2HG, TYMP, CD38, GLS, MYCBP2, ATP5ME, EIF4G2, STAT1, NDUFB6, ST6GAL1, ELL2, SERBP1, MSI2, SP100, NKTR, GRB2, MZT2B, EIF5B, STK17B, ATOX1, HERC2, FBXW7, C4orf3, MDM4, SYNE2, NSD1, SEC31A, PET100, 02-Sep, SCFD1, SSR1, GOLGB1, MEF2C, NDUFA3, DSTN, CASP3, PLCG2, DNAJC3, MT-ND4L, FKBP8, COPA, NDUFB9, FKBP2, IFI27, BCAP31, TRA2A, NDUFA11, CAPZA1, TMEM50A, PAPOLA, MAGT1, HNRNPDL, EIF4G1, SEL1L3, WIPF1, ICAM3, SLC38A2, CFLAR, MT-ND6, KLF13, TMEM256, TCEA1, VAPA, EDEM2, MED13L, N4BP2L2, NCF1, TMC6, ITGB7, ACBD3, RBX1, IFI27L2, METTL7A, PNISR, PRKCSH, PIM2, AP2M1, ACO2, COPZ1, SPTY2D1, SRSF11, TLK1, ASCC3, IFI16, USP34, PJA2, MAP1LC3B, LUC7L3, UGGT1, SEC24A, KMT2C, VPS13C, NXPE3, LILRB4, JAK1, IKZF3, FMNL1, UBR5, CHPF, CKLF, TTC3, VPS36, TXNDC5, BCL2L11, ACTR2, RBM39, CBWD1, PPP2R5C, MDM2, AC012368.1, FUBP1, COX7A2L, PPA1, EIF1AX, ATM, RTF1, AC007952.4, PDK1, ILF3, HIPK2, PPM1K, TMEM156, RPL17, MARK3, RBM26, COBLL1, PTPN1, TCF4, FAM133B, GOLGA3, CD2BP2, BIRC6, MBNL2, SMAP2, SPTBN1, ASH1L, BTN3A2, ATP2A3, ATP2A2, TRAF3IP3, IBTK, FBH1, SDF4, CYLD, GOSR2, TPP2, EBPL, PCBP1, PARP14, ADAM10, TMEM259, CASP10, CREB3L2, CHMP4A, UBA1, SETBP1, SQSTM1, PLD3, TNFSF10, STAT2, UQCC2, LIMS1, RSL24D1, OS9, RPL22L1, HIBCH, GCC2, PSMD14, APOL2, RPS17, TRIP12, HSPB11, SUZ12, NCKAP1L, ZNF292, ITPR2, UPF2, POLR2B, AFTPH, DUSP22, ATP6V0A1, XIST, CHMP4B, LSM14A, ARIH2, TMEM87A, CCDC32, OTULIN, IRF4, CEP128, LMBRD1, ARSA, GOLGA2, SGK1, HDAC7, IFI44, AUP1, EPB41, CNP, PDCD4, EBAG9, SELPLG, PPIP5K2, EML4, ITSN2, TRIP11, RPL38, ABI1, WAPL, HERC5, ANKRD36B, RIPOR2, RBM5, CTSA, TROVE2, ZNF92, NUGGC, NAA20, MON2, PIM1, MRPS34, RNPS1, CPSF6, ARID4B, SNHG25, RPL27A, PDIA4, ERP44, LMO4, OXR1, TMEM208, BLOC1S6, CDC16, NEMF, B4GALT1, AP3D1, CTSD, SPEN, MALAT1, FKBP1A, MT-ND3, UBE2L3, SOD1, AC016745.2, MRPL22, SRSF7, ACAA1, MTRNR2L8, CTSH, TMED3, RPS10, BMS1, APOL1, PNKD, KMT2A, SRPRB, NDUFS8, THOC2, ARID5B, C1orf43, DLG1, TLN1, APOL6, GON4L, SRA1, CEBPZ, MCL1, SF3B2, PIGT, TRANK1, RASA2, C19orf53, UAP1, GSDMD, ARHGAP15, CLPTM1, ARPP19, TFRC, TAP1, NDUFA9, SEMA4A, TMCO1, AP1G1, MRPL57, UQCRC1, EMC3, PAICS, S100A11, MSL3, CRIP1, PSMD2, ZNF37A, DAPP1, VSIR, SDHB, TIMM17B, LLPH, CLIP1, CTSS, RABGAP1L, ITGB1, ZDHHC12, CCT5, PRMT1, NOL8, VPS4B, CHST2, IFI44L, FDPS, HLA-A, VDAC3, MFF, CCT8, ETFA, TRAPPC1, TMEM14B, YWHAQ, CDK17, UQCRC2, MAP3K2, MRPS11, ARPC5L, PSMC4, IFITM1, DBI, PTK2B, PMPCB, HNRNPH3, MRPS7, RAB14, TARSL2, CLEC2D, ATP5F1E, XRN2, DAZAP2, POLR2K, NIN, PSMA4, CHMP2A, CHCHD1, WDR83OS, MRPL55, OXA1L, BUD31, RAD21, ANAPC11, LAMTOR5, PSMA7, GLO1, IMMT, CALR, RPL8, NPC2, GTF3C6, PSMD4, DPM2, AC103591.3, DUSP5, MUC20-OT1, MPC1, LDHB, THOC7, ARL6IP5, CCT7, MRPL40, PHF3, VAMP8, MEF2A, MAPRE1, CCT4, PTGES3, SNRPC, GLRX5, NUDT22, CLPP, POLR1D, SNRPB, RPL13, GMPPB, TSEN15, BAK1, HLA-C, DDT, EMC4, YBX3, CD47, C19orf24, C1D, RAC1, NDUFV2, NUDC, RBMX, RAP1B, FAM173A, UBE2I, CCDC167, SRI, HNRNPF, IRF1, ALKBH7, PRDX2, HADHA, PUM1, PSMA1, TMEM30A, ACADM, DECR1, HSPD1, SSBP1, TNFRSF13B, RAN, MRPL12, SNRPE, NUCB2, SAP18, TKT, IFNG-AS1, DESI1, GNB2, ATP5PO, PLP2, BLOC1S1, SRSF9, TRIR, EZR, SUCLG1, ERAP2, DNAJC4, SF3B6, XAF1, FUCA2, MT-ND2, ZBTB8OS, SLC25A4, CIRBP, SMC1A, HNRNPAB, RPL7A, SRSF3, BRK1, PSMB6, SLC38A5, RPS27, RPS26, PTP4A2, HARS, MRPS23, SARS, RNF114, LGALS1, ECH1, B3GAT3, LITAF, GNAI2, RPS21, TMED2, UBN1, ECHS1, MRPL3, GRK6, CYB561D2, ATF4, HIST1H1E, SLC25A5, ISOC2, CCT3, GABARAPL2, SNRPG, ATF5, KRAS, RNASEH1, PSMB3, TMPO, MRPL43, SH3BGRL3, SLC1A4, ALG14, SPTLC1, NUDT5, NT5C, EIF5A, MIA2, HSP90AA1, CD79A, RPL37A, ZMYND8, TUBA4A, SIVA1, PKM, VPS51, JTB, RPL19, MRPL37, S100A8, ENO1, MAF1, BANF1, GLIPR1, RALA, POLR2C, 09-Sep, HSPE1, ITGAE, CYCS, FLNA, MRPL51, ATP5MC1, ANKRD39, ATXN10, FAM177A1, H1FX, CASP7, PBX2, ZMPSTE24, PDCD10, AP2S1, HIST1H4C, CKS2, RANBP1, MRPL4, AP3S1, ATF6, LGALS3, CNIH1, HIST1H1D, BABAM1, RAB7A, SLC25A39, SMIM12, ACTR10, CANX, RPS29, NAA15, LSM4, ARHGDIB, EFHD2, HMGB2, POLE4, CHMP2B, H2AFZ, CD99, RPS14, PPP6R3, RASAL3, ANXA11, RPS27A, ZBTB20, SNRPA1, ATG4A, FAM96A, POP4, HLA-DRA, APIP, RPL18A, SPAG7, POLR2G, CEP63, NAMPT, AIFM2, ATIC, CDC25B, NUDT1, LYZ, NFYC, DNAJC2, SLC25A3, FABP5, JUND, UBE2S, CFL1, ATP5F1A, MMP24OS, HDGF, PSMG2, EIF3K, SUMO2, RPS12, DAPK3, SBDS, RPL32, CTBP1, MCRIP2, DUS1L, ARL14EP, HMGN2, ALDH3A2, UBE2M, PTMA, ELAC2, HLA-DQA1, RPS5, ECI1, RPS3A, PSME2, DNAJC19, COA6, CSRP1, GAPDH, STX11, OSTM1, TINF2, G6PD, TUBA1B, LINC01480, DFFA, ADK, NUDT16L1, RPS2, B4GALT7, VPS4A, UBE2E1, PITPNA, RPS3, ABHD14B, STK38L, SOD2, KPNA2, SHLD2, KIAA1143, APOBEC3G, TACC1, PFDN2, CLNS1A, TSPO, FTL, CD74, TPI1, SNHG15, RAB27A, S100A10, NIFK, MDFIC, FGD5-AS1, APRT, NFKBIA, SRSF8, MYBL2, GSTP1, SRM, GSTZ1, CMTM6, LDHA, IFRD2, RHOQ, KLF6, PPOX, HLA-DPB1, TIMM50, PRPSAP1, ACTB, PPP1R18, EDF1, NEDD9, STX10, STK25, DDAH2, BTF3, CALM1, RPL29, RPL18, TNFAIP3, EEF2, RPL30, CEBPG, SRGN, CYBB, RPS23, MYO1F, RPL15, EIF1, RPS4Y1, UBE2J1, RPL6, HSPA8, MBD2, DAD1, ADSS, RACK1, FAU, GLUD1, ACTG1, DEDD2, RPS13, COTL1, ATP5MC3, HLA-DPA1		gene expression	enriched	PB_1 cluster/cluster 13 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI27, IFITM3, IFI44L, JCHAIN, LY6E, CLU, IFI6, SIGLEC1, TYMP, RPS3A, RPLP1, EPSTI1, TMEM176B, MT-ND3, TPT1, RPL10, IFITM2, RPL7, RPS24, RPL23, EEF1A1, LMNA, HIST1H1E, RPL9, IFI44, TMEM176A, RPL21, RPS27, RPL27A, APOBEC3A, RPL5, RPS14, RPL15, PLAC8, MT2A, CD63, MX1, RPL13, RPL29, RPS27A, RNASE2, UBA52, RPS11, RPL6, ACTB, RPS2, HLA-C, XIST, ISG15, EMP1, TIMP1, RPL23A, RPS8, HIF1A, ID2, RPS13, SH3BGRL3, TNNT1, EEF1B2, RPL7A, RPS26, RPL13A, BRI3, CTSD, CFL1, CFD, SELL, OAS3, HBEGF, RPS4Y1, HIST1H1D, RPL3, OASL, MIDN, XAF1, RPL38, MT-ND2, MAP3K8, TOMM7, SPI1, DUSP2, RPS6, IRF7, RPL4, HLA-DPB1, RPS20, PSME2, ZBTB43, RPL27, NKG7, ZFAS1, EEF2, KLF10, TPM3, GRN, CD14, RNF213, S100A10, MAFB, MTRNR2L1, DDX3Y, EIF2AK2, RPL10A, PPDPF, TXNIP, STAT1, HLA-DQA2, EIF3L, RPLP0, NAMPT, HIST1H1C, GBP1, TLE3, IFIT3, PLAUR, DNTTIP2, NAPA, EAF1, BLVRA, NAP1L1, CYP27A1, MIR22HG, LGALS1, AC020656.1, AC007952.4, RGCC, G0S2, EIF3E, PKM, EIF4B, JAML, GRASP, PLSCR1, EMP3, ID1, LILRB2, S100A8, PARP14, TPM4, SAMD9L, CBX6, SLC11A1, BST2, FCGR1A, MBOAT7, SEC11A, MT-ND4L, HLA-DPA1, UBE2L6, EGR1, GIMAP7, ADAR, SECTM1, KLF4, SPAG9, FMNL1, AFF4, RBP7, CEBPB, CSRNP1, H2AFJ, CTNNB1, UPP1, MXD1, EIF5A, TRA2B, OAS1, P2RY13, SAMSN1, RSRC2, KCTD12, H1FX, CCR2, CR1, SNHG8, MX2, ACSL1, FRAT2, CYP1B1, TRIM22, CD36, ETS2, S100A9, ALDH1A1, HLA-DRA, HNMT, IL13RA1, LSM6, SLC25A37, NR4A1, CD300E, IER3, WARS, LGALS2, AC103591.3, CXCL2, KIAA1551, CCL3, SGK1, RETN		gene expression	enriched	C MONO_1 cluster/cluster 3 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	MX1, RPL10, IFI44, HIST1H1E, IFI44L, MIR4435-2HG, EPSTI1, IFI6, EIF2AK2, RPLP1, XAF1, SMCHD1, RPS27A, SP100, YWHAE, OAS1, RPS14, HNRNPU, MT-ND3, PAXBP1, IFITM3, HBB, OAS3, SPATS2L, HERC5, KLF2, STAT1, RPL23A, IFI27, USP18, TYMP, HIST1H1C, MX2, IRF7, SMC1A, PRPF4B, PLSCR1, CCZ1, ISG15, ADAR, RRBP1, HSPD1, HIST1H1D, LAP3, ACADVL, RPL13A, LGALS1, DDX11, IFIT3, HIST2H2AC, EIF5A, ZFC3H1, IFITM1, HIST1H1B, MCM4, ANKRD36C, LY6E, KLRB1, DDX21, XIST, FBXO5, RNF213, CTSB, KNL1, N4BP2, ARL4C, TPR, NRGN, SAMD9L, TIMP1, SELL, SFPQ, HCST, BST2, CD160, MAFF, HOPX, RPL27A, JUNB, HIST1H2AC, SRRM2, TYMS, MKI67, LAIR2, MBP, CD81, ISG20, H1FX, MYOM2, AREG, CTSZ, CMC1, HLA-DPB1, CCL4, GIMAP7, PLCG2, AKR1C3, MT2A, PMAIP1, MATK, S100A8, HLA-DRB1, ZNF22, FCGR3A, TOP2A, ASPM, PDCD4, FGFBP2, GRN, PRSS23, CLIC3, PSMB8-AS1, DOK2, TSTD1, TRAF3IP3, RPS4Y1, GZMM, APLP2, ZFAS1		gene expression	enriched	BASO cluster/cluster 20 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI44L, LY6E, ISG15, XAF1, MX1, IFI27, PIM3, EPSTI1, ISG20, EIF2AK2, IFI44, B2M, HLA-DQA2, STAT1, BST2, MT-ND3, USP18, HLA-B, HLA-A, SAMD9L, PARP14, PPP1R14B, RPLP0, RPS11, ZFP36L2, PLSCR1, HLA-DRB5, MT-ND1, VIM, MX2, OAS2, SP110, IFI16, HLA-DRB1, COX5A, UBE2L6, TYMP, NPC2, LGALS9, RPS14, PTMA, ADAR, MT-CO1, RPS18, HLA-C, MNDA, HLA-E, HSH2D, HERC5, TCL1A, ANXA5, FCHSD2, HIST1H1E, PARP9, TNFSF10, LAP3, FCER1G, OAS1, CAPN2, IFITM2, PLA2G16, H3F3B, BRI3, DDX60, GNAS, HESX1, UBE2E3, C12orf75, TRIM22, CD38, CCDC50, SP100, JUND, IFI6, SEC61B, MS4A6A, IFI35, RPL23, VEGFB, SRGN, PYCARD, S100A8, HIST1H1C, PHF11, CLIC3, SPATS2L, NT5C3A, S100A9, RPS20, SAMD9, HLA-F, C19orf66, DRAP1, LGMN, MYADM, TXNIP, GALNT2, FXYD5, HIST1H2AC, NAPA, HIST1H1D, STAT2, GZMB, DDIT4, GLUL, SELL, MIF4GD, TAGLN2, PLXNA4, TAP1, CLEC2B, SH3BGRL, NMI, DUSP22, PTCRA, ARL4C, SLC20A1, AC020916.1, PDIA6, TSC22D1, PSMB9, CD4, RGS1, CTSH, TBC1D4, ZNRF2, IDS, DUSP5, CUEDC1, PTPRE, DNAJC15, MYBL2, GUK1, CYP46A1, MGLL, PMEPA1, FCGRT, GLRX, SOX4, XRN1, RASD1, CRYM, CDK2AP2, TMEM8B, C12orf45, SLC1A5, ALCAM, HLA-DQA1, KDM6B, DRD4, C12orf57, S100A10, CD63, H1FX, RUBCN, GADD45B, SCT, TSPYL2, AL355075.4, ID1, CD52		gene expression	enriched	PDC cluster/cluster 10 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI27, IFITM3, JCHAIN, IFI44L, CLU, LY6E, TPT1, MT-ND3, SIGLEC1, IFI6, HIST1H1E, EPSTI1, RPL27A, TYMP, RPS3A, RPL21, RPL23, RPL7, IFI44, HLA-C, RPL10, RPLP1, MX1, HIST1H1C, RPS27, OASL, APOBEC3A, RPL38, MT2A, TMEM176B, RPL9, RPL23A, RPS26, HIF1A, XAF1, RPL34, RPL13A, RPL37, RPL6, RPL26, ISG15, CD63, RPS11, TMEM176A, TOMM7, RPL15, RPS27A, RPL5, ACTB, RPL3, EEF1A1, LGALS1, SAMSN1, EEF1B2, DNTTIP2, PDE4D, RPS20, IFITM2, RNASE2, PFN1, TNNT1, RPS2, RPL24, SH3BGRL3, G0S2, HIST1H1D, RNF213, RPS29, RPS14, IFIT3, NAPA, RPL37A, PSME2, XIST, CFL1, PPDPF, TPM3, HLA-DQA2, RPS6, BCLAF1, RSAD2, RPS4Y1, PSMB10, RPL10A, LMNA, PKM, IRF7, RNF19A, PSMB3, LST1, HBEGF, ID2, RPL4, DUSP1, SMCHD1, RPL31, MTRNR2L1, CTSD, SYNE2, BRI3, RRBP1, SP100, STAT1, SLC11A1, CEMIP2, BST2, EIF2AK2, MAP3K8, TIMP1, JUNB, FCGR1A, SERP1, MIR22HG, IFITM1, GAPDH, AC007952.4, PLSCR1, LDHA, TPM4, EML4, SLC25A36, IL32, DYNC1H1, GIMAP7, DDX3Y, AFF4, SMIM25, FGL2, ETS2, IER2, H1FX, LGALS2, UPP1, PIK3R1, S100A10, MXD1, TLE3, ZEB2, DDX21, EIF3L, CYP27A1, EMP3, PNPLA8, KLF4, S100A8, ZBTB43, RHOG, SELL, PLAUR, GIMAP1, PDE4B, SUPT16H, EZR, LGALS9, RHOB, GPRIN3, ALDH1A1, LTA4H, RPL36A, CTNNB1, CXCL2, PARP14, CEBPB, TUBA1A, RBP7, HNMT, LILRA5, BCL2A1, GBP1, AC245014.3, PLAC8, ZFP36L1, ETS1, TRA2B, AREG, NCF1, CFD, HLA-DPB1, MTRNR2L8, KCTD12, MAFB, TRGC2, DUSP2, HLA-DRB1, NAMPT, GZMH, CD14, HLA-DRA, VAMP5, HLA-DMB, S100A9, IER3, PTGDS, NKG7, AC103591.3, CTSW, CCL5, CD3G, GZMB, KLRB1, HLA-DPA1		gene expression	enriched	C MONO_2 cluster/cluster 16 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	JCHAIN, RPS3, RPS2, RPL13, RPS3A, RPL10, RPL3, RPS27A, RPS18, RPS14, MT-ND1, RPS12, RPL29, RPL21, RPL19, IFI44L, TXNIP, XAF1, RPS9, RPS19, TPT1, RPL23A, RPS23, RPS7, RPL7A, RPL34, RPL18, MX1, RPLP2, RPL11, MT-CYB, RPS6, RPL26, MT-ATP6, RPL10A, RPL13A, EEF1B2, EEF1A1, IFI6, RPL9, MT-ND3, EIF2AK2, RPS8, RPL18A, RPL27A, RPL7, NACA, MT-ND2, RPS20, HIST1H1E, RPLP1, RPS11, UBA52, MT-ND4, IER5, RPL4, RNF213, MT2A, SP100, NFKBIA, ETS1, TOMM7, MT-CO1, DUSP1, FOS, OAS1, ISG15, JUNB, JUND, IRF7, SYNE2, RPS5, EPSTI1, PIK3R1, SMCHD1, ISG20, HLA-DRB1, MBNL1, LY6E, SAMD9L, RPLP0, IL32, DDX6, RPS4Y1, PRPF4B, SAMSN1, PLSCR1, PARP9, CLEC2D, UTRN, STAT1, ADAR, SAMD9, RIPOR2, JUN, IER2, IFI16, SYTL3, HNRNPU, DDX24, LCP1, SERTAD1, MYBL1, SAMHD1, RPL23, TRIM22, MX2, SRRM2, RNF125, VPS13C, SF3B1, SAMD3, GZMB, BTN3A2, RBM39, HCLS1, RGCC, SLFN5, HIST1H1C, USP15, HOPX, HNRNPA3, DTX3L, IFITM2, ATM, TRGC2, ITGA4, SP110, PRF1, KIAA1551, ALOX5AP, MACF1, PLAC8, SYTL2, CEBPZ, XCL2, AKAP13, HNRNPH1, XIST, CTSW, ARID5B, SYNE1, FLNA, PRRC2C, WIPF1, BZW1, PARP8, IRF9, BTG2, MYADM, HIST1H1D, IFITM1, GNLY, PDE3B, SLFN12L, OASL, NDUFA13, PYHIN1, PDE4D, ZBP1, TNFAIP3, PTPN4, EPB41, DOCK8, IQGAP2, TYMP, DDX17, KTN1, CAPN2, RPS26, ELF1, MYO1F, SH2D2A, TRBC1, PARP14, TMEM123, ATG2A, OGA, BST2, KIAA1109, CD2, SELL, DOCK10, ATF7IP, CEMIP2, MTRNR2L8, GADD45B, PHF11, AKNA, MYH9, ARAP2, APOL6, EML4, N4BP1, IFI35, KLF3, S100A11, LTB, H1FX, IL7R, IFNG, KLRB1, KLRD1, GZMK		gene expression	enriched	CD8 cluster/cluster 2 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFITM3, IFI44L, LY6E, JCHAIN, MX1, XAF1, ISG15, IFI44, RPS14, RPS11, IFI27, IFI6, RPLP1, HLA-DRB5, RPS18, ISG20, EPSTI1, RPS12, IFITM2, STAT1, RPS3A, RPL13, RPL29, RPL23A, IRF7, RPS23, RPL10, RPL18A, HIST1H1E, HLA-DQA2, SP110, RPL27A, RPS20, RPS6, EIF2AK2, COX5A, PARP9, RPL7A, RPL13A, USP18, HLA-DRB1, OAS2, HLA-DPA1, B2M, RPL23, UBE2L6, RPS7, KLF10, RPS2, PPA1, RPS25, SAMD9L, RPL3, RPL24, BST2, MX2, LAP3, RPLP0, BRI3, CAP1, TYMP, RPL27, RPL7, PIM3, HLA-DPB1, RPL35, EEF1B2, MCL1, GMPR, PPP1R14B, PARP14, LCP1, TXNIP, PLAC8, ADAR, MAP2K2, HLA-B, PHF11, HNRNPA2B1, SMCHD1, CD164, RPL31, TPM3, IFIH1, PRPF4B, DRAP1, H3F3B, SHTN1, DDX21, TPM4, IFI16, NAPA, PLEK, HIST1H1D, MTRNR2L1, DDIT4, CNDP2, PTPRC, SRP14, MBD2, CALR, HSP90B1, HLA-DQA1, HLA-A, SEPHS2, HIST1H1C, HSDL2, PSME2, PDIA3, IFI27L2, TRIM22, PLSCR1, IFI35, EFHD2, 06-Sep, HSH2D, FCHSD2, HNRNPU, NAMPT, HSPA5, MEF2A, HNRNPC, SUB1, SPAG7, CHMP5, IRF8, RPL38, FNBP1, IDH3A, SAMD9, SSB, WAS, RHOA, SPATS2L, CACYBP, CD53, HCLS1, IER5, PSMA3, RPS26, CCDC6, DNAJA1, CAPN2, CDV3, SP100, TRA2B, NOP53, BID, CNN2, YWHAE, HSP90AA1, VMP1, DEK, HMOX1, STK17B, NDUFV2, C6orf48, C1orf21, EZR, FABP5, SELL, MNDA, SRP72, YBX3, TSPAN33, HDAC9, SRSF7, CEBPD, DDX3X, S100A11, TSC22D3, XIST, MTRNR2L8, BTG1, ZFP36, GPR183		gene expression	enriched	CDC1 cluster/cluster 24 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI44L, IFITM3, JCHAIN, MT-ND3, MX1, IFI6, XAF1, HIST1H1E, RPL27A, MT-ATP6, MT-CYB, RPL13A, RPL10, EPSTI1, MT-ND2, ALOX5AP, RPS3A, RPL3, HIST1H1C, GZMB, RPL21, IFI44, MT-ND1, HLA-C, RPS14, EIF2AK2, OAS1, MT-ND4, RPS27, RPS6, LY6E, RPL13, TPT1, IFITM1, IRF7, RPS20, ISG15, CEMIP2, MX2, MT-CO1, MT2A, RPS18, ISG20, RPL23A, AREG, HLA-DRB1, RPL7, PDE4D, GIMAP7, SYTL3, RPL38, RPL9, IL32, HIST1H1D, RPLP2, RPL37A, STAT1, RPL27, TYMP, RPS11, LAIR2, PRF1, SAMD9L, XIST, PLSCR1, HLA-DPA1, KLRB1, EEF1B2, MT-ND5, GAPDH, PIK3R1, OAS2, ATG2A, RNF213, LGALS1, PARP9, SMCHD1, KLRC1, SP100, CTSW, IRF9, CD52, BST2, ADAR, RPS9, PRKX, MTRNR2L8, LGALS9, SLA2, GNLY, ETS1, SH2D2A, H1FX, CD38, MYOM2, PSME2, CD74, IFITM2, SEC14L1, ITGA4, FOSB, CD79B, TCIRG1, SP110, CREM, TRIM22, MIR4435-2HG, SAMD9, HLA-DPB1, MAP3K8, ZBP1, RPS4Y1, PRPF4B, FBXO7, PSMB10, TOMM7, CAPN2, USP15, SYAP1, SYNE2, IFI35, TXNIP, UTRN, FLNA, HNRNPU, S100A10, RAB5IF, PTGDS, FXYD5, ARID5B, UBE2L6, DDX6, GNAS, STAT3, EML4, CCL4, TGFB1, TAP1, JUNB, SRRM2, TMEM123, PPDPF, OGA, RPL23, DTX3L, TRA2B, SELL, TSPYL2, ZBTB1, HSH2D, SETX, CEBPB, HSPA5, CLIC3, ATF7IP, HMGB2, CD160, SFPQ, GZMH, MT-ND4L, CCND2, TNFAIP3, PARP14, IFI16, S100A11, PTGDR, TUBA1B, PMAIP1, CALR, ZFP36, LYZ, IER5, PLEKHF1, BAX, COQ7, NFKBIA		gene expression	enriched	NK cluster/cluster 1 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	JCHAIN, IFI27, RPL10, HLA-DPA1, HLA-DPB1, TPT1, IFITM3, MZB1, RPS27, RPS2, HSP90B1, RPL21, RPS3A, RPS24, CST3, EEF1A1, RPL30, RPS27A, RPL13, RPL26, RPL11, HLA-DRB5, RPL34, RPS14, RPS20, RPS18, RPL29, PFDN5, RPS9, HIF1A, UBA52, CD63, RPL24, RPL37, MT-ND3, RPL23A, RPS12, RPL5, TOMM7, NACA, RPL12, RPL19, RPL9, RGS2, RPL38, RPS6, MALAT1, APOBEC3A, RPL37A, TMEM154, RPL13A, RPL27, RPL4, RPS16, LY6E, CDKN1C, RPL6, FCGR3A, CALM2, RPS29, RPL14, RPL8, EEF1B2, FGL2, SMIM25, SUB1, TMA7, HMGB2, JUNB, HLA-DRA, AIF1, TYROBP, ISG15, RPL10A, SNHG25, RPS23, IFI6, RPL23, SELL, RPL18, NAP1L1, C1orf162, SNHG8, MAP3K8, CTSS, CTSD, PER1, COMMD6, RPL22, WASF2, MT2A, GLRX, RPS3, DUSP6, RPL27A, NDUFB2, CPVL, FOSB, NAMPT, ATF4, RPL3, CXCL8, P4HB, CARD16, CASP1, XIST, RPL31, HSPA5, CSF1R, UBALD2, CYBB, BTG1, HMGN1, TNFRSF1B, IL1B, XAF1, ZBTB7A, ARRB2, PLAC8, UQCRH, LDHA, LYST, RNF213, TRABD, EIF3H, C5AR1, PPIB, CALM3, SDCBP, FCGR2A, IFNGR1, ANXA1, OSBPL8, LIMD2, EVI2B, AHNAK, SRSF10, PLCG2, SLC25A6, SF3B1, IRF7, SPCS1, GPX4, CLEC7A, M6PR, POLR2J3.1, KLF4, SPCS3, CD164, HNRNPH3, MS4A7, PSMB1, MYL12B, FMNL1, LGALS3, SKAP2, RAC1, NAGK, PSME2, ARF6, HSPA8, OGT, H2AFZ, TUBA1B, CXCR4, MTDH, SSR4, AC103591.3, USP3, LTA4H, LAP3, LGALS1, EIF3E, SEC61G, EIF3L, GLUL, UQCRQ, CDKN2D, SPN, S100A9, SELPLG, ARF1, TYMP, S100A8		gene expression	enriched	GRAN cluster/cluster 9 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI27, IFITM3, IFI44L, IFI6, LY6E, RPS3A, RPL3, RPS18, RPS14, RPL13, RPLP1, RPS2, EEF1B2, TPT1, RPL9, EEF1A1, RPS6, RPS27A, RPL13A, RPL10, RPS11, RPS8, MX1, RPL27A, RPL23A, TYMP, RPL23, RPL7, RPS24, RPL7A, JCHAIN, IFITM2, RPL21, XAF1, RPL18A, RPLP0, EPSTI1, RPS16, RPS20, RPS23, RPL29, RPL6, RPL15, RPL10A, RPL5, RPS7, IFITM1, IFI44, RPS3, RPS12, ISG15, TOMM7, MT2A, RPL24, RPS26, HLA-DRB1, PLSCR1, IRF7, HLA-DQA2, RPL27, RPL37A, HLA-A, EIF2AK2, ACTB, RPS5, RPS27, PFN1, HIST1H1E, KLF10, RPS4Y1, EIF3L, IFIT3, RPL38, HLA-DPB1, MTRNR2L8, TPM3, SELL, RNF213, UBE2L6, ARPC1B, OAS2, RPL31, STAT1, MT-ND3, MX2, SAMD9L, CLEC10A, OAS3, HIF1A, BST2, HNRNPU, XIST, PARP9, SEC11A, PARP14, PSME2, NOP53, PDIA3, PPDPF, NAMPT, EIF3F, NAPA, RBM39, CUL1, EIF3E, AC020656.1, DDX3Y, PKM, LST1, CMPK2, LGALS9, PIM3, BRI3, CCND3, ZFAS1, MBOAT7, TRA2B, RHOG, SP110, LAP3, EIF5A, STK17B, CALR, HIST1H1D, HLA-DPA1, HIST1H1C, GLIPR2, ISG20, IFI35, TOB1, BATF3, PTP4A2, SAMHD1, HLA-DRB5, CCL3L1, SNHG8, CLK1, PSMB9, ADAR, HSP90B1, ZYX, JUN, ZFP36, MS4A6A, CD63, TIMP1, SAMD9, OAS1, SNHG15, SH3BP5, CTSD, DDIT4, FOS, GBP1, TPM4, H1FX, RNASE2, FCER1A, NEU1, HLA-DQA1, CFD, MAP3K8, HSPA5, ATF3, YBX3, AREG, GRASP, NEAT1, IER2, EREG, DUSP1, CCL3, S100A9, S100A8		gene expression	enriched	CDC2 cluster/cluster 5 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	RPS14, MT-CYB, RPL4, GBP4, RPL10, RPL3, IFI44L, NIFK-AS1, RPL7A, RPS27A, TPT1, JCHAIN, RPLP2, RPS3A, MALAT1, MTRNR2L12, RPS8, MBD2, AC133644.2, CCDC167, EXOSC6, YIPF6, RPL13A, MT-ND3, HAPLN3, ANXA1, HSP90AB1, OAZ2, RPL19, CNBD2, MKRN2, ACTR6, SIAH2, GTF2B, RPS2, RPS20, CYSLTR1, SRSF5, MT-CO1, PTMA, LRRC59, CCND3, IFIH1, RPS6, RGS1, LPAR6, IFI27, DDX5, EEF1D, FAM50A, PFDN5, RPS3, GBP5, OASL, RNGTT, TRA2B, ST8SIA4, RPL10A, ADAR, RPL21, HNRNPDL, ACAP1, RIPOR2, PPCS, SH3YL1, TAP1, XAF1, HIGD2A, H3F3A, MOB4, RPS11, CCT4, RPS4X, BCL2, IFITM1, FOXO1, RPS18, KLF2, FTL, TXNIP, ARGLU1, H3F3B, CYTOR, MRPL21, CTDNEP1, PYCR2, ARL4C, ATP5MG, ATP2B1, SMAD3, RPL27, PSMB9, UBTF, PAK2, METTL26, LAMTOR5, RGCC, DECR1, S100A9, DCPS, TXN, ILF3-DT, SELL, NDUFS6, SLTM, SH3BGRL3, SELENOT, RPL5, BRD7, PRKCSH, UBA52, SVIP, SRGN, TMEM123, IDH2, ATP5PF, NCBP2-AS2, C11orf58, ACYP2, UXT, KLF6, HINT1, WASHC1, CDC42EP3, HMGN1, TNFAIP3, SRRM2, SDHC, IFIT2, GLRX3, ORAI1, STAT3, JUN, C19orf24, MYC, CEBPZ, FAS, ZCCHC7, IFITM3, PLGRKT, RNF114, GZMA, EIF3H, DUSP1, GBP2, TPP2, GNB1, YME1L1, HNRNPUL1, CDC26, EIF4A2, FAAP20, HLA-DPB1, SFXN1, SNHG25, TOMM7, SLC25A6, KLF9, PIM1, PPP1R2, RPL36A, RASGRP2, PNISR, SOCS3, GBP1, GLIPR1, TSPO, BTN3A3, CWF19L2, LRPAP1, EIF3F, CASP4, CD3D, CHD2, IDS, LAPTM5, SPCS3, COX5B, SEPT7, PRDM2, FAM133B, ITM2A, PSMA3-AS1, ARHGAP15, CD82, CDKN2D, ATP5MPL, SDAD1, RAP1A, ANP32A, ACTG1, RPL27A, EPB41, NDUFA6, MDM4, SMG1, KRTCAP2, HSPE1, VSIR, IL7R, CD99, SATB1, NAE1, RBMX, STAU1, HNRNPH1, HNRNPH3, CDC25B, ARHGAP9, SLC4A1AP, RNASEH2C, DYNLL2, TRIR, SSU72, PCM1, NIPSNAP2, ZC3H7A, COMMD6, CD63, IFRD1, HNRNPL, ACTN4, NDUFA13, SUN2, KIF2A, PDE3B, ARPC2, HIST1H1E, PIK3IP1, BSG, ZFAND5, PFN1, TTC37, MAP3K1, YIPF4, TRIM44, PPP1R18, KMT2E, LAT, RAB8B, DNAJB1, PRMT2, CFDP1, TCF7, RORA, COL4A3BP, NMT1, PPP1R15A, MIF, SNRPA1, R3HDM2, ISG15, LAP3, TMEM173, ILF3, POLR2J, MZT2B, STK38, STK17B, RAB8A		gene expression	enriched	T_IFN cluster/cluster 18 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	HBA1, HBA2, HBB, ALAS2, AHSP, IFI27, SLC4A1, GABARAPL2, ATP5F1E, HBD, GUK1, GSPT1, UBB, GLRX5, MPP1, GMPR, ADIPOR1, WNK1, SELENBP1, RNF10, ISCU, NCOA4, ANP32B, FTH1, YPEL3, BCL2L1, HBM, R3HDM4, OST4, FIS1, SIAH2, GYPB, DMTN, HAGH, CCNDBP1, TRIM58, PRDX2, HBQ1, EIF2AK1, RBM38, BLVRB, MAP1LC3B, SKP1, DCAF12, BSG, TERF2IP, EPB42, TALDO1, PRDX6, MARK3, PPP1CB, PIM1, TMOD1, MXI1, ODC1, SEC14L1, SNCA, HPS1, YBX3, CA1, PA2G4, FKBP8, KRT1, MAP2K3, WASF2, FOSB, POLR1D, EIF1B, CHPT1, MARCH8, RPIA, MICAL2, METTL9, NFE2, WDR45, FOS, ISCA1, MKRN1, FECH, RBX1, TESC, RAD23A, LPIN2, FAM210B, OAZ1, STMP1, HK1, CDC34, ASCC2, S100A9, JCHAIN, ANKRD9, SMIM1, MTRNR2L12, SMOX, SELENOK, PNP, VTI1B, SLC25A37, DCUN1D1, NPRL3, ANK1, H2AFJ, S100A8, TUBB2A, EMC3, CDKN2D, ACP1, UBXN6, UQCR11, TOP1, ARF1, UBA52, DDX5, HIST1H1C, ELOB, MARCH2, RPL29, LYL1, RPL36AL, SH3BGRL3, SLC25A39, PCGF5, PCBP2, RPL21, IFIT1B, OSBP2, KLF3, EEF1A1, RPL10, NEAT1, RPS28, RPS9, TSC22D3, RPL13, PABPC1, RPS3A, RPL12, UBC		gene expression	enriched	RBC cluster/cluster 17 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	HLA-DRB5, TXNIP, MT-ND3, ABCA6, MT-CO1, MT-CYB, MT-ATP6, RPS14, MT-CO3, HLA-DPA1, JCHAIN, IFI44L, BTG1, CD27, CCDC88A, MT-ND4, RPS7, MT-ND1, ACTG1, RPL6, RHOC, MT-ND2, XAF1, HLA-DRB1, HLA-A, TRAC, HSPA8, TSC22D3, MTRNR2L8, MX1, TRIM22, RGS1, HLA-DPB1, RPL4, EPSTI1, IFIT3, EIF2AK2, RGS10, SP100, UBE2M, EEF2, VOPP1, MBD2, ARL4C, IFI6, HLA-DQB1, MTRNR2L12, RAB11FIP1, LY6E, BIRC3, S100A4, RPS10, LINC00926, S100A6, DDX5, CYBB, TMEM123, TRA2B, TNFRSF13B, YPEL5, SRGN, HLA-C, ZFP36L2, GNAS, ISG15, ANXA2, TOMM7, BRK1, SMAP2, AHNAK, SMARCB1, LITAF, EIF3L, ISG20, AC007952.4, GABARAPL2, BANK1, ANXA11, MT-ATP8, GPR183, CLIC1, SMCHD1, RGS2, CLEC2D, RNH1, COTL1, RNF213, DYNLL1, SAMD9L, DDX24, MEF2C, AC245014.3, CXCR4, CCNL1, LGALS1, HIST1H1E, H3F3B, CYB561A3, GAPDH, STAT1, H1FX, LTB, HIST1H1C, HIST1H2AC, RHOB, PARP14, SRRM2, ADAR, PRPF4B, VIM, IFITM2, APLP2, S100A8, RIPOR2, MDM4, IRF7, MYC, TAPT1, MX2, FCHSD2, DDX21, MBNL1, UTRN, BCL7A, ETS1, REL, SP110, SAMD9, HIF1A, TCOF1, DDX6, HNRNPH1, COL19A1, TMEM156, IRF8, S100A9, P2RX5, ITPR1, SF3B1, CSNK1G3, ITGA4, EIF5A, USP15, PIK3IP1, SRSF10, TP53INP1, EIF1B, VPS13C, ILF3-DT, CD22, PPM1K, ATF7IP, BST2, SNHG9, SP140L, SELL, TYMP, ELF1, CNOT1, DUSP22, AFF3, TRA2A, PLCG2, MACF1, IL4R, LYST, IFI16, HSH2D, STK17A, ATP2B1, SNX29, ZNF92, ADAM28, JUN, COBLL1, NFKB2, CEMIP2, ASH1L, PAX5, CD69, CLK1, CDK12, MZB1, FOS		gene expression	enriched	B cluster/cluster 7 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI27, JCHAIN, IFITM3, RPL10, RPS27, RPL9, RPS2, TPT1, RPS18, RPS3A, TMSB10, RPS6, TMEM176B, HLA-DRB5, RPL27A, RPL13A, RPL13, RPL23A, EEF1B2, EEF1A1, RPL15, RPL3, HLA-DQA2, CD63, RPL10A, RPL21, RPL27, RPL18A, RPL23, RPS20, HIST1H1E, RPL34, MIDN, LY6E, RPL5, RPS9, HLA-DPB1, RPL7, RPS4X, RPL12, TNNT1, FMNL1, LILRB2, RPS11, HES4, NAMPT, RPL6, ELL2, RPL29, TMEM176A, TOMM7, APOBEC3A, KLF10, RPLP1, RPLP0, RPL4, PPDPF, FTH1, RPL38, RPS3, NEAT1, TPM3, RPS5, RPL35, MT2A, BLOC1S1, ZBTB7A, RPL37A, HLA-DPA1, IFITM1, IFI44L, MT-ND3, PIM3, HIST1H1D, ADM, MALAT1, CFD, GRASP, CYP4F22, LILRB1, SNHG15, GIMAP7, IFI6, ARF5, CDKN1A, MYO9B, ULK1, NFKBIA, ANXA4, CD48, TCIRG1, RPL31, TIMP1, S100A9, MTRNR2L1, CTSH, CCNL1, TRA2B, CTNNB1, AC020916.1, IFI30, NKG7, POLR2J3.1, MAP1LC3B, SLC43A2, MDM2, AFF4, LENG8, EPSTI1, SNHG8, FUS, EIF4G2, LSM6, CDKN2D, MAP3K8, FOXO3, ISG15, P2RY13, DYNLL1, EP300, ATF3, CCDC85B, RNF144B, CSRNP1, NFKBIZ, MIR22HG, BCLAF1, CSTB, TUBA1B, HLA-DRA, ANPEP, CTSD, KLF6, RSRC2, AC020656.1, TMC6, FAM45A, MNDA, CLK1, ZFP36, PIK3AP1, CXCL16, ATG2A, CREBRF, TACC1, CALM3, ADAM10, CPVL, RHOC, G0S2, SCGB3A1, C1QB, GLUL, CD300E, LILRA1, H1FX, XAF1, TNF, RPS27L, GNLY, ID2, JUN, C1QA, LYPD2, IL1B		gene expression	enriched	NC MONO cluster/cluster 4 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	JCHAIN, TPT1, MT-ND1, MT-ATP6, MT-ND3, RPL13A, TOMM7, IFI44L, MT-CYB, MT-ND2, RPS11, RPS20, ETS1, RPL27A, TXNIP, ANXA1, DUSP1, RIPOR2, MBNL1, RPS4Y1, IER5, HIST1H1E, BCL2, DDX6, SOCS3, RGCC, XIST, RPS26, TNFAIP3, RNF213, STK17B, SELL, XAF1, MYC, HNRNPU, TXK, TRA2B, SMCHD1, IL32, PRMT2, DDX24, EPB41, SFPQ, ARGLU1, CXCR4, SRRM2, PRRC2C, ARID5B, HNRNPH1, MTRNR2L12, STAT3, PIM1, ITGA4, ATM, PRPF4B, OXNAD1, MX1, PIK3IP1, LY6E, PDE3B, DDX21, NORAD, S100A4, IKZF1, IL6ST, LEF1, SATB1, SRGN, CYLD, NKTR, SAMHD1, NFKBIA, NFKBIZ, EIF2AK2, TNRC6B, MDM4, GPRIN3, CHD2, SYNE2, TRAT1, MTRNR2L8, LGALS1		gene expression	enriched	CD4 cluster/cluster 0 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	IFI27, IFITM3, CST7, JCHAIN, NCOA4, IFI6, PDZK1IP1, GNAS, TSPAN33, PTMA, LY6E, AC147651.1, TUBA4A, ITM2B, TMSB4X, MT-CO3, S100A8, DYNLL1, MYL12A, S100A9, CMPK2, ODC1, HCST, TAGLN2, IFI27L2, PF4, CAVIN2, AQP10, FTH1, GAPDH, HLA-E, NCK2, CA2, LGALSL, MT-CYB, PRKAR2B, ANAPC5, TMEM91, HEMGN, EVA1B, PDLIM1, OAZ1, HGD, VIM-AS1, EPSTI1, CDKN2D, TMEM158, KIFAP3, ACTG1, FTL, TIMP1, MLH3, PPBP, GNG11, CCDC88C, ARHGDIB, FHL1, HTATIP2, MMD, GP9, ILK, MYL6, IFITM2, RHOC, MIR4435-2HG, MT-ATP6, SMIM5, AMD1, PABPC1, MGAT4B, HIST1H1C, TPM1, C19orf33, TUBA1B, TMEM140, ITGB5, HIST1H2AC, CCL5, MT-ND1, ACTB, EIF1, CTDSPL, CFLAR, AP001189.1, TMSB10, RPS26, EIF2AK1, YPEL3, GPX4, PCMT1, RPS27, RPS18, ACTN1, BEX3, TUBA1C, RPS28, LIMS1, CST3, SUB1, CD99, HIST1H3H, RPL37, ZCCHC17, MPST, PTCRA, ADI1, CD9, UBXN11, PAIP2, EMC3, RPL36, MT-ND2, RPS24, ATP5MPL, GRAP2, HIST1H2BJ, SERF2, CLDN5, LY6G6F, MAP3K7CL, ATP2A3, DAPP1, RPS29, SLC40A1, UIMC1, RNF11, CAPN2, RPL41, CALD1, ISCU, UQCRH, RPL23A, SET, UQCR11, SQSTM1, TST, SEPT11, RPL37A, TSC22D3, TMEM50A, FCER1G, RPL39, JAK1, TACC3, RPS2, SVIP, MTPN, MTRNR2L8, MT-ND3, UBE2J1, UBC, CERS2, CYB5R3, AC090409.1, HSPB1, RPS19, RPL34, EPB41, ATP5F1E, C12orf76, CNPY3, SELP, CTSD, SMIM10L1, RPL15, RPL26, RPL28, CMIP, YBX3, FRMD3, GNAZ, NAP1L4, PLEK, AKIRIN2, ADD3, SPINT2, SRGN, CCDC92, RSU1, ARHGEF12, PLEKHO1, RPS13, YWHAH, RPL36AL, CD68, ANO6, RPS7, USF2, EGFL7, RPS8, NDUFB4, LCN2, GMFG, PARVB, STON2, RIOK3, RPS23, RPL10, INAFM2, GSN, RPS16, RPA1, SH3BGRL, RPL32, UCP2, UBE2B, STRAP, DERA, APP, PRDX5, SCN1B, RPL7A, H2AFJ, UXS1, MFSD1, RACK1, CENPT, RPL18A, ABTB1, PYCR2, RDH11, EID1, CXCL5, FHL2, RPL30, GAS2L1, RAB8A, NDUFA4, NENF, UBE2F, G3BP2, MORF4L1, HIST1H2AG, CRBN, HMG20B, DOK2, RPL8, MT-ATP8, ANKRD9, SEC14L1, RPS19BP1, VAPA, KCTD20, AP2S1, YBX1, TNNC2, UBE2E3, TXNIP, RAB4A, MYLK, PCP2, RPS25, YWHAE, CAMTA1, NDUFA5, HDGF, DAD1, RAB37, TAF10, UBAC2, ANP32B, VSIR, LYPLAL1, PDGFA, PTPN18, WASF2, FOS, TNFSF4, MAGED2, ENKUR, TAL1, RBM38, NT5M, RTN4, BCL2L1, RHEB		gene expression	enriched	PLATE_1 cluster/cluster 6 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Atlanta, Georgia, USA	23	94	years	12	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq; DEGs	JCHAIN, FOSB, IFI44L, MT-CYB, MT-ND3, MT-ND1, RPS18, RPL13, SP100, HIST1H1E, RPL13A, KLF6, RPS27A, IER5, RPL21, MT-ND2, XAF1, FOS, RPS3, RPL10, RPL27A, RNF213, JUN, RPS3A, NOP53, RPL9, UTRN, SYNE2, TOMM7, RPS6, TPT1, RACK1, MACF1, RPL32, RPS12, RPS26, RPS27, RPS8, RPS2, IER2, SAT1, RPL3, RPL4, RPL38, RPS19, PRRC2C, RPS9, MTRNR2L12, TXNIP, RPL6, SMCHD1, RPS23, XIST, IFI16, JUND, SUB1, RPS11, RPL11, GIMAP7, RPL12, BTG2, SMG1, RPL19, DUSP1, PRPF4B, RPS20, RPL27, GNLY, NR4A2, TRIM22, S100A6, PLCG2, VPS13C, SYNE1, EEF1B2, IDS, COX4I1, ADAR, RPL37A, ANKRD11, RPL23A, SRSF7, CD74, PPP1R15A, RPL29, EEF1D, GADD45B, RPL18A, UPF2, MYCBP2, USP15, DDX24, BIRC6, YWHAZ, ZFAND5, CCDC12, PARP14, ARAP2, DDX21, SCAF11, KLF2, SRRM1, CEMIP2, AC044849.1, NFKBIA, POLR2J3.1, CEP350, MYO1F, RPS14, RBBP6, KIAA1109, SLFN12L, ANKRD36C, USP34, TGOLN2, ITGAL, TAPBP, IQGAP2, AKAP9, CD69, ZNF292, SERBP1, YME1L1, ASH1L, INTS6, GZMB, SETX, TUT4, MTRNR2L8, MYBL1, DNAJA1, DIP2A, ACIN1, NPM1, GOLGA4, CNTRL, PIK3R1, KMT2C, ZFC3H1, TUBA1A, PARP8, BDP1, CYLD		gene expression	enriched	EOS cluster/cluster 12 from COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c	
	Amani 	Simranpreet	(2021-02-15)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients with IFN-B1 vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-15)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients without IFN-B1 vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients with corticosteriod vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients with corticosteriod vs COVID-19 patients without corticosteriod	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients without corticosteriod vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients with antiviral treatment vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients with antiviral treatment vs COVID-19 patients without antiviral treatment	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	plasmablasts of CD45 cells; effector CD8 T cells of CD8 T cells		cell type frequency	up	COVID-19 patients without antiviral treatment vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down	COVID-19 patients with IFN-B1 vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down	COVID-19 patients without IFN-B1 vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down	COVID-19 patients treated with corticosteriod vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down	COVID-19 patients with corticosteriod vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down	COVID-19 patients without corticosteriod vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down	COVID-19 patients with antiviral treatment vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down	COVID-19 patients without antiviral vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		Peripheral Blood Mononuclear Cells (PBMCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		protein/cytokine levels	down	COVID-19 patients with IFN-B1 vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		plasmacytoid dendritic cells (pDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pS6 (mTOR) 		protein/cytokine levels	down	COVID-19 patients without IFN-B1 vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		plasmacytoid dendritic cells (pDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pS6 (mTOR) 		protein/cytokine levels	down	COVID-19 patients with corticosteriod vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		plasmacytoid dendritic cells (pDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pS6 (mTOR) 		protein/cytokine levels	down	COVID-19 patients without corticosteriod vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		plasmacytoid dendritic cells (pDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pS6 (mTOR) 		protein/cytokine levels	down	COVID-19 patients with antiviral treatment vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		plasmacytoid dendritic cells (pDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pS6 (mTOR) 		protein/cytokine levels	down	COVID-19 patients without antiviral treatment vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		plasmacytoid dendritic cells (pDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	pS6 (mTOR) 		protein/cytokine levels	up	COVID-19 patients without antiviral treamtnet vs COVID-19 patients with antiviral treatment	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IKBalpha		protein/cytokine levels	down	COVID-19 patients with antiviral treatment vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IKBalpha		protein/cytokine levels	down	COVID-19 patients without antiviral treatment vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IKBalpha		protein/cytokine levels	down	COVID-19 patients treated with corticosteriod vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IKBalpha		protein/cytokine levels	down	COVID-19 patients without corticosteriod vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IKBalpha		protein/cytokine levels	down	COVID-19 patients with IFN-B1 treatment vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Hong Kong, China	18	80	years		myeloid dendritic cells (mDCs)		ex-vivo stimulation of PBMCs; intracellular staining assay; flow cytometry	IKBalpha		protein/cytokine levels	down	COVID-19 patients without IFN-B1 vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 		(2021-02-16)	Atlanta, Georgia, USA	23	94	years	31	CD3- CD20- CD56- HLA-DR+ CD14+ CD16-/+ monocytes		flow cytometry of peripheral blood leukocytes ex vivo stimulated with bacterial cocktail (Pam3CSK14, LPS, & Flagellin)	IL-1B CD14+ monocytes; TNF-alpha CD14+ monocytes; IL-6 CD14+ monocytes; IL-6+ TNF+ CD14+ monocytes		cell type frequency	down	COVID-19 infected patients in response to bacterial cocktail (Pam3CSK14, LPS, & Flagellin) vs healthy in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin)	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S5.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-Shows % of CD14+ monocytes producing cytokines. healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". 	
	Amani 		(2021-02-16)	Atlanta, Georgia, USA	23	94	years	31	CD3- CD20- CD56- HLA-DR+ CD14+ CD16-/+ monocytes		flow cytometry of peripheral blood leukocytes ex vivo stimulated with viral cocktail (polyIC + R848)	IL-1B CD14+ monocytes; TNF-alpha CD14+ monocytes; IL-6 CD14+ monocytes; IL-6+ TNF+ CD14+ monocytes; MCP-1 CD14+ monocytes		cell type frequency	down	COVID-19 infected patients in response to viral cocktail (polyIC + R848) vs healthy in response to viral cocktail (polyIC + R848).	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S5.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-Shows % of CD14+ monocytes producing cytokines. healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". 	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	23	94	years	30	plasma		Olink multiplex inflammation panel; NPX	HGF		protein/cytokine levels	up	ICU COVID-19 patients vs severe COVID-19 patients  	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S6b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care." 	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	23	94	years	16	plasma		Olink multiplex inflammation panel; NPX	HGF, 4E-BP1		protein/cytokine levels	up	ICU COVID-19 patients vs moderate COVID-19 patients  	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S6b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care." 	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	23	94	years	22	plasma		Olink multiplex inflammation panel; NPX	HGF, 4E-BP1, CXCL10, CXCL5		protein/cytokine levels	up	moderate COVID-19 patients vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S6b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	23	94	years	37	plasma		ELISA	EN-RAGE, OSM, TNFSF14		protein/cytokine levels	up	ICU COVID-19 patients vs severe COVID-19 patients  	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care." 	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	23	94	years	37	plasma		ELISA	EN-RAGE, OSM, TNFSF14		protein/cytokine levels	up	ICU COVID-19 patients vs moderate COVID-19 patients  	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	23	94	years	37	plasma		ELISA	EN-RAGE, OSM		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	23	94	years	55	plasma		ELISA	OSM		protein/cytokine levels	up	moderate COVID-19 patients vs healthy 	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD4; CD28		antibody response 	up	Clusters 0, 10-11, 16, 18, 21, 23 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1		
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD4; CD28		antibody response 	down	Clusters 1-9, 12-15, 17, 19-20, 22, 24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD19; CD20		antibody response 	up	Clusters 7, 9, 21 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD19; CD20		antibody response 	down	Clusters 0-6, 10-20, 22-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD8; CD56		antibody response 	up	Clusters 2, 7, 9, 16 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD8; CD56		antibody response 	down	Clusters 0-1, 3-6, 10-15, 17-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD69; CD95		antibody response 	up	Clusters 3, 6, 11, 14, 16 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD69; CD95		antibody response 	down	Clusters 0-2, 4-5, 7-10, 12-13, 15, 17-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD3; CD94; CD127; CD197; CD45RA		antibody response 	up	Clusters 0, 2, 12, 16, 18, 20-23 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD3; CD94; CD127; CD197; CD45RA		antibody response 	down	Clusters 1, 3-11, 13-15, 17, 19, 24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD34; TCRa7		antibody response 	up	Clusters 2, 9, 18-19, 21 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD34; TCRa7		antibody response 	down	Clusters 0-1, 2-7, 10-17, 20, 22-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD33; CD86; CD11c		antibody response 	up	Clusters 3-5, 11, 16, 21 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD33; CD86; CD11c		antibody response 	down	Clusters 0-2, 6-10, 12-15, 17-20, 22-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CDC1c-BDCA1; FCER1a		antibody response 	up	Clusters 5, 7, 14, 17, 21-22 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CDC1c-BDCA1; FCER1a		antibody response 	down	Clusters 0-4, 6, 9-13, 15-16, 19-20, 23-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	isotype 2; isotype 3; isotype 4		antibody response 	up	Clusters 0, 2-4, 9, 14, 22 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	isotype 2; isotype 3; isotype 4		antibody response 	down	Clusters 1, 5-7, 10-13, 15-21, 23-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD25; CD45RO		antibody response 	up	Clusters 0, 3, 11, 16 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD25; CD45RO		antibody response 	down	Clusters 1-2, 4-10, 12-15, 17-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	isotype 1; anti		antibody response 	up	Clusters 0, 2, 9, 14, 17, 22 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	isotype 1; anti		antibody response 	down	Clusters 1, 3-7, 10-13, 15-16, 18-21, 23-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	HLA		antibody response 	up	Clusters 3-5, 7, 10, 15-16, 21 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	HLA		antibody response 	down	Clusters 0-2, 6, 9, 11-14, 17-20, 22-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD14		antibody response 	up	Clusters 3, 11, 16, 22 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD14		antibody response 	down	Clusters 0-2, 4-10, 12-15, 17-21, 23-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD16		antibody response 	up	Clusters 1, 4, 21 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD16		antibody response 	down	Clusters 0, 2-3, 5-20, 22-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	TCRgd; CD274-PD		antibody response 	up	Clusters 9, 14, 17, 22 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	TCRgd; CD274-PD		antibody response 	down	Clusters 0-8, 10-13, 15-16, 18-21, 23-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD25; CD163		antibody response 	up	Clusters 11 & 22 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD25; CD163		antibody response 	down	Clusters 0-10, 12-21, 23-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD370-CLEC9A		antibody response 	up	Clusters 18 & 21 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD370-CLEC9A		antibody response 	down	Clusters 0-17, 19-20, 22-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD38		antibody response 	up	Clusters 1, 11, 13, 15-16, 20 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Atlanta, Georgia, USA	47	75	years	7	Peripheral Blood Mononuclear Cells (PBMCs)		CITE-seq	CD38		antibody response 	down	Clusters 0, 2-10, 12, 14, 17-19, 21-24 from COVID-19 patients	time of clinical onset	2 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental	
	Amani 	Simranpreet	(2021-02-16)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, ABTB2, TRIM14, FAM111A, GBP4, GCH1, GBP2, CASP4, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, PSME2, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, TAP1, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2,EHD4, IL1RN, CCNYL1, HK2, TMEM140, CLIC4, CD86, PIK3AP1, TIPARP, TLK2, ATP10A, SLFN5, NLRC5, PPA1		gene expression	up	5 days vs 0 days	time of symptoms	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs.Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-16)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	RBM43, CD274, P2RY14, BBX, AIDA, PCGF5, PYHIN1, GBP5, DCK, SLFN5, TLK2, NR4A3, CD69, TMEM140, MAX, NAMPT, CCRL2		gene expression	down	5 days vs 0 days	time of symptoms	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs.Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-16)	Moderate COVID-19 Patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, TRIM25, VCPIP1, ANKFY1, TRIM14, FAM111A, GBP4, GCH1, GBP2, CASP4, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, PSME2, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, TAP1, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2, EHD4, IL1RN, TMEM140, TLK2, ATP10A, NLRC5, PPA1, MAX, CD69, NR4A3, TLK2, BBX, AIDA, PCGF5, PYHIN1, GBP5		gene expression	up	10 days vs 0 days	time of symptoms	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-16)	Moderate COVID-19 Patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	RBM43, P2RY14, DCK, NAMPT, CCRL2, HK2, CCNYL1, CLIC4, CD86, PIK3AP1, TIPARP		gene expression	down	10 days vs 0 days	time of symptoms	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-16)	Moderate COVID-19 Patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, BST2, IFITM3, OAS2, PARP9, CNP, IFI35, IRF7, PLSCR1, FAM111A, GCH1, GBP2, CASP4, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, PSME2, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, TAP1, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, SLFN5, PPA1, MAX, CD69, BBX, PYHIN1, GBP5, DCK, RBM43, P2RY14		gene expression	up	5 days vs 0 days	time of symptoms	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-16)	Moderate COVID-19 Patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	NAMPT, CCRL2, HK2, CCNYL1, CLIC4, CD86, PIK3AP1, TIPARP, DTX3L, STAT2, ADAR, OAS3, CNP, PML, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, TRIM14, GCH1, GBP2, CASP4, TRAFD1, UBE2L6, USP25, ZNFX1, CCRL2, EHD4, IL1RN, TMEM140, NR4A3, TLK2, ATP10A, NLRC5, CD69, AIDA, PCGF5		gene expression	down	5 days vs 0 days	time of symptoms	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-16)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, ABTB2, TRIM14, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2, EHD4, IL1RN, CCNYL1, HK2, TMEM140, CD86, TIPARP, TLK2, ATP10A, PPA1, NAMPT, CCRL2, MAX, NR4A3, FAM111A, GBP4, GCH1, GBP2, CASP4		gene expression	down	15 days vs 0 days	time of symptoms	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-16)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	RBM43, CD274, P2RY14, BBX, AIDA, PCGF5, PYHIN1, GBP5, DCK, SLFN5, TLK2, NR4A3, CD69, MAX, VCPIP1, FAM111A, GBP4, GCH1, GBP2, CASP4, PHF11, PSME2, TAP1, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, USP25, CLIC4, PIK3AP1, TIPARP, CD69, ATP10A, NLRC5, SLFN5, PPA1		gene expression	up	15 days vs 0 days	time of symptoms	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-16)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	RBM43, CD274, BBX, AIDA, PCGF5, PYHIN1, GBP5, DCK, SLFN5, TLK2, NR4A3, CD69, FAM111A, GBP4, GCH1, PHF11, PSME2, TAP1, PPM1K, ISG20, ZBP1, XRN1, HSH2D, USP25, PIK3AP1, TIPARP, ATP10A, NLRC5, PPA2, PARP12, NAMPT, CCNYL1, CD86		gene expression	up	10 days vs 0 days	time of symptoms	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-16)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, TRIM14, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, ABTB2, FAM111A, GBP4, GBP3, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2, EHD4, IL1RN, HK2, TMEM140, TIPARP, PPA1, NAMPT, MAX, GCH1, GBP2, CASP4, PSME2, CLIC4, P2RY14, RBM43		gene expression	down	10 days vs 0 days	time of clinical onset	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-18)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PYHIN1, DCK, NR4A3, CD69, PIK3AP1, TIPARP, PPA2, NAMPT, CCNYL1, CD86, LGALS9, VCPIP1, ABTB2, TRIM14, CCRL2, EHD4, IL1RN, HK2 		gene expression	up	20 days vs 0 days	time of clinical onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-18)	Severe COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, OGFR, SELL, TRIM25, ANKFY1, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, FAM111A, GBP4, GBP3, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, TMEM140, PPA1, MAX, GCH1, GBP2, CASP4, PSME2, CLIC4, P2RY14, RBM43, TAP1, PARP12, XRN1, HSH2D, TLK2, ATP10A, NLRC5, SLFN5, PCGF5, GBP5, AIDA, BBX, P2RY14, CD274		gene expression	down	20 days vs 0 days	time of clinical onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PYHIN1, DCK, PPA2, FAM111A, GBP4, GBP2, GCH1, CASP4, TRAFD1, RTP4, PHF11, TRIM21, GPB3, MAX, TMEM140, TLK2, SLFN5, GBP5, AIDA, PPA1, CD274, RBM43		gene expression	up	20 days vs 0 days	time of clinical onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, OGFR, SELL, TRIM25, ANKFY1, CXCL10, NMI, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, PSME2, CLIC4, P2RY14, TAP1, PARP12, XRN1, HSH2D, ATP10A, NLRC5, PCGF5, BBX, P2RY14, LGALS9, VCPIP1, ABTB2, TRIM14, CCNYL1, CD86, EHD4, IL1RN, HK2, NR4A3, CD69, PIK3AP1, TIPARP		gene expression	down	20 days vs 0 days	time of clinical onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-18)	Moderate COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PYHIN1, DCK, NR4A3, CD69, PIK3AP1, TIPARP, PPA2, NAMPT, CCNYL1, CD86, CCRL2, EHD4, IL1RN, HK2, GCH1, XRN1, ZCCHC2, ZNFX1		gene expression	up	15 days vs 0 days	time of clinical onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-18)	Moderate COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, OGFR, SELL, TRIM25, ANKFY1, CXCL10, NMI, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, IRF9, SMCHD1, MOV10, TMEM140, PPA1, MAX, PSME2, CLIC4, P2RY14, RBM43, TAP1, PARP12, TLK2, ATP10A, NLRC5, SLFN5, PCGF5, GBP5, AIDA, BBX, P2RY14, CD274, LGALS9, VCPIP1, ABTB2, TRIM14, FAM111A, GBP4, GBP2, CASP4, TRAFD1, RTP4, PHF11, TRIM21, GPB3		gene expression	down	15 days vs 0 days	time of clinical onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	NR4A3, PIK3AP1, TIPARP, PPA2, NAMPT, CCNYL1, CCRL2, EHD4, IL1RN, HK2, PLSCR1, OGFR, SELL, TRIM25, LGALS9, VCPIP1, ABTB2, NAMPT, MAX, CLIC4, PCGF5, CD274, PPA1		gene expression	up	15 days vs 0 days	time of clinical onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, ANKFY1, CXCL10, NMI, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, TMEM140, PSME2, CD86, P2RY14, RBM43, TAP1, PARP12, XRN1, HSH2D, ATP10A, NLRC5, SLFN5, GBP5, AIDA, BBX, P2RY14, TRIM14, FAM111A, GBP4, GBP2, TRAFD1, RTP4, PHF11, TRIM21, GPB3, GCH1, PYHIN1, DCK		gene expression	down	15 days vs 0 days	time of clinical onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PIK3AP1, PPA2, EHD4, HK2, OGFR, TRIM25, LGALS9, ABTB2, NAMPT, MAX, CLIC4, STAT2, ADAR, BST2, IFITM3, IRF7, ANKFY1, GBP2, CASP4, TRAFD1, IRF9, TMEM140, CD86, P2RY14		gene expression	up	10 days vs 0 days	time of clinical onset	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, IFI35, IL15RA, DHX58, RSAD2, IFIT2, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, PNPT1, SP110, PPM1K, ISG20, ZBP1, RNF213, SMCHD1, ZCCHC2, USP25, ZNFX1, PSME2, RBM43, TAP1, PARP12, XRN1, ATP10A, NLRC5, SLFN5, GBP5, AIDA, BBX, PPA1, CD274, TRIM14, FAM111A, PHF11, TRIM21, GPB3, GCH1, PYHIN1, DCK, SELL, VCPIP1, IL1RN, CCNYL1, TIPARP, CD69, NR4A3, TLK2, PCGF5		gene expression	down	10 days vs 0 days	time of clinical onset	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PIK3AP1, PPA2, EHD4, HK2, OGFR, TRIM25, LGALS9, TRIM14, NAMPT, CLIC4, ANKFY1, TMEM140, CD86, P2RY14, IL15RA, CCRL2, IL1RN, CCNYL1, HK2, TIPARP, NR4A3		gene expression	up	5 days vs 0 days	time of clinical onset	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-18)	ICU COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; hierarchical clustering	PARP14, DTX3L, STAT2, ADAR, OAS2, PARP9, TDRD7, PML, IRF7, IFI35, DHX58, RSAD2, IFIT2, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, PNPT1, SP110, PPM1K, ISG20, ZBP1, RNF213, SMCHD1, ZCCHC2, USP25, ZNFX1, PSME2, RBM43, TAP1, PARP12, XRN1, NLRC5, SLFN5, GBP5, AIDA, BBX, PPA1, CD274, ABTB2, FAM111A, PHF11, TRIM21, GPB3, GCH1, PYHIN1, DCK, VCPIP1, CD69, TLK2, PCGF5, GBP4, GBP2, CASP4, TRAFD1, CXCL10, NMI, RTP4, UBE2L6, IFIT3, IRF9, HSH2D, MOV10, MAX		gene expression	down	5 days vs 0 days	time of clinical onset	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15a; Fig 1g	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/ 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 		(2021-02-18)	COVID-19 patients	18	94	years	34	Peripheral Blood Mononuclear Cells		bulk RNA-seq; SIMoA technology; correlation analysis	IFN-alpha		protein/cytokine levels	positively correlated	correlated with average ISG expression	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S15b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". 	
	Amani 	Simranpreet	(2021-02-18)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	52	Peripheral Blood Mononuclear Cells		phospho CyTOF; hierarchical clustering	pDCs (plasmacytoid dendritic cells)		cell type frequency	down	ICU, severe, & moderate COVID-19 patients vs healthy & convalescent COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1		
	Amani 	Simranpreet	(2021-02-18)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	52	Peripheral Blood Mononuclear Cells		phospho CyTOF; hierarchical clustering	plasmablast; Effector_CD8_T_cells		cell type frequency	up	ICU, severe, & moderate COVID-19 patients vs healthy & convalescent COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1		
	Amani 	Simranpreet	(2021-02-18)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	52	Peripheral Blood Mononuclear Cells		phospho CyTOF; hierarchical clustering	pDCs.pS6, mDCs.Ikba		protein/cytokine levels	down	ICU, severe, & moderate COVID-19 patients vs healthy & convalescent COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1		
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	52	Peripheral Blood Mononuclear Cells		phospho CyTOF; hierarchical clustering	mDCs.HLA_DR		protein/cytokine levels	down	ICU, severe, & moderate COVID-19 patients and convalescent COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1		
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	52	Peripheral Blood Mononuclear Cells		phospho CyTOF; hierarchical clustering	IL6, MCP.3		protein/cytokine levels	up	ICU, severe, & moderate COVID-19 patients vs healthy & convalescent COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1		
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	52	Peripheral Blood Mononuclear Cells		phospho CyTOF	EN.RAGE, TNFSF14, OSM		protein/cytokine levels	up	ICU & severe COVID-19 patients vs healthy, moderate & convalescent COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1		
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA 	23	94	years	30	Peripheral Blood Mononuclear Cells		phospho CyTOF	mDC HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA 	23	94	years	21	Peripheral Blood Mononuclear Cells		phospho CyTOF	mDC HLA-DR		protein/cytokine levels	down	moderate COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA 	23	94	years	17	Peripheral Blood Mononuclear Cells		phospho CyTOF	mDC HLA-DR		protein/cytokine levels	up	moderate COVID-19 patients vs Severe COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Hong Kong, China	18	80	years	40	Peripheral Blood Mononuclear Cells		phospho CyTOF	mDC HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Hong Kong, China	18	80	years	45	Peripheral Blood Mononuclear Cells		phospho CyTOF	mDC HLA-DR		protein/cytokine levels	down	moderate COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	30	Peripheral Blood Mononuclear Cells		phospho CyTOF	C monocyte (C mono) HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Hong Kong, China	18	80	years	40	Peripheral Blood Mononuclear Cells		phospho CyTOF	C monocyte (C mono) HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	TNFSF14, TNF		gene expression	down	ICU COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	S100A12		gene expression	up	ICU COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	TNFSF14, TNF		gene expression	down	severe COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	S100A12		gene expression	up	severe COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	TNF		gene expression	up	moderate COVID-19 patients vs ICU COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	S100A12		gene expression	up	severe COVID-19 patients vs moderate COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	TNFSF14		gene expression	up	moderate COVID-19 patients vs Severe COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	Peripheral Blood Mononuclear Cells		bulk RNA-seq; relative expression of genes encoding cytokines	S100A12		gene expression	up	ICU COVID-19 patients vs moderate COVID-19 patients	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA	23	94	years	15	plasma		CITE-seq; correlation	EN-RAGE		protein/cytokine levels	positively correlated	correlated with S100A12 in myeloid and dendritic cell cluster	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 5e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	69	plasma		qPCR	16S (bacterial rRNA gene)		gene expression	up	severe & ICU COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 6a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F6/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-19)	Atlanta, Georgia, USA & Hong Kong, China	18	94	years	69	plasma		TLR4-based reporter assay	LPS 		protein/cytokine levels	up	severe & ICU COVID-19 patients vs healthy	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 6b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F6/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases were organ failure necessitating intensive care unit (ICU) care."	
	Amani 	Simranpreet	(2021-02-19)	COVID-19 patients in Atlanta, USA & Hong Kong, China	18	94	years	69	plasma		Olink multiplex cytokine assay; NPX; Spearman's correlations	IL-6, TNF, MCP-3, EN-RAGE, OSM, TNFSF14		protein/cytokine levels	positively correlated	each correlated with bacterial DNA or LPS (copies/mL plasma)	time of clinical onset			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32788292	(2020-08-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/	Fig 6c; Fig S19b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F6/ ; https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1 	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases were organ failure necessitating ICU care."	
	Amani 	Simranpreet		St Louis, Missouri, USA	22	89	years	37	Peripheral Blood Mononuclear Cells			CD45+ CD19+ IgD- CD71+ CD38+ CD20- plasmablasts		cell type frequency	up	primary COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 1B	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F1.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	22	89	years	37	Peripheral Blood Mononuclear Cells			CD45+ CD3+ CD8+ T cells; CD45+ CD3+ CD4+ T cells; CD45+ CD3- CD19- CD14++ CD16- classical monocytes; CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes; CD45+ CD3- CD19- CD14+ CD16+ non-classical monocytes		cell type frequency	down	primary COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 1A & C	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F1.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	22	89	years	37	CD45+ CD3- CD19- CD14+ CD16+ non-classical monocytes			HLA-DR		protein/cytokine levels	down	primary COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 1D	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F1.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	45	Peripheral Blood Mononuclear Cells			CD45+ CD3- CD19- CD14++ CD16- classical monocytes; CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes; CD45+ CD3- CD19- CD14+ CD16+ non-classical monocytes		cell type frequency	down	primary COVID-19 patients vs influenza patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 1C	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F1.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	45	CD45+ CD3+ CD8+ T cells, CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes			HLA-DR		protein/cytokine levels	down	primary COVID-19 patients vs influenza patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 1D & 1E	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F1.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	22	CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes			HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs moderate COVID-19 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig S1C	http://advances.sciencemag.org/cgi/content/full/sciadv.abe3024/DC1		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	105	Peripheral Blood Mononuclear Cells			IFN-gamma, IL-17a, G-CSF, TNFalpha, RANTES, MIP-1beta, MIP-1alpha, MIG, IP-10, IL-9, IL-7, IL-5, IL-4, IL-3, IL-2R, IL-22, IL-2, IL-1Ra, IL-1Beta (IL-1b), IL-1alpha (IL-1a), IL-17f, IL-17a, IL-15, IL-13, IL-12, IL-10, IFN-alpha, GM-CSF, FGF, eotaxin		protein/cytokine levels	down	primary COVID-19 patients vs influenza patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 2B-C	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F2.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	105	Peripheral Blood Mononuclear Cells			VEGF, MCP1, IP-10, HGH, EGF		protein/cytokine levels	up	primary COVID-19 patients vs influenza patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 2B-C	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F2.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	22	89	years	87	Peripheral Blood Mononuclear Cells			ex-vivo stimulation of PBMCs; NF-kB p65 (Ser529) staining; GeoMFI		protein/cytokine levels	up	primary COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	2nd paragraph in Results section "Cytokine Associations.." 	https://advances.sciencemag.org/content/6/50/eabe3024		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	105	Peripheral Blood Mononuclear Cells			GCSF, IFNg, MIG, IL1Ra, IL2R, IL9, IL17a, MIP1a		protein/cytokine levels	down	primary COVID-19 patients vs influenza patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig S3-4	http://advances.sciencemag.org/cgi/content/full/sciadv.abe3024/DC1		
	Amani 			St Louis, Missouri, USA	22	92	years	97	Peripheral Blood Mononuclear Cells			IP-10, IL8		protein/cytokine levels	up	validation COVID-19 patients vs healthy				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 3B & 3D	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F3.large.jpg		
	Amani 			St Louis, Missouri, USA	18	92	years	115	Peripheral Blood Mononuclear Cells			IP-10, TNFalpha, IL-1alpha, IL-1beta		protein/cytokine levels	down	validation COVID-19 patients vs influenza				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 3B-C	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F3.large.jpg		
	Amani 	Simranpreet		St Louis, Missouri, USA	22	92	years	97	Peripheral Blood Mononuclear Cells			IL12, EGF (epidermal growth factor), HGF, IL2, IL8, IP10, MIP1b		protein/cytokine levels	up	validation COVID-19 patients vs healthy				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig S6-7	http://advances.sciencemag.org/cgi/content/full/sciadv.abe3024/DC1		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	92	years	115	Peripheral Blood Mononuclear Cells			IP10, IL1a, IL1b, IL4, IL9, IL17a, IL17f, MIG, TNFa, FGF, eotaxin, GCSF, IFNg, IL1Ra, IL2R		protein/cytokine levels	down	validation COVID-19 patients vs influenza				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig S6-7	http://advances.sciencemag.org/cgi/content/full/sciadv.abe3024/DC1		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	97	Peripheral Blood Mononuclear Cells			HGF, IL8, IP10, MCP1, MIP1b		protein/cytokine levels	up	primary COVID-19 patients vs healthy				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig S3-4	http://advances.sciencemag.org/cgi/content/full/sciadv.abe3024/DC1		
	Amani 	Simranpreet		St Louis, Missouri, USA	18	89	years	6	Peripheral Blood Mononuclear Cells			HLA-DRA		protein/cytokine levels	down	severe COVID-19 patients vs severe influenza patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 5D	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F5.large.jpg	-all 3 COVID-19 patients died 	
	Amani 			St Louis, Missouri, USA	18	89	years	6	monocytes/macrophages		GSEA	STAT1, STAT2, STAT3		gene expression	down	COVID-19 patients vs influenza patients	severe COVID-19 vs severe influenza			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33187979	(2020-12-09)	https://advances.sciencemag.org/content/6/50/eabe3024/	Fig 5F	https://advances.sciencemag.org/content/advances/6/50/eabe3024/F5.large.jpg		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	80	Peripheral Blood Mononuclear Cells		general immunophenotyping flow cytometry panel	CD8+ T cells; CD16+ monocyte; CD14+ monocyte, CD56+ CD16- NK cells; CD56+ CD16+ NK cells		cell type frequency	up	nonhospitalized COVID-19 patients vs hospitalized COVID-19 patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 1C, 1F-I	https://www.jci.org/articles/view/140491/figure/1/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	80	Peripheral Blood Mononuclear Cells		general immunophenotyping flow cytometry panel	B cells		cell type frequency	up	hospitalized COVID-19 patients vs nonhospitalized COVID-19 patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 1D	https://www.jci.org/articles/view/140491/figure/1/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	25	86	years	58	Peripheral Blood Mononuclear Cells		general immunophenotyping flow cytometry panel	B cells; Dendritic Cells (DCs)		cell type frequency	down	nonhospitalized COVID-19 patients vs healthy patients	time of symptom onset	19-40	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 1D & 1K	https://www.jci.org/articles/view/140491/figure/1/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	58	Peripheral Blood Mononuclear Cells		general immunophenotyping flow cytometry panel	CD14+ CD16+ monocytes		cell type frequency	up	nonhospitalized COVID-19 patients vs healthy patients	time of symptom onset	19-40	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 1J	https://www.jci.org/articles/view/140491/figure/1/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	60	Peripheral Blood Mononuclear Cells		immunophenotyping flow cytometry & T cell gating panels	CD56+ CD16+ NK cells; CD14+ monocyte; dendritic cells		cell type frequency	down	hospitalized COVID-19 patients vs healthy patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 1F, 1H, & 1K	https://www.jci.org/articles/view/140491/figure/1/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	66	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69; OX40; PD1; TIGIT; PD-L1		protein/cytokine levels	up	hospitalized COVID-19 patients vs healthy patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 2A-C, 2G-H	https://www.jci.org/articles/view/140491/figure/2/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	59	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	TIGIT; PD-L1		protein/cytokine levels	up	nonhospitalized COVID-19 patients vs healthy patients	time of symptom onset	19-40	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 2G-H	https://www.jci.org/articles/view/140491/figure/2/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	85	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69; OX40; PD1; HLA-DR; CD154; TIM3		protein/cytokine levels	up	hospitalized COVID-19 patients vs nonhospitalized COVID-19 patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 2A-F	https://www.jci.org/articles/view/140491/figure/2/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	85	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD38-expressing CD4+ T cells		cell type frequency	down	hospitalized COVID-19 patients vs nonhospitalized COVID-19 patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 2I	https://www.jci.org/articles/view/140491/figure/2/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	66	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69; CD38; PD-L1		protein/cytokine levels	up	hospitalized COVID-19 patients vs healthy patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 3A-B & 3G	https://www.jci.org/articles/view/140491/figure/3/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	85	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69; CD38; OX-40; CD154; HLA-DR; TIM3; PD-L1		protein/cytokine levels	up	hospitalized COVID-19 patients vs nonhospitalized COVID-19 patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 3A-G	https://www.jci.org/articles/view/140491/figure/3/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	85	B cells		general immunophenotyping flow cytometry & B cell gating panels	CD69; CD95		protein/cytokine levels	up	hospitalized COVID-19 patients vs nonhospitalized COVID-19 patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 4A-B	https://www.jci.org/articles/view/140491/figure/4/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	85	B cells		general immunophenotyping flow cytometry & B cell gating panels	PD1		protein/cytokine levels	down	hospitalized COVID-19 patients vs nonhospitalized COVID-19 patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 4E	https://www.jci.org/articles/view/140491/figure/4/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	59	B cells		general immunophenotyping flow cytometry & B cell gating panels	CD69; CD27; PD1		protein/cytokine levels	up	nonhospitalized COVID-19 patients vs healthy patients	time of symptom onset	19-40	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 4A, 4D-E	https://www.jci.org/articles/view/140491/figure/4/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	66	B cells		general immunophenotyping flow cytometry & B cell gating panels	CD69; CD95		protein/cytokine levels	up	hospitalized COVID-19 patients vs healthy patients	time of symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 4A-B	https://www.jci.org/articles/view/140491/figure/4/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	23	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	HLA-DR; OX40; TIM3		protein/cytokine levels	positively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 5A-C	https://www.jci.org/articles/view/140491/figure/5/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	25	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	HLA-DR; OX40; TIM3		protein/cytokine levels	up	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 5A-C	https://www.jci.org/articles/view/140491/figure/5/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	23	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	PD-L1		protein/cytokine levels	negatively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 5D	https://www.jci.org/articles/view/140491/figure/5/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	25	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	PD-L1		protein/cytokine levels	down	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 5D	https://www.jci.org/articles/view/140491/figure/5/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	23	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	HLA-DR; TIGIT; PD-L1		protein/cytokine levels	positively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 6A-C	https://www.jci.org/articles/view/140491/figure/6/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	25	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	HLA-DR; TIGIT; PD-L1		protein/cytokine levels	up	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 6A-C	https://www.jci.org/articles/view/140491/figure/6/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	23	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD27; CD28		protein/cytokine levels	negatively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 6D-E	https://www.jci.org/articles/view/140491/figure/6/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	25	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD27; CD28		protein/cytokine levels	down	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 6D-E	https://www.jci.org/articles/view/140491/figure/6/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	39	CD4+ T cells; CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	PD1; TIGIT; HLA-DR		protein/cytokine levels	positively correlated	increased age in years in nonhospitalized COVID-19 patients	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 7A-C; 7E-G	https://www.jci.org/articles/view/140491/figure/7/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	39	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD28		protein/cytokine levels	negatively correlated	increased age in years in nonhospitalized COVID-19 patients	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 7D	https://www.jci.org/articles/view/140491/figure/7/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	39	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD27; CD28		protein/cytokine levels	negatively correlated	increased age in nonhospitalized COVID-19 patients	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 7H-I	https://www.jci.org/articles/view/140491/figure/7/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	36	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69; CD38		protein/cytokine levels	up	hospitalized ICU patients vs hospitalized no ICU patients	time after symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 8A-B	https://www.jci.org/articles/view/140491/figure/8/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	36	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD38; PDL1		protein/cytokine levels	up	hospitalized ICU patients vs hospitalized no ICU patients	time after symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 8C-D	https://www.jci.org/articles/view/140491/figure/8/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	36	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD137		protein/cytokine levels	down	hospitalized ICU patients vs hospitalized no ICU patients	time after symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 8E	https://www.jci.org/articles/view/140491/figure/8/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	36	B cells		general immunophenotyping flow cytometry & B cell gating panels	CD27		protein/cytokine levels	up	hospitalized ICU patients vs hospitalized no ICU patients	time after symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 8G	https://www.jci.org/articles/view/140491/figure/8/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	36	B cells		general immunophenotyping flow cytometry & B cell gating panels	HLA-DR		protein/cytokine levels	down	hospitalized ICU patients vs hospitalized no ICU patients	time after symptom onset	4-43	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Fig 8H	https://www.jci.org/articles/view/140491/figure/8/		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	25	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69		protein/cytokine levels	up	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 2A	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	25	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69; CD154; Tim3		protein/cytokine levels	up	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 2C-E	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	23	CD4+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD137		protein/cytokine levels	positively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 2B	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	20	B cells		general immunophenotyping flow cytometry & B cell gating panels	FcRL4		protein/cytokine levels	positively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	40	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 3A	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	20	B cells		general immunophenotyping flow cytometry & B cell gating panels	CD95		protein/cytokine levels	positively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 3B	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	20	B cells		general immunophenotyping flow cytometry & B cell gating panels	CD27		protein/cytokine levels	negatively correlated	correlated with days after symptom onset in nonhospitalized COVID-19 patients	time after symptom onset	45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 3D	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	29	B cells		general immunophenotyping flow cytometry & B cell gating panels	HLA-DR		protein/cytokine levels	up	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 3C	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	22	86	years	29	B cells		general immunophenotyping flow cytometry & B cell gating panels	PD1		protein/cytokine levels	down	nonhospitalized COVID-19 patients: visit 2 vs visit 1	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 3E	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	45	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD69		protein/cytokine levels	positively correlated	increased age in years in hospitalized COVID-19 patients	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 4A	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	45	CD8+ T cells		general immunophenotyping flow cytometry & T cell gating panels	CD27; CD28		protein/cytokine levels	negatively correlated	increased age in years in hospitalized COVID-19 patients	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 4B-C	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Birmingham, Alabama, USA	19	88	years	45	B cells		general immunophenotyping flow cytometry & B cell gating panels	CD69; CD95; FcRL4		protein/cytokine levels	positively correlated	increased age in hospitalized COVID-19 patients	time after symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33119547	(2020-10-29)	https://www.jci.org/articles/view/140491	Suppl Fig 4D-F	https://www.jci.org/articles/view/140491#sd		
	Amani 	Simranpreet		Rome, Italy	unknown	unknown	years	8	whole blood cells		whole blood count (WBC) analysis	lymphocytes 		cell type frequency	down	severe COVID-19 patients vs mild COVID-19 patients	time after hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32514047	(2020-06-08)	https://www.nature.com/articles/s41418-020-0572-6	Fig 1A & paragraph above Fig 1.	https://www.nature.com/articles/s41418-020-0572-6/figures/1	Significant in cell count and percentage frequency. Severe defined as "with fever, cough and ARDS [PaO2= (partial pressure of arterial oxygen)/FIO2 (Fraction of inspired oxygen) Rati0 < 300mmHg]." Mild defined as "mild conjunctivitis, axillary temperature of 37.5C, or with no clinical sign"	
	Amani 	Simranpreet		Rome, Italy	unknown	unknown	years	8	whole blood cells		whole blood count (WBC) analysis	neutrophils		cell type frequency	up	severe COVID-19 patients vs mild COVID-19 patients	time after hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32514047	(2020-06-08)	https://www.nature.com/articles/s41418-020-0572-6	Fig 1A & paragraph above Fig 1.	https://www.nature.com/articles/s41418-020-0572-6/figures/1	Significant in only percentage frequency. Severe defined as "with fever, cough and ARDS [PaO2 = (partial pressure of arterial oxygen)/FIO2 (Fraction of inspired oxygen) Ratio < 300mmHg]." Mild defined as "mild conjunctivitis, axillary temperature of 37.5C, or with no clinical sign"	
	Amani 	Simranpreet		Rome, Italy	unknown	unknown	years	18	Peripheral Blood Mononuclear Cells		flow cytometry  	PMN-MDSC (Myeloid-Derived Suppressor Cells)		cell type frequency	up	severe COVID-19 patients vs mild COVID-19 patients	time after hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32514047	(2020-06-08)	https://www.nature.com/articles/s41418-020-0572-6	Fig 4C 	https://www.nature.com/articles/s41418-020-0572-6/figures/4	Severe defined as "with fever, cough and ARDS [PaO2 = (partial pressure of arterial oxygen)/FIO2 (Fraction of inspired oxygen) Ratio < 300 mmHg]." Mild defined as "mild conjunctivitis, axillary temperature of 37.5 C, or with no clinical sign"	
	Amani 	Simranpreet		Rome, Italy	unknown	unknown	years	17	Peripheral Blood Mononuclear Cells		flow cytometry  	PMN-MDSC (Myeloid-Derived Suppressor Cells)		cell type frequency	up	severe COVID-19 patients vs healthy patients	time after hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32514047	(2020-06-08)	https://www.nature.com/articles/s41418-020-0572-6	Fig 4C 	https://www.nature.com/articles/s41418-020-0572-6/figures/4	Severe defined as "with fever, cough and ARDS [PaO2 = (partial pressure of arterial oxygen)/FIO2 (Fraction of inspired oxygen) Ratio < 300 mmHg]." Mild defined as "mild conjunctivitis, axillary temperature of 37.5 C, or with no clinical sign"	
	Amani 	Simranpreet		Rome, Italy	unknown	unknown	years	17	Peripheral Blood Mononuclear Cells		flow cytometry  	PMN-MDSC (Myeloid-Derived Suppressor Cells)		cell type frequency	up	mild COVID-19 patients vs healthy patients	time after hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32514047	(2020-06-08)	https://www.nature.com/articles/s41418-020-0572-6	Fig 4C 	https://www.nature.com/articles/s41418-020-0572-6/figures/4	Severe defined as "with fever, cough and ARDS [PaO2 = (partial pressure of arterial oxygen)/FIO2 (Fraction of inspired oxygen) Ratio < 300 mmHg]." Mild defined as "mild conjunctivitis, axillary temperature of 37.5 C, or with no clinical sign"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	207	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	eosinophils; non-classical monocytes; neutrophils; classical monocytes; intermediate monocytes; B cells		cell type frequency	up	moderate & severe COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1B 	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate was defined as: "SARS-CoV-2 infection requiring hospitalization without supplementary oxygen (1); infection requiring non-invasive supplementary oxygen (<3 l/min to maintain SpO2 >92%) (2); and infection requiring non-invasive supplementary oxygen (>3 l/min to maintain SpO2 >92%, or >2 l/min to maintain SpO2 >92% and had a high-sensitivity C-reactive protein (CRP) >70) and received tocilizumab)." Severe disease status (clinical score 4 or 5) was defined as infection meeting all criteria for clinical score 3 and also requiring admission to the ICU and >6 l/min supplementary oxygen to maintain SpO2 >92% (4); or infection requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) in addition to glucocorticoid or vasopressor administration (5)"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	207	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	type 1 dendritic cells; type 2 dendritic cells; plasmacytoid dendritic cells; CD8+ T cells; CD4+ T cells; natural killer T cells; natural killer cells		cell type frequency	down	moderate & severe COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1B	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate was defined as: "SARS-CoV-2 infection requiring hospitalization without supplementary oxygen (1); infection requiring non-invasive supplementary oxygen (<3 l/min to maintain SpO2 >92%) (2); and infection requiring non-invasive supplementary oxygen (>3 l/min to maintain SpO2 >92%, or >2 l/min to maintain SpO2 >92% and had a high-sensitivity C-reactive protein (CRP) >70) and received tocilizumab)." Severe disease status (clinical score 4 or 5) was defined as infection meeting all criteria for clinical score 3 and also requiring admission to the ICU and >6 l/min supplementary oxygen to maintain SpO2 >92% (4); or infection requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) in addition to glucocorticoid or vasopressor administration (5)"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	eosinophil		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as concentration of millions of cells epr millilitre of blood.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	monocytes; neutrophils		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percent of live single cells.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	T cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percent of live single cells.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	167	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	T cells		cell type frequency	down	moderate COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percent of live single cells and as concentration of millions of cells per millilitre of blood. 	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	167	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	neutrophils; eosinophils		cell type frequency	up	moderate COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percent of live single cells and as concentration of millions of cells per millilitre of blood. 	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	167	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	monocytes		cell type frequency	up	moderate COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percent of live single cells. 	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	monocytes; neutrophils; eosinophils		cell type frequency	up	severe COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percent of live single cells and as concentration of millions of cells per millilitre of blood. 	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	T cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1C	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percent of live single cells and as concentration of millions of cells per millilitre of blood. 	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	VEGFA, EGF, PDGFAA, sCD40L, PDGFAB/B, CXCL1, IL-7, CCL4, IL-8, TGFalpha, Eotaxin2, CCL17, CXCL5, IL-17F, TPO, IL-33, SDF1a/B, IL-20, LIF, IFNL2, IL-18, CCL5, IgE, CCL27, CCL22, CXCL13, TRAIL, CCL15, IL-1RA, CXCL9, CCL2, IL-6, CCL1, CX3CL1, TNFalpha, IL-15, MCSF, CCL8, IL-10, CXCL10, CCL21, GCSF, IL-12p40, IL-1a, IL-17A, FGF2, IL-1b, IL-22, IL-4, IL-17E/IL-25, IL-2, IL-12p70, GMCSF, IL-13, TNFbeta, IFNgamma, CCL7, CCL13, Eotaxin, Eotaxin3, IFNalpha2, IL-3, FLT3L, IL-5, IL-27, TSLP, IL-23, IL-16, IL-21, IL-g, CCL3, SCF		protein/cytokine levels	positively correlated	COVID-19 patients vs healthy patients. Shared by moderate and severe COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1D	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. "Correlation matrices across all time points of 71 cytokines from patient blood, comparing patients with moderate and severe disease."	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	IL-6, IL-18, CCL1, IL-17A, IFNgamma		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients.	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1E-G	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. "Presented as log10-transformed concentrations"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	167	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	IL-6, IL-18, IL-1a, CCL1, IFNalpha, IFNgamma		protein/cytokine levels	up	moderate COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1E-G	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. "Presented as log10-transformed concentrations"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	IL-6, IL-18, IL-1a, CCL1, IFNalpha, IFNgamma, IL-17A		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time post-symptom onset	3 to 51	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 1E-G	https://www.nature.com/articles/s41586-020-2588-y/figures/1	Moderate and severe defined in commments for Fig 1B of same publication. "Presented as log10-transformed concentrations"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	VEGFA, EGF, PDGFAA, sCD40L, PDGFAB/BB, CXCL1, IL-7, CCL4, IL-8, TGFalpha, Eotaxin2, CCL17, CXCL5, IL-17F, TPO, IL-33, SDF1a/B, IL-20, LIF, IFNL2, IL-18, CCL5, IgE, CCL27, CCL22, CXCL13, TRAIL, CCL15, IL-1RA, CXCL9, CCL2, IL-6, CCL1, CX3CL1, TNFalpha, IL-15, MCSF, CCL8, IL-10, CXCL10, CCL21, GCSF, IL-12p40, IL-1a, IL-17A, FGF2, IL-1b, IL-22, IL-4, IL-17E/IL-25, IL-2, IL-12p70, GMCSF, IL-13, TNFbeta, IFNgamma, CCL7, CCL13, Eotaxin, Eotaxin3, IFNalpha2, IL-3, FLT3L, IL-5, IL-27, TSLP, IL23, IL-16, IL-21, IL-9, CCL3, SCF		protein/cytokine levels	positively correlated	COVID-19 patients vs healthy patients. Shared by moderate and severe COVID-19 patients in early phase of disease (<10 DfSO (Days of Symptom Onset)) and in late phase of disease (>10 DfSO)	time post-symptom onset	3 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 2A	https://www.nature.com/articles/s41586-020-2588-y/figures/2	Moderate and severe defined in commments for Fig 1B of same publication. "Correlation matrices...comparing cytokine concentrations in patients with moderate or severe disease during the early phase (<10 DfSO) or late phase (>10 DfSO) of disease"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	VEGFA, EGF, PDGFAA, sCD40L, PDGFAB/BB, CXCL1, IL-7, CCL4, IL-8, TGFalpha, Eotaxin2, CCL17, CXCL5, IL-17F, TPO, IL-33, SDF1a/B, IL-20, LIF, IFNL2, IL-18, CCL5, IgE, CCL27, CCL22, CXCL13, TRAIL, CCL15, IL-1RA, CXCL9, CCL2, IL-6, CCL1, CX3CL1, TNFalpha, IL-15, MCSF, CCL8, IL-10, CXCL10, CCL21, GCSF, IL-12p40, IL-1a, IL-17A, FGF2, IL-1b, IL-22, IL-4, IL-17E/IL-25, IL-2, IL-12p70, GMCSF, IL-13, TNFbeta, IFNgamma, CCL7, CCL13, Eotaxin, Eotaxin3, IFNalpha2, IL-3, FLT3L, IL-5, IL-27, TSLP, IL23, IL-16, IL-21, IL-9, CCL3, SCF		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients in late phase of disease (>10 DfSO)	time post-symptom onset	10 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 2B; 1st Paragraph under "Longitudinal immune..." section	https://www.nature.com/articles/s41586-020-2588-y/figures/2 ; https://www.nature.com/articles/s41586-020-2588-y#Sec3 	Moderate and severe defined in commments for Fig 1B of same publication. "Correlation matrices...comparing cytokine concentrations in patients with moderate or severe disease during the late phase (>10 DfSO) of disease"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	IFNalpha, IL-1beta, IL-18, Eotaxin-2		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	10 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 2B-C & 2E; 2nd-4th Paragraphs under "Longitudinal immune..." section	https://www.nature.com/articles/s41586-020-2588-y/figures/2 ; https://www.nature.com/articles/s41586-020-2588-y#Sec3 	Moderate and severe defined in commments for Fig 1B of same publication. "Correlation matrices...comparing cytokine concentrations in patients with moderate or severe disease during the late phase (>10 DfSO) of disease"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry	monocytes		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 2D; 3rd Paragraph under "Longitudinal immune..." section	https://www.nature.com/articles/s41586-020-2588-y/figures/2 ; https://www.nature.com/articles/s41586-020-2588-y#Sec3 	Moderate and severe defined in commments for Fig 1B of same publication. "Correlation matrices...comparing cytokine concentrations in patients with moderate or severe disease during the late phase (>10 DfSO) of disease"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry	eosinophils		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	10 to 20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 2E; 4th Paragraph under "Longitudinal immune..." section	https://www.nature.com/articles/s41586-020-2588-y/figures/2 ; https://www.nature.com/articles/s41586-020-2588-y#Sec3 	Moderate and severe defined in commments for Fig 1B of same publication. "Correlation matrices...comparing cytokine concentrations in patients with moderate or severe disease during the late phase (>10 DfSO) of disease"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	157	Peripheral Blood Mononuclear Cells		flow cytometry & ELISA	IL-5, IgE, IL-6, IL-22, IL-17A		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients 	time post-symptom onset	10 to 20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 2E-F; 4th-5th Paragraphs under "Longitudinal immune..." section	https://www.nature.com/articles/s41586-020-2588-y/figures/2 ; https://www.nature.com/articles/s41586-020-2588-y#Sec3 	Moderate and severe defined in commments for Fig 1B of same publication. "Correlation matrices...comparing cytokine concentrations in patients with moderate or severe disease during the late phase (>10 DfSO) of disease"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	151	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs.	IFNgamma, IFNalpha, TRAIL, TNFalpha		protein/cytokine levels	positively correlated	severe & moderate COVID-19 patients vs healthy COVID-19 patients. Correlated with viral load. 	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 3B	https://www.nature.com/articles/s41586-020-2588-y/figures/3	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	112	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis	Eotaxin2, IL-20, LIF, IL-20, SCF, IFNL, IL-16, IL-21, TPO, IL-33, TSLP, IL-23, IL-17F, TGFalpha, IL-27, IFNgamma, IL-15, IFNalpha2, FLT3L, FGF2, IL-2, IL-17A, IL-1b, IL-12p70, IL-9, CCL3, IL-1a, IL-17E/IL25, IL-22, IL-4, GMCSF, TNFalpha, CX3CL1, CCL7, IL-13, TNFbeta, IL-3, CCL5, CCL22, CCL8, TRAIL, CXCL10, CCL1, IL-6, IL-10, GCSF, MCSF, IL-18, CCL2, IL-1RA, CXCL9, CCL27, CCL21, IL-12p40, SDF1A/SDF1B, CCL15, CXCL13, IgE		protein/cytokine levels	up	cluster 3 vs clusters 1-2. All clusters are of COVID-19 patients.	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 3C	https://www.nature.com/articles/s41586-020-2588-y/figures/3	Moderate and severe defined in commments for Fig 1B of same publication. Corresponds to signatures B-D	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	170	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis	TGFalpha, IL-23, TSLP, IL-33, TPO, IL-17F, Eotaxin3, CCL13, IL20, LIF, SCF, IL-21, IFNL, IL-16, CCL21, SDF1a/SDF1B, Eotaxin, IL-9, IL-22, IL-4, IL-17E/IL-25, CCL7, IFNgamma, TNFbeta, IL-13, GMCSF, IL-15, IFNalpha2, IL-1a, IL-1b, IL-17A, IL-2, FGF2, CCL3, IL-12p70, IL-3, IL-12p40, IL-5, FLT3L		protein/cytokine levels	up	cluster 3 vs clusters 1-2. All clusters are of COVID-19 patients.	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 4A	https://www.nature.com/articles/s41586-020-2588-y/figures/4	Moderate and severe defined in commments for Fig 1B of same publication. Corresponds to signatures B'-C'	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	96	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis	IL-27, IFNgamma, IL-15, IFNalpha2, FLT3L, FGF2, IL-2, IL-17A, IL-1b, IL-12p70, IL-9, CCL3, IL-1a, IL-17E/IL25, IL-22, IL-4, GMCSF, TNFalpha, CX3CL1, CCL7, IL-13, TNFbeta, IL-3, CCL5, CCL22, CCL8, TRAIL, CXCL10, CCL1, IL-6, IL-10, GCSF, MCSF, IL-18, CCL2, IL-1RA, CXCL9, CCL27, CCL21, IL-12p40, SDF1A/SDF1B, CCL15, CXCL13, IgE		protein/cytokine levels	up	cluster 2 vs cluster 1. Both clusters are of COVID-19 patients.	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 3C	https://www.nature.com/articles/s41586-020-2588-y/figures/3	Moderate and severe defined in commments for Fig 1B of same publication. Corresponds to signatures C-D	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	112	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis	EGF, PDGFAA, sCD40L, PDGFAB/PDGFBB, Eotaxin, CCL13, IL-7, VEGFA, Eotaxin2, CXCL1, CXCL5, CCL4, IL-8, CCL17		protein/cytokine levels	up	clusters 2-3 vs cluster 1. All clusters are of COVID-19 patients.	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 3C; 2nd paragraph under "Early cytokine..." section	 https://www.nature.com/articles/s41586-020-2588-y/figures/3 ; https://www.nature.com/articles/s41586-020-2588-y#Sec5 	Moderate and severe defined in commments for Fig 1B of same publication. Corresponds to signature A / "inflammatory markers" in text. 	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	170	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis	EGF, PDGFAA, sCD40L, PDGFAB/PDGFBB, Eotaxin, CCL13, IL-7, VEGFA, Eotaxin2, CXCL1, CXCL5, CCL4, IL-8, Eotaxin, IL-9, IL-22, IL-4, IL-17E/IL-25, CCL7, IFNgamma, TNFbeta, IL-13, GMCSF, IL-15, IFNalpha2, IL-1a, IL-1b, IL-17A, IL-2, FGF2, CCL3, IL-12p70, IL-3, IL-12p40, IL-5, FLT3L, CCL22, CCL5, CXCL13, IgE, CCL27, CCL15, CCL8, TRAIL, IL-10, CXCL10, GCSF, MCSF, CXCL9, IL-6, CCL1, CCL2, TNFalpha, CX3CL1, IL-1RA, IL-18, IL-27		protein/cytokine levels	up	clusters 2-3 vs cluster 1. All clusters are of COVID-19 patients.	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 4A; 1st paragraph under "Retrospective..." section	https://www.nature.com/articles/s41586-020-2588-y/figures/4 ; https://www.nature.com/articles/s41586-020-2588-y#Sec6  	Moderate and severe defined in commments for Fig 1B of same publication. Corresponds to signature A' & C' - D' .	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	112	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis, mutual information analysis	CCL2, IFNalpha2, CCL21O, CCL1, IL-5, IL-1RA, IL-1b, MCSF, IL-16, TGFalpha, CCL8, CXCL9, IL-2, CCL4, IL-6		protein/cytokine levels	positively predictive	predictive of severe disease outcomes	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Fig 3E	 https://www.nature.com/articles/s41586-020-2588-y/figures/3 	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	112	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis, mutual information analysis	IFNalpha		protein/cytokine levels	positively predictive	associated with longer hospital stays and death	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	last paragraph in "Early cytokine..." section	 https://www.nature.com/articles/s41586-020-2588-y#Sec5 	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	112	Peripheral Blood Mononuclear Cells		flow cytometry, ELISA, serial nasopharyngeal swabs, unsupervised clustering analysis, mutual information analysis	IFNalpha, IFNlambda, IL-1RA, CCL1, CLL2, M-CSF, IL-2, IL-16, CCL21		protein/cytokine levels	positively predictive	predictive of death	time post-symptom onset	0 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	last paragraph in "Early cytokine..." section	https://www.nature.com/articles/s41586-020-2588-y#Sec5 	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	Peripheral Blood Mononuclear Cells		flow cytometry	non-conventional monocytes; CD16high neutrophils; CD16int neutrophils		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2A	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as concentration of millions of cells per mL of blood.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	Peripheral Blood Mononuclear Cells		flow cytometry	CD8 cells; plasmacytoid dendritic cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2A	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as concentration of millions of cells per mL of blood.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	204	Peripheral Blood Mononuclear Cells		flow cytometry	internal monocytes; non-conventional monocytes; CD16high neutrophils; CD16int neutrophils		cell type frequency	up	moderate & severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2A	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as concentration of millions of cells per mL of blood.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	204	Peripheral Blood Mononuclear Cells		flow cytometry	CD8 cells; CD4 cells; plasmacytoid dendritic cells; type 1 dendritic cells; type 2 dendritic cells; natural killer T cells		cell type frequency	down	moderate & severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2A	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as concentration of millions of cells per mL of blood.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	163	Peripheral Blood Mononuclear Cells		flow cytometry	natural killer cells		cell type frequency	down	moderate COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2A	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as concentration of millions of cells per mL of blood.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	CD4+ T cells		flow cytometry	naive cells		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2B	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	CD4+ T cells		flow cytometry	Central memory cells; CD4+ Tfh cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2B	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	CD8+ T cells		flow cytometry	Central memory cells; effector memory cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2B	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	163	CD4+ T cells		flow cytometry	central memory cells; CD4+ effector Treg cells; CD4+ Tfh cells		cell type frequency	up	moderate COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2B	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	163	CD8+ T cells		flow cytometry	naive cells; effector memory cells		cell type frequency	down	moderate COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2B	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	CD4+ T cells		flow cytometry	CD4+ effector Treg cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2B	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	CD8+ T cells		flow cytometry	Central memory cells; effector memory cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2B	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	CD4+ T cells		flow cytometry & ELISA	effector memory cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	CD4+ T cells		flow cytometry; phenotyping	CD4+ TCR cells		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	CD4+ T cells		flow cytometry; phenotyping	CD4+ IFNgamma cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	155	neutrophils; monocytes; internal monocytes; conventional monocytes		flow cytometry; phenotyping	HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of cells	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	204	CD4+ T cells		flow cytometry; phenotyping	CD4+ TCR cells; CD4+ IL-17 cells		cell type frequency	up	moderate & severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	204	CD8+ T cells		flow cytometry; phenotyping	CD8+ granzyme B cells; CD8+ TCR cells		cell type frequency	up	moderate & severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	163	neutrophils		flow cytometry; phenotyping	HLA-DR		protein/cytokine levels	down	moderate COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of cells	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	neutrophils; monocytes; internal monocytes		flow cytometry; phenotyping	HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as percentage of parent population (CD4+ T cell or CD8+ T cell).	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	90	CD4+ T cells		flow cytometry; phenotyping	CD4+ IFNgamma cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 2C	https://www.nature.com/articles/s41586-020-2588-y/figures/6	Moderate and severe defined in commments for Fig 1B of same publication. Measured as concentration of millions of cells per mL of blood.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	169	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL2, IL5, IL10, CCL15, CCL22, CXCL10, CXCL13, GMCSF, CX3CL1, TNFb, TGFa, Eotaxin2, VEGFA		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 3	https://www.nature.com/articles/s41586-020-2588-y/figures/7	Moderate and severe defined in commments for Fig 1B of same publication. Plotted as log10-transformed concentrations.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	169	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	PDGF-AA, TRAIL		protein/cytokine levels	down	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 3	https://www.nature.com/articles/s41586-020-2588-y/figures/7	Moderate and severe defined in commments for Fig 1B of same publication. Plotted as log10-transformed concentrations.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	171	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL3, IL7, IL8, IL10, IL12p40, IL15, IL21, CCL2, CCL3, CCL4, CCL5, CCL15, CCL17, CCL22, CCL27, CXCL9, CXCL10, CXCL13, GCSF, TNFa, TGFa, Eotaxin2, VEGFA, EGF, sCD40L, MCSF		protein/cytokine levels	up	moderate COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 3	https://www.nature.com/articles/s41586-020-2588-y/figures/7	Moderate and severe defined in commments for Fig 1B of same publication. Plotted as log10-transformed concentrations.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	171	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL23, IFNL, Eotaxin, Eotaxin3, TSLP		protein/cytokine levels	down	moderate COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 3	https://www.nature.com/articles/s41586-020-2588-y/figures/7	Moderate and severe defined in commments for Fig 1B of same publication. Plotted as log10-transformed concentrations.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	92	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL3, IL5, IL7, IL8, IL10, IL12p40, IL15, IL21, CCL2, CCL3, CCL4, CCL5, CCL15, CCL17, CCL22, CCL27, CXCL9, CXCL10, CXCL13, GCSF, TNFa, TGFa, Eotaxin2, VEGFA, EGF, sCD40L, MCSF, GCSF, TNFb, TSLP		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 3	https://www.nature.com/articles/s41586-020-2588-y/figures/7	Moderate and severe defined in commments for Fig 1B of same publication. Plotted as log10-transformed concentrations.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	92	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL21, IL23, Eotaxin, Eotaxin2, Eotaxin3		protein/cytokine levels	down	severe COVID-19 patients vs healthy patients	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 3	https://www.nature.com/articles/s41586-020-2588-y/figures/7	Moderate and severe defined in commments for Fig 1B of same publication. Plotted as log10-transformed concentrations.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	152	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL-1Ra		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time post-symptom onset	10 to 20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 4A; 2nd paragraph under "Longitudinal..." section	https://www.nature.com/articles/s41586-020-2588-y/figures/8	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	39	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	CCL8, CCL13, CCL2		protein/cytokine levels	positively correlated	severe COVID-19 patients vs healthy patients. Correlated with NP viral load	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 6A	https://www.nature.com/articles/s41586-020-2588-y/figures/10	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	112	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	TNFb, TNFa, IL4		protein/cytokine levels	positively correlated	Correlated with NP viral load in moderate COVID-19 patients vs healthy patients.	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 6B	https://www.nature.com/articles/s41586-020-2588-y/figures/10	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	39	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL17A, IL17F, CCL2, CXCL9, IL5, IL1RA, Eotaxin, TNFa, CCL3, CCL27, TRAIL, CCL8, CCL13, CCL1, SCF		protein/cytokine levels	positively correlated	Correlated with NP viral load in severe COVID-19 patients vs healthy patients.	time post-symptom onset	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 6B	https://www.nature.com/articles/s41586-020-2588-y/figures/10	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	10	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	TNFa, IL18		protein/cytokine levels	up	COVID-19 patients: high expression (associated with higher length of hospital stay) vs low expression (associated with lower length of hospital stay)	time post-symptom onset	5 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 6C	https://www.nature.com/articles/s41586-020-2588-y/figures/10	Moderate and severe defined in commments for Fig 1B of same publication. "Length of hospital stay plotted per patient against an individual's baseline plasma cytokine measurements (<12 days from symptom onset), which were grouped according to high or low expression"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	15	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IL1RA		protein/cytokine levels	up	COVID-19 patients: high expression (associated with higher length of hospital stay) vs low expression (associated with lower length of hospital stay)	time post-symptom onset	5 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 6C	https://www.nature.com/articles/s41586-020-2588-y/figures/10	Moderate and severe defined in commments for Fig 1B of same publication. "Length of hospital stay plotted per patient against an individual's baseline plasma cytokine measurements (<12 days from symptom onset), which were grouped according to high or low expression"	
	Amani 	Simranpreet		New Haven, Connecticut, USA	20	100	years	94	Peripheral Blood Mononuclear Cells		flow cytometry; ELISA	IFNa2, IL6		protein/cytokine levels	up	deceased (during COVID-19 treatment) vs discharged (from hospital) patients	time post-symptom onset	5 to 11	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	32717743	(2020-07-27)	https://www.nature.com/articles/s41586-020-2588-y	Extended Data Fig 6D	https://www.nature.com/articles/s41586-020-2588-y/figures/10	Moderate and severe defined in commments for Fig 1B of same publication.	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD4 T cells; CD8 T cells		immune cell phenotyping; flow cytometry	naive CD4+ CD45RA+ CCR7+ T cells; naive CD8+ CD45RA+ CCR7+ T cells		cell type frequency	down	COVID-19 patient vs healthy donors	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2A ; 1st Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"nave CD4+ and CD8+ (CD45RA+CCR7+) T cells was low on day 14 (24.2% and 6%, respectively) relative to that of five healthy donors (HD) (Median [IQR] (42.9% [35.3-49.8] and 29.5% [13.4-45], respectively) and remained so to the end of the follow-up"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD4 T cells; CD8 T cells		immune cell phenotyping; flow cytometry	naive CD4+ CD45RA+ CCR7+ T cells; naive CD8+ CD45RA+ CCR7+ T cells		cell type frequency	down	COVID-19 patient vs healthy donors	time post-symptom onset	14 to 24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2A ; 1st Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"nave CD4+ and CD8+ (CD45RA+CCR7+) T cells was low on day 14...[relative to healthy donors] and remained so to the end of the follow-up"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD4 T cells; CD8 T cells		immune cell phenotyping; flow cytometry	CD4+ CCR7-CD45RA- effector memory T cells; CD8+ CCR7-CD45RA- effector memory T cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2A; 1st Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"CD4+ and CD8+ (CCR7-CD45RA-) effector memory T cells was high on day 14 (51.7 and 28.6%, respectively) relative to that of HD (28.2% [21.8-29.4] and 23.5% for CD4+ and CD8+ T cells, respectively) and peaked at day 24 (67.4% and 46.2%, respectively)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD4 T cells; CD8 T cells		immune cell phenotyping; flow cytometry	CD4+ CCR7-CD45RA- effector memory T cells; CD8+ CCR7-CD45RA- effector memory T cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2A; 1st Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"CD4+ and CD8+ (CCR7-CD45RA-) effector memory T cells...peaked at day 24 (67.4% and 46.2%, respectively) [relative to healthy donors]"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD8 T cells		immune cell phenotyping; flow cytometry	activated CD8+ T cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2b; 2nd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"Activated CD8+ T cells peaked on day 20 (27.5% and 0.6% [0.4-0.8], for the COVID-19 patient and HD [Healthy Donors], respectively)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD4 T cells; CD8 T cells		immune cell phenotyping; flow cytometry	exhausted PD1+ CD57+ CD4+ T cells; exhausted PD1+ CD57+ CD8+ T cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2c; 2nd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of exhausted and senescent CD4+ and CD8+ T cells (PD-1+CD57+) increased in the COVID-19 patient from day 14 (7.43 and 56.1%, respectively)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD4 T cells		immune cell phenotyping; flow cytometry	exhausted PD1+ CD57+ CD4+ T cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2c; 2nd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of exhausted and senescent CD4+ and CD8+ T cells (PD-1+CD57+) increased in the COVID-19 patient... peaking on day 24 for CD4+ T cells (25.3%) and...were dramatically higher than in the HD (1.6% [0.6-6.3] and 18.4%, [14-36], respectively)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD8 T cells		immune cell phenotyping; flow cytometry	exhausted PD1+ CD57+ CD8+ T cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2c; 2nd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of exhausted and senescent CD4+ and CD8+ T cells (PD-1+CD57+) increased in the COVID-19 patient... peaking on... day 22 for CD8+ T cells (68.3%) and were dramatically higher than in the HD (1.6% [0.6-6.3] and 18.4%, [14-36], respectively)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD3+ T cells		immune cell phenotyping; flow cytometry	gamma delta CD3+ T cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2d; 3rd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of gamma-delta T cells was markedly high on day 14 (92%), relative to that of the HD [Healthy Donors] (6.2% [4-8.9])"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	CD3+ T cells		immune cell phenotyping; flow cytometry	gamma delta CD3+ T cells		cell type frequency	down	COVID-19 patient: day 15 vs day 14	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2d; 3rd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of gamma-delta T cells was markedly high on day 14 (92%), relative to that of the HD (6.2% [4-8.9]), lower on day 15 (38.8%)"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	CD3+ T cells		immune cell phenotyping; flow cytometry	gamma delta CD3+ T cells		cell type frequency	up	COVID-19 patient: day 24 vs day 15	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2d; 3rd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of gamma-delta T cells was markedly high on day 14 (92%), relative to that of the HD (6.2% [4-8.9]), lower on day 15 (38.8%), and increased continuously from day 20 until day 24 (83.4%)."	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	gamma delta CD3+ T cells (delta- T cells)		immune cell phenotyping; flow cytometry	CD16		protein/cytokine levels	up	COVID-19 patient vs healthy donors	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2d; 3rd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"high frequency of the marker CD16...(83.4[%]) on day 15 relative to that of HD (40.2% [17-52] ...for CD16...) which persisted until death"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	gamma delta CD3+ T cells (delta- T cells)		immune cell phenotyping; flow cytometry	CD16		protein/cytokine levels	up	COVID-19 patient vs healthy donors	time post-symptom onset	16 to 24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2d; 3rd Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"high frequency of the marker CD16...(83.4[%]) on day 15 relative to that of HD (40.2% [17-52] ...for CD16...) which persisted until death"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD19+ B cells		immune cell phenotyping; flow cytometry	activated memory CD19+ CD27+ CD21- B cells; CD19+ CD38+ CD27+ plasmablasts/antibody-secreting cells (ASC); exhausted CD19+ CD27- CD21low/neg B cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2e; 4th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of activated memory (CD19+CD27+CD21-) B cells and plasmablasts/antibody-secreting cells (ASC) (CD19+CD38+CD27+) peaked on day 20 (24.1 and 34.3%, respectively) and was markedly higher than that in HD (2.6% [2.1-3.8] and 0.32% [0.25-0.75], respectively), as was that of exhausted CD19+CD27-CD21low/neg B cells (21.5% versus 2.1% [1.2-4.4] in HD)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD3- NK cells; CD56dim CD57+ NK cells; NK cells		immune cell phenotyping; flow cytometry	NK cell		cell type frequency	down	COVID-19 patient vs healthy donors	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2f; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"total NK cell frequency decreased from day 16 (10.3%) to day 24 (3.6%) and remained lower than in HD (40.7% [40-43])"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	CD3- NK cells; CD56dim CD57+ NK cells; NK cells		immune cell phenotyping; flow cytometry	NK cell		cell type frequency	down	COVID-19 patient: day 24 vs day 16	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2f; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"total NK cell frequency decreased from day 16 (10.3%) to day 24 (3.6%) and remained lower than in HD (40.7% [40-43])"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD3- NK cells; CD56dim CD57+ NK cells; NK cells		immune cell phenotyping; flow cytometry	NK cell		cell type frequency	down	COVID-19 patient vs healthy donors	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2f; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"total NK cell frequency decreased from day 16 (10.3%) to day 24 (3.6%) and remained lower than in HD (40.7% [40-43])"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	CD56++ CD16+ NK cells; CD56+ CD16+ NK cells		immune cell phenotyping; flow cytometry	NK CD56dim cells; NK CD56bright cells		cell type frequency	down	COVID-19 patient vs healthy donors	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2f; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"a much lower frequency of NK CD56dim cells than in HD, with a nadir at day 14 (2.2%), associated with the total absence of NK CD56bright cells (32% [28-36] and 1.7% [0.9-3.8] in HD, respectively)"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	CD56dim CD57+ NK cells		immune cell phenotyping; flow cytometry	differentiated Ki67+ CD56dim CD57+ NK cells		cell type frequency	up	COVID-19 patient: day 16 vs day 14	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2g; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"high frequency of differentiated CD56dim CD57+ NK cells was cycling (Ki67+) on day 14 (15.6%), peaked on day 16 (60.3%)"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	CD56dim CD57+ NK cells		immune cell phenotyping; flow cytometry	differentiated Ki67+ CD56dim CD57+ NK cells		cell type frequency	down	COVID-19 patient: day 24 vs day 16 	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2g; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of differentiated CD56dim CD57+ NK cells ...peaked on day 16 (60.3%), and then continuously decreased to day 24 (7.37%)"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	NK cells		immune cell phenotyping; flow cytometry	NKG2A+ NK cells		cell type frequency	up	COVID-19 patient: day 16 vs day 14	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2h; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of NK cells expressing the inhibitory marker NKG2A markedly increased from day 14 (8%) to day 16 (44.6%)"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	NK cells		immune cell phenotyping; flow cytometry	NKG2A+ NK cells		cell type frequency	up	COVID-19 patient: day 20 vs day 16 	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2h; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of NK cells expressing the inhibitory marker NKG2A ....day 16 (44.6%), peaked on day 20 (50.6%)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	NK cells		immune cell phenotyping; flow cytometry	NKG2A+ NK cells		cell type frequency	up	COVID-19 patient vs healthy donors	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2h; 5th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of NK cells expressing the inhibitory marker NKG2A ....peaked on day 20 (50.6%), and remained much higher than in HD (33% [27-41])"	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1			immune cell phenotyping; flow cytometry	classical CD14+ CD16- monocytes		cell type frequency	down	COVID-19 patient: day 20 vs day 16 	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2i; 6th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of classical CD14+CD16- monocytes steadily decreased from day 16, through days 20."..73.2% for day 16, 29.8% for day 20	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1			immune cell phenotyping; flow cytometry	classical CD14+ CD16- monocytes		cell type frequency	down	COVID-19 patient: day 22 vs day 20 	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2i; 6th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of classical CD14+CD16- monocytes steadily decreased from day 16, through days 20 and 22, to day 24" Day 20: 29.8%. Day 22: 12.2%	
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1			immune cell phenotyping; flow cytometry	classical CD14+ CD16- monocytes		cell type frequency	down	COVID-19 patient: day 24 vs day 22 	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2i; 6th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of classical CD14+CD16- monocytes steadily decreased from day 16, through days 20 and 22, to day 24". Day 22: 12.2%. Day 24: 5.7%	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6			immune cell phenotyping; flow cytometry	intermediate CD16+ CD14+ monocytes; non-classical CD14- CD16+ monocytes		cell type frequency	down	COVID-19 patient vs healthy donors	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 2i; 6th Paragraph under "Kinetics..." section	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/2  ; https://link.springer.com/article/10.1007/s10875-020-00839-x#Sec6 	"frequency of intermediate CD16+CD14+ and non-classical CD14-CD16+ monocytes remained extremely low throughout the follow-up, with a nadir at day 15 (0.4 and 0.02% versus 4.4% [2.9-5.8] and 4% [3.3-5.1] for HD, respectively)"	
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, TRAIL, IP-10, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, IL-7, Midkine, IL-1a, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, LBP, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, IL-6, MIG, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Flt-3 Ligand, IL-23, IL-17E/IL-25, CCL28, CXCL14/BRAK		protein/cytokine levels	up	COVID-19 patient at day 14 vs healthy donors at day 1	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	PDGF-BB, RANTES, EGF, Chemerin, Eotaxin, IL-31, PD-L1/B7-H1, CD40 Ligand/TNFSF5, Granzyme A		protein/cytokine levels	down	COVID-19 patient at day 14 vs healthy donors at day 1	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, TRAIL, IP-10, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, IL-7, Midkine, IL-1a, GM-CSF, IL-17, G-CSF, CD14, IL-2Ra, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, LBP, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, IL-6, MIG, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Flt-3 Ligand, IL-23, IL-17E/IL-25, IL-31, Aggrecan, PD-L1/B7-H1, CD40 Ligand/TNFSF5, Fas Ligand/TNFSF6, CCL28, CXCL14/BRAK, Granzyme A		protein/cytokine levels	up	COVID-19 patient at day 15 vs healthy donors at day 1	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	RANTES, EGF, Chemerin, Eotaxin		protein/cytokine levels	down	COVID-19 patient at day 15 vs healthy donors at day 1	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, CD163, IL-9, IL-8, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, IP-10, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, IL-7, Midkine, IL-1a, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, LBP, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, IL-6, MIG, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Flt-3 Ligand, IL-23, IL-17E/IL-25, CCL28, CXCL14/BRAK, IL-31, Aggrecan, PD-L1/B7-H1, CD40 Ligand/TNFSF5, Granzyme A		protein/cytokine levels	up	COVID-19 patient at day 16 vs healthy donors at day 1	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	PDGF-BB, RANTES, EGF, Chemerin, Eotaxin, Fas Ligand/TNFSF6		protein/cytokine levels	down	COVID-19 patient at day 16 vs healthy donors at day 1	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, IP-10, PDGF-BB, GRO-a, RANTES, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, IL-7, Midkine, IL-1a, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, LBP, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, MIG, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Flt-3 Ligand, IL-23, IL-17E/IL-25, CCL28, CXCL14/BRAK, IL-31, Aggrecan, PD-L1/B7-H1		protein/cytokine levels	up	COVID-19 patient at day 20 vs healthy donors at day 1	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	CD40 Ligand/TNFSF5, EGF, Chemerin, Eotaxin, Fas Ligand/TNFSF6		protein/cytokine levels	down	COVID-19 patient at day 20 vs healthy donors at day 1	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, IP-10, PDGF-BB, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, IL-7, Midkine, IL-1a, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, LBP, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, MIG, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Flt-3 Ligand, CXCL14/BRAK		protein/cytokine levels	up	COVID-19 patient at day 22 vs healthy donors at day 1	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	CD40 Ligand/TNFSF5, EGF, Chemerin, Eotaxin, Fas Ligand/TNFSF6, Granzyme A, CCL28, IL-31, Aggrecan, IL-6, TRAIL, RANTES		protein/cytokine levels	down	COVID-19 patient at day 22 vs healthy donors at day 1	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, TRAIL, IP-10, PDGF-BB, GRO-a, RANTES, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, IL-7, Midkine, IL-1a, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, LBP, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, MIG, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, CXCL14/BRAK		protein/cytokine levels	up	COVID-19 patient at day 24 vs healthy donors at day 1	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Males in Paris, France	21.5	80	years	6	serum		immune cell phenotyping; ELISA	CD40 Ligand/TNFSF5, EGF, Chemerin, Eotaxin, Fas Ligand/TNFSF6, Granzyme A, CCL28, IL-31, Aggrecan		protein/cytokine levels	down	COVID-19 patient at day 24 vs healthy donors at day 1	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-1ra, IFABP, TRAIL, IP-10, PDGF-BB, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, IL-1a, GM-CSF, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, MIG, IL-6, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Ftl-3 Ligand, EGF, IL-23, IL-17E/IL-25, CD40 Ligand/TNFSF5, Fas Ligand/TNFSF6, CCL28, Aggrecan		protein/cytokine levels	up	COVID-19 patient at day 14 vs septic shock patients at day 1	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, RANTES, IL-7, Midkine, IL-17, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, LBP, Chemerin, Eotaxin, CXCL14/BRAK, PD-L1/B7-H1, Granzyme A		protein/cytokine levels	down	COVID-19 patient at day 14 vs septic shock patients at day 1	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-13, IL-15, MIF, IL-16, IL-12(p40), IL-1b, IFABP, TRAIL, IP-10, PDGF-BB, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, SDF-1a, GM-CSF, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, MIP-1a, TGFa, MIP-1b, MCP-1, IFN-g, MIG, IL-6, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Ftl-3 Ligand, EGF, Chemerin, IL-23, IL-17E/IL-25, IL-31, PD-L1/B7-H1, CD40 Ligand/TNFSF5, Fas Ligand/TNFSF6, CCL28, Aggrecan, CXCL14/BRAK, Granzyme A		protein/cytokine levels	up	COVID-19 patient at day 15 vs septic shock patients at day 1	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, TNF-b, CD163, RANTES, IL-7, IL-17, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, LBP, Eotaxin		protein/cytokine levels	down	COVID-19 patient at day 15 vs septic shock patients at day 1	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	MIF, IL-1b, IFABP, TRAIL, IP-10, PDGF-BB, HGF, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, LBP, MIP-1a, TGFa, MIG, IL-6, 4-1BB/TNFRSF9/CD137, MCP-3, Ftl-3 Ligand, EGF, Chemerin, IL-23, IL-17E/IL-25, IL-31, PD-L1/B7-H1, CD40 Ligand/TNFSF5, Fas Ligand/TNFSF6, CCL28, Aggrecan, TRAIL, CXCL14/BRAK		protein/cytokine levels	up	COVID-19 patient at day 16 vs septic shock patients at day 1	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-16, IL-12(p40), IL-1ra, GRO-a, LIF, IL-2, VEGF, IL-4, IL-3, TNF-a, Basic FGF, IFN-a2, SDF-1a, RANTES, IL-7, Midkine, IL-1a, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IFN-g, IL-2Ra, Eotaxin		protein/cytokine levels	down	COVID-19 patient at day 16 vs septic shock patients at day 1	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-1ra, IFABP, TRAIL, IP-10, PDGF-BB, GRO-a, RANTES, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, SCF, Granzyme B, Fas/TNFRSF6/CD95, MCP-1, IL-21, MIP-1a, TGFa, MIG, CTACK, 4-1BB/TNFRSF9/CD137, MCP-3, Ftl-3 Ligand, EGF, Chemerin, IL-23, IL-17E/IL-25, IL-31, CD40 Ligand/TNFSF5, Fas Ligand/TNFSF6, CCL28, Aggrecan		protein/cytokine levels	up	COVID-19 patient at day 20 vs septic shock patients at day 1	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, Basic FGF, SDF-1a, IL-7, Midkine, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IFN-g, IL-2Ra, SCGF-b, LBP, Eotaxin, IL-6, CXCL14/BRAK		protein/cytokine levels	down	COVID-19 patient at day 20 vs septic shock patients at day 1	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IFABP, PDGF-BB, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, SCGF-b, MCP-1, MIP-1a, TGFa, MIG, 4-1BB/TNFRSF9/CD137, MCP-3, Ftl-3 Ligand, EGF, IL-23, CD40 Ligand/TNFSF5, CCL28, TRAIL		protein/cytokine levels	up	COVID-19 patient at day 22 vs septic shock patients at day 1	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	RANTES, IL-18, IL-13, TNF-b, Basic FGF, SDF-1a, IL-7, Midkine, GM-CSF, IL-17, G-CSF, CD14, ST2/IL-1R4, IFN-g, IL-2Ra, LBP, Eotaxin, IL-6, CXCL14/BRAK, IL-17E/IL-25, PD-L1/B7-H1, Fas Ligand/TNFSF6, Granzyme A, IL-1a		protein/cytokine levels	down	COVID-19 patient at day 22 vs septic shock patients at day 1	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, IP-10, PDGF-BB, GRO-a, RANTES, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, SCF, Granzyme B, Fas/TNFRSF6/CD95, IL-21, MCP-1, IL-17, MIP-1a, TGFa, MIG, CTACK, MCP-3, Ftl-3 Ligand, EGF, CD40 Ligand/TNFSF5, CCL28, TRAIL, IFN-a2, SDF-1a, GM-CSF, Fas Ligand/TNFSF6		protein/cytokine levels	up	COVID-19 patient at day 24 vs septic shock patients at day 1	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Mostly Males in Paris, France	45	80	years	6	serum		immune cell phenotyping; ELISA	IL-7, Midkine, G-CSF, CD14, ST2/IL-1R4, IL-2Ra, LBP, Chemerin, Eotaxin, CXCL14/BRAK, IL-17E/IL-25, PD-L1/B7-H1, Granzyme A, SCGF-b, MIP-1b		protein/cytokine levels	down	COVID-19 patient at day 24 vs septic shock patients at day 1	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	IL-18, IL-13, TNF-b, CD163, IL-9, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, M-CSF, IL-10, IL-1ra, IFABP, TRAIL, IP-10, HGF, LIF, IL-2, IL-4, IL-12(p70), SDF-1a, IL-17, CD14, Granzyme B		protein/cytokine levels	up	COVID-19 patient: day 24 vs days 22, 20, 16, 15, 14	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	SCGF-b, LBP, MIP-1a, TGFa, MIP-1b, 4-1BB/TNFRSF9/CD137, Flt-3 Ligand, CD40 Ligand/TNFSF5, CXCL14/BRAK		protein/cytokine levels	down	COVID-19 patient: day 24 vs days 22, 20, 16, 15, 14	time post-symptom onset	24	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	ST2/IL-1R4, Fas/TNFRSF6/CD95, SCGF-b		protein/cytokine levels	up	COVID-19 patient: day 22 vs days 24, 20, 16, 15, 14	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	TRAIL, IP-10, IL-6, CCL28, Fas Ligand/TNFSF6/CD95, Granzyme A		protein/cytokine levels	down	COVID-19 patient: day 22 vs days 24, 20, 16, 15, 14	time post-symptom onset	22	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	IL-9, IL-8, PDGF-BB, GRO-a, RANTES, VEGF, IL-7, Granzyme B, MIG, EGF		protein/cytokine levels	up	COVID-19 patient: day 20 vs days 24, 22, 16, 15, 14	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	IFABP, CD14		protein/cytokine levels	down	COVID-19 patient: day 20 vs days 24, 22, 16, 15, 15	time post-symptom onset	20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	IL-3, Midkine, GM-CSF, IL-21, CTACK, MCP-3, Flt-3 Ligand, Chemerin, IL-23, IL-17E/IL-25, IL-31, Aggrecan, PD-L1/B7-H1, CCL28, CD40 Ligand/TNFSF5, Fas Ligand/TNFSF6/CD95, CXCL14/BRAK, Granzyme A		protein/cytokine levels	up	COVID-19 patient: day 15 vs days 24, 22, 20, 16, 14	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	CD163, M-CSF, ST2/IL-1R4		protein/cytokine levels	down	COVID-19 patient: day 15 vs days 24, 22, 20, 16, 14	time post-symptom onset	15	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	IL-13, TNF-b, CD163, IL-8, IL-15, MIF, IL-16, IL-12(p40), IL-1b, IL-10, IL-1ra, GRO-a, b-NGF, HGF, IL-5, LIF, IL-2, VEGF, IL-4, IL-3, IL-12(p70), TNF-a, Basic FGF, IFN-a2, IL-7, SDF-1a, Midkine, GM-CSF, IL-17, IL-1a, G-CSF, MCP-1, IFN-g, CTACK, Eotaxin		protein/cytokine levels	down	COVID-19 patient: day 16 vs days 24, 22, 20, 16, 15	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	LBP		protein/cytokine levels	up	COVID-19 patient: day 16 vs days 24, 22, 20, 16, 15	time post-symptom onset	16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	IL-1ra, IFABP, TRAIL, IP-10, p-NGF, HGF, LIF, IL-2, SDF-1a, IL-1a, IL-17		protein/cytokine levels	up	COVID-19 patient: day 14 vs days 22, 20, 16, 15	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	Basic FGF, MIP-1a, SCF, IFN-a2, TNF-a, VEGF, IL-5, G-CSF, TGFa, MIP-1b, MCP-1, IFN-g, IL-6, 4-1BB/TNFRSF9/CD137		protein/cytokine levels	up	COVID-19 patient: day 14 vs days 24, 22, 20, 16, 15	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Male in Paris, France	80	80	years	1	serum		immune cell phenotyping; ELISA	IL-9, RANTES, Granzyme B, EGF, Chemerin, PD-L1/B7-H1, CD40 Ligand/TNFSF5		protein/cytokine levels	down	COVID-19 patient: day 14 vs days 24, 22, 20, 16, 15	time post-symptom onset	14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	chronic	32829467	(2020-08-22)	https://link.springer.com/article/10.1007/s10875-020-00839-x	Fig 3.	https://link.springer.com/article/10.1007/s10875-020-00839-x/figures/3		
	Amani 	Simranpreet		Caucasians in Sassari, Italy	59	90	years	60			venepuncture	whole blood cells (WBCs); monocytes; neutrophils		cell type frequency	down	COVID-19 pneumonia patients vs non-COVID-19 pneumonia patients	time since hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32794454	(2020-07-31)	https://jidc.org/index.php/journal/article/view/32794454/2297	Table 2.	https://jidc.org/index.php/journal/article/view/32794454/2297	"cases with COVID-19 and non-COVID-19 pneumonia were matched for age and gender" "COVID-19 patients were  more  often  smokers  (66%  vs.  20%,  p  =  0.0003)  and  more  likely  to  die  during  the  follow-up  (30%  vs.  3%, p = 0.006)."	
	Amani 	Simranpreet		Caucasians in Sassari, Italy	59	90	years	60			venepuncture	platelets; lymphocyte:monocyte		cell type frequency	up	COVID-19 pneumonia patients vs non-COVID-19 pneumonia patients	time since hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32794454	(2020-07-31)	https://jidc.org/index.php/journal/article/view/32794454/2297	Table 2.	https://jidc.org/index.php/journal/article/view/32794454/2297	-also had higher MPV values (Mean Platelet Volume). Lymphocyte-to-monocyte ratio (LMR) was higher in COVID-19 pneumonia patients vs non-COVID-19 pneumonia patients 	
	Amani 	Simranpreet		Caucasians in Sassari, Italy	59	90	years	60			venepuncture	C-reactive protein (CRP)		protein/cytokine levels	down	COVID-19 pneumonia patients vs non-COVID-19 pneumonia patients	time since hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32794454	(2020-07-31)	https://jidc.org/index.php/journal/article/view/32794454/2297	Table 2.	https://jidc.org/index.php/journal/article/view/32794454/2297	"cases with COVID-19 and non-COVID-19 pneumonia were matched for age and gender" "COVID-19 patients were  more  often  smokers  (66%  vs.  20%,  p  =  0.0003)  and  more  likely  to  die  during  the  follow-up  (30%  vs.  3%, p = 0.006)."	
	Amani 	Simranpreet		Caucasians in Sassari, Italy	59	90	years	60			venepuncture	Alanine Aminotransferase: Aspartate aminotransferase (AST/ALT)		protein/cytokine levels	up	COVID-19 pneumonia patients vs non-COVID-19 pneumonia patients	time since hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32794454	(2020-07-31)	https://jidc.org/index.php/journal/article/view/32794454/2297	Table 2.	https://jidc.org/index.php/journal/article/view/32794454/2297	-the De Ritis ratio (Alanine Aminotransferase/Aspartate aminotransferase (AST/ALT)) was significantly higher in COVID-19 pneumonia patients vs non-COVID-19 pneumonia patients	
	Amani 	Simranpreet		Caucasian COVID-19 Patients in Sassari, Italy	59	90	years	30			venepuncture	neutrophils; neutrophil:lymphocyte		cell type frequency	up	COVID-19 pneumonia non-survivors vs COVID-19 pneumonia survivors 	time since hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32794454	(2020-07-31)	https://jidc.org/index.php/journal/article/view/32794454/2297	Table 3.	https://jidc.org/index.php/journal/article/view/32794454/2297	-Neutrophil-to-Lymphocyte ratio (NLR) & derived NLR were significantly higher in non-survivors than in survivors	
	Amani 	Simranpreet		Caucasian COVID-19 Patients in Sassari, Italy	59	90	years	30			venepuncture	platelets		cell type frequency	down	COVID-19 pneumonia non-survivors vs COVID-19 pneumonia survivors 	time since hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32794454	(2020-07-31)	https://jidc.org/index.php/journal/article/view/32794454/2297	Table 3.	https://jidc.org/index.php/journal/article/view/32794454/2297	"cases with COVID-19 and non-COVID-19 pneumonia were matched for age and gender" "COVID-19 patients were  more  often  smokers  (66%  vs.  20%,  p  =  0.0003)  and  more  likely  to  die  during  the  follow-up  (30%  vs.  3%, p = 0.006)."	
	Amani 	Simranpreet		Caucasian COVID-19 Patients in Sassari, Italy	59	90	years	30			venepuncture	Alanine Aminotransferase:Aspartate aminotransferase (AST/ALT)		protein/cytokine levels	up	COVID-19 pneumonia non-survivors vs COVID-19 pneumonia survivors 	time since hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32794454	(2020-07-31)	https://jidc.org/index.php/journal/article/view/32794454/2297	Table 3.	https://jidc.org/index.php/journal/article/view/32794454/2297	"cases with COVID-19 and non-COVID-19 pneumonia were matched for age and gender" "COVID-19 patients were  more  often  smokers  (66%  vs.  20%,  p  =  0.0003)  and  more  likely  to  die  during  the  follow-up  (30%  vs.  3%, p = 0.006)."	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	CD83, NFKBIA, CCL3, OSM, JUN, PLK2, SOCS1, GADD45B, PMAIP1, CD69, SOCS3, NR4A1, TNF, CXCR4, DUSP8, NR4A3, AREG, NR4A2, ZC3H12A, DUSP2, AVPI1, TEX14, SAMSN1, IFNG, MAP3K8, FFAR2		gene expression	up	rehabilitation stage vs treatment & convalescence stages	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 2a.	https://www.nature.com/articles/s41392-020-00457-4/figures/2/	Treatment stage = immediately after hospital admission & treated with medicine. Convalescence stage = once the body temperature is normal for +3 days and minimum 2 consecutive negative COVID-19 tests at least one day apart "After the body temperature was normal for more than 3 days and at least two consecutive SARS-CoV-2 nucleic acid tests for respiratory samples (throat swab, nasopharyngeal swab, and sputum) were negative at least one day apart". Rehabilitation stage = hospital discharge, "SpO2 and RR returned to normal in severe patients, CT imaging of the lungs showed obvious absorption of inflammation, and the nucleic acid tests were negative on 2 consecutive occasions "	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	MZB1, IGKC, TXNDC5, IFI27, FUT7, SGMS2, FPR2, DUSP6, THBD, GIMAP8, PDK4, B4GALT6, TNFSF14, CXCR2, KMO, CD180, CXCL8, CXCL2, LILRA4, EGR1		gene expression	down	rehabilitation stage vs treatment & convalescence stages	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 2a.	https://www.nature.com/articles/s41392-020-00457-4/figures/2/	Treatment stage = immediately after hospital admission & treated with medicine. Convalescence stage = once the body temperature is normal for +3 days and minimum 2 consecutive negative COVID-19 tests at least one day apart "After the body temperature was normal for more than 3 days and at least two consecutive SARS-CoV-2 nucleic acid tests for respiratory samples (throat swab, nasopharyngeal swab, and sputum) were negative at least one day apart". Rehabilitation stage = hospital discharge, "SpO2 and RR returned to normal in severe patients, CT imaging of the lungs showed obvious absorption of inflammation, and the nucleic acid tests were negative on 2 consecutive occasions "	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	PMAIP1, CD69, SOCS3, NR4A1, TNF, CXCR4, DUSP8, NR4A3, AREG, NR4A2, ZC3H12A, DUSP2, AVPI1, TEX14, SAMSN1, IFNG, MAP3K8, FFAR2, MZB1, IGKC, TXNDC5, IFI27, FUT7, SGMS2, FPR2, DUSP6, THBD, GIMAP8, PDK4, B4GALT6, TNFSF14, CXCR2, KMO, CD180, CXCL8		gene expression	down	convalescence stage vs treatment stage	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 2a.	https://www.nature.com/articles/s41392-020-00457-4/figures/2/	Treatment stage = immediately after hospital admission & treated with medicine. Convalescence stage = once the body temperature is normal for +3 days and minimum 2 consecutive negative COVID-19 tests at least one day apart "After the body temperature was normal for more than 3 days and at least two consecutive SARS-CoV-2 nucleic acid tests for respiratory samples (throat swab, nasopharyngeal swab, and sputum) were negative at least one day apart". Rehabilitation stage = hospital discharge, "SpO2 and RR returned to normal in severe patients, CT imaging of the lungs showed obvious absorption of inflammation, and the nucleic acid tests were negative on 2 consecutive occasions "	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	AL355916.3-AS-2 (HIF1A); MAP3K8-AS-1 (MAP3K8); SLC2A3-AS-1 (SLC2A3); LRIG1-AS-1 (LRIG1); ARRDC3-AS-2 (ARRDC3); LITAF-AS-1 (LITAF); FOSL2-AS-1 (FOSL2); SLC38A2-AS-2 (SLC38A2); SLC38A2-AS-1 (SLC38A2); RNF103-AS-1 (RNF103); LINC-SLC38A2-1 (SLC38A2); LINC-DNAJB1-1 (DNAJB1); RORA-AS-8 (RORA); RORA-AS-7 (RORA); GPR174-AS-1 (GPR174); LINC-LITAF-1 (LITAF); PDCD4-AS-1 (PDCD4); UBE2B-AS-1 (UBE2B); LITAF-AS-2 (LITAF); LINC-ARL4C-6 (ARL4C); WDR37-AS-1 (IDI1); LINC-RHOB-1 (RHOB); DUSP10-AS-1 (DUSP10); CREM-AS-1 (CREM); LINC-NFKBIZ-1 (NFKBIZ); hsa-miR-186-5p (FRMD4B); hsa-miR-141-3p (YWHAG, IL6R); EIF4A2-AS-1 (EIF4A2); LINC-DUSP2-2 (DUSP2); LINC-IER5-2 (IER5); LINC-ARL4C-2 (ARL4C); SMCDH1-AS-2 (SMCHD1); PDE3B-AS-2 (PDE3B)		gene expression	up	rehabilitation stage vs treatment & convalescence stages	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 2b	https://www.nature.com/articles/s41392-020-00457-4/figures/2/	expression profile of DEmiRNA and DElncRNA (differentially expressed microRNA and long noncoding RNA). Genes are in parentheses after each response component (lncRNA or miRNA). Treatment stage = immediately after hospital admission & treated with medicine. Convalescence stage = once the body temperature is normal for +3 days and minimum 2 consecutive negative COVID-19 tests at least one day apart "After the body temperature was normal for more than 3 days and at least two consecutive SARS-CoV-2 nucleic acid tests for respiratory samples (throat swab, nasopharyngeal swab, and sputum) were negative at least one day apart". Rehabilitation stage = hospital discharge, "SpO2 and RR returned to normal in severe patients, CT imaging of the lungs showed obvious absorption of inflammation, and the nucleic acid tests were negative on 2 consecutive occasions "	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	hsa-miR-12136 (RORA); hsa-miR-130a-5p (PDE4D); hsa-miR-501-3p (RORA); hsa-miR-20b-5p (RORA, PIK3R1); hsa-miR-421 (RAB30); hsa-miR-23a-3p (TBC1D15, KLF3); hsa-miR-200c-3p (ZEB1, SFXN1); hsa-miR-127-5p (BHLHE40); hsa-miR-539-5p (RORA); hsa-miR-15b-5p (TGFBR3, BTG2); FKBP5-AS-1 (FKBP5)		gene expression	down	rehabilitation stage vs treatment & convalescence stages	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 2b	https://www.nature.com/articles/s41392-020-00457-4/figures/2/	expression profile of DEmiRNA and DElncRNA (differentially expressed microRNA and long noncoding RNA). Genes are in parentheses after each response component (lncRNA or miRNA). Treatment stage = immediately after hospital admission & treated with medicine. Convalescence stage = once the body temperature is normal for +3 days and minimum 2 consecutive negative COVID-19 tests at least one day apart "After the body temperature was normal for more than 3 days and at least two consecutive SARS-CoV-2 nucleic acid tests for respiratory samples (throat swab, nasopharyngeal swab, and sputum) were negative at least one day apart". Rehabilitation stage = hospital discharge, "SpO2 and RR returned to normal in severe patients, CT imaging of the lungs showed obvious absorption of inflammation, and the nucleic acid tests were negative on 2 consecutive occasions "	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	AL355916.3-AS-2 (HIF1A); MAP3K8-AS-1 (MAP3K8); SLC2A3-AS-1 (SLC2A3); LRIG1-AS-1 (LRIG1); ARRDC3-AS-2 (ARRDC3); LITAF-AS-1 (LITAF); FOSL2-AS-1 (FOSL2); SLC38A2-AS-2 (SLC38A2); SLC38A2-AS-1 (SLC38A2); RNF103-AS-1 (RNF103); LINC-SLC38A2-1 (SLC38A2); LINC-DNAJB1-1 (DNAJB1); RORA-AS-8 (RORA); RORA-AS-7 (RORA); GPR174-AS-1 (GPR174); LINC-LITAF-1 (LITAF); PDCD4-AS-1 (PDCD4); UBE2B-AS-1 (UBE2B); LITAF-AS-2 (LITAF); LINC-ARL4C-6 (ARL4C); WDR37-AS-1 (IDI1); LINC-RHOB-1 (RHOB)		gene expression	down	convalescence stage vs treatment stage	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 2b	https://www.nature.com/articles/s41392-020-00457-4/figures/2/	expression profile of DEmiRNA and DElncRNA (differentially expressed microRNA and long noncoding RNA). Genes are in parentheses after each response component (lncRNA or miRNA). Treatment stage = immediately after hospital admission & treated with medicine. Convalescence stage = once the body temperature is normal for +3 days and minimum 2 consecutive negative COVID-19 tests at least one day apart "After the body temperature was normal for more than 3 days and at least two consecutive SARS-CoV-2 nucleic acid tests for respiratory samples (throat swab, nasopharyngeal swab, and sputum) were negative at least one day apart". Rehabilitation stage = hospital discharge, "SpO2 and RR returned to normal in severe patients, CT imaging of the lungs showed obvious absorption of inflammation, and the nucleic acid tests were negative on 2 consecutive occasions "	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	DUSP10-AS-1 (DUSP10); CREM-AS-1 (CREM); LINC-NFKBIZ-1 (NFKBIZ); hsa-miR-186-5p (FRMD4B); hsa-miR-141-3p (YWHAG, IL6R); EIF4A2-AS-1 (EIF4A2); LINC-DUSP2-2 (DUSP2); LINC-IER5-2 (IER5); LINC-ARL4C-2 (ARL4C); SMCDH1-AS-2 (SMCHD1); PDE3B-AS-2 (PDE3B); hsa-miR-12136 (RORA); hsa-miR-130a-5p (PDE4D)		gene expression	up	convalescence stage vs treatment stage	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 2b	https://www.nature.com/articles/s41392-020-00457-4/figures/2/	expression profile of DEmiRNA and DElncRNA (differentially expressed microRNA and long noncoding RNA). Genes are in parentheses after each response component (lncRNA or miRNA). Treatment stage = immediately after hospital admission & treated with medicine. Convalescence stage = once the body temperature is normal for +3 days and minimum 2 consecutive negative COVID-19 tests at least one day apart "After the body temperature was normal for more than 3 days and at least two consecutive SARS-CoV-2 nucleic acid tests for respiratory samples (throat swab, nasopharyngeal swab, and sputum) were negative at least one day apart". Rehabilitation stage = hospital discharge, "SpO2 and RR returned to normal in severe patients, CT imaging of the lungs showed obvious absorption of inflammation, and the nucleic acid tests were negative on 2 consecutive occasions "	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	AREG, H4C15, DUSP2, DUSP8, NR4A3, OSM, WNT7A, ZC3H12A, CD83, CXCR4, JUN, SOCS1, TRAF4, PIM3, HCRTR1, CCL3L3, DDIT4, IL1B, PER1		gene expression	up	severe COVID-19 patients vs moderate & mild COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from up-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	TNF, IFNG, SERTAD1, IL5RA, H2BC3, H2BC8, H1-4, H1-2, AVPI1, MAP3K8, DENND2B, TSPYL2, HEXIM1, H2BC18, H2BC5, H2AX, H3C12, H4C5		gene expression	down	severe COVID-19 patients vs moderate & mild COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from up-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	AREG, DUSP2, DUSP8, NR4A3, CD83, CXCR4, SOCS1, SOCS3, SIK1B, DUSP5, DLG2, NFKBIZ, TRAF4, PIM3, DDIT4, IL1B, PER1, PIK3R1, DUSP10, H3-3B		gene expression	down	mild COVID-19 patients vs severe & moderate COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from up-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	PLK2, TNF, SERTAD1, FFAR2, IL5RA, H2BC3, H2BC8, H2BC18		gene expression	up	mild COVID-19 patients vs severe & moderate COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from up-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	H2C15, OSM, IGFBP3, JUN, GADD45B, SERTAD1, FFAR2, HCRTR1, CCL3L3, H4-16		gene expression	down	moderate COVID-19 patients vs severe & mild COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from up-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	IFNG, SOCS1, SOCS3, SIK1B, DUSP5, DLG2, NFKBIZ, H1-4, H1-2, PIK3R1, MAP3K8, DENND2B, TSPYL2, HEXIM1, H3C12, H4C5		gene expression	up	moderate COVID-19 patients vs severe & mild COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from up-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	LILRA4, CHID1, OAS1, CX3CR1, TNFAIP8L2, CD180, FPR2, IGHV3-7, IGHV3-11, IGHV4-34, IGHV3-23, IGHV5-51, IGLV2-14, IGKV3-20, TXNDC5, IGHV6-1, IGKV1D-39, IGHV3-21, IGLV3-21, LCN2, IGLV1-44, IGHV2-5, IGLV1-40, IGLV1-51, IGHV4-59, IGHV1-69D, IGHV3-30, IGKV4-1, IGLV1-47, IGHV3-49, IGHV3-48, TICAM2, IGLV3-19, MZB1, IGKV2-28, IGKV3-15, IGHV2-26, IGLV3-25, IGHG3, IGLV3-1, IGLV7-43, IGHG1, IGHV2-70, JCHAIN, IGHV4-39, IGHV3-64D, IGHV3-73		gene expression	down	severe COVID-19 patients vs moderate & mild COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from down-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	RSAD2, IL1RAP, IFIT3, MUC6, IFI27		gene expression	down	mild COVID-19 patients vs severe & moderate COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from down-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	CHID1, TNFAIP8L2, CD180, IGHV3-7, IGHV3-11, IGHV3-23, IGHV5-51, IGKV3-20, IGLV2-14, IGLV3-21, LCN2, IGLV1-44, IGHV1-69D, IGHV3-30, IGLV1-47, TICAM2, IGLV3-19, MZB1, IGLV3-1, IGLV7-43, IGHV2-70, IGHV3-64D, IGHV3-73		gene expression	up	mild COVID-19 patients vs severe & moderate COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from down-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	CDC42EP2, IGHV3-73, IGHV2-70		gene expression	down	moderate COVID-19 patients vs severe & mild COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from down-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	XAF1, IL1RAP, IFIT3, OAS1, CX3CR1, EGR1, MUC6, IFI27, TNFAIP8L2, IGHV2-5		gene expression	up	moderate COVID-19 patients vs severe & mild COVID-19 patients	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 3b	https://www.nature.com/articles/s41392-020-00457-4/figures/3/	Core genes from down-regulated gene sets (GO) in Recovery from COVID-19 (convalescence stage & rehabilitation stage) vs treatment stage. Measured in slope(log2 FC) ("slope of the linear regression equation of Log2 fold change of DEG")	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	LINC-YWHAZ-1; CDKN1A-AS-1; HLA-DRB1-AS-4; AL355916.3-AS-2; OSM; CCL3L3; CCL3-AS-1; CXCR4; IFNG; PIK3R1; CXCR5-AS-1; hsa-miR-141-3p; KRAS-AS-1; RIPK1-AS-1; AREG; LINC-ATF4-2; NR4A1; SOCS3; JUNB; NFKB1-AS-1; DUSP8; LINC-DUSP2-2; hsa-miR-31-5p; RASGRP1-AS-2; MAP3K8; JUN; CXCL8; CXCL2; TNF; DUSP2; NLRP3-AS-1; LINC-TNFAIP3-1; GADD45B; MAP3K8-AS-1; DUSP10-AS-1; LINC-JUND-1; MALT1-AS-2; IL1b; IL6; Tnf; AP-1; Bcbeta; Nfkbia; Socs3; Tnfaip3; Tp12; NF-kappaB; IkappaBalpha; NF-kappaB; Ptgs2; c-Jun; TNFlambdaTA		gene expression	up	Recovery from COVID-19 (convalescence & rehabilitation stages) vs treatment stage	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 5a-b	https://www.nature.com/articles/s41392-020-00457-4/figures/5/	Colors in Fig 5a-b "maps the linear regression slope of Log2 fold change of a gene". "The genes displayed are selected from the DEGs and the genes regulated by DEmiRNAs or DElncRNAs with a more significant differential expression..."	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	TLR2; CX3CR1; YWHAG; CCR1; hsa-miR-12136; FLT3; IL1RAP; DUSP6; hsa-miR-2115-3p; LINC-IFI16-1; OAS1; IFI16-AS-1; IKBKE-AS-1; TICAM2; TNFSF14; BLNK; TRAF2; IKKs; CREB; MKK3J6; TRAF2sigma; TAB1sigmabeta; TNFR1; IL15; FADD; Ccl2; Cxcl1; Cxcl2; Cxcl3; Cxcl10		gene expression	down	Recovery from COVID-19 (convalescence & rehabilitation stages) vs treatment stage	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 5a-b	https://www.nature.com/articles/s41392-020-00457-4/figures/5/	Colors in Fig 5a-b "maps the linear regression slope of Log2 fold change of a gene". "The genes displayed are selected from the DEGs and the genes regulated by DEmiRNAs or DElncRNAs with a more significant differential expression..."	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2; WGCNA	black module; tan module		gene expression	positively correlated	correlated with clinical stage	time since hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 6b	https://www.nature.com/articles/s41392-020-00457-4/figures/6/		
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2; WGCNA	purple module; grey60 module; green module; greenyellow module		gene expression	negatively correlated	correlated with clinical stage	time since hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 6b	https://www.nature.com/articles/s41392-020-00457-4/figures/6/		
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2; WGCNA	lightcyan module		gene expression	negatively correlated	correlated with clinical stage	time since hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 6b	https://www.nature.com/articles/s41392-020-00457-4/figures/6/		
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2; WGCNA	greenyellow module		gene expression	positively correlated	correlated with clinical type 	time since hospital admission	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig 6b	https://www.nature.com/articles/s41392-020-00457-4/figures/6/		
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	CCL3L3, CXCL2, CXCL8, IL1B, H2AC18, ZNF250, GLDC		gene expression	up	convalescence stage vs treatment stage	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/		
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	LINC-PID1-2, SETD5-AS-1, PDCD4-AS-1, LINC-SDE2-1, PYHIN1-AS-1, FLI1-AS-3, CNCT2-AS-2, LINC-NBPF14-1, AL355916.3-AS-2, PRR5L-AS-3, IRS2-AS-1, TIMP2-AS-1, LINC-PARP16-2, H2BC11-AS-1, SUN2-AS-4, SLC38A2-AS-2, COTL1-AS-3, hsa-miR-7706, hsa-miR-98-3p, hsa-miR-10395-3p, hsa-miR-6842, hsa-miR-3615, hsa-miR-10395-3p, hsa-miR-340-3p, hsa-miR-128-3p, hsa-miR-128-3p, hsa-miR-4485-3p, hsa-miR-190a-3p, hsa-let-7a-3p, hsa-miR-511-5p, hsa-miR-1908-5p, X_45691, hsa-miR-12136, hsa-miR-548d-3p, hsa-miR-548d-3p, hsa-miR-581, hsa-miR-2115-3p		gene expression	up	rehabilitation stage vs convalescence stage	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/		
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	CCL3-AS-1, LINC-PID1-2, FAM72B-AS-1, LINC-H2BC21-1, LINC-TRIM69-1, LINC-PPIAL4F-4, LINC-H2BC5-1, SCOC-AS-2, TEX14-AS-2, LINC-DUSP1-2, COTL1-AS-3, NLRP3-AS-2, DKK1-AS-1, KPNB1-AS-2, hsa-miR-10395-3p, hsa-miR-195-3p, hsa-miR-139-5p, hsa-miR-877-5p, hsa-miR-92b-3p, hsa-miR-671-3p, hsa-miR-1908-5p, hsa-miR-4646-3p, hsa-miR-26b-5p, hsa-miR-144-5p, hsa-miR-144-3p, hsa-miR-138-5p, hsa-miR-138-5p, hsa-miR-10399-3p, hsa-miR-1249-5p, hsa-miR-276-3p		gene expression	up	convalescence stage vs treatment stage	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	differentially expressed lncRNAs & miRNAs (2nd & 3rd rows)	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	SETD5-AS-1, LINC-NBPF14-1, LINC-SLC3A2-1, ZBTB37-AS-1, LIN-IER5-2, LINC-EAPP-3, CALM1-AS-1, C12orf57-AS-1, SARAF-AS-1, LINC-DUSP2-2, LINC-TRIM69-1, LINC-DUSP1-2, ACTG1-AS-1, B4GALT4-AS-1, LINC-IBTK-5, IRS2-AS-1, LINC-RBM24-3, LINC-HSP90AA-1-1, LINC-DARS2-1, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-192a-5p, hsa-miR-652a-3p, hsa-miR-4521, hsa-miR-132-5p, hsa-miR-708a-3p, hsa-let-7d-3p, hsa-miR-218-5p, hsa-miR-218-5p, hsa-miR-432-5p, hsa-miR-3194-3p, hsa-miR-511-5p, hsa-miR-4485-3p, hsa-miR-509-5p, hsa-miR-509-5p		gene expression	up	rehabilitation stage vs treatment stage	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	differentially expressed lncRNAs & miRNAs (2nd & 3rd rows)	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	hsa-miR-100-5p, hsa-miR-10395-3p, hsa-miR-138-5p, hsa-miR-144-5p, hsa-miR-144-3p, hsa-miR-181c-5p, hsa-miR-186-5p, hsa-miR-26a-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-32-5p, hsa-miR-388-3p, hsa-miR-33a-3p, hsa-miR-374a-5p, hsa-miR-374b-5p, hsa-miR-374c-5p, hsa-miR-376a-3p, hsa-miR-376a-3p, hsa-miR-4772-5p, hsa-miR-4791, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-548w, hsa-miR-6718-5p, hsa-miR-95-3p, X_46332		gene expression	up	convalescence stage (stage 2) vs treatment stage (stage 1)	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 2.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-miRNA	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	hsa-let-7e-5p, hsa-miR-10399-3p, hsa-miR-10a-5p, hsa-miR-11400, hsa-miR-1249-5p, hsa-miR-1273h-3p, hsa-miR-130b-5p, hsa-miR-139-5p, hsa-miR-139-3p, hsa-miR-145-5p, hsa-miR-1908-5p, hsa-miR-195-3p, hsa-miR-320a-3p, hsa-miR-328-3p, hsa-miR-3615, hsa-miR-423-5p, hsa-miR-423-3p, hsa-miR-424-3p, hsa-miR-4646-3p, hsa-miR-4659b-3p, hsa-miR-484, hsa-miR-490-3p, hsa-miR-5193, hsa-miR-584-5p, hsa-miR-625-3p, hsa-miR-6501-5p, hsa-miR-671-3p, hsa-miR-6772-3p, hsa-miR-6842-3p, hsa-miR-7706, hsa-miR-7977, hsa-miR-877-5p, hsa-miR-92b-3p, hsa-miR-941, hsa-miR-941, hsa-miR-941, hsa-miR-941, hsa-miR-941, hsa-miR-942-5p, 20_26672, 3_30806		gene expression	down	convalescence stage (stage 2) vs treatment stage (stage 1)	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 2.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-miRNA	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	hsa-let-7a-3p, hsa-miR-10a-5p, hsa-miR-11400, hsa-miR-1249-5p, hsa-miR-125a-5p, hsa-miR-126-3p, hsa-miR-1260a, hsa-miR-1260b, hsa-miR-1268a, hsa-miR-1268a, hsa-miR-1268b, hsa-miR-1271-5p, hsa-miR-1273h-3p, hsa-miR-1275, hsa-miR-1278, hsa-miR-128-3p, hsa-miR-128-3p, hsa-miR-1291, hsa-miR-1298-5p, hsa-miR-1306-5p, hsa-miR-1307-5p, hsa-miR-130b-5p,  hsa-miR-132-5p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-142-5p, hsa-miR-142-3p, hsa-miR-1468-5p, hsa-miR-147b-3p, hsa-miR-148b-5p, hsa-miR-150-5p, hsa-miR-150-3p, hsa-miR-151a-3p, hsa-miR-181a-3p, hsa-miR-181a-2-3p, hsa-miR-181c-3p, hsa-miR-188-5p, hsa-miR-1908-5p, hsa-miR-192-5p, hsa-miR-195-3p, hsa-miR-200a-5p, hsa-miR-215-5p, hsa-miR-24-1-5p, hsa-miR-24-3p, hsa-miR-24-3p, hsa-miR-24-2-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-29a-3p, hsa-miR-301a-5p, hsa-miR-3074-5p, hsa-miR-30a-3p, hsa-miR-30c-5p, hsa-miR-30c-5p, hsa-miR-30d-3p, hsa-miR-30e-3p, hsa-miR-31-5p, hsa-miR-3150a-5p, hsa-miR-3157-3p, hsa-miR-3158-3p, hsa-miR-3158-3p, hsa-miR-3194-3p, hsa-miR-32-3p, hsa-miR-320a-3p, hsa-miR-320b, hsa-miR-320b, hsa-miR-328-3p, hsa-miR-330-5p, hsa-miR-331-5p, hsa-miR-339-3p, hsa-miR-340-3p, hsa-miR-345-5p, hsa-miR-3615, hsa-miR-363-3p, hsa-miR-370-3p, hsa-miR-378a-5p, hsa-miR-378d, hsa-miR-378d, hsa-miR-3909, hsa-miR-3912-3p, hsa-miR-423-5p, hsa-miR-423-3p, hsa-miR-4473, hsa-miR-4521, hsa-miR-484, hsa-miR-4659b-3p, hsa-miR-4661-5p, hsa-miR-4662a-5p, hsa-miR-4746-5p, hsa-miR-4772-5p, hsa-miR-493-3p, hsa-miR-499a-5p, hsa-miR-509-3-5p, hsa-miR-5100, hsa-miR-511-5p, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-5193, hsa-miR-543, hsa-miR-548ah-3p, hsa-miR-548av-3p, hsa-miR-548av-3p, hsa-miR-548o-3p, hsa-miR-548av-3p, hsa-miR-548o-3p, hsa-miR-548p, hsa-miR-548ah-3p, hsa-miR-548av-3p, hsa-miR-548av-3p, hsa-miR-552-3p, hsa-miR-556-5p, hsa-miR-580-3p, hsa-miR-581, hsa-miR-627-3p, hsa-miR-642a-5p, hsa-miR-6503-3p, hsa-miR-6513-3p, hsa-miR-659-5p, hsa-miR-671-3p, hsa-miR-6737-3p, hsa-miR-6772-3p, hsa-miR-6806-3p, hsa-miR-6842-3p, hsa-miR-6843-3p, hsa-miR-6852-3p, hsa-miR-6868-3p, hsa-miR-7-1-3p, hsa-miR-708-3p, hsa-miR-7706, hsa-miR-873-5p, hsa-miR-874-3p, hsa-miR-877-3p, hsa-miR-941, hsa-miR-941, hsa-miR-941, hsa-miR-941, hsa-miR-941, hsa-miR-9985, hsa-miR-99a-5p, 10_5081, 12_10755, 12_11464, 12_09959, 14_12653, 19_21335, 19_21414, 19_22404, 1_2457, 20_26672, 21_27422, 21_27527, 21_27824, 2_23385, 3_30806, 5_35532, 6_36051, 8_41549, GL000221.1_46977, KI270742.1_46865, X_45571, X_45691		gene expression	up	rehabilitation stage (stage 3) vs convalescence stage (stage 2)	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 2.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-miRNA	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	hsa-let-7b-5p, hsa-let-7b-3p, hsa-let-7d-5p, hsa-let-7d-3p, hsa-let-7f-1-3p, hsa-let-7f-2-3p, hsa-miR-10395-3p, hsa-miR-10399-5p, hsa-miR-103a-2-5p, hsa-miR-12136, hsa-miR-1246, hsa-miR-127-5p, hsa-miR-1277-5p, hsa-miR-1296-5p, hsa-miR-1301-3p, hsa-miR-130a-5p, hsa-miR-130a-3p, hsa-miR-133a-3p, hsa-miR-133a-3p, hsa-miR-133b, hsa-miR-134-5p, hsa-miR-144-5p,  hsa-miR-144-3p, hsa-miR-145-3p, hsa-miR-146a-5p, hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-16-5p, hsa-miR-181c-5p, hsa-miR-182-5p, hsa-miR-183-5p, hsa-miR-190a-5p, hsa-miR-190b-5p, hsa-miR-191-5p, hsa-miR-200c-3p, hsa-miR-20a-3p, hsa-miR-20b-5p, hsa-miR-21-3p, hsa-miR-2115-5p, hsa-miR-2115-3p, hsa-miR-233-3p, hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-miR-26a-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-299-5p, hsa-miR-3065-5p, hsa-miR-3140-3p, hsa-miR-324-5p, hsa-miR-324-3p, hsa-miR-326, hsa-miR-329-3p, hsa-miR-329-3p, hsa-miR-337-3p, hsa-miR-388-5p, hsa-miR-33a-3p, hsa-miR-34a-5p, hsa-miR-3605-3p, hsa-miR-3609, hsa-miR-365a-5p, hsa-miR-369-3p, hsa-miR-374a-5p, hsa-miR-374b-5p, hsa-miR-382-5p, hsa-miR-365a-5p, hsa-miR-369-3p, hsa-miR-370-3p, hsa-miR-374a-5p, hsa-miR-374b-5p, hsa-miR-376a-3p, hsa-miR-376a-3p, hsa-miR-376c-3p, hsa-miR-377-5p, hsa-miR-382-5p, hsa-miR-421, hsa-miR-424-5p, hsa-miR-4454, hsa-miR-425-3p, hsa-miR-431-5p, hsa-miR-431-3p, hsa-miR-432-5p, hsa-miR-4485-3p, hsa-miR-451a, hsa-miR-4775, hsa-miR-485-5p, hsa-miR-485-3p, hsa-miR-486-5p, hsa-miR-486-5p, hsa-miR-491-5p, hsa-miR-493-5p, hsa-miR-494-3p, hsa-miR-501-5p, hsa-miR-505-3p, hsa-miR-539-5p, hsa-miR-539-3p, hsa-miR-548ap-3p, hsa-miR-548ap-3p, hsa-miR-548c-5p, hsa-miR-548o-5p, hsa-miR-548am-5p, hsa-miR-548au-5p, hsa-miR-548ad-5p, hsa-miR-548ae-5p, hsa-miR-548ay-5p, hsa-miR-548c-5p, hsa-miR-548o-5p, hsa-miR-548am-5p, hsa-miR-548au-5p, hsa-miR-548d-5p, hsa-miR-548d-3p, hsa-miR-548ad-5p, hsa-miR-548ae-5p, hsa-miR-548ay-5p, hsa-miR-548d-3p, hsa-miR-548h-3p, hsa-miR-548z, hsa-miR-548j-5p, hsa-miR-548ap-5p, hsa-miR-548l, hsa-miR-548c-5p, hsa-miR-548o-5p, hsa-miR-548am-5p, hsa-miR-548au-5p, hsa-miR-548t-3p, hsa-miR-548aa, hsa-miR-548ap-3p, hsa-miR-548h-3p, hsa-miR-548z, hsa-miR-550a-3p, hsa-miR-550a-3p, hsa-miR-550a-3p, hsa-miR-574-3p, hsa-miR-582-5p, hsa-miR-589-3p, hsa-miR-590-3p, hsa-miR-629-5p, hsa-miR-652-3p, hsa-miR-654-5p, hsa-miR-664a-5p, hsa-miR-6718-5p, hsa-miR-766-3p, hsa-miR-769-3p, hsa-miR-93-5p, hsa-miR-93-3p, hsa-miR-96-5p, hsa-miR-98-5p, hsa-miR-98-3p, 15_14774, 16_16385, 3_29425, 3_30618, 9_43073, X_46332, 10_5081, 12_9959, 5_33657		gene expression	down	rehabilitation stage (stage 3) vs convalescence stage (stage 2)	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 2.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-miRNA	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	hsa-let-7g-5p, hsa-let-7g-3p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-125b-5p, hsa-miR-1260a, hsa-miR-1260b, hsa-miR-1271-5p, hsa-miR-1278, hsa-miR-128-3p, hsa-miR-128-3p, hsa-miR-129-5p, hsa-miR-129-5p, hsa-miR-1291, hsa-miR-1298-5p, hsa-miR-1307-5p, hsa-miR-132-5p, hsa-miR-135b-5p, hsa-miR-138-5p, hsa-miR-138-5p, hsa-miR-140-5p, hsa-miR-141-3p, hsa-miR-142-5p, hsa-miR-142-3p, hsa-miR-148b-5p, hsa-miR-17-3p, hsa-miR-181a-2-3p, hsa-miR-181b-2-3p, hsa-miR-181c-3p, hsa-miR-186-5p, hsa-miR-192-5p, hsa-miR-194-5p, hsa-miR-194-5p, hsa-miR-196a-5p, hsa-miR-200a-5p, hsa-miR-200a-3p, hsa-miR-215-5p, hsa-miR-218-5p, hsa-miR-218-5p, hsa-miR-24-1-5p, hsa-miR-24-2-5p, hsa-miR-27a-5p, hsa-miR-27a-3p, hsa-miR-29a-5p, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-29b-3p, hsa-miR-29c-5p, hsa-miR-301a-5p, hsa-miR-30a-3p, hsa-miR-30d-3p, hsa-miR-30e-3p, hsa-miR-31-5p, hsa-miR-3157-3p, hsa-miR-3194-3p, hsa-miR-32-5p, hsa-miR-32-3p, hsa-miR-330-5p, hsa-miR-340-3p, hsa-miR-363-3p, hsa-miR-374b-3p, hsa-miR-3909, hsa-miR-3912-3p, hsa-miR-4473, hsa-miR-4504, hsa-miR-4521, hsa-miR-455-5p, hsa-miR-4662a-5p, hsa-miR-4772-5p, hsa-miR-4791, hsa-miR-499a-5p, hsa-miR-508-3p, hsa-miR-509-5p, hsa-miR-509-5p, hsa-miR-509-3-5p, hsa-miR-511-5p, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-514a-3p, hsa-miR-548ah-3p, hsa-miR-548av-3p, hsa-miR-548aq-3p, hsa-miR-548ar-3p, hsa-miR-548av-3p, hsa-miR-548bc, hsa-miR-548aq-3p, hsa-miR-548o-3p, hsa-miR-548av-3p, hsa-miR-548o-3p, hsa-miR-548av-3p, hsa-miR-548p, hsa-miR-548ah-3p, hsa-miR-548av-3p, hsa-miR-548u, hsa-miR-551b-3p, hsa-miR-556-5p, hsa-miR-581, hsa-miR-615-3p, hsa-miR-642a-5p, hsa-miR-6503-3p, hsa-miR-659-5p, hsa-miR-6806-3p, hsa-miR-6842-3p, hsa-miR-7-1-3p, hsa-miR-708-3p, hsa-miR-7706, hsa-miR-873-5p, hsa-miR-9-5p, hsa-miR-9-5p, hsa-miR-9-5p, hsa-miR-95-3p, hsa-miR-9985, hsa-miR-99a-5p, 10_5081, 10_5091, 12_9959, 17_19009, 19_21414, 21_27526, 21_27527, 21_27730, 21_27824, 21_27825, 21_27847, 2_23385, 5_35532, 6_36051, 6_36891, 9_44124, X_45571, X_45691, 2_25223		gene expression	up	rehabilitation stage (stage 3) vs treatment stage (stage 1)	time since hospital admission	0 to 31; 58 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 2.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-miRNA	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	hsa-let-7b-5p, hsa-let-7b-3p, hsa-let-7d-5p, hsa-let-7d-3p, hsa-let-7f-1-3p, hsa-miR-10399-3p, hsa-miR-103a-2-5p, hsa-miR-106b-3p, hsa-miR-12136, hsa-miR-1226-3p, hsa-miR-127-5p, hsa-miR-1273h-5p, hsa-miR-1292-5p, hsa-miR-1296-5p, hsa-miR-1301-3p, hsa-miR-130a-5p, hsa-miR-133a-3p, hsa-miR-133a-3p, hsa-miR-134-5p, hsa-miR-1343-3p, hsa-miR-139-3p, hsa-miR-145-5p, hsa-miR-145-3p, hsa-miR-148a-5p, hsa-miR-15b-5p, hsa-miR-18a-3p, hsa-miR-190a-5p, hsa-miR-191-5p, hsa-miR-197-3p, hsa-miR-200c-3p, hsa-miR-20b-5p, hsa-miR-2110, hsa-miR-2277-5p, hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-miR-25-5p, hsa-miR-27b-5p, hsa-miR-30c-2-3p, hsa-miR-3140-3p, hsa-miR-3177-3p, hsa-miR-3191-3p, hsa-miR-323a-3p, hsa-miR-323b-3p, hsa-miR-324-5p, hsa-miR-324-3p, hsa-miR-326, hsa-miR-329-3p, hsa-miR-329-3p, hsa-miR-337-3p, hsa-miR-339-5p, hsa-miR-3605-3p, hsa-miR-3614-5p, hsa-miR-365a-5p, hsa-miR-376c-3p, hsa-miR-377-5p hsa-miR-382-5p hsa-miR-3940-3p hsa-miR-409-5p hsa-miR-412-5p hsa-miR-421 hsa-miR-425-3p hsa-miR-431-5p hsa-miR-431-3p hsa-miR-432-5p hsa-miR-433-3p hsa-miR-4433b-5p hsa-miR-4446-3p hsa-miR-4454 hsa-miR-4485-3p hsa-miR-485-5p hsa-miR-485-3p hsa-miR-486-5p hsa-miR-486-3p hsa-miR-486-5p hsa-miR-486-3p hsa-miR-487b-3p hsa-miR-491-5p hsa-miR-493-5p hsa-miR-494-3p hsa-miR-500a-3p hsa-miR-501-3p hsa-miR-505-3p hsa-miR-548j-5p hsa-miR-548ap-5p hsa-miR-550a-3p hsa-miR-550a-3p hsa-miR-550a-3p hsa-miR-574-3p hsa-miR-584-5p hsa-miR-629-5p hsa-miR-6501-5p hsa-miR-6511b-3p hsa-miR-652-3p hsa-miR-654-5p hsa-miR-664a-5p hsa-miR-6741-5p hsa-miR-6852-5p hsa-miR-6894-3p hsa-miR-766-5p hsa-miR-766-3p hsa-miR-769-3p hsa-miR-92b-3p hsa-miR-93-5p hsa-miR-93-3p hsa-miR-98-3p hsa-miR-99b-5p 15_14774 3_30618		gene expression	down	rehabilitation stage (stage 3) vs treatment stage (stage 1)	time since hospital admission	0 to 31; 58 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 2.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-miRNA	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	CXCL2, H2AC18, AC011195.1, AC022217.2, CCL3, AC109326.1, FAM72B-AS-1, LINC-IER2-1, LINC-LMNTD1-2, LINC-NBPF26-1, LINC-PID1-2, LINC-PPIAL4F-4, LINC-RHOB-1, LINC-TAF12-1, LINC-TRIM69-1, LINC-ZNF330-2, TEX14-AS-2		gene expression	up	convalescence stage (stage 2) vs treatment stage (stage 1)	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-includes lncRNA, protein coding, miscRNA, snRNA, snoRNA, gene, Mt tRNA, Mt rRNA, ribozyme, etc (see Class column)	
	Amani 	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	DKK1-AS-1, IGKC, IGKV4-1, IGLV6-57, IGLV1-51, IGLV3-19, IGLV2-14, IGLV3-1, IGHG1, IGHV3-7, IGHV4-39, IGHV5-51, TXNDC5, IGKV3-20, IGKV1-33, IGHV1D-39, IGHV3-30, IGHV3-64D, LINC-TMEM121-17		gene expression	down	convalescence stage (stage 2) vs treatment stage (stage 1)	time since hospital admission	0 to 49	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-includes lncRNA, protein coding, miscRNA, snRNA, snoRNA, gene, Mt tRNA, Mt rRNA, ribozyme, etc (see Class column)	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	AL355916.3-AS-2, ANKRD12-AS-1, ARHGAP15-AS-8, ARID5A-AS-1, ARNTL-AS-4, ATP5F1C-AS-2, ATRX-AS-1, BAG2-AS-1, C12orf57-AS-1, C22orf39-AS-2, CALM1-AS-1, CD6-AS-1, CEP85L-AS-3, CHCHD2-AS-1, CHD4-AS-3, CNOT2-AS-2, CNOT6L-AS-1, COTL1-AS-3, CPT1A-AS-1, DCAF10-AS-1, DNAJB6-AS-1, EIF4E3-AS-1, ELF1-AS-1, EML4-AS-1, KMT2E, DBF4, IFRD1, RGPD5, RB1CC1, STRAP, HSF2, SLC66A1, NFE2L3, SLC2A3, PSD, MGAT4A, TM9SF3, PPP2R5C, CYLD, YTHDC1, OTUB2, IKZF5, GADD45B, SLC10A1, PPP1R16B, CLN5, LEPROTL1, HBP1, EZH2, DHX40, AREG, SEPSECS, CLEC2B, CDKN1B, HECA, MAN2A1, ARRDC3, PDE4D, SMC4, SLC25A36, KDM3A, PRKD3, SRSF7, NFE2L2, CA14, CCND2, NR4A3, FAM53C, TEX14, PYROXD1, TBC1D15, CXCR4, RBBP6, MORF4L2, ATP8A1, H1-3, CCNT1, PHF10, NOL11, DNAJB1, H3-3B, WDR74, SARAF, SLC38A2, PPHLN1, TPP2, CEMIP2, DHX9, GTF2B, NUP54, MTMR6, CDR2, PMAIP1, RPS27A, LNPK, LRIG1, PIK3R1, KLHL35, TWF1, TMEM45B, PDE3B, JMY, CAMK4, SMARCA5, NR4A2, BTG3, WNT7A, WHAMM, ATAD2, B3GNT7, DUSP2, CDC42SE2, BTG2, ARHGAP27, DCAF16, SNRK, ZC3H12A, AIMP1, PGRMC2, SFXN1, RAD21, FBXO33, KLHDC2, DENND2B, RRM1, RHOH, RGPD8, ADPRM, NUDCD2, RNF139, ZNF274, MLLT3, ZBTB21, CHD2, TOMM20, KLHL15, NDUFV2, PER1, NPM1, H2AW, C5orf24, H3C13, H2AC21, TM2D3, H1-5, DUSP8, PDE4B, NELL2, BRWD1, HEXIM1, H1-2, SRSF10, NDUFA4, H2AC13, CHRNG, KPNA5, H3C12, H4-16, ZNF789, RNU5B-1, SNORA33, ZNF525, ZDBF2, ZBTB10, CFAP45, RBMXL1, AC006042.2, TNF, H2BC15, RNF103, HYPK, MRPS31P5, CFB, ZNF350, OTOAP1, SNORD3B-2, HNRNPA3P9, H2AC19, FP325311.1, H4C6, H2BC17, H2AC12, H3C11, H3C1, SIK1B, H2AC14, H2BC3, RNVU1-4, H2AC4, AP001160.5, H2BC10, H4C1, H2AC17, Z99129.4, AC018445.3, AC103394.1, AC023818.1, AL138713.1, AL135905.2, FAM49A-AS-1, GCC2-AS-1, GPR174-AS-1, H2BC11-AS-1, HBP1-AS-1, HIVEP2-AS-2, ISY1-RAB43-AS-1, IQGAP1-AS-1, ITPKB-AS-1, KAT6A-AS-4, KIF2A-AS-1, KLF12-AS-1, LASP1-AS-1, LINC-ARL4D-2, LINC-ARMCX3-2, LINC-BTG1-1, LINC-CYTIP-1, LINC-DAD1-3, LINC-DNAJB1-1, LINC-DUSP2-2, LINC-EAPP-3, LINC-FBXL18-1, LINC-FOXD4L6-4, LINC-KLF2-1, LINC-LITAF-1, LINC-NBPF14-1, LINC-NBPF15-4, LINC-NBPF20-5, LINC-PARP16-2, LINC-RSL24D1-1, LINC-SDE2-1, LINC-SLC3A2-1, LINC-SNRPB-2, LINC-SYNCRIP-2, LINC-SYNCRIP-4, LINC-TNFAIP3-2, LITAF-AS-2, LRIG1-AS-1, LRRC8B-AS-1, MAX-AS-1, NFE2L2-AS-1, NELL2-AS-1, NOP58-AS-2, NTSR1-AS-1, NUFIP2-AS-1, OGDH-AS-1, PASK-AS-2, PDCD4-AS-1, PDE3B-AS-2, POMP-AS-1, PPP2R2D-AS-2, PPP4R3A-AS-2, RAB21-AS-2, RAB5A-AS-1, RASGRP1-AS-1, RASGRP1-AS-2, RASSF5-AS-1, RBBP6-AS-1, RIPK1-AS-1, RNF103-AS-1, RNF38-AS-1, SAMD12-AS-2, SCAF8-AS-1, SARAF-AS-1, SARAF-AS-2, SETD5-AS-1, SGTB-AS-1, SLC38A2-AS-2, SLC35B3-AS-1, SLC35D1-AS-1, SLC38A1-AS-2, SLC39A13-AS-2, SLTM-AS-3, SMN1-AS-2, SNRK-AS-1, SNX9-AS-1, SPDYE1-AS-1, STAT3-AS-1, TENM1-AS-2, TMED10-AS-1, TOP2B-AS-1, TPP1-AS-2, TPP2-AS-1, TSPYL2-AS-1, TUBA1A-AS-1, UBE2B-AS-1, WDR74-AS-2, ZBTB37-AS-1, ZNF350-AS-1, ZNF430-AS-1		gene expression	up	rehabilitation stage (stage 3) vs convalescence stage (stage 2)	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-includes lncRNA, protein coding, miscRNA, snRNA, snoRNA, gene, Mt tRNA, Mt rRNA, ribozyme, etc (see Class column)	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	ANKDD1A-AS-2, PDK4, PPP5C, AGPS, CP, XK, TNFRSF1A, SPTB, FCGR2B, VPS9D1, STX7, SMOX, P2RX7, SH2D3C, BLNK, FKBP5, SPECC1L, TPTEP1, KIAA0930, TCL1A, PCYT1B, CA2, LYL1, LILRB1, PTPRS, CHN2, PIP5K1B, ERLIN1, TRIM37, ABI3, PF4V1, UNC93B1, PTPN6, TREML2, CISH, DOK1, DNAJC6, KMO, RAB29, SGK1, FKBP15, IFIT3, PYROXD2, CXorf21, EGR1, TNFSF10, FLT3, EGR2, NFE2, TNFSF14, SIGLEC9, HEATR5A, CBFA2T3, COLGALT1, MPP1, EPHB2, GIMAP6, CD180, KIAA0513, TMOD1, HEMGN, GMPR, PLCB2, CYP1B1, CALHM2, PARVG, PRICKLE1, DUSP6, SLC14A1, TRPM2, FCRL5, SLC27A3, MARCHF1, FGD2, GBGT1, SURF6, LCN2, ST14, CDC42EP2, DCP1B, GPATCH11, LRRK1, ZNF618, CD1D, B4GALT3, DMTN, VAV2, CCR5, HK3, SCIMP, CDC42EP3, AIM2, CHCHD4, CCR1, SGMS2, ARFIP1, NCF1C, SPINT1, MAP1A, LAIR1, CX3CR1, RGS14, YWHAG, FAXDC2, MZB1, POLH, PHR2, GIMAP8, FRMD3, MOB3A, TRIB1, MOB1B, GAPT, THBD, GIMAP7, CIITA, FUT7, CXCR2, ZNF322, P2RY13, CHST15, NCF1B, BACE2, TANGO2, LPAR5, ZNF445, IFIT1, C16orf54, BTLA, SMIM15, ATP2A1, HBG2, TOR4A, TMA16, MT-CO2, MT-CYB, MT-CO1, CES1, MT-ND4, GP1BB, SMIM5, AP662899.3, TRIM27, IPO7, IGLV1-44, IGLC3, IGHG3, IGHD, S1PR3, CEBPD, GPX1, NFAM1, LILRA4, PLEKHO2, AP003419.1, AC012184.2, ERICH1-AS-2, ERICH1-AS-3, FGD3-AS-1, FGL2-AS-1, FKBP5-AS-1, FLI1-AS-3, FYB1-AS-3, FZD1-AS-1, IFI16-AS-1, IL32-AS-1, IRS2-AS-1, LINC-ADRB2-1, LINC-CDH26-5, LINC-LPCAT1-3, LINC-PID1-2, LINC-VSIG4-1, PCGF3-AS-5, PID1-AS-1, PREX1-AS-1, PREX1-AS-3, PRKCB-AS-7, PRR5L-AS-2, PRR5L-AS-3, PTGER2-AS-2, PTAFR-AS-1, PYHIN1-AS-1, RNF213-AS-1, SCIMP-AS-2, SNTB1-AS-2, ST6GAL1-AS-4, STK10-AS-1, SUN2-AS-4, TIMP2-AS-1, VAV3-AS-1, TRAF3IP3-AS-2		gene expression	down	rehabilitation stage (stage 3) vs convalescence stage (stage 2)	time since hospital admission	13 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-includes lncRNA, protein coding, miscRNA, snRNA, snoRNA, gene, Mt tRNA, Mt rRNA, ribozyme, etc (see Class column)	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	AL355916.3-AS-2, ARID5A-AS-1, BAG2-AS-1, CD6-AS-1, CEP85L-AS-3, CHCHD2-AS-1, CHD4-AS-3, CNOT2-AS-2, CNOT6L-AS-1, DNAJB6-AS-1, EIF4E3-AS-1, ELF1-AS-1, RGPD5, CYLD, YTHDC1, OTUB2, IKZF5, GADD45B, SLC10A1, PPP1R16B, CLN5, LEPROTL1, HBP1, AREG, CDKN1B, HECA, ARRDC3, PDE4D, CA14, NR4A3, AVPI1, FAM53C, PYROXD1, B4GALT4, HCRTR1, ZNF639, CXCR4, ZC3H7A, HNRNPA2B1, NR4A1, MORF4L2, G0S2, MTRR, H1-3, CDKN1A, TMEM255A, C1orf61, FFAR2, CASD1, DNAJB9, ELL3, PSMA1, CCNT1, SAT1, IQCN, ZNF331, CASZ1, DNAJB1, H3-3B, OSER1, SLC41A1, WDR74, BTG1, SARAF, BHLHE40, SLC38A2, TPP2, CEMIP2, ERCC5, ANXA1, HNRNPA1, GCC2, STAM, IER3, RAB30, SDCBP, GTF2B, RABGGTB, SELENOI, DUSP5, GABARAPL1, MTMR6, FAM222A, TOB1, PMAIP1, MRPL9, C1orf56, EIF2D, DUSP10, NUP210L, DUSP11, RHOB, RPS27A, LRIG1, PHLDB2, NFKBIZ, CENPC, RPS3A, PLK2, PIK3R1, FEM1C, PNRC1, DYNLT1, IGFBP3, GPR174, CASK, ZEB1, CNBD2, PDCD4, TMEM86A, SLC2A13, FBXO4, CAMK4, ZFP36L2, NR4A2, CHD1, LONRF1, BTG3, WNT7A, EME1, KLF10, AZIN1, SAMSN1, OTOA, WHAMM, ATAD2, B3GNT7, SAMD8, EIF4A2, DUSP2, H2BC5, CDC42SE2, RUNX1, BTG2, ARHGAP27, ABCG1, ICOSLG, IER2, ZNF394, GRASP, EIF4A1, NXF1, JAK1, RAVER2, IER5, REL, SPATA17, BNIPL, ICOS, TIPARP, CCNL1, SNRK, ZC3H12A, RFC4, PRSS12, SLU7, PHKG1, NFIL3, PIGA, FBXO33, KLHDC2, CFL2, ARL5B, ARIH1, DENND2B, ZNF143, NDEL1, MIDN, MVD, TUBA1A, SERTAD3, TTC21A, H1-4, RHOH, MAT2A, GPR183, ADPRM, NUDCD2, RNF139, ZNF145, JUNB, ENC1, LRRC34, EIF2AK3, CYCS, SNX32, GOLGB1, ZBTB21, NABP1, AP000769.1, ZNF791, KLHL15, FBXO45, MARCKSL1, DDIT3, BAIAP2, B3GNT4, JUN, IMPDH2, NDUFV2, TMEM107, NPM1, METTL23, RPS17, C16orf72, ADGRG3, H3C13, TSPYL2, H2AC20, H2AC21, TM2D3, DUSP8, PDE4B, SOCS3, H1-10, SOCS1, ZNF267, GNG2, INSIG1, HEXIM1, B3GLCT, H1-2, ARL4C, FAM166A, H2AX, LITAF, ASTL, ZNF250, CD55, CHRNG, H2AC11, H2AC7, KPNA5, SLC39A10, SERTAD1, ENTPD4, PELI1, SPTAN1, H4-16, RPS6KL1, PIM3, ZNF789, CALM1, RPL39, RNU5A-1, RNU5B-1, SNORA33, SNORA65, RNVU1-3, RNVU1-6, RNVU1-21, H2BC18, ZDBF2, CXorf65, BRD2, PPP1R10, ZBTB10, C17orf107, RNVU1-7, SNORA80B, SNORD101, RNVU1-30, MIR616, AC011195.1, CFAP45, RBMXL1, AC022217.2, ERV3-1, DDX3X, H2AC9P, SNORD100, RNU2-63P, RPL32P1, DNAJC19P5, RGS17P1, HLA-DPA2, TNF, H2BC15, H2AC5P, ATP5PDP4, FAM21EP, NPM1P26, AC243919.1, AL162615.1, RNVU1-2, RNF103, HYPK, CFB, RNF103-CHMP3, AC122718.2, RNU6-638P, SCARNA21, SMIM35, MORF4L1P3, ZNF10, ZNF350, ATP5MFP4, OTOAP1, CHMP4BP1, CEP95, AC034105.3, SNORD3B-2, SNORD3A, RN7SL336P, SNORD3B-1, H4C15, RNVU1-31, H2AC19, FP325311.1, H2BC8, RNVU1-25, SNORD28, SNORA16A, H4C6, H2BC17, H2AC12, H3C11, RNVU1-26, CCL4, H3C1, SIK1B, H2BC3, H2AC8, H4C5, LINC00869, RNVU1-4, CCL3, RNVU1-2A, H2AC4, AP001160.5, H2BC10, MIR6077, H2AC17, AC092139.2, TSTD3, AC015813.6, AC108704.3, AC109326.1, AC018445.3, AC103394.1, AC00449.1, AP000648.4, TEX54, AL031777.2, MIR5087, AL135905.2, EPC1-AS-2, FAM49A-AS-1, FAM72B-AS-1, FNBP1-AS-3, FOSL2-AS-1, FRMD4A-AS-3, FUS-AS-1, GCC2-AS-1, GLS-AS-1, GNA13-AS-1, GPR132-A-1, GPR174-AS-1, GPR61-AS-1, GPR65-AS-1, GSPT1-AS-3, GTF2A1-AS-2, H1-4-AS-1, H2BC11-AS-1, HBP1-AS-1, HIVEP2-AS-2, HERPUD2-AS-1, HIF1A-AS-1, HLA-A-AS-1, HLA-DQB1-AS-1, HLA-DRB1-AS-2, HLA-DRB1-AS-4, HLA-F-AS-1, HNRNPUL1-AS-1, HOOK3-AS-1, HUWE1-AS-1, ID2-AS-1, IFI30-AS-1, IRF2BP2-AS-1, ISY1-RAB43-AS-1, IQCN-AS-1, ITPKB-AS-1, JMJD1C-AS-6, JOSD1-AS-1, KANK1-AS-2, KCNB1-AS-4, KLF12-AS-1, KRAS-AS-1, KYNU-AS-2, LASP1-AS-1, LCP1-AS-1, LGALS1-AS-1, LINC-ABHD2-2, LINC-ARL15-1, LINC-ARL4C-2, LINC-ARL4C-6, LINC-ARL4D-2, LINC-ARL4D-6, LINC-ARMCX3-2, LINC-ATF4-1, LINC-ATF4-2, LINC-BTG1-1, LINC-C15orf39-1, LINC-C1orf194-1, LINC-CCDC200-1, LINC-CD44-1, LINC-CD47-2, LINC-CEACAM21-2, LINC-CLEC2D-3, LINC-DAD1-3, LIND-DAD1-5, LINC-DARS2-1, LINC-DHRSX-1, LINC-DNAJB1-1, LINC-DUSP1-2, LINC-DUSP2-2, LINC-EAPP-3, LINC-EPHB6-2, LINC-FBXL18-1, LINC-GRAP-3, LINC-GRAPL-5, LINC-H2BC12-1, LINC-H2BC13-9, LINC-H2BC21-1, LINC-H2BC5-1, LINC-H3-2-12, LINC-H4-16-1, LINC-HSP90AA1-1, LINC-IBTK-6, LINC-IER2-1, LINC-IER5-2, LINC-IFI30-1, LINC-IRF2BP2-1, LINC-IRF2BPL-2, LINC-JARID2-4, LINC-JUND-1, LINC-KIAA2013-1, LINC-KLF2-1, LINC-KLF6-2, LINC-KLF6-3, LINC-KMT2E-1, LINC-LITAF-1, LINC-LMNTD1-1, LINC-LRRC75A-1, LINC-MLLT3-1, LINC-MORF4L1-1, LINC-MRPL20-1, LINC-MYLIP-2, LINC-NABP1-1, LINC-NBPF26-1, LINC-NBPF14-1, LINC-NBPF15-4, LINC-NBPF20-5, LINC-NFKBIZ-1, LINC-OR6S1-1, LINC-OTUD1-2, LINC-P4HB-1, LINC-PARP16-2, LINC-PCIF1-1, LINC-PIK3IP1-1, LINC-PIK3IP1-2, LINC-PIN1-1, LINC-PPIAL4F-4, LINC-PPIAL4G-6, LINC-PPIAL4H-2, LINC-PPIAL4H-3, LINC-PPP1R15A-1, LINC-PPP6R3-1, LINC-PRSS12-1, LINC-RBM24-3, LINC-RHOB-1, LINC-RLIM-1, LINC-RSRP1-1, LINC-RSL24D1-1, LINC-SDE2-1, LINC-SAMD11-8, LINC-SIAH2-1, LINC-SIRT4-2, LINC-SLC38A2-1, LINC-SLC9A8-2, LINC-SLC3A2-1, LINC-SNRPB-2, LINC-SNX6-1, LINC-SPRY1-1, LINC-SRGN-1, LINC-STK17B-1, LINC-TAF12-1, LINC-SYNCRIP-2, LINC-SYNCRIP-4, LINC-TFRC-3, LINC-TMEM107-1, LINC-TNFAIP3-1, LINC-TOX3-4, LINC-TOB2-2, LINC-TRIM69-1, LINC-TSPOAP1-1, LINC-TXNIP-1, LINC-VMP1-1, LINC-YPEL5-1, LINC-YWHAZ-1, LINC-ZBTB37-1, LINC-ZFAND5-2, LINC-ZFAT-4, LINC-ZNF213-3, LINC-ZNF330-2, LITAF-AS-1, LITAF-AS-2, LRIG1-AS-1, LRRC8B-AS-1, MALT1-AS-2, MACO1-AS-1, MAEA-AS-3, MAP3K2-AS-3, MAP3K8-AS-1, MAPK1-AS-3, MAX-AS-1, MEI1-AS-2, MLLT3-AS-1, MSMB-AS-1, MYL6-AS-1, NBPF10-AS-4, NFE2L2-AS-1, NFE2L2-AS-3, NFKB1-AS-1, NLRP3-AS-1, NOP58-AS-2, NUFIP2-AS-1, OGDH-AS-1, OXCT1-AS-1, PABPC4-AS-1, PASK-AS-2, PDCD4-AS-1, PDE3B-AS-2, PHF11-AS-1, PHC2-AS-3, PIGX-AS-3, PLEK-AS-1, PLEKHG2-AS-1, PLEKHO1-AS-1, POLDIP3-AS-1, POMP-AS-1, PPP2R2D-AS-2, PPM1K-AS-2, PPP1R11-AS-1, PPP1R35-AS-1, PPP4R3A-AS-2, PREX1-AS-2, PTK6-AS-1, PTPN1-AS-3, RAB21-AS-2, RAB8B-AS-2, RAB5A-AS-1, RASGRP1-AS-1, RASGRP1-AS-2, RAB1B-AS-3, RASSF5-AS-1, RCC1-AS-1, RCE1-AS-1, RBMXL1-AS-2, REL-AS-1, RFTN1-AS-5, RGPD8-AS-2, RHOA-AS-3, RIPK1-AS-1, RNF103-AS-1, RNF19B-AS-1, RNF38-AS-1, RORA-AS-7, RORA-AS-8, RPL10-AS-2, RPL38-AS-1, RPLP1-AS-1, RUNX1-AS-8, SARAF-AS-1, SARAF-AS-2, SAMSN1-AS-2, SEC14L1-AS-3, SEMA4D-AS-3, SERPINB1-AS-1, SETD5-AS-1, SGTB-AS-1, SH2D2A-AS-1, SH3PXD2A-AS-5, SIAH2-AS-1, SIRT1-AS-3, SIRT4-AS-1, SLC2A3-AS-1, SLC37A1-AS-1, SLC38A2-AS-1, SLC39A10-AS-1, SLC49A4-AS-1, SLC38A2-AS-2, SLCO3A1-AS-2, SMAP2-AS-1, SMCHD1-AS-2, SNRK-AS-2, SNX25-AS-1, SNRK-AS-1, SNX9-AS-1, SNX9-AS-2, SNX9-AS-5, SPATA13-AS-2, SPDYA-AS-1, SPOP-AS-3, SPTBN1-AS-3, SRGN-AS-1, SRGN-AS-2, STAT3-AS-1, STK17A-AS-1, SYAP1-AS-1, TENM1-AS-2, TENM1-AS-1, TCAF2-AS-1, TEX14-AS-2, TEX2-AS-1, THAP9-AS-1, THRAP3-AS-2, THRAP3-AS-3, TMEM248-AS-2, TMSB10-AS-1, TNFRSF10B-AS-2, TNFRSF1B-AS-1, TNFRSF1B-AS-2, TNIK-AS-2, TNIK-AS-3, TOP2B-AS-1, TPP1-AS-2, TPP2-AS-1, TREM1-AS-1, TRNAU1AP-AS-1, TSPYL2-AS-1, TUBA1A-AS-2, TUBB4B-AS-1, TXNL1-AS-1, UBE2B-AS-1, USP22-AS-1, UVRAP-AS-4, WDR26-AS-1, WDR37-AS-1, WDR48-AS-1, WDR74-AS-1, WDR74-AS-2, WDR74-AS-3, WDR81-AS-1, WDR90-AS-3, XPO9-AS-1, ZBED1-AS-1, ZBTB37-AS-1, ZFC3H1-AS-1, ZNF253-AS-3, ZNF350-AS-1, ZNF516-AS-2, ZNF610-AS-1, ZNF687-AS-1, ZNF708-AS-1, ZNF93-AS-1, ZRANB1-AS-1, ZSCAN22-AS-1, ABCG1-AS-4, AC116366.3-AS-1, ACTG1-AS-1, AGO2-AS-1, ANKRD12-AS-1, APMAP-AS-1, ARHGAP15-AS-8, ARNTL-AS-4, ARRDC3-AS-2, ASAP1-AS-3, ATG5-AS-4, ATXN7-AS-3, B4GALT4-AS-1, BRAF-AS-1, BRAF-AS-2, BMF-AS-2, BSDC1-AS-3, C12orf57-AS-1, C21orf91-AS-1, C22orf39-AS-2, C22orf39-AS-3, CACYBP-AS-1, CALM1-AS-1, CAMK2D-AS-2, CAPZA1-AS-1, CARD19-AS-1, CARD19-AS-2, CCDC200-AS-2, CCDC200-AS-4, CCDC200-AS-5, CCDC93-AS-1, CCL3-AS-1, CCM2-AS-2, CD47-AS-1, CD6-AS-3, CD74-AS-1, CDKN1A-AS-1, CDKN1B-AS-1, CEMIP2-AS-3, CEP85L-AS-3, CHD1-AS-1, CHD3-AS-1, CHD4-AS-3, CIRBP-AS-2, CLIP4-AS-1, CROCC-AS-3, CSNK1D-AS-1, CXCR5-AS-1, DLGAP1-AS-8, DUSP10-AS-1, EIF4A2-AS-1, ELMO1-AS-1, ELMO2-AS-2, ELOVL5-AS-1, EML4-AS-3, EML3-AS-2, IFRD1, MYLIP, HIVEP2, PLAUR, MATR3, RGPD5, STRAP, SH2D2A, HERPUD1, NFE2L3, NOP58, PRDM1, MXD1, SLC2A3, IDI1, NUCKS1, BCL3, AP3M2, TCOF1, MGAT4A, EPN2, TFRC, SDHA, FOSL2, TRAF4, CAMSAP3, FAM76B, PPP2R5C, P2RY10, TP53INP2, CLDND1, HSP90AA1, COBLL1, AGBL5, DNAJA1, KIZ, PABPC4, NAT14, IL5RA, EZR, CWF19L1, CREM, HSP90AB1, OSM, JOSD1, HIF1A, EIF5, NFKBIA, GMPR2, STK4, RNMT, SMCHD1, INTS6, N4BP1, RIPK2, DCTN6, TULP2, FSCN3, FBXO24, TLE4, ZFAND5, MAP3K8, UBE2S, RNF43, DDX5, RPL34, KLF3, HSPA8, CD5, CD69, CLEC2B, IFNG, KLRB1, SRSF3, CD83, HMGCS1, BCL6, SELENOK, XRN1, WDR48, CYTIP, ID2, SF3B1, SRSF7, PLCL1, NFE2L2, KIAA1324, RGS2, BCAS2, IVNS1ABP, PTCH2, RSRP1, UBE2B, RORA, TGFBR3		gene expression	up	rehabilitation stage (stage 3) vs treatment stage (stage 1)	time since hospital admission	0 to 31; 58 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-includes lncRNA, protein coding, miscRNA, snRNA, snoRNA, gene, Mt tRNA, Mt rRNA, ribozyme, etc (see Class column)	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2	CP, STX7, P2RX7, SH2D3C, BLNK, FKBP5, SPECC1L, ERLIN1, ABI3, UNC93B1, TREML2, CISH, DOK1, KBTBD7, FLT3, LAX1, BHLHE41, SLC36A1, MED20, PLGLB2, TNFSF14, MKKS, S1PR4, FAM78A, FGD3, KLHDC7B, EPSTI1, EPHB2, GIMAP6, CD180, RSAD2, CMPK2, TMEM60, RNASEL, ITM2C, DPM2, SIT1, PPIL1, IRF4, RNF144B, TLR2, BUD13, CALHM2, SMARCAL1, SEPTIN11, DUSP6, PTRH2, TRPM2, MOB3C, FCRL5, GTL, MEIS1, FAM50B, FGD2, ZC3HAV1L, LCN2, NACC2, NRBF2, POLR3A, PCDC11, ST14, ZC3H12C, CDC42EP2, VIPAS39, RPP38, MARVELD1, PPEF2, MEGF11, RGS12, CCDC17, FNDC5, VAV2, IL6R, LY6E, CCR5, FBXL13, C1orf74, DENND2D, TNFAIP8L2, SLC22A15, CCR1, CFAP100, SGMS2, MON1A, SHROOM1, NCF1C, SPRED1, IFI27, PLD4, TRIM66, TEF, DOLPP1, LAIR1, FADD, CX3CR1, RGS14, YWHAG, MZB1, POLH, PAQR8, PHR2, GIMAP8, SHCBP1, ZDHHC16, FRMD3, EGFL7, RXFP4, HSPA6, TRIB1, CYB561D1, CMKLR1, KCTD13, B3GNT8, IL17RA, CHID1, SLC25A20, PARP10, THBD, GIMAP7, SNX18, CXCR2, BHLHA15, DLSTP1, FRAT2, SLC35C1, NCF1B, PDSS1P1, TMEM121B, FANCF, GAS6, TANGO2, SEMA4B, MUC6, PGBD2, ZNF74, C16orf54, KLHDC8B, RXRA, SOWAHD, SLX4, IL1RAP, ATP2A1, ZKSCAN7, HBG2, MYO18A, BORCS6, FAM177B, KLHL14, INKA2, GPAA1, TOR4A, ZNF544, PHETA1, TMA16, WDHD1, ATL1, TRIM27, DHX16, SDHAF1, ITPRIPL2, IGLV1-44, IGLV4-69, IGLV1-51, IGLV1-47, IGLV7-43, IGLV1-40, IGLV3-25, IGLV3-21, IGLV3-19, IGLV3-10, IGLV3-1, IGHG3, IGHD, IGHG1, IGHV6-1, IGHV2-5, IGHV1-3, IGHV3-11, IGHV3-21, IGHV2-26, IGHV4-34, IGHV4-39, IGHV3-48, IGHV3-49, IGHV5-51, IGHV3-73, GIMAP1, LPAL2, CEBPD, OR2A1, ATP5PBP1, IGHV4-59, TGIF2P1, HGH1, AC002543.1, TMEM250, CCR12P, TXNDC5, IGKV3-20, IGKV2-24, IGKV3-11, PLEKHO2, IGKV1-33, IGKV2D-29, IGKV1-12, TICAM2, APOBEC3D, IGKV2-28, IGKV3-15, IGKV1-27, AC139495.2, IGKV1D-39, IGKV2-29, TYRO3P, BOP1, IGHV3-30, IGHV2-70, ZNF2, PRAG1, IGKV1D-13, AC008895.1, IGHV7-4-1, IGHV1-69D, AC025048.6, EPB41-AS-1, ERICH1-AS-2, ERICH1-AS-3, ETS1-AS-2, FGD3-AS-1, FGL2-AS-1, FLI1-AS-3, GSAP-AS-3, IFI16-AS-1, IKBKE-AS-1, IKZF1-AS-3, IRS2-AS-1, LIMD1-AS-1, LINC-ACTBL2-6, LINC-AC253572.1-2, LINC-AMPH-1, LINC-ANKRD20A4-23, LINC-CCDC69-2, LINC-CD47-1, LINC-CHST15-3, LINC-IFI16-1, LINC-LAX1-1, LINC-NUTM2F-3, LINC-TMEM121-17, LINC-TMEM121-18, LINC-TMEM64-3, LINC-UBE2D2-2, LINC-ZNF638-2, MBP-AS-2, NFYC-AS-1, PCED1B-AS-3, PCED1B-AS-4, PID1-AS-1, PIK3CD-AS-3, PREX1-AS-1, PREX1-AS-3, PRKCB-AS-7, PRR5L-AS-2, PRR5L-AS-3, PTAFR-AS-1, PYHIN1-AS-1, RBM6-AS-3, RIPOR2-AS-3, RNF213-AS-1, SAMHD1-AS-6, SCML4-AS-1, SEMA4D-AS-2, SEPTIN9-AS-3, SEPTIN9-AS-7, SNTB1-AS-2, ST6GAL1-AS-4, ST6GAL1-AS-1, STK10-AS-1, TLR5-AS-1, TRAF3IP3-AS-2, VIPR1-AS-1, ZHX2-AS-2, AC019117.4-AS-1, AC119396.1-AS-3, AHNAK-AS-3, ALKBH3-AS-2, ANXA6-AS-1, ANKRD55-AS-1, APOL1-AS-1, ARID5B-AS-4, BACH1-AS-6, CAMK2D-AS-1, CCDC88C-AS-1, CD48-AS-1, CREBRF-AS-2, CXXC5-AS-2, DGKD-AS-3, DLGAP1-AS-9, DNMBP-AS-1, DPSYL2-AS-1, CD38, FAM214B, EEF1AKNMT, STAB1, CC2D2A, FAM160A2, COL17A1, TNFRSF1A, SPTB, ZNF532, RARB, EXOSC5, CEACAM1, ARG2, NFE2L1, ZNF213, COQ9, OAS1, AARS1, ZC3HC1, TBC1D2, TIMM13, TTC28, PCK2, MTG2, ZMYND8, POFUT1, TSC22D1, NIPAL2, LILRB1, LYL1, OLFM2, DYRK1B, GRWD1, SNX8, LARP4B, MINPP1, TSPAN14, AKAP10, VDR, CCND3, FBRSL1, GNPDA1, PDGFRB, FRMD4B, NEK4, OTOF, FN1, DHCR24, EDEM3, NID1, KMO, CENPF, B4GALT6, YIPF4		gene expression	down	rehabilitation stage (stage 3) vs treatment stage (stage 1)	time since hospital admission	0 to 31; 58 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Suppl. Dataset 1.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	-includes lncRNA, protein coding, miscRNA, snRNA, snoRNA, gene, Mt tRNA, Mt rRNA, ribozyme, etc (see Class column)	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2.	OSM, MAP3K8, HSP90AB1, PPP1R16B		gene expression	up	rehabilitation & convalescence stages vs treatment stage: moderate COVID-19 patients vs mild COVID-19 patients 	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S4.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	Start with DEGs of Recovery from COVID-19 (rehabilitation & convalescence stages vs treatment stage). Then selected DEGs of those DEGs between 3 clinical types. Color of the gene in the figure "reflects the slope of the linear regression equation of Log2 fold change during recovery from COVID-19, and the shape reflects the comparison between which 2 groups [of the clinical types] it came from"	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2.	GAS6		gene expression	down	rehabilitation & convalescence stages vs treatment stage: moderate COVID-19 patients vs mild COVID-19 patients 	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S4.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	Start with DEGs of Recovery from COVID-19 (rehabilitation & convalescence stages vs treatment stage). Then selected DEGs of those DEGs between 3 clinical types. Color of the gene in the figure "reflects the slope of the linear regression equation of Log2 fold change during recovery from COVID-19, and the shape reflects the comparison between which 2 groups [of the clinical types] it came from"	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2.	CCNT1, PER1, KLF10, NR4A3, ZFBP36L2, LITAF, AREG, TRAF4, DUSP8, CXCR4, CXCL2, PDE4D, DUSP2		gene expression	up	rehabilitation & convalescence stages vs treatment stage: severe COVID-19 patients vs mild COVID-19 patients 	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S4.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	Start with DEGs of Recovery from COVID-19 (rehabilitation & convalescence stages vs treatment stage). Then selected DEGs of those DEGs between 3 clinical types. Color of the gene in the figure "reflects the slope of the linear regression equation of Log2 fold change during recovery from COVID-19, and the shape reflects the comparison between which 2 groups [of the clinical types] it came from"	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2.	TNFSF14, SPRED1, DNAJC6		gene expression	down	rehabilitation & convalescence stages vs treatment stage: severe COVID-19 patients vs mild COVID-19 patients 	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S4.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	Start with DEGs of Recovery from COVID-19 (rehabilitation & convalescence stages vs treatment stage). Then selected DEGs of those DEGs between 3 clinical types. Color of the gene in the figure "reflects the slope of the linear regression equation of Log2 fold change during recovery from COVID-19, and the shape reflects the comparison between which 2 groups [of the clinical types] it came from"	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2.	XRN1, RPS27A, SRSF10, PER1, ZC3H12A, TRAF4, OSM, CD83, AREG, CCL3L3, PPP1R16B, DUSP2, CXCL2, CFB, DUSP8		gene expression	up	rehabilitation & convalescence stages vs treatment stage: severe COVID-19 patients vs moderate COVID-19 patients 	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S4.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	Start with DEGs of Recovery from COVID-19 (rehabilitation & convalescence stages vs treatment stage). Then selected DEGs of those DEGs between 3 clinical types. Color of the gene in the figure "reflects the slope of the linear regression equation of Log2 fold change during recovery from COVID-19, and the shape reflects the comparison between which 2 groups [of the clinical types] it came from"	
	Amani	Simranpreet		COVID-19 patients in Kunming, China	3.5	69	years	18	Peripheral Blood Mononuclear Cells		RNA-seq; DESeq2.	TNFSF14, DNAJC6		gene expression	down	rehabilitation & convalescence stages vs treatment stage: severe COVID-19 patients vs moderate COVID-19 patients 	time since hospital admission	0 to 75	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33361761	(2020-12-24)	https://www.nature.com/articles/s41392-020-00457-4/	Fig S4.	https://www.nature.com/articles/s41392-020-00457-4#Sec18/	Start with DEGs of Recovery from COVID-19 (rehabilitation & convalescence stages vs treatment stage). Then selected DEGs of those DEGs between 3 clinical types. Color of the gene in the figure "reflects the slope of the linear regression equation of Log2 fold change during recovery from COVID-19, and the shape reflects the comparison between which 2 groups [of the clinical types] it came from"	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	leukocyte CD45+ cells		immunophenotyping; flow cytometry	neutrophils; eosinophils; neutrophil:T cell (NTR)		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 1A & 1E	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F1.large.jpg	-neutrophil:T cell ratio measured via flow cytometry 	
	Amani	Simranpreet		Philadelphia, PA, USA	29	81	years	34	leukocyte CD45+ cells		immunophenotyping; flow cytometry; CBCs	neutrophils; neutrophil:T cell (NTR); polymorphonuclear leukocytes (PMNs):lymphocyte (NLR)		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 1A & 1E-F	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F1.large.jpg	-neutrophil:T cell ratio measured via flow cytometry & PMN:lymphocyte ratio measured via CBCs	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	leukocyte CD45+ cells		immunophenotyping	Dendritic cells (DC); total T cells; CD4+ T cells; CD8+ T cells; CD8+ mucosal-associated invariant T (MAIT) cells; total Natural Killer (NK) cells; Innate Lymphoid Cells (ILCs)		cell type frequency	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 1A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F1.large.jpg		
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	leukocyte CD45+ cells		immunophenotyping	Dendritic cells (DC); total T cells; CD4+ T cells; CD8+ T cells; total Natural Killer (NK) cells; B cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 1A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F1.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	leukocyte CD45+ cells		immunophenotyping	total T cells; CD4+ T cells; CD8+ T cells; total Natural Killer (NK) cells; CD8+ mucosal-associated invariant T (MAIT) cells; Innate Lymphoid Cells (ILCs)		cell type frequency	down	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114/	Fig 1A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F1.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	leukocyte CD45+ cells		immunophenotyping; flow cytometry	neutrophil:T cell (NTR)		cell type frequency	up	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114/	Fig 1A & 1E	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F1.large.jpg	-neutrophil:T cell ratio measured via flow cytometry 	
	Amani	Simranpreet		Philadelphia, PA, USA	29	81	years	34	leukocyte CD45+ cells		Complete Blood Counts (CBCs); Spearman's correlations	neutrophil:T cell (NTR); polymorphonuclear leukocytes (PMNs):lymphocyte (NLR)		cell type frequency	positively correlated	correlated with APACHE III score in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 1G	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F1.large.jpg	-neutrophil:T cell ratio measured via flow cytometry & PMN:lymphocyte ratio measured via CBCs.	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	whole blood		immunophenotyping; flow cytometry	CD27+ CD38+ B cells (B cell plasmablasts)		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	whole blood		immunophenotyping; flow cytometry	CD27+ CD38+ B cells (B cell plasmablasts)		cell type frequency	up	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	whole blood		immunophenotyping; flow cytometry	CD21- CD27- B cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2B	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	whole blood		immunophenotyping; flow cytometry	CD21+ CD27+ B cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2B	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	whole blood		immunophenotyping; flow cytometry	CD21+ CD27+ B cells		cell type frequency	down	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2B	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	24	64	years	19	whole blood		immunophenotyping; flow cytometry	CD21- CD27- B cells		cell type frequency	up	moderate COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2B	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	24	64	years	16	CD21- CD27- B cells		ELISA	CD11c+ cells		cell type frequency	down	moderate COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2C	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg	CD11c+ frequency from nonplasmablast B cell subsets that were defined in Fig 2A	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	plasma or serum		ELISA	SARS-CoV-2 spike RBD-specific IgM; SARS-CoV-2 spike RBD-specific IgG		protein/cytokine levels	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2D	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	61	years	19	plasma or serum		ELISA	SARS-CoV-2 spike RBD-specific IgM; SARS-CoV-2 spike RBD-specific IgG		protein/cytokine levels	up	recovered COVID-19 patients vs healthy patients	time since onset of symptoms	17 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2D	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Moderate & Severe COVID-19 patients in Philadelphia, PA, USA	29	81	years	34	plasma or serum		ELISA	SARS-CoV-2 spike RBD-specific IgM; SARS-CoV-2 spike RBD-specific IgG		protein/cytokine levels	positively correlated	correlated with days since onset of symptoms in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 2E	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F2.large.jpg		
	Amani	Simranpreet		Moderate & Severe COVID-19 patients in Philadelphia, PA, USA	29	81	years	34	whole blood		immunophenotyping; flow cytometry	CD27+ CD38+ B cells (B cell plasmablasts)		cell type frequency	positively correlated	correlated with D20 value (top ranked 20 clones)	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 3C	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F3.large.jpg	"D20 rank measure in moderate and severe disease also correlated positively with the plasmablast fraction" (2nd paragraph under "Profound oligoclonal..." section in Results	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	whole blood		immunophenotyping; multiparametric flow cytometry	CD16+ Natural Killer (NK) cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 4A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F4.large.jpg	"Proportion of CD16+ cells in NK cell subset"	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	CD16+ Natural Killer (NK) cells; CD16+ neutrophils; CD16+ immature granulocytes		immunophenotyping; multiparametric flow cytometry; MFI	CD16		protein/cytokine levels	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 4B-C, 4E	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F4.large.jpg	"MFI of CD16 on neutrophil,...NK cell, and immature granulocyte subsets. MFI was calculated within CD16+ cells."	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	monocytes		immunophenotyping; multiparametric flow cytometry; MFI	HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 4G	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F4.large.jpg	"MFI of HLA-DR on monocytes"	
	Amani	Simranpreet		Moderate & Severe COVID-19 patients in Philadelphia, PA, USA	29	81	years	34	monocytes		immunophenotyping; multiparametric flow cytometry; MFI	HLA-DR		protein/cytokine levels	down	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 4G	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F4.large.jpg	"MFI of HLA-DR on monocytes"	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	34	whole blood		immunophenotyping; multiparametric flow cytometry	CD38+ memory CD4+ T cells; HLA-DR+ CD38+ memory CD4+ T cells; PD-1+ memory CD4+ T cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	whole blood		immunophenotyping; multiparametric flow cytometry	HLA-DR+ CD38+ memory CD4+ T cells		cell type frequency	up	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5A	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Moderate & Severe COVID-19 patients in Philadelphia, PA, USA	29	81	years	34	whole blood		immunophenotyping; multiparametric flow cytometry; Spearman's correlations	HLA-DR+ CD38+ memory CD4+ T cells; HLA-DR+ CD38+ memory CD8+ T cells		cell type frequency	positively correlated	correlated with percent of plasmablasts in severe & moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5C	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg	percent of HLA-DR+ CD38+ memory CD4+ T cells & percent HLA-DR+ CD38+ memory CD8+ T cells	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	34	whole blood		immunophenotyping; multiparametric flow cytometry	HLA-DR+ CD38+ CD8+ mucosal-associated invariant T (MAIT) cells 		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5D	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	24	64	years	19	whole blood		immunophenotyping; multiparametric flow cytometry	HLA-DR+ CD38+ CD8+ mucosal-associated invariant T (MAIT) cells 		cell type frequency	up	moderate COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5D	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	34	whole blood		immunophenotyping; multiparametric flow cytometry	CD38+ memory CD8+ T cells; HLA-DR+ CD38+ memory CD8+ T cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5B	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	21	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; multiparametric flow cytometry	Perf+ Granz B+ cytotoxic memory CD8+ T cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5E	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	whole blood		immunophenotyping; multiparametric flow cytometry	HLA-DR+ CD38+ memory CD8+ T cells; CD38+ memory CD8+ T cells		cell type frequency	up	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5B	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	29	64	years	19	whole blood		immunophenotyping; multiparametric flow cytometry	HLA-DR+ CD38+ memory CD8+ T cells		cell type frequency	up	moderate COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5B	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	29	81	years	21	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; multiparametric flow cytometry	PD-1+ CD38+ Perf+ Granz B+ cytotoxic memory CD8+ T cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 5F	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F5.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	53	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; z-scored scaled flow cytometry; hierarchical clustering	HLA_DRMF1_inMonocytes; HLA_DR_MFI_inBcells; HLA_DR_MFI_inDC; CD16p_MFI_inMonocytes; CD16p_MFI_inNeutrophils; CD16p_MFI_inNK; CD161p_MFI_inMemCD8; CD14MFI_inMonocytes; DC_inCD45; HLA_DRp_inNeutrophils; Bc_inCD45; Monocytes_inCD45; Ttm_CD8; Ttm_CD4; CD27p_temRA; Ki67p_inCD21pCD27nBc; Ki67p_inCD21pCD27pBc; CD16p_inMonocytes; CXCR5p_MemCD8; CXCR5p_inTemRA_CD8; CXCR5p_inTtm_CD4; CXCR5p_inTem_CD4; CXCR5p_inTcm_CD4; Tc_inCD45; ILC_inCD45; CD15_MFI_inNeutrophils; CD56hiCD16n_NK; Tem_CD8; nonnconvMo_inMonocytes; intMo_inMonocytes; Tem_CD4		cell type frequency	down	severe COVID-19 patients vs healthy, moderate COVID-19, & recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 6a	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F6.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	53	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; z-scored scaled flow cytometry; hierarchical clustering	CD11cp_inCD21pCD27pBc; Ki67p_inTem_CD4; Ki67p_inTcm_CD4; Ki67p_inTtm_CD4; Ki67p_inTem_CD8; Ki67p_inTemRA_CD8; Ki67p_inTcm_CD8; CD38p_inTcm_CD8; HLA_DRpCD38p_inNK; Tregs_inMemCD4; CD161pCD38p_inNK; CD69p_MemCD8; CD69p_MemCD4; CD25p_MemCD8; Tcm_CD8; CD11cp_inCD21pCD27nBc; CD21nCD27p_inBc; CD69pKi67p_MemCD8; HLA_DRpCD38p_incTfh_CD4; CD123p_nonILC; CXCR5p_MemCD4; cTfh_MemCD4; cTfh_MemCD4; CD38p_MemCD8; CD38p_MemCD4; Ki67p_MemCD8; Ki67p_MemCD4; CXCR5p_inTtm_CD8; CXCR5p_inTcm_CD8; Eosinophils_inCD45; CXCR5p_inTem_CD8; HLA_DRpCD38p_inTem_CD8; HLA_DRpCD38p_inTemRA_CD8; Ki67p_inTtm_CD8; HLA_DRpCD38p_inTtm_CD8; CD38p_inTtm_CD8; CD38p_inTem_CD8; CD38p_inTemRA_CD8; CD69pKi67p_MemCD4; Ki67p_CD21nCD27nBc; Ki67p_CD21nCD27pBc; CD16p_MFI_nonILC; HLA_DRpCD38p_MemCD4; HLA_DRp_MemCD4; PD1p_inTemRA_CD8; PD1p_inTem_CD8; PD1p_inTcm_CD4; PD1p_inTtm_CD4; PD1p_inTem_CD4; PD1p_inTcm_CD8; PD1p_inTtm_CD8; Ki67p_inNeutrophils; HLA_DRp_inTemRA_CD8; HLA_DRp_inTcm_CD8; HLA_DRp_inTtm_CD8; HLA_DRp_inTem_CD8; HLA_DRp_MemCD8; HLA_DRpCD38p_MemCD8; CD38p_inTem_CD4; HLA_DRpCD38p_inTem_CD4; HLA_DRp_inTem_CD4; HLA_DRp_inTtm_CD4; HLA_DRpCD38p_inTtm_CD4; HLA_DRpCD38p_inTcm_CD4; HLA_DRp_inTcm_CD4; Plasmablast_inBc; CD38p_inTtm_CD4; Neutrophils_inCD45; PD1p_MemCD4; PD1p_MemCD8; CXCR5p_MemCD8; CD161p_inMonocytes; Tem_CD4; CD27n_TemRA; TemRA_CD8; TemRA_CD4		cell type frequency	up	severe COVID-19 patients vs healthy, moderate COVID-19, & recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 6a	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F6.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	53	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; z-scored scaled flow cytometry; hierarchical clustering	nonILC_inCD45; CD21nCD27n_inBc; Ki67p_nonILC		cell type frequency	up	moderate COVID-19 patients vs healthy, severe COVID-19, & recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 6a	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F6.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	53	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; z-scored scaled flow cytometry; hierarchical clustering	CD11cp_nonILC; CD16p_inNK		cell type frequency	down	severe COVID-19 patients vs healthy, moderate COVID-19, & recovered COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 6a	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F6.large.jpg		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	53	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; z-scored scaled flow cytometry; hierarchical clustering	Neutrophils_inCD45; PD1p_MemCD8; PD1p_MemCD4		cell type frequency	down	moderate COVID-19 patients & healthy patients vs severe & recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig 6a	https://immunology.sciencemag.org/content/immunology/5/49/eabd7114/F6.large.jpg		
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	25	Peripheral Blood Mononuclear Cells (PBMCs)		immunophenotyping; flow cytometry	D-dimer, procalcintonin, ferritin		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S1H	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	Peripheral Blood Mononuclear Cells (PBMCs)		Complete Blood Counts (CBCs)	whole blood cells (WBCs); polymorphonuclear leukocytes (PMNs)		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S1J	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	viable CD45+ cells		immunophenotyping; flow cytometry; CBCs; Spearman's correlations	PD-1+ Memory CD4+ T cells; HLA-DR+ Memory CD8+ T cells; HLA-DR+ Memory CD4+ T cells		cell type frequency	positively correlated	correlated with APACHE III score in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S1L	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-significant higher APACHE III score in severe COVID-19 patients vs moderate COVID-19 patients, APACHE III score positively correlated with age of patient	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	viable CD45+ cells		immunophenotyping; flow cytometry; CBCs; Spearman's correlations	T cells; CD8+ mucosal-associated invariant T (MAIT) cells; Natural Killer (NK) cells; B cells		cell type frequency	negatively correlated	correlated with APACHE III score in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S1K	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-significant higher APACHE III score in severe COVID-19 patients vs moderate COVID-19 patients, APACHE III score positively correlated with age of patient	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	viable CD45+ cells		multiparametric flow cytometry; Spearman's correlations	immature granulocytes		cell type frequency	negatively correlated	correlated with days since onset of symptoms in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3C	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as percent immature granulocytes within viable CD45+ cells	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	neutrophils		MFI	CD15		protein/cytokine levels	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3B	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as CD15 MFI within total neutrophils	
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	neutrophils		MFI	CD16		protein/cytokine levels	down	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3B	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as CD15 MFI within total eosinophils	
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	viable CD45+ cells		multiparametric flow cytometry	conventional (CD11c+ CD123lo/-) dendritic cells (DC); plasmacytoid (CD11c- CD123+) dendritic cells (DC)		cell type frequency	down	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3F	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as percent in viable CD45+ cells	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	CD3- CD19- cells		multiparametric flow cytometry	conventional (CD11c+ CD123lo/-) dendritic cells (DC); plasmacytoid (CD11c- CD123+) dendritic cells (DC)		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3F	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as percent in viable CD45+ cells	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	CD3- CD19- cells		multiparametric flow cytometry	conventional (CD11c+ CD123lo/-) dendritic cells (DC); plasmacytoid (CD11c- CD123+) dendritic cells (DC)		cell type frequency	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3F	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as percent in viable CD45+ cells	
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	CD3- CD19- cells		multiparametric flow cytometry	CD56bright CD16- Natural Killer (NK) cells; CD56dim CD16+ Natural Killer (NK) cells		cell type frequency	down	severe COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3G	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as percent in CD3- CD19- cells	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	CD3- CD19- cells		multiparametric flow cytometry	CD56dim CD16+ Natural Killer (NK) cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3G	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as percent in CD3- CD19- cells	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	CD3- CD19- cells		multiparametric flow cytometry	CD56bright CD16- Natural Killer (NK) cells; CD56dim CD16+ Natural Killer (NK) cells		cell type frequency	down	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S3G	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	-measured as percent in CD3- CD19- cells	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	T cells		multiparametric flow cytometry; Spearman's correlations	central memory CD4 T cells; central memory CD4 T cells		cell type frequency	negatively correlated	correlated with days since onset of symptoms in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S4E	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as percent of	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	T cells		multiparametric flow cytometry; Spearman's correlations	PD-1+ Memory CD4+ T cells		cell type frequency	positively correlated	correlated with age in years in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S4E	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as percent of	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	T cells		multiparametric flow cytometry; Spearman's correlations	HLA-DR+ CD4+ cTfh cells; HLA-DR+ CD38+ CD4+ cTfh cells; CD38+ CD8+ mucosal-associated invariant T (MAIT) cells; HLA-DR+ CD8+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S4G-I	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as percent of	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	Perf+ Granz B+ CD8+ T cells		multiparametric flow cytometry; Spearman's correlations	CD38+ cells		cell type frequency	up	severe COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S4K	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as percent in Perf+ Granz B+ CD8+ T cells	
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	T cells		multiparametric flow cytometry; Spearman's correlations	CD69+ CD8+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	severe COVID-19 patients vs recovered patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S4H	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as percent of	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	T cells		multiparametric flow cytometry; Spearman's correlations	Ki-67+ CD8+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S4H	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as percent of	
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	B cells		flow cytometry; Spearman's correlations	CD21+ CD27+ non-plasmablast B cells		cell type frequency	positively correlated	correlated with age in years in moderate & severe COVID-19 patients	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S5D	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as percent of	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	CD21+ CD27+ non-plasmablast B cells		flow cytometry; MFI	CD21		protein/cytokine levels	down	severe COVID-19 patients vs healthy patients 	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S5C	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as CD21 MFI in total non-plasmablast B cells	
	Amani	Simranpreet		Philadelphia, PA, USA	24	64	years	19	CD21+ CD27+ non-plasmablast B cells		flow cytometry; MFI	CD21		protein/cytokine levels	down	moderate COVID-19 patients vs healthy patients 	time since onset of symptoms	1 to 16	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S5C	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as CD21 MFI in total non-plasmablast B cells	
	Amani	Simranpreet		Philadelphia, PA, USA	20	64	years	14	CD21+ CD27+ non-plasmablast B cells		flow cytometry; MFI	CD21		protein/cytokine levels	down	moderate COVID-19 patients vs recovered COVID-19 patients 	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S5C	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1	measured as CD21 MFI in total non-plasmablast B cells	
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	CD4+ effective memory T (Tem) cells; CD4+ transitional memory T (Ttm) cells		multiparametric flow cytometry	CD38+ HLA-DR+ CD4+ central memory T (Tcm) cells; PD-1 CD4+ central memory T (Tcm) cells; CD38+ HLA-DR+ CD4+ effective memory T (Tem) cells; PD-1 CD4+ effective memory T (Tem) cells; CD38+ HLA-DR+ CD4+ transitional memory T (Ttm) cells; PD-1 CD4+ transitional memory T (Ttm) cells; CD38+ CD4+ effective memory T (Tem) cells; CD38+ CD4+ transitional memory T (Ttm) cells		cell type frequency	up	severe COVID-19 patients vs healthy patients 	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	CD4+ central memory T (Tcm) cells; CD4+ transitional memory T (Ttm) cells		multiparametric flow cytometry	Ki-67+ CD4+ central memory T (Tcm) cells; PD-1 CD4+ transitional memory T (Ttm) cells		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients 	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Moderate & Severe COVID-19 Patients in Philadelphia, PA, USA	29	81	years	34	CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD8+ central memory T (Tcm) cells; CD8+ transitional memory T (Ttm) cells		multiparametric flow cytometry	Ki-67+ CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; PD-1 CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; Ki-67+ CD8+ central memory T (Tcm) cells; PD-1 CD8+ central memory T (Tcm) cells; Ki-67+ CD8+ transitional memory T (Ttm) cells; PD-1 CD8+ transitional memory T (Ttm) cells		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients 	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Philadelphia, PA, USA	24	81	years	39	CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD8+ effective memory T (Tem) cells; CD8+ central memory T (Tcm) cells; CD8+ transitional memory T (Ttm) cells		multiparametric flow cytometry	CD38+ CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD38+ HLA-DR+ CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD38+ CD8+ central memory T (Tcm) cells; CD38+ HLA-DR+ CD8+ central memory T (Tcm) cells; HLA-DR+ CD8+ central memory T (Tcm) cells; CD38+ CD8+ effective memory T (Tem) cells; CD38+ HLA-DR+ CD8+ effective memory T (Tem) cells; HLA-DR+ CD8+ effective memory T (Tem) cells; CD38+ CD8+ transitional memory T (Ttm) cells; CD38+ HLA-DR+ CD8+ transitional memory T (Ttm) cells; PD-1 CD8+ transitional memory T (Ttm) cells		cell type frequency	up	severe COVID-19 patients vs healthy patients 	time since onset of symptoms	1 to 25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD8+ effective memory T (Tem) cells; CD8+ central memory T (Tcm) cells; CD8+ transitional memory T (Ttm) cells		multiparametric flow cytometry	CD38+ CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD38+ HLA-DR+ CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD38+ HLA-DR+ CD8+ central memory T (Tcm) cells; CD38+ CD8+ effective memory T (Tem) cells; CD38+ HLA-DR+ CD8+ effective memory T (Tem) cells; CD38+ CD8+ transitional memory T (Ttm) cells; CD38+ HLA-DR+ CD8+ transitional memory T (Ttm) cells		cell type frequency	up	severe COVID-19 patients vs recovered COVID-19 patients 	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Philadelphia, PA, USA	20	81	years	34	CD4+ effective memory T (Tem) cells; CD4+ transitional memory T (Ttm) cells		multiparametric flow cytometry	CD38+ HLA-DR+ CD4+ effective memory T (Tem) cells; CD38+ CD4+ transitional memory T (Ttm) cells		cell type frequency	up	severe COVID-19 patients vs recovered COVID-19 patients 	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Philadelphia, PA, USA	24	64	years	19	CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD8+ effective memory T (Ttm) cells		multiparametric flow cytometry	CD38+ HLA-DR+ CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells; CD38+ HLA-DR+ CD8+ effective memory T (Tem) cells		cell type frequency	up	moderate COVID-19 patients vs healthy patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Philadelphia, PA, USA	20	64	years	14	CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells		multiparametric flow cytometry	CD38+ HLA-DR+ CD8+ terminally differentiated effector memory cells re-expressing CD45RA T (Temra) cells		cell type frequency	up	moderate COVID-19 patients vs recovered COVID-19 patients	time since onset of symptoms	1 to 32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32669287	(2020-06-15)	https://immunology.sciencemag.org/content/5/49/eabd7114	Fig S9	https://immunology.sciencemag.org/content/suppl/2020/07/15/5.49.eabd7114.DC1		
	Amani	Simranpreet		Paris, France	52	77	years	45	peripheral venous blood		flow cytometry quantification	CD45 monocytes; CD45 classical (CD14Hi CD16-) monocytes		cell type frequency	down	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 1A-B; Appendix Fig S1B-C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0001/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title 		
	Amani	Simranpreet		Paris, France	52	77	years	45	monocytes		MFI	CD14		protein/cytokine levels	down	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2A; Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title 		
	Amani	Simranpreet		Paris, France	52	77	years	45	monocytes		FSC-A	CD14		protein/cytokine size	up	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/		
	Amani	Simranpreet		Paris, France	52	77	years	45	monocytes		flow cytometry quantification	large (FSC-Hi) monocytes		cell type frequency	up	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/		
	Amani	Simranpreet		Paris, France	52	77	years	45	conventional (FSC-Lo) monocytes; large (FSC-Hi) monocytes		MFI	CD16		protein/cytokine levels	up	All COVID-19 Patients: conventional (FSC-Lo) monocytes vs large (FSC-Hi) monocytes	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/		
	Amani	Simranpreet		Paris, France	52	77	years	45	conventional (FSC-Lo) monocytes; large (FSC-Hi) monocytes		flow cytometry quantification	intermediate (CD14Hi CD16+) monocytes		cell type frequency	up	All COVID-19 Patients: conventional (FSC-Lo) monocytes vs large (FSC-Hi) monocytes	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/		
	Amani	Simranpreet		Paris, France	52	77	years	45	Peripheral Blood Mononuclear Cells (PBMCs)		RT-qPCR	IL8, IL6, CCL2		gene expression	up	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2F; Fig S2F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title  		
	Amani	Simranpreet		Paris, France	52	77	years	45	Peripheral Blood Mononuclear Cells (PBMCs)		RT-qPCR	IL8		gene expression	positively correlated	correlated to monocyte size measured in Forward Scatter Statistics (FSC)	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/		
	Amani	Simranpreet		Paris, France	52	77	years	22	Peripheral Blood Mononuclear Cells (PBMCs)		Forward Scatter Statistics (FSC)	monocyte		cell type size	up	type 2 diabetes ICU COVID-19 patients vs non-diabetes general ward COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 2G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0002/	-monocyte size quantified (Forward Scatter Statistics (FSC) FSC-A)	
	Amani	Simranpreet		Paris, France	52	77	years	42	Peripheral Blood Mononuclear Cells (PBMCs)		RT-qPCR	IRF5, IFNB1		gene expression	up	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 3A; Fig S3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0003/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title 		
	Amani	Simranpreet		Paris, France	52	77	years	42	Peripheral Blood Mononuclear Cells (PBMCs)		MFI; Spearman's test	IRF5		gene expression	positively correlated	correlated to IFNB1 mRNA expression	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0003/		
	Amani	Simranpreet		Paris, France	52	77	years	45	Peripheral Blood Mononuclear Cells (PBMCs)		MFI; Spearman's test	IRF5		protein/cytokine levels	positively correlated	correlated to HLA-DR expression measured in MFI	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 3F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0003/		
	Amani	Simranpreet		Paris, France	52	77	years	45	intermediate (CD14Hi CD16+) monocytes		MFI	IRF5		protein/cytokine levels	up	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 3E; Fig S3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0003/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title  		
	Amani	Simranpreet		Non-Diabetes COVID-19 Patients in Paris, France	52	77	years	15	monocytes; classical (CD14Hi CD16-) monocytes 		MFI	IRF5		protein/cytokine levels	up	non-diabetes ICU COVID-19 patients vs non-diabetes general ward COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 3G-H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0003/		
	Amani	Simranpreet		Type 2 Diabetes COVID-19 Patients in Paris, France	54	77	years	30	classical (CD14Hi CD16-) monocytes 		MFI	IRF5		protein/cytokine levels	up	type 2 diabetes ICU COVID-19 patients vs type 2 diabetes general ward COVID-19 patients	COVID duration at inclusion	7 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 3H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0003/		
	Amani	Simranpreet		Paris, France	52	77	years	22	intermediate (CD14Hi CD16+) monocytes		MFI	IRF5		protein/cytokine levels	up	type 2 diabetes ICU COVID-19 patients vs non-diabetes general ward COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 3H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0003/		
	Amani	Simranpreet		Type 2 Diabetes COVID-19 Patients in Paris, France	54	77	years	30	peripheral venous blood		flow cytometry	CD45 monocytes		cell type frequency	down	type 2 diabetes ICU COVID-19 patients vs type 2 diabetes general ward COVID-19 patients	COVID duration at inclusion	7 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0004/		
	Amani	Simranpreet		Type 2 Diabetes COVID-19 Patients in Paris, France	54	77	years	30	peripheral venous blood		phenotypic analysis	CD45 CD8+ monocytes; CD45 classical (CD14Hi CD16-) monocytes 		cell type frequency	down	type 2 diabetes ICU COVID-19 patients vs type 2 diabetes general ward COVID-19 patients	COVID duration at inclusion	7 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0004/		
	Amani	Simranpreet		Type 2 Diabetes COVID-19 Patients in Paris, France	54	77	years	30	peripheral venous blood		t-SNE mapping	CD14+ monocytes; CD8+ lymphocytes		cell type frequency	down	type 2 diabetes ICU COVID-19 patients vs type 2 diabetes general ward COVID-19 patients	COVID duration at inclusion	7 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/figure/emmm202013038-fig-0004/		
	Amani	Simranpreet		Paris, France	52	77	years	45	peripheral venous blood		Clinical laboratory full blood count (FBC) records	monocytes		cell type frequency	down	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	time since admission to hospital	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Table S1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Paris, France	52	77	years	45	monocytes		flow cytometry-based counts	CD14+ monocytes; CD14Hi CD16- classical monocytes		cell type frequency	down	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Table S2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Paris, France	52	77	years	45	peripheral venous blood		immunophenotypic analysis; multiparametric flow cytometry	CD45 lymphocytes; CD45 B cells; CD45 CD8+ lymphocytes; CD45 CD4+ lymphocytes; CD45 CD4+ CD8+ lymphocytes; CD45 CD4- CD8- lymphocytes		cell type frequency	down	non-diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S1B-C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Paris, France	52	77	years	45	peripheral venous blood		immunophenotypic analysis; multiparametric flow cytometry	CD45 granulocytes		cell type frequency	up	non-diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Type 2 Diabetes Patients in Paris, France	54	77	years	60	peripheral venous blood		immunophenotypic analysis; multiparametric flow cytometry	CD45 lymphocytes; CD45 monocytes; CD45 B cells; CD45 CD8+ lymphocytes; CD45 CD4+ lymphocytes; CD45 CD4+ CD8+ lymphocytes; CD45 CD4- CD8- lymphocytes		cell type frequency	down	type 2 diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S1B-C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Type 2 Diabetes Patients in Paris, France	54	77	years	60	peripheral venous blood		immunophenotypic analysis; multiparametric flow cytometry	CD45 granulocytes		cell type frequency	up	type 2 diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Type 2 Diabetes Patients in Paris, France	54	77	years	60	Peripheral Blood Mononuclear Cells (PBMCs)		RT-qPCR	IL8, IL6, CCL2, IL1B		gene expression	up	type 2 diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S2F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Paris, France	54	77	years	45	Peripheral Blood Mononuclear Cells (PBMCs)		RT-qPCR	IL8, IL6, CCL2, IL1B		gene expression	up	non-diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S2F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Paris, France	54	77	years	45	plasma		Immunophenotyping	IL8		protein/cytokine levels	up	type 2 diabetes COVID-19 patients vs non-diabetes COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S2H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Type 2 Diabetes Patients in Paris, France	54	77	years	60	Peripheral Blood Mononuclear Cells (PBMCs)		RT-qPCR	IRF5, IFNB1		gene expression	up	type 2 diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Paris, France	54	77	years	45	Peripheral Blood Mononuclear Cells (PBMCs)		RT-qPCR	IRF5, IFNB1		gene expression	up	non-diabetes COVID-19 patients vs type 2 diabetes non-COVID-19 patients	COVID duration at inclusion	5 to 17	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32816392	(2020-09-11)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/	Appendix Fig S3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461002/#__sec1title		
	Amani	Simranpreet		Tartu, Estonia	21	92	years	142	plasma		Olink inflammation panel	CASP8, TNFSF14, CCL7, IL7, IL6, S100A12, OSM, TGFB1, CSF1, HGF, VEGFA, CCL2, SIRT2, IL18R1, CXCL1, TGFA, STAMBP, IL18, LIF, IL10, PD-L1, CCL8, IL5		protein/cytokine levels	up	COVID-19 patients vs healthy 	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 2: HC_vs_P tab	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		Tartu, Estonia	21	92	years	142	plasma		Olink inflammation panel	CD6		protein/cytokine levels	down	COVID-19 patients vs healthy 	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 2: HC_vs_P tab	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	117	plasma		Olink inflammation panel	HGF, TNFSF14, LIF, CDCP1, IL4, S100A12, IL10RA, MMP10, IL7, TGFB1, IL33, CD40, IL2, SULT1A1, CSF1		protein/cytokine levels	up	ICU COVID-19 patients vs non-ICU COVID-19 patients	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 2: ICU_vs_nonICU tab	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	117	plasma		Olink inflammation panel	CD6		protein/cytokine levels	down	ICU COVID-19 patients vs non-ICU COVID-19 patients	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 2: ICU_vs_nonICU tab	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL11, CCL8, IFNg, PD-L1, CCL7, CCL2, CSF1, VEGFA, IL18R1, CASP8, CCL23, IL7		protein/cytokine levels	positively correlated	each correlated with CXCL10	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3; Fig 4B & 4D	https://www.nature.com/articles/s41598-020-77525-w/figures/4/ ; https://www.nature.com/articles/s41598-020-77525-w#Sec18/ 	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	IL6, CCL2, PD-L1, IL10, CSF1, VEGFA, CASP8, IL18R1, CCL8, CCL23, CXCL11, S100A12, IFNg, HGF, IL7, TNFSF14, OSM, TGFB1		protein/cytokine levels	positively correlated	each correlated with CCL7	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3; Fig 4E, 4H, & 4J	https://www.nature.com/articles/s41598-020-77525-w/figures/4/ ; https://www.nature.com/articles/s41598-020-77525-w#Sec18/ 	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL11, CXCL10, CCL8, IFNg, PD-L1, CCL7, CCL2, IL18R1, CASP8, CCL23, IL7, IL6, HGF, TGFB1, IL10, S100A12, TNFSF14, OSM, CSF1		protein/cytokine levels	positively correlated	each correlated with VEGFA	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CCL8, IFNg, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, CASP8, CCL23		protein/cytokine levels	positively correlated	each correlated with CXCL11	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation	CXCL11, IFNg		protein/cytokine levels	positively correlated	correlated with IL7	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation	CCL8		protein/cytokine levels	positively correlated	correlated with TGFB1	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CCL8, PD-L1, CXCL11, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, CASP8, CCL23		protein/cytokine levels	positively correlated	each correlated with IFNg	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CCL8, IFNg, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL18R1, CASP8, CCL23, HGF, CXCL11, S100A12, OSM, TNFSF14, TGFB1, IL7		protein/cytokine levels	positively correlated	each correlated with IL6	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CCL8, IFNg, PD-L1, CCL7, CCL2, CSF1, VEGFA, IL6, IL18R1, CASP8, CCL23, IL7, HGF, OSM, S100A12, TGFB1, CXCL11		protein/cytokine levels	positively correlated	each correlated with IL10	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CCL8, IFNg, PD-L1, CCL7, CCL2, IL10, VEGFA, IL6, IL18R1, CASP8, CCL23, HGF, IL7, TGFB1, TNFSF14, S100A12, OSM, CXCL11		protein/cytokine levels	positively correlated	each correlated with CSF1	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	PD-L1, CCL7, IL10, CSF1, VEGFA, IL6, IL18R1, CASP8, CCL23, TNFSF14, S100A12, HGF, TGFB1, IL7		protein/cytokine levels	positively correlated	each correlated with OSM	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CCL8, IFNg, CXCL11, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, OSM, IL18R1, CASP8, CCL23, IL7, HGF, TGFB1, S100A12, TNFSF14		protein/cytokine levels	positively correlated	each correlated with PD-L1	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CXCL11, CCL8, IFNg, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, OSM, IL6, CASP8, CCL23, HGF, S100A12, IL7, TGFB1		protein/cytokine levels	positively correlated	each correlated with IL18R1	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CCL8, IFNg, PD-L1, CCL7, CXCL11, IL10, CSF1, VEGFA, IL6, IL18R1, CASP8, CCL23, HGF, IL7, S100A12, TNFSF14, TGFB1		protein/cytokine levels	positively correlated	each correlated with CCL2	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, OSM, HGF, TNFSF14, CASP8, TGFB1, CCL23, IL7		protein/cytokine levels	positively correlated	each correlated with S100A12	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	PD-L1, CCL7, CCL2, CSF1, VEGFA, IL6, OSM, S100A12, HGF, CASP8, IL7, TGFB1, CCL23		protein/cytokine levels	positively correlated	each correlated with TNFSF14	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CCL8, IFNg, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, CXCL11, TGFB1, S100A12, TNFSF14, CCL23, IL7, HGF		protein/cytokine levels	positively correlated	each correlated with CASP8	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, CASP8, OSM, S100A12, TNFSF14, CCL23, TGFB1, IL7		protein/cytokine levels	positively correlated	each correlated with HGF & with TGFB1	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	HGF		protein/cytokine levels	positively correlated	correlated with TGFB1	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CXCL11, IFNg, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, CASP8, OSM, S100A12, TNFSF14, HGF, IL7, TGFB1		protein/cytokine levels	positively correlated	each correlated with CCL23	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, CXCL11, IFNg, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, IL7		protein/cytokine levels	positively correlated	each correlated with CCL8	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Hospitalized COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA analysis NPX measurements; Spearman's correlation; Pearson p-value	CXCL10, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, OSM, TNFSF14, CASP8, S100A12, TGFB1, HGF, CCL23, CCL8		protein/cytokine levels	positively correlated	each correlated with IL7	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Table 3.	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	Count (total number of samples across first, middle, and last observations): 142, Also in Suppl Fig 5C	
	Amani	Simranpreet		Tartu, Estonia	21	92	years	159	plasma		PEA profiling; Spearman's correlation matrix	CXCL10, PD-L1, CCL7, CCL2, IL10, CSF1, VEGFA, IL6, IL18R1, OSM, TNFSF14, CASP8, S100A12, TGFB1, HGF, CCL23, CCL8, CXCL11, IFNg, IL7		protein/cytokine levels	positively correlated	each correlated with sCD14 and with sCD25	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 5C	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		PEA profiling	sCD14, sCD25		protein/cytokine levels	up	ICU COVID-19 patients vs healthy	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 5A-B	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	T cells		PEA profiling	sCD25		protein/cytokine levels	up	non-ICU COVID-19 patients vs healthy	time since onset of symptoms	1 to 44	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 5A	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		Tartu, Estonia	42	92	years	21	T cells		PEA profiling	sCD25		protein/cytokine levels	up	ICU COVID-19 patients vs non-hospitalized (mild) COVID-19 patients	time since onset of symptoms	1 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 5A	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	macrophages; monocytes		PEA profiling	sCD14		protein/cytokine levels	up	non-ICU COVID-19 patients vs healthy	time since onset of symptoms	1 to 44	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 5B	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	21	plasma		Legendplex 13-plex Inflammation panel	IL6, TNFA, CXCL10, IL10		protein/cytokine levels	up	ICU COVID-19 patients vs mild non-hospitalized COVID-19 patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 3: B1, C1, D1, L1	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	31	plasma		Legendplex 13-plex Inflammation panel	CXCL10		protein/cytokine levels	up	non-ICU COVID-19 patients vs mild non-hospitalized COVID-19 patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 3D1	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		non-ICU COVID-19 Patients in Tartu, Estonia	21	92	years	25	plasma		Legendplex 13-plex Inflammation panel; loess regression	IL1B, IL6, CXCL10, IL10, IFNA2		protein/cytokine levels	negatively correlated	correlated with time since initial symptoms in non-ICU COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 3: A2, B2, D2, G2, L2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		ICU COVID-19 Patients in Tartu, Estonia	42	92	years	15	plasma		Legendplex 13-plex Inflammation panel; loess regression	IL6, CXCL10, IFN-L1, IL10, IFNG		protein/cytokine levels	negatively correlated	correlated with time since initial symptoms in ICU COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 3: B2, D2, E2, L2, M2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		Legendplex 13-plex Inflammation panel	CRP, PCT		protein/cytokine levels	up	ICU COVID-19 patients vs non-ICU COVID-19 patients	time since onset of symptoms	0 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: B2, C2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/		
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		Legendplex assay; OLINK assay	lymphocytes; basophil; eosinophil		cell type frequency	down	ICU COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: D1, H1, I1	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell	
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		Legendplex assay; OLINK assay	neutrophil; neutrophil:lymphocyte (NLR)		cell type frequency	up	ICU COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: E1, F1	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell, NLR stands for neutrophil:lymphocyte ratio	
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		Legendplex assay; OLINK assay	neutrophil; neutrophil:lymphocyte (NLR); whole blood cell (WBC)		cell type frequency	up	ICU COVID-19 patients vs healthy patients	time since onset of symptoms	0 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: E2, F2, G2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell, NLR stands for neutrophil:lymphocyte ratio	
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		Legendplex assay; OLINK assay	basophil; lymphocyte		cell type frequency	down	ICU COVID-19 patients vs healthy patients	time since onset of symptoms	0 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: D2, H2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell	
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	plasma		Legendplex assay; OLINK assay	neutrophil		cell type frequency	up	non-ICU COVID-19 patients vs healthy patients	time since onset of symptoms	0 to 44	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: E2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell	
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		Legendplex assay; OLINK assay	whole blood cell (WBC)		cell type frequency	up	ICU COVID-19 patients vs non-ICU COVID-19 patients	time since onset of symptoms	0 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: G2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell	
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	plasma		Legendplex assay; OLINK assay	basophil; eosinophil		cell type frequency	down	non-ICU COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: H1, I1	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell	
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	plasma		Legendplex assay; OLINK assay	basophil		cell type frequency	down	non-ICU COVID-19 patients vs healthy patients	time since onset of symptoms	0 to 44	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Suppl Fig 1: H2	https://www.nature.com/articles/s41598-020-77525-w#Sec18/	-measured in % of cell	
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		LIPS method	S1 IgG; S2 IgG; RBD IgG; NC IgG; RBD IgA		antibody response	up	Peak levels: ICU COVID-19 patients vs healthy patients	time since initial symptoms	0 to 54	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1A-D, 1K	https://www.nature.com/articles/s41598-020-77525-w/figures/1	"Peak levels of IgG antibodies against SARS-CoV-2 spike protein subunits (A) S1, (B) S2, (C) its receptor binding domain (RBD) and (D) nucleocapsid protein (NC)" "Peak levels of IgA antibodies to RBD"	
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	plasma		LIPS method	S1 IgG; S2 IgG; RBD IgG; NC IgG; RBD IgA		antibody response	up	Peak levels: non-ICU COVID-19 patients vs healthy patients	time since initial symptoms	0 to 44	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1A-D, 1K	https://www.nature.com/articles/s41598-020-77525-w/figures/1	"Peak levels of IgG antibodies against SARS-CoV-2 spike protein subunits (A) S1, (B) S2, (C) its receptor binding domain (RBD) and (D) nucleocapsid protein (NC)" "Peak levels of IgA antibodies to RBD"	
	Amani	Simranpreet		ICU COVID-19 patients in Tartu, Estonia	42	92	years	15	plasma		LIPS method	S1 IgG; S2 IgG; RBD IgG; NC IgG; RBD IgA		antibody response	positively correlated	correlated with days since initial symptoms in ICU COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1G & 1M	https://www.nature.com/articles/s41598-020-77525-w/figures/1	"Peak levels of IgG antibodies against SARS-CoV-2 spike protein subunits (A) S1, (B) S2, (C) its receptor binding domain (RBD) and (D) nucleocapsid protein (NC)" "Peak levels of IgA antibodies to RBD"	
	Amani	Simranpreet		non-ICU COVID-19 patients in Tartu, Estonia	21	92	years	25	plasma		LIPS method	S1 IgG; RBD IgG; NC IgG; RBD IgA		antibody response	positively correlated	correlated with days since initial symptoms in non-ICU COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1G & 1M	https://www.nature.com/articles/s41598-020-77525-w/figures/1	"Peak levels of IgG antibodies against SARS-CoV-2 spike protein subunits (A) S1, (B) S2, (C) its receptor binding domain (RBD) and (D) nucleocapsid protein (NC)" "Peak levels of IgA antibodies to RBD"	
	Amani	Simranpreet		COVID-19 patients in Tartu, Estonia	21	92	years	33	plasma		LIPS method; Spearman's correlation matrix	S1 IgG; RBD IgG; RBD IgA		antibody response	positively correlated	correlated with microneutralization titers (MN value) in non-ICU & ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1H	https://www.nature.com/articles/s41598-020-77525-w/figures/1	-anti-SARS-CoV-2 antibodies 	
	Amani	Simranpreet		COVID-19 patients in Tartu, Estonia	21	92	years	33	plasma		LIPS method; Spearman's correlation matrix	NC IgG; RBD IgG; RBD IgA		antibody response	positively correlated	correlated with S1 IgG in non-ICU & ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1H	https://www.nature.com/articles/s41598-020-77525-w/figures/1	-S1 IgG also positively correlated with MN, however as titers are not captured as response components, it was left out	
	Amani	Simranpreet		COVID-19 patients in Tartu, Estonia	21	92	years	33	plasma		LIPS method; Spearman's correlation matrix	NC IgG; RBD IgG; RBD IgA; S1 IgG		antibody response	positively correlated	correlated with RBD IgG in non-ICU & ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1H	https://www.nature.com/articles/s41598-020-77525-w/figures/1	-also positively correlated with MN, however as titers are not captured as response components, it was left out	
	Amani	Simranpreet		COVID-19 patients in Tartu, Estonia	21	92	years	33	plasma		LIPS method; Spearman's correlation matrix	NC IgG; RBD IgG; S1 IgG		antibody response	positively correlated	correlated with RBD IgA in non-ICU & ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1H	https://www.nature.com/articles/s41598-020-77525-w/figures/1	-also positively correlated with MN, however as titers are not captured as response components, it was left out	
	Amani	Simranpreet		COVID-19 patients in Tartu, Estonia	21	92	years	33	plasma		LIPS method; Spearman's correlation matrix	NC IgG		antibody response	positively correlated	correlated with S2 IgG in non-ICU & ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1H	https://www.nature.com/articles/s41598-020-77525-w/figures/1		
	Amani	Simranpreet		COVID-19 patients in Tartu, Estonia	21	92	years	33	plasma		LIPS method; Spearman's correlation matrix	S1 IgG; RBD IgG; RBD IgA		antibody response	positively correlated	correlated with NC IgG in non-ICU & ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1H	https://www.nature.com/articles/s41598-020-77525-w/figures/1		
	Amani	Simranpreet		non-ICU COVID-19 patients in Tartu, Estonia	21	92	years	25	plasma		LIPS method; two-sample Wilcoxon test	RBD IgA		antibody response	positively correlated	correlated with RBD IgG levels in non-ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1J	https://www.nature.com/articles/s41598-020-77525-w/figures/1		
	Amani	Simranpreet		ICU COVID-19 patients in Tartu, Estonia	42	92	years	15	plasma		LIPS method; two-sample Wilcoxon test	RBD IgA		antibody response	positively correlated	correlated with RBD IgG levels in ICU COVID-19 patients	time since initial symptoms	none	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 1J	https://www.nature.com/articles/s41598-020-77525-w/figures/1		
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		OLINK NPX assay	IL6, IL10, CXCL10, CXCL11, IFNg, CCL2, CCL7, CCL8, PD-L1, IL18R1		protein/cytokine levels	up	ICU COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 2: A1, B1, C1, D1, E1, F1, G1, H1, I1, J1	https://www.nature.com/articles/s41598-020-77525-w/figures/2		
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	plasma		OLINK NPX assay	IL6, CXCL10, CCL7, CCL8, IL18R1		protein/cytokine levels	up	non-ICU COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 2: A1, C1, G1, H1, J1	https://www.nature.com/articles/s41598-020-77525-w/figures/2		
	Amani	Simranpreet		ICU COVID-19 Patients in Tartu, Estonia	42	92	years	15	plasma		OLINK NPX assay; loess regression	IL6, IL10, CXCL10, CXCL11, IFNg, CCL2, CCL7, CCL8, PD-L1, IL18R1		protein/cytokine levels	negatively correlated	correlated with time since initial symptoms in ICU COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 2: A2, B2, C2, D2, E2, F2, G2, H2, I2, J2; Fig 3I2 & 3J2	https://www.nature.com/articles/s41598-020-77525-w/figures/2 ; https://www.nature.com/articles/s41598-020-77525-w/figures/3 		
	Amani	Simranpreet		non-ICU COVID-19 Patients in Tartu, Estonia	21	92	years	25	plasma		OLINK NPX assay; loess regression	CXCL10, CXCL11		protein/cytokine levels	negatively correlated	correlated with time since initial symptoms in non-ICU COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 2: C2 & D2	https://www.nature.com/articles/s41598-020-77525-w/figures/2		
	Amani	Simranpreet		Tartu, Estonia	23	92	years	134	plasma		PEA profiling NPX	CASP8, TNFSF14, IL7, S100A12, OSM, TGFB1, CSF1, HGF, CCL23, VEGFA		protein/cytokine levels	up	ICU COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 3: A1, B1, C1, D1, E1, F1, G1, H1, I1, J1	https://www.nature.com/articles/s41598-020-77525-w/figures/3		
	Amani	Simranpreet		Tartu, Estonia	21	92	years	144	plasma		PEA profiling NPX	CASP8, TNFSF14, IL7, S100A12, OSM		protein/cytokine levels	up	non-ICU COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 3: A1, B1, E1, F1, G1	https://www.nature.com/articles/s41598-020-77525-w/figures/3		
	Amani	Simranpreet		Tartu, Estonia	21	92	years	125	plasma		PEA profiling NPX	CASP8, IL7		protein/cytokine levels	up	mild non-hospitalized COVID-19 patients vs healthy patients	early stage of disease	0 to 3	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 3: A1, G1	https://www.nature.com/articles/s41598-020-77525-w/figures/3		
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	40	plasma		PEA profiling NPX	HGF		protein/cytokine levels	up	ICU COVID-19 patients vs non-ICU COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 3: C1	https://www.nature.com/articles/s41598-020-77525-w/figures/3		
	Amani	Simranpreet		COVID-19 Patients in Tartu, Estonia	21	92	years	21	plasma		PEA profiling NPX	HGF		protein/cytokine levels	up	ICU COVID-19 patients vs mild non-hospitalized COVID-19 patients	time since initial symptoms	0 to 30	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33239683	(2020-11-25)	https://www.nature.com/articles/s41598-020-77525-w	Fig 3: C1	https://www.nature.com/articles/s41598-020-77525-w/figures/3		
	Amani	Simranpreet		Salt Lake City, Utah, USA	24	63	years	23	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR; univariable linear regression	viral N1 mRNA		protein/cytokine levels	positively correlated	correlated with younger age (in years). Younger males were more likely to be positive for SARS-CoV-2.	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 1c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0001/	Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR	ACE2		gene expression	up	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 2a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0002/	Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR	ACE2		gene expression	positively correlated	correlated with viral load (viral N1 mRNA in log(FC), ACE2 mRNA also in log(FC)	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0002/	Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR	IL8, IP10, TNFalpha		gene expression	up	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 3a-c; Table 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0003/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0004/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR	TRAF1		gene expression	down	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 3d; Table 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0003/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0004/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	11	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR; univariable linear regression	TRAF1		gene expression	negatively correlated	correlated with viral load (viral N1 mRNA in log(FC), viral E1 mRNA)	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 3e; 2nd paragraph in Section 3.5. Inflammatory Responses...; Table 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0003/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0004/ 	Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR; univariable linear regression	IL8, IP10, TNFalpha		gene expression	positively correlated	correlated with viral load (viral N1 mRNA in log(FC))	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 3f-h; Table 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0003/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0004/  	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR; univariable linear regression	IP10		gene expression	negatively correlated	correlated with age (in years)	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 3i; Table 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0003/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0004/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		BioLegend & log[pg/ml]	IP-10		protein/cytokine levels	up	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients ("measured control values")	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0005/	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		BioLegend & log[pg/ml]; linear regression	IP-10		protein/cytokine levels	positively correlated	strongly associated with viral load (viral N1 mRNA)	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	3rd paragraph in Section 3.5. Inflammatory Responses...	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/#phy214761-sec-0014title	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR	IFN-lambda1, IFN-lambda2		gene expression	up	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 4a & 4c ; Table 6	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0004/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0006/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		BioLegend & log(pg/mL)	IFNlambda2,3		protein/cytokine levels	down	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 4d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0004/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		BioLegend & log(pg/mL)	IFNlambda2,3		protein/cytokine levels	negatively correlated	correlated with viral load measured as N1 mRNA 	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 4h	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0004/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR; linear regression	IFN-lambda1, IFN-lambda2		gene expression	positively correlated	correlated with viral load measured as N1 mRNA 	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 4e-f	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0004/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Chemagic MSM I extraction platform & RT-PCR; linear regression	IFN-lambda1, IFN-lambda2, IFN-gamma, IFN-alpha2		gene expression	positively correlated	correlated with viral load measured as N1 protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0007/	"natural log(FC in mRNA expression) as the dependent variables and natural log(viral N1) detection as the independent variable" . "Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		BioLegend & log(pg/mL); linear regression	IFN-lambda2,3, IFN-gamma, IFN-alpha2		protein/cytokine levels	down	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 8; 2nd paragraph in Section 3.6. IFN Responses...	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0008/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/#phy214761-sec-0014title 	"reductions in IFN-alpha2, IFNg and IFN-gamma2,3 in patients with viral infection that averaged 66%, 49%, and 40%, respectively, relative to control patients." "Older patients were more likely to be male and negative [for SARS-CoV-2]" , More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		BioLegend & log(pg/mL); linear regression	BST-2 (Tetherin), IFIT-1, IFIT-3, MX-1		gene expression	up	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 9; 1st paragraph in Section 3.7. ISG Responses...	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0009/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/#phy214761-sec-0014title 	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		DDA mass spectrometry; chi squared tests	BST-2 (Tetherin), IFIT-1, IFIT-3		gene expression	positively correlated	with positive clinical testing for SARS-CoV-2 	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 10; 1st paragraph in Section 3.7. ISG Responses...	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0010/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/#phy214761-sec-0014title 	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		DIA mass spectrometry; linear regression	Tetherin, IFIT1, IFIT3, MX1		gene expression	up	SARS-CoV-2 positive patients vs SARS-CoV-2 negative patients	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 5a-d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0005/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		DIA mass spectrometry; linear regression	IFIT3		gene expression	positively correlated	correlated with N1 mRNA	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 5e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0005/ 	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		DIA & DDA mass spectrometries; linear regression	IFIT3, N1		gene expression	positively correlated	correlated with IFIT3 protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Fig 5f-g; 1st paragraph in Section 3.7. ISG Responses...	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/figure/phy214761-fig-0005/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/#phy214761-sec-0014title 	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNbeta		protein/cytokine levels	positively correlated	correlated with GMCSF, IFNalpha2 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNgamma		protein/cytokine levels	positively correlated	correlated with GMCSF, IFNalpha2, IFNbeta proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNlambda23		protein/cytokine levels	positively correlated	correlated with GMCSF, IFNalpha2, IFNbeta, IFNgamma proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFN1beta		protein/cytokine levels	positively correlated	correlated with IFNalpha2, IFNbeta, IFNgamma, IFNlambda23 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL6		protein/cytokine levels	positively correlated	correlated with IFNbeta protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL8, IL10		protein/cytokine levels	positively correlated	correlated with IL6 protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL12p70		protein/cytokine levels	positively correlated	correlated with IL10 & IFNlambda1 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL12p70		protein/cytokine levels	negatively correlated	correlated with GMCSF protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IP10		protein/cytokine levels	positively correlated	correlated with IL6, IL8, IL10 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		DIA mass spectrometry (log FC); Spearman's correlations	IFIT3		protein/cytokine levels	positively correlated	correlated with IP10 & IL10 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0011/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		DIA mass spectrometry (log FC); Spearman's correlations	IFIT3		gene expression	positively correlated	correlated with IP10 & IFIT3 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	TNFalpha		gene expression	negatively correlated	correlated with IFNalpha2, IFNgamma, IFNlambda23 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IP10		gene expression	positively correlated	correlated with IP10 & IL6 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IP10		gene expression	negatively correlated	correlated with IFNgamma & IFNlambda23 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL10		gene expression	negatively correlated	correlated with IFNbeta, IFNalpha2, IFNgamma, IFNlambda23 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL6		gene expression	negatively correlated	correlated with IP10 protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNlamba1, IFNlambda2		gene expression	positively correlated	correlated with IP10 protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNbeta1		gene expression	positively correlated	correlated with IL12p70 protein	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNalpha2		gene expression	positively correlated	correlated with IL12p70 & IFNlambda1 proteins	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 12	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0012/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNbeta1		gene expression	positively correlated	correlated with IFNalpha2 mRNA	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNgamma		gene expression	positively correlated	correlated with GMCSF, IFNalpha2, IFNbeta1 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNlambda1		gene expression	positively correlated	correlated with IFNalpha2, IFNgamma, IFNbeta1 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNlambda2		gene expression	positively correlated	correlated with IFNalpha2, IFNgamma, IFNbeta1, IFNlambda1 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IFNlambda3		gene expression	positively correlated	correlated with IFNalpha2, IFNgamma, IFNbeta1, IFNlambda1, IFNlambda2 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL6		gene expression	positively correlated	correlated with GMCSF, IFNalpha2, IFNgamma, IFNbeta1, IFNlambda3, IFNlambda2 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL8		gene expression	positively correlated	correlated with GMCSF, IFNalpha2, IFNgamma, IFNbeta1 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IL10		gene expression	positively correlated	correlated with GMCSF, IFNgamma, IFNlambda2, IL8 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	IP10		gene expression	positively correlated	correlated with IFNlambda1, IFNlambda2, IL8, IL10 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	40	nasopharyngeal epithelial cells		Spearman's correlations	TNFalpha		gene expression	positively correlated	correlated with GMCSF, IL8, IL10, IP10 mRNAs	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet		Salt Lake City, Utah, USA	11	90	years	12	nasopharyngeal epithelial cells		Spearman's correlations	IFIT3		gene expression	positively correlated	correlated with IL10 mRNA	N/A	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33625796	(2020-10-23)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/	Table 13	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903990/table/phy214761-tbl-0013/	"Older patients were more likely to be male and negative [for SARS-CoV-2]", More males than females in cohorts. Patients "may have come from 9 states within the Mountain West of the United States"	
	Amani	Simranpreet: Comment made		Dubai, UAE	3	70	years	82	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	RPL41, CALM1, RPL17, TMEM45A, PPP1CB, SLC25A6, TUBA1A		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 2 right side	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0010/		
	Amani	Simranpreet		Dubai, UAE	3	70	years	82	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	OTOF, OTOA, CXCL12, IFIH1, IL10, ACE2, CXCL10, CCL2, IFIT1, INF2, TNFSF9, PARP12, IFI44, TMPRSS2		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 2 right side	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0010/		
	Amani	Simranpreet		Dubai, UAE	3	70	years	69	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	C1R, C4A, C4B, C6, C7, C8B, F11, F13A1, F2, F2RL2, F7, KNG1, MASP1, SERPINC1, SERPIND1, SERPINE1, SERPINE2, ACVR1C, ACVRL1, AMHR2, BMP10, BMP2, CCL25, CD70, CNTFR, CXCL12, GDF7, IL11, IL12B, IL19, IL1RL1, IL1RL2, IL23R, IL2RA, IL31RA, IL34, IL36RN, INHBA, INHBC, INHBE, MPL, NODAL, PRLR, THPO, TNFRSF8, TNFSF11, TNFSF15, TSLP, AOX1, CNTFR, EGF, IL11RA, LEPR, PDGFB, PDGFRA, PDGFRB, BMP2, FST, GDF6, GDF7, PITX2, SMAD6, THBS2, THBS4, ITGB3, MYLK4, MYLK2, MAPK11, PTGS1, PTGIR, NOS3, RPL41, RPL41, RPL21, RPS8, RPS3A, RPL17, RPL23A, RPL36A, RPL13A, 		gene expression	up	mild COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0015/	-mild defined as having "cough, fever, fatigure or asymptomatic symptoms" (graphical abstract)	
	Amani	Simranpreet		Dubai, UAE	3	70	years	69	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	C1S, C2, C5, CFI, F5, F8, ITGAM, PROC, VWF, ACVR2B, BMP7, BMP8A, BMP8B, CCL2, CCR5, CCR7, CLCF1, CSF1, CSF1R, CSF2RA, CTF1, CXCL9, EDA, GDF11, GDF6, GDF9, IFNLR1, IL10RA, IL12RB1, IL12RB2, IL15RA, IL17RA, IL17RB, IL17RE, IL1A, IL20RB, IL21B, IL21R, IL22RA1, IL27RA, IL2RB, IL3RA, LEPR, LIF, RELT, TGFB2, TGFB3, TNFRSF11A, TNFRSF25, TNFRSF9, IL15RA, PDGFA, SOCS7, TMPRSS2, BMPR1B, MYC, RBL1, SMAD1, SMAD7, SMURF1, TGFB2, TGFB3, TBXAS1, TLN2, ITPR1, VWF, PLCB3, P2RY1, RASGRP2, PIK3R5, MYLK, PLCB2, PLCB1, PIK3R2, FERMT3, PIK3CD, ITPR3, MAPK13, RPL11, RPL18, RPS25, RPLP2, RPS12, FAU, RPL37A, RPL23, RPS20, RPS4X, RPS17, RPL34, RPL8, RPL10A, RPL35, RPSA, RPL27, RPL5, RPS6, RPS14, RPL19, RPLP0, RPL31, RPS2, RPS27, RPS27A, RPL18A, RPL7A, RPL3, RPL6, RPL10, RPL15, RPL4, RPS11, RPS16, RPS18, RPS23, RPL12, RPL32		gene expression	down	mild COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0015/	-mild defined as having "cough, fever, fatigure or asymptomatic symptoms" (graphical abstract)	
	Amani	Simranpreet		Dubai, UAE	3	70	years	49	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	C4A, C6, C7, C8B, F11, F12, F2, F7, KNG1, MASP1, SERPINC1,  ACVR1C, ACVRL1, AMHR2, BMP10, BMP2, BMP6, CD70, CNTFR, CXCL12, GDF7, IL1RL2, IL2RA, IL31RA, INHBA, INHBE, MPL, PRLR, THPO, TNFRSF8, TNFSF11, TSLP, AOX1, CNTFR, EGF, PDGFB, PDGFRA, PDGFRB, BMP2, FST, GDF6, GDF7, PITX2, SMAD6, THBS2, THBS4, ITGB3, MYLK4, MYLK2, MAPK11, PTGIR, RPL41, RPL21, RPS8, RPS3A, RPL17, RPL23A, RPL36A, RPL13A, CCL3L1, RPS27, RPL4, RPS11, RPS18, RPS23, RPL12, RPL32, RPS15A, RPS15, RPL26, RPLP1, RPL13, RPL30, RPL41		gene expression	up	moderate COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0015/		
	Amani	Simranpreet		Dubai, UAE	3	70	years	35	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	C1R, C4A, C1S, C2, C5, F12, ITGAM, PLG, PROC, PROCR, C6, C7, C8B, F8, F11, F13A1, F2, F2RL2, F7, KNG1, MASP1, SERPINC1, SERPIND1, SERPINE1, SERPINE2, ACVR1C, ACVRL1, AMHR2, BMP10, BMP2, CCL25, CD70, CNTFR, CXCL12, GDF7, IL11, IL12B, IL19, IL1RL1, IL1RL2, IL23R, IL2RA, IL31RA, IL34, IL36RN, INHBA, INHBC, INHBE, MPL, NODAL, PRLR, THPO, TNFRSF8, TNFSF11, TNFSF15, TSLP, AOX1, CNTFR, EGF, IL11RA, LEP, PDGFB, PDGFRA, PDGFRB, BMP2, FST, GDF6, GDF7, PITX2, SMAD6, THBS2, THBS4, ITGB3, MYLK4, MYLK2, MAPK11, PTGS1, PTGIR, RPL41, RPL41, RPL21, RPS8, RPS3A, RPL17, RPL23A, RPL36A, RPL13A, VWF, TNFSF9, TGFB3, LEP, IL3RA, IL21R, IL22RA1, IL1A, IL12RB1, IL12RB2, IL15RA, IL17RB, GDF6, FASLG, CSF1, CCL3L1, BMP6, CCL22, BMP8A, BMP8B, BMP7, GFAP, LEPR, ACE2, TGFB3, TLN2, ITPR1, P2RX1, TBXA2R, PIK3R6, TBXAS1, RPLP2, RPS12, FAU, RPS20, RPS4X, RPS17, RPL8, RPL10A, RPL35, RPSA, RPL27, RPS6, RPS14, RPL19, RPLP0, RPS2, RPS27, RPS27A, RPL7A, RPL3, RPL6, RPL10, RPL15, RPL4, RPS11, RPS11, RPS18, RPS23, RPL12, RPL32, RPS15A, RPS15, RPL26, RPLP1, RPL13, RPL30, RPL13		gene expression	up	severe COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0015/		
	Amani	Simranpreet		Dubai, UAE	3	70	years	49	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	C1S, C2, C5, CFI, F5, F8, F2RL2, ITGAM, PLG, PROC, PROCR, VWF, ACVR2B, BMP7, BMP8A, BMP8B, CCR5, CCR7, CLCF1, CSF1, CSF1R, CSF2RA, CTF1, CXCL9, EDA, GDF11, GDF6, GDF9, IFNLR1, IL10RA, IL12RB1, IL12RB2, IL15RA, IL17RA, IL17RB, IL17RE, IL1A, IL20RB, IL21B, IL21R, IL22RA1, IL27RA, IL2RB, IL3RA, LEP, LIF, RELT, TGFB2, TGFB3, TNFRSF11A, TNFRSF25, TNFRSF9, IL15RA, PDGFA, SOCS7, TMPRSS2, BMPR1B, MYC, RBL1, SMAD1, SMAD7, SMURF1, TGFB2, TGFB3, TBXAS1, TLN2, ITPR1, VWF, PLCB3, RASGRP2, PIK3R5, MYLK, PLCB2, PLCB1, PIK3R2, FERMT3, PIK3CD, ITPR3, MAPK13, RPL18, RPL11, RPS25, RPLP2, RPS12, FAU, RPL37A, RPL23, RPS20, RPS4X, RPS17, RPL8, RPL10A, RPL35, RPSA, RPL5, RPS6, RPL19, RPLP0, RPL31, RPS2, RPL18A, RPL7A, RPL3, RPL15, SERPINE1, SERPINE2, TNFSF9, LEPR, INHBC, IL36RN, IL23R, IL1RL1, IL19, IL12B, IL11RA, FASLG, CCL22, GFAP, LEPR, ACE2, P2RX1, TBXAS1, PIK3R6, RPS27A		gene expression	down	moderate COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0015/		
	Amani	Simranpreet		Dubai, UAE	3	70	years	35	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	CFI, CCR5, CSF1R, CSF2RA, CTF1, CXCL9, EDA, GDF11, IFNLR1, IL10RA, IL17RA, IL17RE, IL20RB, IL21B, IL27RA, IL2RB, RELT, TGFB2, TNFRSF11A, TNFRSF25, TNFRSF9, IL15RA, TMPRSS2, BMPR1B, MYC, RBL1, SMAD1, SMAD7, SMURF1, TGFB2, TGFB3, TBXAS1, PLCB3, RASGRP2, PIK3R5, MYLK, PLCB2, PLCB1, PIK3R2, FERMT3, PIK3CD, ITPR3, MAPK13, RPL11, RPL37A, RPL23, RPL34, RPS16, RPL34		gene expression	down	severe COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0015/		
	Amani	Simranpreet		Dubai, UAE	3	67	years	86	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	CSF2, TNFSF11, TNFRSF11B, IL18R1, IFIT1B, C4BPA, FCGR1A, NCR1, IFI27L		gene expression	up	mild & moderate COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 5 & caption	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0025/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0035title 	"log2 fold change of...DEGs of COVID-19 patients compared with controls." (Fig 5 caption)	
	Amani	Simranpreet		Mild & Moderate COVID-19 Patients in Dubai, UAE	3	67	years	47	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	CSF2, TNFSF11, TNFRSF11B, IL18R1, IFIT1B, C4BPA, FCGR1A, NCR1		gene expression	up	mild & moderate COVID-19 patients: males vs females				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Fig 5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/figure/f0025/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0035title 	-more females than males (17 females vs 30 males). Fig 5 shows violin plots showing significant differences between males and females in FCGR1A & CSF2 expression. Both genes are already included in this signature. 	
	Amani	Simranpreet		Dubai, UAE	3	70	years	82	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	MTRNR2L2, IGFN1, AQP7P1, MUC19, FBN3, MUC17, MYO18B, KCNQ2, DUSP5P1, PGA4, INS-IGF2, KCNA2, CCDC168, PGA3, NBPF6, GPRIN2, GRIN2B, DNM1P50, HERC2P7, DSCAM, MYOCD, ABCC8, HSD3BP4, MROH2A, KIF26A, MROH5, MUC12, GRIK4, DDX11L5, NBPF4, MROH2B, MYH2, MYH8, COL11A1, C3P1, MYH13, NCAN, CNTNAP4, IQSEC3, DUXAP8, IQGAP3, DDX11L1, KCNH5, NOVA2, INSRR, HERC2P11, IL31RA, KCNH4, DLK1, MYH6, CD8B2, MSTO2P, JPH4, DRD5P2, CLCN1, AQP7P3, HPSE2, MYH1, DGKK, GRIN2A, FNDC1, CDHR1, IGSF9B, LMTK3, KCNC1, PDGFRB, MYT1, CASR, IQCA1L, LCT, ATP1A3, LHFPL4, LPA, MYO3A, MYH4, HRNR, NES, ITGB3, ITPRID1, TNXA, NEFM, IGDCC4, CADM2, CLVS2, GLIS1, TFAP2B, KCNJ9, KCNU1, DCC, PDX1, HKDC1, GRIN2D, ABCG4, PDZK1P1, GRIK3, CAMK2A, MYPN, WNK4, CAPN11, DUSP27, DEFA1B, LHX9, MYADML, MYO7B, ITGA2B, GRIA3, FIGN, HS6ST3, APLNR, TNN, DCHS1, LGI2, NXF4, DPP6, CNTNAP5, HTR4, IGSF22, DAZ3, DSG1, NETO1, LRP1B, DDX11L9, CPNE4, MYBPC2, MDGA2, MBD3L3, PPIEL, ALOX12B, GRID2, MMP23B, MBD3L4, PEAR1, NXPE1, HSPB6, JPH2, KCNQ4, KCNH1, GLP1R, IGLON5, CAPN6, ALPG, GRM1, MTRNR2L9, KCNA6, GJA5, MRGPRE, ARGFX, GLI1, MMP23A, HNRNPA3P1, VSTM2A, DDX11L16, FFAR3, GRM8, CPNE6, WSCD1, WT1, HSPA12B, ACAN, GRM6, CXorf49B, LMLN2, HMGCLL1, CNTN6, CNKSR2, FAT3, ITIH2, CDC6, TLR9, MPL, CD163L1, KCNJ12, GRIK1, THSD7B, THPO, CCDC155, MYT1L, ZIC4, F11, FRMPD4, DAO, KCNJ10, WNT7A, DDC, FGF1, DNAJB8, NACAD, NFATC4, CXorf49, MUCL3, HTR3E, NEUROD1, MYH7, FIGNL2, HOXA3, NXF5, HTR5A, GRIA2, BMPER, DAZ4, ALX4, H3P4, IGDCC3, NBR2, HK3, GRM3, KIRREL1, HECW1, KCNQ3, TLE6, CNTN2, LRP2, MORC1, KCNT2, MUC3A, TGM7, AADACL3, VAX1, MOXD2P, CDH5, DUXAP9, DAZ2, FOXL1, ALPI, ATP1A2, FLT4, KCNT1, HTR1A, GRID1, TFAP2D, ACP4, CCDC92B, BMP10, COMMD4P1, CPNE9, NYAP1, KCNK10, HOXB9, HPCAL4, AMY2A, CRTAC1, MUSK, HGFAC, TLE7, AMY1A, LRFN2, GREM2, KIR2DS4, ALPP, CPS1, CDH20, DSG4, CA11, CRHR2, HNRNPA1P10, MDGA1, ASB10, CRHR1, KPRP, MYO1A, PDYN, KEL, CCER1, GRIN1, CNTFR, MPP2, KIRREL2, FIBCD1, HOXC12, FGA, MRC1, GLDC, CBARP, GRID2IP, MS4A18, CDO1, PPIAL4D, KCNIP2, VAT1L, NEFH, PPFIA4, CPA5, GLP2R, GPC6, CD70, KCNA4, FUT5, HNRNPCL2, GYS2, CPZ, CALN1, FTCD, H2AB2, ALOXE3, TIMD4, TH, FGB, LBP, HOXD12, CREB3L3, KIF4B, KIF12, CABP5, HTR3D, DPEP3, KCNC2, DUSP15, ACSBG2, LIMS2, HNRNPCL1, LGI3, DTNA, DES, MYLK2, LIM2, DYTN, F2, KCNK9, KIR2DL3, DAAM2, GRIN3A, GPIHBP1, TGM6, DDX12P, HSFX2, CCDC154, APOC4-APOC2, HERC2P4, CPLX2, CA7, MUC6, AMBP, PPFIA3, TLX1, DCDC2C, GPR149, KIR3DL1, CCNYL3, ITGAD, KIF5A, CCDC63, CDH10, PDGFRA, MMP16, DRD3, MYLK4, COMP, GNAT1, MYL3, GRK1, THBS2, HOXA11, HTR3C, ITIH1, CAPN14, DSPP, DDX11L2, TICRR, CILP2, KBTBD13, IL36B, KDR, NF1P2, MARCO, CALCR, KCNC3, DDN, KCNN1, TMC1, GNAO1, LMX1B, CDHR5, FOXD4L4, CDCP2, HSPB7, APLN, C4A, TGM5, CDX2, CD248, HOXC6, MN1, LPL, KCNIP1, GUSBP4, THY1, CXCL11, IGF2BP1, COL9A1, FETUB, MAPK4, TIE1, NBPF22P, MYBPH, DBH, C7, LHX3, CD300LG, CD1B, CAMKV, DUSP26, CXADRP2, C8A, FRG1JP, CRB2, CLDN2, CBX2, DNMT3L, AADACL4, AANAT, MATN4, FOXD4L3, TNNI1, PPFIA2, NOTUM, PDZRN4, CALHM4, IMPA1P1, CRISP1, CCDC169-SOHLH2, KCNMA1, GREB1, CCDC144NL, MMD2, MAST1, MYO1H, H2AB1, HRH3, ITIH3, KLF17, APOA5, TNFRSF8, GPX5, GUSBP16, LOXL3, KIR3DL3, MCF2, MROH7-TTC4, GNG13, ACCSL, FHL5, MST1L, MYO3B, WNT1, MOV10L1, C8B, CASP14, LILRP2, MPPED1, HES7, ITGA10, MYOZ3, CCKBR, IGSF21, GSTM2P1, TNR, THEG, HJV, KIR2DL1, AMBN, DRGX, GSX1, HEPH, IFNL1, FNDC5, DMBX1, ACR, ARID3C, CCKAR, FOXD4L5, HPR, INKA2, FGD5P1, CABP2, CPA1, H4C12, F7, HOXC11, CA4, GSTA7P, FCRLB, CDH4, TLL1, GRM4, MS4A15, HOXA7, FAIM2, CCDC177, KCND1, MEOX1, HOXC10, LHX8, ACHE, CNGB3, HOXA4, AMER2, GRIA4, LHCGR, IGF2, LIN28B, HOXC4, CDSN, HHIPL2, WNT10B, HOXC5, LDB2, NAT8L, DUSP13, LINGO1, NYAP2, AMHR2, ISX, LHX1, WNT2, CLCA1, ATP1B2, IZUMO3, FOXA2, KIF2B, CPN1, HCN1, GJA8, CASQ2, CARMIL3, PDZD7, G6PC, FREM3, ALPK2, FGD5, HOXB8, MCHR2, CALHM1, KANK4, HSFX1, LGALS12, KIF15, TMIE, GJD2, HMGA1P7, FRG2C, CCDC196, ACSM5, CYLC2, MYBPC3, PDZD3, GJA3, DRP2, HOXD3, FTCDNL1, CD34, NELL1, DPT, HMCN1, MBD3L2, NXPH1, KCNH7, CPLX3, DLL3, DCD, DACT1, CLDN14, CD5L, MDFIC2, PPIAL4F, MMRN1, KLF18, JCAD, INSC, PERM1, CXCL12, CASKIN1, IL13, DHRS4L1, GRIK5, LHX5, NXPE4, MYO16, HBG1, FSTL3, WNT8B, HAO2, KCP, VRTN, ISLR2, HOXB6, INTS4P2, CLIP3, MST1P2, GPA33, CKM, HFM1, THBS4, CCDC197, CDK5R2, ISM1, HAPLN2, ARSF, FREM1, APOB, CBLN4, HDGFL1, LRFN5, CBLIF, GOT1L1, KIR3DL2, NOC2LP2, ART1, FKBP10, LRIT2, DPEP1, CA10, HPD, AQP12A, IL17REL, MRGPRF, CCDC42, TM6SF2, CPA2, WNT8A, HSD3B2, CCDC105, KCNK3, HCRTR1, GPC5, IL1RAPL1, CILP, ATP1A4, CIDEA, COLEC11, CDIPTOSP, CROCCP2, KCNK16, ITGA7, CALR4P, CASP1P2, CDC25C, DCLK3, KIF18B, CCER2, CAMK2B, LCE1E, LMAN1L, HNF4A, ARSI, IFNL2, CUZD1, MBD3L2B, CD1A, FCGR1CP, DBX2, ARSH, LRIT3, ABLIM2, FSHR, IL2RA, DCT, ASB15, HNRNPA1P33, NEFL, HAPLN1, DCSTAMP, MYL7, AMER3, KCNK12, C9, HOXA13, H1-8, MPO, GUCA1A, MYOG, NOX3, CLK2P1, PDILT, LEFTY2, GPSM1, MRGPRX3, MPZ, DDX4, NALCN, LHX6, TINAG, HTRA3, FOXN1, MOXD1, KL, FLG, FRG2B, CBLN1, CDC14C, TIFAB, CRP, GPR12, KNG1, ILDR2, IL21, CPA6, MEI4, AQP2, NCR2, CASP12, C8G, HOXA2, CASQ1, KCNA5, CLPSL1, FAAHP1, CDK15, HOXB1, IGFL1, DDX11L10, HORMAD2, KCNIP3, HOXA10, NEB, PEBP4, HOXC8, WSCD2, APOL5, CCDC185, MMP27, CCT8L2, ASCL1, KREMEN2, HAND2, FAP, NYX, ABCG2, KCNK13, FUT1, MYOC, IRX1, GJA1, CCL13, HNF1A, IFNL4, HLA-G, CCL11, CDK3, ARL2-SNX15, AMPD1, CCL24, GPR139, MYBPC1, VSTM1, CLDND2, MMP28, HTR1B, CALHM5, CLPS, MYL4, MS4A4A, IL10, LCNL1, MRGPRX2, HTR1E, GPRC6A, CCM2L, CPB2, GLYATL1, MMP19, INHBA, GRK6P1, GRIA1, CAVIN4, KCND2, DIO3, MSI1, MPP3, IL25, INTS4P1, HRC, FMO9P, DNAJA1P5, TFAP2E, KCNAB3, ARL9, CBLN2, GLYAT, C4B, KNCN, HECW2, HCG22, KCNJ4, FMOD, DSC1, H2AB3, COMMD4P2, ISM2, HMGB3P1, AQP12B, LHFPL3, TKTL1, KCNA10, ACER1, CNTNAP3P2, CMTM5, GPBAR1, PPIAL4E, FRG2DP, PDGFB, FUT9, HMSD, HEPN1, CDH16, MYADML2, FUNDC2P2, DNTT, HSD3B1, HNRNPKP3, HCRTR2, LMO3, HOXC9, MTTP, MEI1, IGSF23, FUT7, KCNK4, ZIC5, LCN6, A1CF, MYOZ1, HOXB5, CIB3, KCNV2, TMOD1, DRD5, DPRX, DSC2, PDIA2, IGSF1, GTF2A1L, WNT9B, TLX2, DAZL, IL1RAPL2, CCDC83, KCNJ11, FOLH1B, TGM4, HOXD13, HOXD9, HTR7, HMGB4, GRIP2, DPPA2P3, CCDC85A, FRG2, GSTM5, GREM1, ATP1B4, FCN2, IL22, FLT3, CDH19, AACSP1, ACOT12, DNAH8, H1-7, HTR2A, HTATSF1P2, CPT1C, HMCN2, LCN9, NXPH4, WNT3, NXPE2, FOXH1, HOXB4, GPD1, HS3ST3A1, GUSBP10, HEPACAM, CNGB1, KIF1A, CDH15, ACKR1, HIVEP3, G6PC2, HOXC13, F9, LIPF, GJA10, KDM4E, CDH18, CA9, FEZF2, KCNK17, KIRREL3, LRFN1, IL3, IL12B, DAB1, LCN10, FKBP1AP1, MCM10, MLXIPL, LIPM, KCNH8, IRX4, HOXA9, HAVCR1, CPLX1, HTR2C, CNTD2, ITLN2, CDHR2, ALOX12, INHBC, CLDN19, DOCK3, IGFL3, TKTL2, CXXC1P1, KIF25, CDCA2, DPPA2, MAPK8IP1P2, IQCJ, DKKL1, MS4A3, MOGAT2, HPN, MRO, CDC42P3, NXF2, CRIP3, COL9A3, HEYL, CORO6, EBF2, HSD17B6, TMBIM7P, DDX53, LMOD2, ZIM2, HCG4, FOXP3, AMZ1, DEFA1, FOXF1, CLRN1, DIAPH3, CPB1, MYOM3, APOH, MTNR1B, ACOXL, CD1D, MEDAG, HEATR9, INHA, KIF26B, FGL1, INPP5J, IZUMO1R, ITGA11, DPF3, IL11, KCTD8, NBPF13P, KAZALD1, MYOZ2, KLRG2, THEGL, IGKV2D-14, LCE5A, HSPA7, TGIF2-RAB5IF, HTR1F, ITLN1, NBPF7, DDI1, MBD3L5, FABP7, GNAT2, HSFY2, MSX2P1, FOXB1, CCDC172, MRAP, CIDEC, KCNK15, CXorf51A, MEP1B, CITED1, CCDC144CP, CCL21, LCN1, DGAT2L6, LEFTY1, VSTM4, PEG3, HSD11B1, KIR2DL4, DPH3P1, FSCB, CDX1, MEOX2, APOBEC1, HOXB7, MOGAT1, LEXM, CD300C, TNFSF11, APOC4, CNTN1, ITIH6, TNNT2, DLSTP1, CNGA2, DUSP9, HOXD8, H2BW3P, TNNC2, KIF14, FOXD4L6, F10, IQCJ-SCHIP1, LRIT1, PPM1J, LGI4, CALCA, CDY1B, CXADRP3, KCNH6, HIPK4, DAZ1, C4BPA, MCHR1, GZMM, FLG2, DHRS7C, MTMR11, MYO15A, LIPK, HOXD1, IFNL3, CCL18, FSD1, HOXA1, NDUFA4L2, IGKV2-14, IGHE, DOK7, KCNJ3, KIF7, TM4SF4, MBL2, ABI3BP, FGG, FOXR1, FNDC8, CCL25, FOXO6, MMP8, PPM1N, NOX1, HS3ST4, INHBE, KCNQ5, ARSL, LGALS14, TMIGD3, AMTN, HAO1, ART5, GNG3, CCDC3, HOXD11, GREB1L, CLDN5, TMIGD1, KCNJ8, HROB, COL8A2, DTX1, ABCG5, CRISP3, HSD17B14, DCLK2, GPER1, DPF1, MSGN1, AMPH, MYMK, CXorf51B, CCDC116, NGF, LAMP5, HAND1, MYL2, HEPHL1, PFKFB1, FNDC7, MASP1, CCDC140, MATN1, HMX1, GYPB, LINGO2, LRP5L, ITGA8, CCDC27, CIB4, CRNN, MPPED2, MMP17, TG, MYH3, IRGC, MSANTD3-TMEFF1, MNX1, TGM1, GLYATL1B, CCR2, IGHV1OR15-3, CALY, MYOM2, MTCL1, MMP21, H4C11, DNAH17, GSG1L, DKK2, AQP8, DOC2GP, COLGALT2, PPDPFL, DCST1, HIF3A, GPR150, NOX5, MAP6D1, GJB6, CCL8, MS4A12, VAX2, CNPY1, TFR2, DRD1, DNMT3B, NAA11, FADS6, GYPA, IL17A, MRGPRX1, FRG1BP, GPC2, MBL1P, NDST4, CRH, FAR2P1, CPEB1, GPR142, LGALS16, LBHD2, HS3ST5, MMP26, NAALAD2, CMKLR1, MC5R, DUXA, CAMK1G, DBIL5P, HSFY1, CCR8, JAKMIP3, FOXD4L1, ACOD1, ALX3, KERA, IL27, TLL2, KCNF1, PPIAL4C, MS4A14, KLF1, CALHM3, WNT6, DCX, FOXD3, TNP2, IGHVII-22-1, ACP7, MMP20, GRXCR1, CD247, COX4I2, GP5, ACOT6, APOBEC3B, KHK, LELP1, CD101, CDH24, GSG1L2, FSCN2, MROH3P, FAT4, IL1RL2, CNNM1, TIMM8A, CAGE1, CBLN3, F13B, MYH7B, FDPSP2, VSIG8, LGALS13, TNMD, AMELX, ABCG8, DBX1, GJC2, FOXC2, NCBP2L, CMTM1, NCR3, A3GALT2, HCN3, KCTD16, MYOD1, CDH22, CCDC70, HPCA, ACSL6, DCAF12L2, FFAR4, KCNS2, CDH9, IL1F10, DSCC1, MRGPRX4, FCAMR, IL17RD, GPR148, KCNE5, GRIN2C, CDH6, CCL3L1, KHDRBS2, IBSP, IRX6, CD8B, MAP3K15, KCNA7, MCCD1, IGHV3-30, NDP, PDPN, MARCHF4, IHH, CDY2B, DCLRE1CP1, TMOD4, CNMD, IL36A, LDB3, MYO7A, F13A1, CCL19, TINCR, GPR101, FOXS1, CADPS, CPXM2, IZUMO2, GRK7, APOBEC3H, MYF6, IL26, FOXR2, HOXD10, GPR141, TNNI3K, DIO2, DCAF12L1, MEF2B, HIGD1B, CNTNAP1, HOXB3, LIPI, LCE1D, BMP5, CLRN2, HAPLN3, IL9R, KRTDAP, KCNN2, MYCN, CNBD2, LCE3E, GKN2, H3Y2, FEV, CYLC1, CDH7, FZD9, DMBT1, MELK, CMA1, PDZD4, GK2, GSX2, ARL14EPL, MYRFL, IGFBP1, AQP10, MAPK8IP2, MEGF10, IGHV1OR15-1, IGHV3-30-2, FOXF2, JAKMIP1, LILRB1, LDLRAD2, HOXA5, LMOD1, TM4SF20, CCL27, FTMT, DRICH1, PDZK1, APOA4, VCX, IGHEP1, LCE2D, CD109, GPHA2, FBP2, GRPR, IFITM10, MSX2, C6, CPED1, KCNJ1, GPR1, FANCD2OS, IGLC5, MYH15, TNNT1, LMX1A, HSPB2-C11orf52, CCDC188, CCK, IL13RA2, LCE1C, IL1RL1, MMEL1, IGFALS, HBBP1, MYZAP, MS4A13, HEATR4, NOTCH4, INSYN2A, H2BW2, NOSTRIN, VCX2, CALML6, MARCHF11, DNM3, LRCH2, CNR1, HCN2, CXorf66, MARCOL, IGHV3-33-2, ITGBL1, KY, TM4SF5, MYL1, LCE2A, FABP3, LHB, CBY2, DHDH, NCAM2, MAPK11, GSTT2B, H3Y1, IGHVIII-22-2, DSCR8, GNRH2, CLCNKA, FOLH1, IL36RN, LPAR4, CPLX4, HRH1, KCNK18, CKMT2, ASB12, CCN6, ACSM1, DLC1, IL11RA, CCN4, FBN1, NDOR1, CRX, CPNE7, FSHB, CD5, TFDP3, HHIP, HTR1D, GPHB5, MAS1L, GP1BA, FRG2KP, LBX2, DDIAS, MC4R, HOXD4, LIMS4, FANCB, GPR152, KCNH2, DAOA, MYBPHL, GRXCR2, MEGF6, DACH2, INS, KCNA1, KCTD19, DCAF13P3, IL23R, KISS1, HMX2, FOXB2, CDRT15P1, CLSTN2, IGKV1D-35, TNFRSF4, DCST2, KISS1R, MEPE, IGLC6, HIC1, THSD7A, DMP1, PPEF1, MSH4, CXCR2P1, GJC3, WNT11, HMMR, VCAM1, MS4A2, MELTF, DUPD1, IL37, LRCOL1, HGF, IFNA4, DPPA3, DACH1, ASB5, IGFL2, ASAH2, LCE3D, IL17C, CAMKK1, MPP4, FGFR4, GYPE, DCHS2, MYL10, LCE2C, CASP5, TNFRSF13B, HSF4, APOA1, PF4, IFNA10, F2RL2, NAALADL1, TLX3, LILRA4, NODAL, TM4SF19-TCTEX1D2, FBLN2, PDZRN3, FOXE3, INSL4, IZUMO1, GSC, FKBP9P1, GNRHR, CADM3, MSTN, IGHV3-32, MYH16, MAS1, CLRN3, MEST, IL31, HUS1B, LIAS, LGALS4, NXF3, JAM2, ARL17A, MC3R, LCE6A, CDC25A, ICAM5, GUCA2A, CABP1, HLA-H, DLL4, KAAG1, WNT10A, MEA1, DOK6, DEFA3, PDHA2, CNDP1, AMY1B, NEU2, GNAT3, CORO7-PAM16, METAP1D, CCR9, IAPP, IL22RA2, MATN3, CPSF4L, LOXHD1, IGHV3-22, CDAN1, FOXD4, MTUS2, FIGLA, CAPNS2, GPR15, MEP1A, IL4, MMAA, GJA9, GP9, LCE1A, TNFSF15, LIPN, AMH, CARTPT, DPEP2NB, HRG, GSS, APOF, CCL7, BMP6, MOG, CDRT15L2, FMR1NB, DDX25, IL20, CNN1, NAGS, NACA2, ACMSD, FBN2, HSFX3, CLPSL2, CNBD1, WNK3, LCE2B, DEPDC1, IGLL1, FMO1, KPTN, CD209, HSF5, DNM1, HMX3, HHATL, LHFPL1, DGKG, GNB3, FGD1, CCDC198, CPO, A4GNT, ACRBP, NOVA1, CNRIP1, FABP5P3, CNTNAP2, IGHV3-75, MMP13, DDX43, CDCA7, ARTN, CA14, APOC2, MXRA8, LBX1, GPT, TMC2, CCL1, KYAT1, CAV3, WTAPP1, IGFBPL1, LLCFC1, TNFSF9, AMY1C, HSPB2, HJURP, MC2R, TGFBR3L, NBPF18P, KCNA3, CABS1, GSTA5, FOXD2, CAMP, IGLJ3, LHFPL6, MOCS1, LGR5, TFAMP1, CR1L, TGM3, MUC2, FOLR2, GTSF1L, CBS, GLI2, NETO2, ACSM6, HMHB1, CXCL10, CLUL1, FLNC, DEFA5, HCG4B, A2MP1, LILRB5, INSM2, LEP, KCNS1, LCE1B, CARD18, FOXN4, GUCA1C, KANK3, HTR6, CDH23, HSPB3, HBE1, DCLRE1B, MYF5, CDY2A, WNT16, DNAJB5, CCL23, A2ML1, HRCT1, HIGD2B, GPR151, CDCA5, MS4A4E, HOXA6, MBOAT4, MLNR, CCDC182, HERC2P10, GRIFIN, BMP8B, PEX5L, FILIP1L, GNLY, MSH5-SAPCD1, INO80B-WBP1, MMP11, DARS2, HIGD1C, KIF2C, NCAM1, MT1DP, DUXB, MSS51, ATP10A, H1-9P, INSYN1, PPIAP30, CCDC9B, NHLH2, IFIT1B, LHX4, CDRT15, NCAPG, HSD17B3, HRH4, PENK, IMPG1, FAXC, CCR10, IL34, IFITM5, CORO2B, MSX1, CRMP1, APOBEC2, MRGPRG, MMP2, TLN2, APOOP5, TMC3, APOC3, GSDMC, IGKV1-35, CCN3, IQCF6, CC2D2B, CARD17, MSC, MYOM1, JAKMIP2, IFNA1, DPP4, GUCA2B, CCDC73, MRC2, NGB, IGKV1-37, CALB2, CCDC150, DYNC1I1, F12, LCN8, IGHV3-36, FABP12, ISL2, CAMK2N2, HEMGN, HLA-DRB6, KCTD17, CALR3, IGHV3-37, HTR2B, CDC45, KCNG3, FIBIN, LMO1, GKN1, IGKV2D-10, WNT2B, MSANTD1, CCL2, TICAM2, KHDC1L, CCDC184, DPPA5, DEPDC7, MYH11, LEPR, AQP7, FOXD1, HSP90AB4P, MUC22, IGLL3P, KRBOX1, IGHV3-29, IGLV5-37, MESP2, IL4I1, EBLN1, MOS, MPIG6B, IGHV3-63, CD1C, KIFC2, ISY1-RAB43, ART4, MS4A6E, IGHV3-52, LGALS2, HR, ARL13A, FCN3, CCDC178, NDNF, KHDC3L, GZMH, HHIPL1, IGF2BP3, ACBD4, DBIL5P2, CPAMD8, HYAL3, BMP2, IL17B, LEUTX, IGKV3-34, LGSN, MAP2K4P1, MS4A5, CPXM1, CKMT1B, AARD, GJD4, IDO2, LPAR5, CCDC54, HELT, GSTT2, VSTM2B, WNT3A, CARNS1, KCTD4, DAND5, KDM4D, FNDC4, INA, DGKI, CCDC166, TMCO5B, LRP3, FOLR3, CRABP1, HBZ, HS3ST2, HCN4, DNLZ, KSR2, H2BW1, KCNC4, MRGPRD, IGHV3-42, HERC2P3, IGKV3D-34, IQCF2, IGHV3-41, IGSF11, NXPH2, ITIH4, ABHD1, HSFY1P1, GJE1, FEZ1, TM4SF18, MTMR9LP, IRX2, BMP1, LINGO4, H2BP1, DNAJB3, DPPA4, HAP1, GPR153, IFNA5, HAS1, TGFB1I1, GJB1, IGLC4, FRZB, IL12RB2, GTF2H2B, LANCL3, EBI3, IGKV2-10, THAP8, AATK, THSD1, KCNJ5, FERD3L, IGKJ3, GP2, IRGM, JAM3, MYRF, MYMX, HAS2, NDST3, CCDC87, DCLK1, NXPH3, COX6B2, FRRS1, IFNA8, CA3, NFAM1, IRS4, DEPDC1B, KIF5C, MAP2, HAL, FMN2, GSTT4, VASH2, KRBA1, FUOM, CARD14, GUCA1B, KLC3, FANCE, LIX1, GK3P, FCER2, NCR1, NEU4, DSCAML1, H2BC12, LIPG, CCDC141, HSF2BP, HLX, IL17F, H2AC7, GJD3, FTLP10, LMBRD1, KLF14, MMP3, DHRS2, LHX2, ASB11, FSCN3, CCDC36, CLC, MAPT, MYLPF, ABLIM3, MYRIP, MEIKIN, HENMT1, FGFBP3, CRLF2, H3-5, MB21D2, IGKJ4, NAT2, HTR7P1, IGHV3-60, IL17RB, IGLV3-2, IGHVII-1-1, CXorf58, FOXI3, MS4A10, NEDD8-MDP1, CCDC38, CD300LB, IGSF5, IGSF9, INAFM2, IGLV4-3, IGHV3-71, DEPDC5, APCS, NDUFAF4P1, IGLV9-49, IGHV3-57, FJX1, GRIP1, TIAF1, FXN, ARL5C, CARMIL2, HPDL, BMP15, ASB17, GLIPR1L1, ABHD14A-ACY1, IGKV2-18, IGKV1-17, COX6A2, NFE4, KBTBD12, HSD17B7P2, HSPA12A, DGCR5, IGLV3-27, IFITM4P, GNG11, NXNL1, IGHVII-65-1, IGLVI-70, KCNG4, CLDN24, GPR119, CD300E, DEFA9P, HASPIN, CDH17, IGLC7, VSIG1, DEFA4, MAP7D2, IFIH1, IGHVIII-5-2, BMP8A, ISLR, CCBE1, ASB16, CXCR3, CDRT15P2, HIC2, ALOX15B, CNTN4, TIGIT, NAT16, CA1, CDKL4, CRISP2, MDFI, DEFA6, IGKV2D-40, CLDN15, CD300LD, IGHVIII-13-1, FOXO3B, ITGB1BP2, FABP4, IFNA17, GSDMA, MAP3K10, LIPC, IL1A, NBPF10, ALX1, INSM1, HNRNPA1L2, IFNA7, FCGR2B, GPAT2, MEIOB, MTMR8, CORT, LIN28A, HAPLN4, CREG2, DHRS4, TMCO2, LPAL2, EBF3, CAPN12, IGKV3D-7, TM4SF19, LDHC, CLDN25, CCDC183, MTNR1A, KCNB2, IQSEC2, ITPR1, LCE4A, AMELY, IGHVII-30-1, IGKV2D-26, LOXL2, H4C13, CDX4, LCE1F, COLQ, LRP4, CNTN5, CD28, FTHL17, IFNA13, IGHV3-43, CLDN34, KIFC1, FCGR2C, APOC1P1, JPH3, MT1A, LIPJ, ART3, NBEAP1, DMC1, CNTN3, GUSBP3, TNFSF18, FHIT, NCOR1P1, LRFN3, IL24, GPRIN1, MUSTN1, CYCSP52, CAPZA3, FASLG, DUSP8, TLCD4-RWDD3, CCDC158, KLRF2, CCN5, ISG15, IGKV1-8, E2F1, HAAO, IMPG2, IQCF3, FBLL1, PF4V1, CCDC179, CABP7, CCNE1, FCRL3, IGKV3D-25, GRM2, GLOD5, IGHV3-38, COLEC10, CRB1, H2BC1, LIN7A, TGIF2LX, GRK5, IGKV3-7, CASP16P, IGHV3-66, CRELD1, NFE2, TMC7, IQCF5, MTHFD2P1, HLA-DOB, IFNA14, NANOG, THEM5, TNP1, IGKV1D-37, TMIGD2, CBX8, CDH8, IGKV1D-13, CDCA3, GOSR2, E2F2, CALCB, EBF1, HP, DOC2A, TMCO5A, IDI2, IGHVIII-44, DLEU7, LGR6, C1S, IGLV1-41, CARD9, CCNI2, NECAB2, IGLVVI-25-1, IGKV2D-23, DPP10, LNP1, HPGDS, INSYN2B, MBLAC1, F5, KCNG2, GTSF1, IGLVI-63, TGFB3, LARGE2, HSP90B2P, FER1L4, GNB1L, CCDC68, IFNA2, COL9A2, CBLL2, AQP1, MSTO1, IGLV3-29, GPRC5D, ABRA, IGLVIV-65, IGKV7-3, MSMP, H2AC2P, IGHVIII-67-3, ACSM4, TIGD3, IFNA21, CALD1, HCRT, IGLJ2, CCDC102B, FSD2, HOGA1, CABLES1, HBD, FLT1, MED15P9, IL12RB1, FRS3, WNT5B, MARK2P9, COX8C, CDH12, CNGA3, MYOCOS, IL18BP, IGKV1-13, IGKV2-29, HYAL4, NOTO, FANCG, CXorf65, IGLVIV-64, H2AC20, DHFRP3, KCNMB4, PEAK3, IGHV3-73, FATE1, HMGN2P46, HTR3A, IGLV10-54, IGLVI-20, IGHV3-65, LILRB4, IGLJ6, FANCA, KHDC1, NDST2, DPRXP4, DUOXA2, IL2, GNGT2, MOGAT3, KCNE2, PPIP5K1, IL21R, ITIH5, IGHVII-78-1, IFNE, H2AC1, CBY3, COX7B2, DSG3, MXRA5, IGLV2-5, MOBP, NEURL1, CKLF-CMTM1, DKK3, IGLV4-69, ACP5, ARIH2OS, PELI3, NEURL2, DLG2, CAMTA1, IGHV1-24, IGLV5-48, HABP2, H2AC12, MUC7, H4C1, CLDN6, IGHVII-28-1, IL9, IGKJ2, IGKV3-31, IGHVIII-38-1, IGKJ5, NCAPH, FGFBP2, MSANTD2, IGHV3-16, FNDC9, KATNBL1P6, LCTL, MED12L, KCNK7, CD93, IGHV3-13, GPR143, IGHV3-49, TNFSF12-TNFSF13, IGHV3-35, DNM1P46, IGHV3-50, GNG8, IGHVII-51-2, FLRT2, NAT8B, NOX4, NCKAP5, DACT2, IGHVII-49-1, IGLV3-12, H3-4, ASAH2B, IGLV1-50, GNG7, HGH1, MTMR7, MYEOV, IGLV11-55, TIAM1, MRAS, DCANP1, APOA2, ABTB2, GTF2IRD1P1, COCH, FDXACB1, IGHV6-1, IGKV1D-17, CCR3, CKMT1A, IGHVIII-47-1, IGLV3-16, LENEP, KCNJ6, IGLV3-30, IGHJ6, APOBR, LRMDA, ACADL, CD177, GNRH1, IFNA22P, IGHVII-53-1, HES3, VPS53, TNRC18P1, TNFRSF17, PDLIM3, NBPF15, ACE, FLVCR2, GYG2, KCNN3, IGLV3-13, IFNA16, KCNG1, IGHV3-62, GZMK, IGKV1-32, IL15RA, DOK2, DEFA11P, TNFRSF11A, CKAP2L, IL3RA, DEPDC4, IGHVII-43-1, KLB, H2BC17, CLTCL1, IL5, CPN2, HOXB13, NHEJ1, CPOX, NECAP1, NOD2, MMP15, DEFB1, GTF2H4, CDC25B, KCTD7, IGLV2-33, DHX37, H3C4, IFNW1, TK1, DBF4B, MROH8, H2AC15, IGHVII-44-2, NDUFAF7, DYRK4, CLTRN, ITPKA, HAS3, IGKV6D-41, IGLV8-61, DEFA8P, IGLVIV-59, MMP9, KSR1, IGLV7-46, CD244, THRSP, IGKV2D-18, CNGA1, FSTL4, ACSM2A, MT4, CDKN3, IGHV3-6, IGHV3-19, ITGAM, CPVL, MAP3K7CL, IGKV2D-30, IGHVIV-44-1, VPS37D, AMIGO3, TIGD5, IGLVI-56, IGLVIV-53, DSEL, C5, LIPE, IGKV3D-31, MT1HL1, H2AP, CBFA2T3, KIF17, DCN, GRHL3, ALPK3, MEIOC, CLMP, IGLV3-22, CLSTN3, INO80E, DRD4, GPR146, IGLV4-60, GP6, TNNI2, GTF2IP23, DOK5, HBQ1, CA6, IFNK, MT1L, C2, H4C4, IGHV3-64, HYAL6P, H3C13, DGKQ, IGLV10-67, ASB9P1, CCDC192, DIO1, IGKV1D-27, NXF2B, CCSER1, FRG1HP, HEG1, TNFRSF6B, IGHMBP2, NDUFC2-KCTD14, KLRF1, TNFAIP8L3, IGKV2-40, TLCD3B, TNNT3, HS6ST2, FZD7, KIF3C, KIF23, IGHVII-15-1, CDPF1, TFPT, IGKV5-2, INSL3, APOM, H1-6, KLF16, IGHV3-47, NFASC, ITGA5, IGHVII-46-1, CCDC7, FCGR1B, KANTR, FAHD2A, IGHV4-28, EBF4, CCR4, FTH1P3, FABP9, H3C7, DUSP21, CCR7, FIGNL1, KCNAB1, FOXI2, IFNB1, MPC1L, CLVS1, IGHVIII-76-1, CAV1, FOXM1, IGLJ5, H2BC13, MEGF8, IGKV2-4, IGKV3-25, IGLV7-35, CLCA3P, IGHV3-25, H2BS1, IDUA, NFKBID, CDK2, GPM6A, IQCF1, IGLV3-26, H2AC17, NOTCH2NLA, IGKV6-21, E2F7, KALRN, IGHJ2, LIMS3, COMMD10, IGHV7-56, PFN3, IGKV1D-12, DOHH, TNFRSF11B, IL17RE, IGFBP6, FOXRED2, CALML5, IGLV5-45, HBA1, CLNK, LMOD3, CCDC200, BMP4, IGKV1D-16, IGLVIV-66-1, CD7, IGLJ7, NEXN, TNNI3, HDC, DGKB, MOGS, VASH1, CDT1, IGFL4, HTR3B, GNAI1, BMP7, ARAP3, GSDME, FHOD3, CYGB, CAMK1, IGKV2-26, CAPN3, AMDHD2, IGHV3-72, ACE2, GJC1, CCL22, IGHVII-33-1, MT1H, DEFA10P, IGLVV-58, INMT, CDC20B, CPE, FCRL4, IGHV3-76, IGKV2-36, CPNE5, FFAR1, GSC2, CCNJL, IGHV1-68, TIGD7, ACSM2B, H2BC10, IGKV2-23, MT1B, CCNYL2, CAND2, HESX1, HAUS7, FBLN7, LDLRAD3, CCIN, IGKV6D-21, HBG2, MASP2, IFFO1, CCL26, MMRN2, IGKV2D-28, JMJD7-PLA2G4B, HEMK1, IL22RA1, HORMAD1, IGHV7-34-1, FRY, CD226, LIN52, TLR2, IGHV3-7, DLK2, GPLD1, IGLV2-28, NBPF1, ACOT1, LEMD1, ITGA1, PDGFD, IGHV4-59, ACRV1, IGKV1D-22, F2RL3, LCN12, IFNG, HMBS, MTHFD1L, GPRASP2, MXI1, KCNMB2, HRK, KCNJ14, CCDC142, IGKV1D-8, CLSPN, DNAH14, FHDC1, IGHV3-54, CASKIN2, IGHV7-27, HGD, MBD3L1, FKBP1B, ARSJ, IGKV2D-38, NHLH1, MARK4, DAGLA, LGALS9C, IGHV3-20, FCHO1, CCL3L3, IGLVVI-22-1, CD40LG, FKBP6, CNIH2, IGKV1-12, CLCNKB, CLDN20, VASN, TNIP3, TIMELESS, NGEF, CRTAM, ITPRIPL1, MATK, MESP1, NCAPG2, TNK1, GLIS2, FABP2, PFKM, IL36G, CRISPLD2, HCAR1, CDCA8, PPM1E, HDAC8, INKA1, MTFR2, VAV2, IGKV1D-32, COLEC12, FASTKD1, INPP5F, CMC2, HSPB9, CD207, IGHVII-30-21, LNX2, COQ3, MSRA, IGKV2-24, NOD1, IGLV3-31, FST, DMPK, IGHV5-78, IGLV3-9, F8, LCE3A, N4BP3, MRPL45P2, COL10A1, LIF, IGHV1-67, MEGF11, H2AC4, IKBKG, CABLES2, IGHVIII-2-1, CLCN5, HES5, CD19, CXCL14, IGKV2D-24, ATP13A5, CRTC1, AMOTL1, IMMP2L, ARL10, IGLV2-34, IGLV3-10, APLP1, TNFSF8, INCA1, INSL5, IGLV3-32, TNIK, CDK11A, IGHV3-79, VSIG10L, IGKV2-38, GJA4, TNFRSF18, CARD10, FCGBP, NDN, CLDN18, DBN1, LPIN3, FAR2P2, TFF2, CD200, MRM1, GRWD1, ARL17B, VPREB3, NFKBIL1, CCL17, TLDC2, CCR5, TF, KNL1, FDCSP, FREM2, DDX31, CCNF, KCNK2, MRPS31P5, CDH11, IGLV1-62, CCDC175, CPXCR1, KLRG1, DKK4, LMCD1, KIR3DX1, TLCD5, IGLVI-42, IFNA6, FOXE1, H2BC14, IGHVIII-67-4, CDC20, DCAF4, PDGFRL, DGAT1, CIT, MYO15B, IGKV1-22, MYL9, CCDC85C, IL19, DDR2, IGHV3-23, FCRL6, HYAL1, ARG1, CBLC, GRP, ASB2, LENG9, CIP2A, CD72, LDC1P, DAPK2, IGHJ4, HERC2P2, FRAS1, CAD, CCDC136, TIGAR, CA5BP1, IGHD5-18, IFI6, CCNA1, IGKV2-19, LPO, FANCC, GRK4, IGKV1D-42, CNTF, DNMT3A, CORIN, LCAT, ARVCF, CCDC159, FHL1, FKBP7, IGLVV-66, CDH2, ABCC6, ACP3, GNMT, ITGB7, ARL6IP6, KCTD15, CLIP2, HBM, CCL15-CCL14, HOXB2, DCBLD1, IGKV1D-43, FADS2, NGFR, PFAS, NEURL4, CNFN, IGHD5-5, PPIAL4G, ITGA9, IGHV1-17, IGKV2D-36, CRAMP1, CIB2, HCST, MMP12, PDIA3P1, CLCN4, IGHVII-62-1, HRH2, CLCN6, MCPH1, KIF18A, FKBP2, CAPN8, CPT1B, FITM1, TLR5, GLB1L3, PDIA5, DERL3, CDR2L, FCHSD1, HSFX4, DNAJB7, IGLV3-4, IGKV1-6, IGLVVII-41-1, IGLV3-25, MXD3, DMGDH, AMER1, PDGFA, HACD1, FRRS1L, KCTD13, FAHD2B, FUT6, MECR, THRB, TNS2, IBA57, MAT1A, FER1L5, CD84, NOXA1, IGLVI-38, GPAM, CCDC15, APOL3, IGLV6-57, KIF4A, NAT8, PFKFB4, IGF2R, LMNB2, MDP1, IGHV3-15, LRFN4, ICOSLG, DDX11, MROH6, ACAD10, WNK2, CD8A, IGLV2-18, CXCL5, H2AC13, CALCRL, TFPI2, MTRES1, CNIH3, IGLV3-17, LOXL4, IGHVIII-26-1, CAMKMT, ACOX2, AMIGO1, H1-1, CLYBL, FZR1, CIDEB, CCDC22, IGHV2-26, CD160, IGHJ5, CCR6, CRCT1, CD99P1, HSPE1-MOB4, TINAGL1, ITSN1, IL2RB, GPC3, FES, CLDN11, CREB5, GSTM1, FABP1, CCDC28B, FKBPL, KBTBD11, NAIP, AR, CCHCR1, LARS2, DOK1, GORAB, AARSD1, IL27RA, NDC80, MMP1, FBLN1, KCNIP4, NDUFAF6, FPGT-TNNI3K, LETM2, LRCH1, IGHVII-60-1, THTPA, ACKR2, MCAM, ABCC6P1, MCOLN2, LCE3C, A1BG, HTD2, CADM4, CXCR5, LMNTD2, IGHJ2P, IFI27L1, MMP7, MTCP1, TLR8, CCDC106, IGHV1-45, CMTM2, CAMKK2, CRADD, MAPK12, CLASRP, IGHV1-14, CD1E, IGHV8-51-1, AS3MT, GNAZ, KCNJ16, MAP3K6, TNFRSF9, DYSF, CABP4, HSD3B7, GZMB, CNPY4, IGHV7-81, NDRG4, IGLV3-15, CPA4, FN3K, MAP2K6, CD80, LILRA1, IGHV4-4, GPR89B, CX3CR1, PDK1, CXCL13, WWC2, NAA80, IGHV3-53, IGHJ3, IGBP1P1, AMDHD1, IGLJ4, MAP4K2, DUS3L, HFE, IGKV2D-19, HERC2, MARVELD1, GTPBP3, THAP2, CCDC88A, FZD5, ITGAE, IGHVIII-25-1, MAP3K9, FANCD2, THOC3, GJB7, KPNA7, IGHV1-69, IGLV3-7, MRVI1, LMF1, MTARC1, LIG1, IKZF4, IGHJ1, ATP10D, TMPPE, FCF1P2, PFN4, CADM1, IGHJ1P, CCL14, MATN2, IL23A, CD163, DSE, IGHV1-12, MCF2L, DAB2, DPEP2, APELA, MED18, IL12A, ASB4, DYNAP, ATP13A4, CLCN2, IGHV4-55, IGHD3-9, CREB3L4, ABHD16B, IGHVII-26-2, LMAN2L, IKBKE, MAP7D3, CCDC61, IGF1, WNT5A, CD300LF, FCGR1A, IRS1, E2F6, DGKD, IGLVI-68, HPX, PDZD9, IGHVIII-82, CCNB3, CCNB1, VSIG4, KIF20A, CRLF1, DYRK3, MARCHF3, H2BC11, IGLV3-6, ACADS, TGIF2LY, FERMT1, ATP23, CDK1, DCP1B, KANK2, FAH, MEIS3, FHL3, HAUS5, CDKL2, PEG10, HMGA2, GJB2, GPHN, INCENP, TNFRSF25, LILRA6, MSH5, H2AC14, ASB9, FNTB, IGHD4-4, IGHJ3P, NAV3, FAAH, MED27, TGFB2, ICOS, CD86, KCNJ13, CLCF1, CRPPA, MAP3K20, NBPF11, AMN, MTR, LDHAL6A, MORC2, MYOT, GPRASP1, TIGD6, TNK2, HSPA6, NCAPD3, IQCM, KCNMB1, ARSB, ARL11, CR1, GTSE1, CCDC62, ZIK1, HLA-L, MMD, ARL14, FADS1, DHRS12, KCNAB2, CAMSAP3, IVL, TNKS1BP1, HDAC6, LEMD2, KDM5B, GZMA, LONRF2, IGHV3-21, CCL16, GMNC, ICAM4, LDHAL6B, KCNV1, IPO5P1, IGHVII-74-1, COPZ2, HAVCR2, NCMAP, IGKV2-30, FOXO4, IGLV7-43, THG1L, KCNK5, MVD, HOMER3, CCDC77, H4C7, CDON, KMT5C, MOB3C, DTNB, DACT3, IL10RA, NEK8, CCDC167, TNFRSF10A, CXCL9, HSD11B2, ABCD1, GPR135, CBWD6, GPX6, CCDC88B, LONRF3, CLIC3, DYNC1H1, IGHV4-39, LMBR1L, MND1, FGFR1, LRAT, DDX51, MST1, CDK18, PEX26, HSPA1L, KNOP1, MYLK, CDY1, COX7A1, LINGO3, CRIPT, IGLV5-52, KDM8, JPH1, CISD2, ISY1, F8A2, ABI3, FUT4, H1-3, CCDC110, CNKSR3, FMNL3, IGHV1-58, IGHD1-26, MOB3B, MERTK, HPSE, IGLV1-36, COPA, HEXIM2, GTF2H5, IFI35, PEX14, DHRS1, WTIP, LDHD, HUNK, FAAP24, LARGE1, KMO, CAMK4, MLYCD, CPA3, LEF1, DOCK6, NFATC1, TNFSF4, FOXP4, IYD, H3C14, IGHV7-40, LILRA5, IFNLR1, TM6SF1, FCMR, DPP9, GLIPR1L2, H3C10, HLA-J, ABT1, HTN3, CPLANE2, CCDC149, MCF2L2, DHRS4L2, CD27, NOC3L, THUMPD2, CDC42EP5, INMT-MINDY4, IGKV2D-29, AQP6, HARBI1, MYPOP, INTS9, CYB561D1, LBHD1, MTARC2, ARSK, IGKV3D-20, AASS, ING5, THEM6, FOXJ2, JSRP1, H3C15, DTWD1, MAPKBP1, JAG2, CACTIN, FOXL2NB, DOK4, KIF21B, CC2D1B, IGHD3-10, PDLIM2, CCDC163, NOTCH3, HDX, TIAM2, HIP1, IGKJ1, TMCC3, LFNG, FMC1-LUC7L2, MROH9, DET1, HERC5, TNS1, CRABP2, KCNMB3, ACAP3, PEX5, NCR3LG1, LILRA2, TMCO4, CAMK2N1, ALS2CL, FOXA3, CD3D, KCNN4, ARC, MMP25, NEGR1, GTF2H2C, CDKL3, HELZ2, PDF, CLCN7, HELQ, MSL3P1, FKRP, VSIG10, CDK11B, LIPT1, TNFSF14, ITFG2, GUSBP1, ME2, MVB12A, NAALADL2, ACP6, LRP8, HMGCS2, MORN4, ABHD16A, CBLB, TLNRD1, DDO, VPS16, LAT, IPCEF1, NACC2, CCDC18, ABHD5, HEXD, IGHV3-74, CNTD1, FNDC10, FMO6P, CCDC134, MAP3K14, NAT9, FOLR1, FUT10, PEX12, MTFP1, HARS2, TIPIN, INGX, IL17RA, MESD, CDC7, HECTD3, TMA16, KRI1, PEX11G, HES2, CCDC103, LENG1, FASTKD3, GPRC5B, MCEMP1, ARID3A, H2BC9, BMF, NCLN, NCF4, CAMTA2, GTF2IRD2, DBNDD1, MEN1, IGSF3, CD79B, FANCI, ASB1, DUS2, MCM8, HS3ST3B1, PDSS1, MTHFSD, HNF1B, GPANK1, CCT6P3, INSIG2, INPP4A, LIN37, KIF6, LAT2, LOXL1, INAFM1, IRAK2, CDRT1, IL20RB, WRN, CWH43, MSR1, LIMCH1, CCDC162P, MCIDAS, JRK, ACOT7, PDPR, GLI4, KLF8, NAB2, IFIT2, LGI1, MON1A, LDOC1, H3C8, CXorf56, GSTM4, E2F3, TFB1M, ACSBG1, LCK, ABCB6, IGHV2-5, CCDC144B, ADA2, FGF14, FGF5, ABCD4, IGHV1-3, IFIT1, TMEM51, CCDC58, IL18R1, IRF5, CCDC9, TLR6, IRF7, IL1R2, CCL4L2, CCL4, CD40, CD6, COX19, DECR2, FGFR2, HUS1, TLR3, JAK3, IFIT5, TLR7, MAPK7, IL15, SMAD1, CD22, IGSF8, FCRL2, IL16, IFIT3, TP53, CXCL3, CD4, IRF4, CD33, TNF, IFI44L, IFI44, HDAC5, IL6R, FGF13, IFT122, CXCL6, TMPRSS3, TLR4, CD36, EGFR, TUBG1, HERC1, GJB4, CCDC82, CCNT1, CCDC107, HDAC10, IL4R, IFI27, IRX3, MFN2, SLC25A32, CCDC12, H4C8, CCAR2, ILKAP, TMEM63A, IRX5, CCL5, IL17D, CHD6, IGF2BP2, C3, CD2, INHBB, SLC11A2, POLD3, SLC5A3, IRF9, CDK10, IGF1R, COL28A1, TLR1, IL32, IL6, SMURF2, SMAD4, IFT140, TMEM41B, TMEM65, DUSP3, TNFAIP8, ELF4, IFI16, PAX9, MAK, CD37, IGFBP3, H3C6, CCDC30, TRIM27, IFI30, IL10RB, IL1R1, TRIM44, TMPRSS4, IFT172, S100A9, IL7, DUSP4, GJB3		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_vs_COVID tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	82	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	TEX9, ANXA1, TAX1BP1, DSTN, TSPAN1, TSPAN19, WDPCP, SLC25A6, RPS25, RPS7, PIFO, WDR78, FOS, C9orf116, MORN2, NPM1, PTGES3, MYCBP, KPNA3, CHMP3, UQCR11, SEPTIN7, LDHA, MAP3K19, PPP1CB, ATF4, ACTG1, LZTFL1, ARPC2, KIF21A, WDR38, LRP11, EIF4B, TAB2, WDR66, SH3BGRL3, RBBP7, STK17B, HNRNPA3, HNRNPDL, RPL22, ATP5F1B, RPL11, AMD1, YWHAQ, AGR2, TRIM29, SAXO2, CTSS, KLF5, GDI2, SUB1, PPDPF, CHMP4B, TUBB, DMAC2L, CCDC173, TAF7, YPEL5, CFAP206, PTMA, TPPP3, CLU, YWHAE, TRIM2, KLF10, H3-3B, TMBIM6, IQCG, RPL36, SERPINB3, RPS3, TSPAN6, DAZAP2, TMC5, RND3, MNS1, PPP1CC, ARL6IP5, ATP5F1E, TRIB1, EFCAB1, WEE1, TTC29, EIF4A2, RAB11A, TEX26, CAST, NAP1L1, NDUFA4, CEBPD, CNN3, NFKBIA, NCL, MBNL1, BASP1, SLC25A5, PHB2, NDUFS5, EIF2S3, CIB1, ARHGAP5, UBQLN2, CXCL17, RPL29, UFC1, PTP4A2, ENPP4, ANKRD66, COX7C, ALDH3A1, HSD17B13, HSPA5, ARPC3, ATP6V0C, PFN2, MYL6, ANKUB1, SNX3, SPAG6, SMS, CSTB, ZNF354B, ARMC3, SDCBP, YBX1, RPL39, SOD2, SUMO2, COX4I1, UGT2A1, HLA-DPB1, CALM2, SET, UCP2, PPP1R15A, FAM229B, CCDC146, ZMYND10, PTRHD1, RAB7A, YBX3, TEX101, NAMPT, ARHGDIB, SMDT1, RPL27A, NSA2, VAPA, SERP1, LCP1, KRT5, ELOC, RP1, RNF11, ST13, TMEM123, HLA-DRA, HIPK1, LITAF, HLA-DPA1, C5orf49, SPATA18, MYL12B, ANAPC13, DNAJA4, MYL12A, UBE2D3, FOSB, EIF5, NET1, SLC38A2, RSPH1, RPS19, HMGN2, UBE2D1, RPL38, FAM221A, SOD1, GADD45B, RPL18, GNG5, ADAM32, TACSTD2, TAGLN2, RPL37, EIF4G2, ORC4, ZFP36L1, ASB3, CCDC170, YWHAB, RHOA, ZNF664, FAM81B, HNRNPA1, TUBB4B, C16orf72, KRT17, ZC2HC1A, FAM228B, ATOX1, PELI1, CITED2, PDLIM1, VIM, HIPK3, RPL17-C18orf32, EIF3E, NTS, MORF4L1, BTG1, SNTN, MUC16, ATP5F1C, EEF2, JUND, GNB1, PPEF2, EIF3H, MUC4, PFDN5, MAP1LC3B, SELENOK, FNTA, FMO3, RPS10, SRP14, ZFAND5, TOMM7, CCDC190, ALDH1A1, RPL9, PRDX6, ENPP5, IGFBP2, TM4SF1, TFPI, STOML3, RPLP2, B3GNT5, UQCRQ, PERP, MIF, HNRNPA2B1, ADH7, CD164, CCDC65, ACTB, EVI2B, YWHAZ, HSPA8, DUSP1, TMEM212, PRDX5, C9orf24, RPS17, PROM1, TWF1, CFAP53, PCBP2, KRT8, ANXA2, CETN2, NFE2L2, STATH, GNAS, JUN, ID2, MRPS31, RPS12, RPL37A, TMA7, BCL2A1, LRRIQ1, UBB, PNRC1, IFT57, COMMD6, EZR, GPX4, NDUFB2, TBCA, KIAA1328, RPL23, RPS20, UBC, KLF4, FAM241A, RHOB, PLLP, TUBA1A, RPL24, ATP5MG, EEF1G, GSTA2, EIF3L, FAM216B, NUCB2, FOXA1, RPS4X, HSP90AB1, RPL10A, PAIP2, RPS26, PPP2CB, C11orf88, FAU, CCNI, CYSTM1, CKB, RPL5, CALM1, ANP32B, CRIP1, RPL34, GSTA1, CCN2, H3-3A, EIF1, ZNF207, RPL28, KLF6, CCNL1, FAM183A, S100A11, RPL31, ZNF91, RPL8, RPS6, C20orf85, RPSA, HLA-DQB1, CCN1, PPIA, ADSS2, GAPDH, FTL, RPL35, LAPTM5, HINT1, RPL27, DYNLL1, RPS14, RPL19, RPLP0, RPS28, RPS2, RPS27A, RPS23, RPL18A, CXCL8, PCBP1, SH3BGRL, IGHA1, EEF1B2, MTRNR2L7, RPL6, RPS27, HBB, TPT1, SPA17, RPL15, RPL3, RPL4, C12orf75, RPL7A, PABPC1, RPL10, RPS11, TBC1D8B, JCHAIN, BTF3, RPL12, RPS16, RPS5, RPS15A, HSP90AA1, RPL7, EEF1A1, MIPOL1, RPL32, RACK1, RPS18, RPL13, RPL36A, RPS15, IGFBP7, RPLP1, RPL26, RPL17, RPL30, CYSLTR1, RPL13A, FTH1, RPL23A, PLCG2, IGKC, HLA-V, RPS3A, IGHG1, RPS8, MORC4, HLA-DQA1, RPL21, MTRNR2L3, BLOC1S6, RPL41, OMG, TMEM45A		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_vs_COVID tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	64	70	years	33	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	IGFN1, MUC19, RASA4DP, COL5A3, OTOG, FBN3, PGA3, MUC17, STRCP1, PGA4, PGA5, MYO18B, TP53TG3C, TP53TG3B, OVCH1, WDR87, PALM2AKAP2, HERC2P7, CCDC168, MYH6, XIRP2, MROH5, NUTM2E, PEG3, MYOCD, MYO7B, C3P1, UNC13A, ITPRID1, RASA4B, MYH8, MYH1, TRPM1, CDHR1, RGPD4, NRAP, NPR1, LAMC3, OPCML, NPC1L1, MUC12, FREM1, SMYD1, MYH13, DAAM2, NRXN2, IQCA1L, RBFOX1, MYH4, TPTE, RELN, TBX5, XKR7, IGSF22, TRIM67, HERC2P11, MYPN, PDGFRB, FNDC1, IL31RA, PDZK1P1, PRLR, SORCS3, IQGAP3, INSRR, TRIM6-TRIM34, SH3GL1P2, MYT1, TRDN, SEMA5B, LCT, C4orf50, NOVA2, SH3TC2, NPHS1, LHX9, NCAN, NLRP5, NEFM, NRG3, NRG1, MYO3A, NXF5, RAB3C, UROC1, IGSF9B, CAPN11, LMTK3, ULK4P3, IQSEC3, NLGN1, PALM3, PAH, ALX4, NFATC4, PRKAG3, ITGB3, HEPH, TENM3, RFX4, ONECUT2, FAT3, PRG4, SLIT3, PKD1L1, SORCS1, WNK4, MAGED4, OTOF, PGC, BNIP5, GFRA2, ALOXE3, TP53TG3D, LRP1B, FGF1, OPN1LW, ITIH2, TFAP2D, PAX2, TRPV5, STC2, PKHD1, FIGN, TLR9, FRMD1, MRC1, TOPAZ1, PGLYRP2, RBPMS2, TG, ALPG, MYT1L, HEYL, PIWIL1, TTC24, NRK, BCL6B, NUTM1, SPRR2B, OPN4, GFRA1, TICRR, MS4A18, MUC3A, GCKR, RALYL, IGDCC3, PLD5, TBATA, TPTE2P1, WT1, VIPR2, MYH7, GCK, TGM7, RAB6D, TCP10L2, TRPC4, LRP2, SNPH, SPHKAP, NUTM2F, TBCE, NELL1, CNTFR, WNT7A, NEFH, NETO1, MPP2, CDH20, TIMD4, AOX1, TCHH, ALPI, PRDM6, CCDC155, STK32A, MPL, PGR, FIBCD1, THBS4, JCAD, MUSK, OR1F1, SGIP1, BMPER, TBX3, TEX15, TRABD2B, NPEPPSP1, MYO1H, OPALIN, GFPT2, TGM6, NOBOX, NUP210L, CDC6, PKD2L1, USP32P3, LMLN2, NTM, NPHP3-ACAD11, PACSIN1, PTH1R, TRPM5, PDGFRA, TRIM49, NPIPB8, MUCL3, SPACA5, PKLR, TNXA, F2, C8B, PDYN, MAGED4B, PRDM16, PEAR1, OR7E156P, PHOX2B, NACAD, TRIM49C, WSCD1, DIRAS1, MYL3, WFIKKN2, SUN5, SLC24A3, LBP, FAM90A2P, GRM8, FLT4, AMBP, PDZD3, PCSK9, NSG2, OGDHL, TBX15, OR2H1, USH2A, CCNYL3, OTOP3, INSC, TDRD5, CD163L1, TDRD9, RBP3, OPN5, NEUROD1, PIP5K1P1, TMPRSS5, REG1CP, TOB2P1, ALPP, PCARE, NKD2, SCRT2, NXPE1, GRM4, COL6A2, RFPL2, PXDNL, CABP5, SH2D5, DDC, VWA5B2, FCRLB, LMX1B, REG4, PHF21B, PDZRN4, SORCS2, TAS1R2, CD300LG, ELOVL2, HERC2P4, PDILT, STRC, VSTM2A, MYLK4, TNFRSF8, PRG2, PDZRN3, CDH5, FUT1, MYO1A, UMOD, CDH10, TRIM10, NPSR1, TMC1, NR5A1, FRMPD4, CLDN14, GSTA7P, PAX4, F11, PAK5, NRL, TMPRSS9, TLE6, TPTE2, THY1, TRPC7, CA11, NKAIN1, HFM1, FSTL3, NYAP1, THSD7B, FKBP10, OTOAP1, TULP1, CCDC169-SOHLH2, STX16-NPEPL1, P2RX3, TRIM49D1, STK32B, SOD3, C7, PITX2, FIGNL2, GDF7, ULK4P2, F7, MYOZ3, AMHR2, NXF2, XIRP1, IGLON5, OR2AT4, MN1, SLITRK3, OLFM4, NBPF22P, TACR3, SERPINC1, FOXD4L5, CDHR2, RBPJL, ELOVL3, ITIH3, LMX1A, MOV10L1, TEAD4, PIWIL3, TPO, TRIM50, THPO, MASP1, EMILIN1, TRIM43, OTOA, PNMA8B, VSTM5, CD70, STMN4, VWC2, NOL4, TRIM51, FGD5, CDHR5, TAF7L, NLGN2, CDCP2, ULBP1, MPP3, TCHHL1, MYLPF, SUGCT, CDC25C, MMP16, CDK3, TCAM1P, NPR3, NR1H4, THBS2, CCKBR, NUTM2G, NKAIN2, SIM1, CDCA2, MYO3B, CLCNKA, MYLK2, PDZD7, FOXN1, IGSF21, XCR1, CCDC154, CCL25, MRGPRX3, ISX, FGD5P1, HMCN2, DES, TRPC2, CD247, CNGB3, CYLC2, MAPK4, OR7C1, PAQR6, PAX1, SLC9A2, RET, NID1, RCVRN, TBR1, G6PC, TECTB, P4HA3, PGLYRP4, TGM5, MMP19, NR2E3, NLGN4X, MYBPC3, RHBDL3, FLG, FRG2C, SH2D2A, NR2F1, EGF, GCNT7, MYH3, SEMA6B, SEMA6D, FSD1, PRH2, DAB1, PIK3R6, CD1A, VAT1L, UGT3A1, NPAS1, DIAPH3, MINDY4B, TIFAB, OR9Q1, GSG1L, OR4F17, PFKFB1, VSX1, FRMPD3, FGF18, LDB2, TIE1, SP6, CDH4, TBX4, CXCL12, RASD2, MUC6, BAAT, OCA2, CA10, TEX11, VAX1, SPIN3, IL1RL2, SPRED3, NTRK1, PIK3C2G, CDH15, MPPED1, CDH19, SLFN14, MINAR1, ALPK2, CXXC1P1, TNXB, BMP2, TRPM3, TFAP2E, FRZB, MMP28, SHC2, LDB3, TNR, VWDE, TNNI1, HLA-G, TARM1, NYAP2, CD34, SNTG1, PRCD, PHF24, ALG1L9P, PRB1, ACVR1C, TLL1, NID2, IL34, TSPYL6, ISLR2, NLRP11, FAM9A, FUNDC2P2, MS4A4A, ONECUT1, PERM1, TRPV3, SOGA3, TTBK1, IGF2BP1, MYO16, FNDC5, LMO1, NLRP8, RAD54L, PTH2R, TRAIP, RDM1, VRTN, RASA4, CDH22, ISM1, TRHR, NALCN, ITLN1, NRCAM, WSCD2, CCDC85A, CDK15, PDGFB, IGF2, SOX10, NAALAD2, CD1E, FUT7, TNFSF11, SH3GL3, RGPD2, TPBGL, NEB, C6, WDR88, PRH1, ITIH1, MPO, TAS1R3, FZD9, SCUBE1, MRO, SEMA6C, MOXD1, WDR64, INHBE, NDUFA4L2, NODAL, ONECUT3, PIWIL2, TGM4, TAL1, GFI1B, NKAIN3, PTGER3, FREM3, FTCDNL1, UCN2, OTUD7A, PKN3, NNMT, NTNG1, IL12B, TRIML2, CA4, CD8B, PRDM14, ODF3, NIPAL4, TAC3, PNPLA5, WNT3, NAALADL1, CCM2L, UBE2F-SCLY, VWC2L, IGSF1, FRMPD1, NLRP9, MYRFL, RANBP3L, VSTM4, LMOD1, SNAP25, BMP10, MYO7A, CD109, JAKMIP3, TRIM9, RBP5, WNT9B, SH3GL1P1, VSTM1, ILDR2, PXT1, SH2D4B, TEX38, SMAD6, RAD51, NWD2, CNGB1, SOX30, EMILIN3, ACVRL1, PRICKLE1, TGM1, STKLD1, NEFL, CDH16, MYOM3, TRPM8, DDX4, OR2A20P, CDC25A, TRPC5OS, KNG1, PCSK1, FAM90A25P, TSSK1B, G6PC2, FLT3, IFITM10, USH1G, MYOM2, SMTN, UBE2L5, C4A, FSCN2, RBFOX3, IL2RA, TRPA1, NAGS, FMOD, VIL1, SPRY3, OIT3, SLFNL1, FGF11, CLDN19, FUT9, BMP1, CCDC144CP, WNT3A, PAPPA2, MIPEPP3, TRIM74, MAJIN, TSPAN32, TSPAN18, STK32C, TEX13C, SLC9A3, ITIH6, PCSK2, P2RY6, PITPNM2, FRG1JP, TERB1, TENM1, MMP13, XKR6, LMO3, CDCA7, IL17RD, CCDC178, FOXP3, MYO15A, FGD1, TRIM71, MYBPC1, SMPDL3B, A1CF, TFR2, STARD13, NRXN1, WFDC8, LRP5L, TSGA13, REEP1, RAB44, HMCN1, OLFM2, TVP23A, TCEAL2, LIAS, CDH24, STRIP2, PCDH10, RASL10B, XKR5, CCDC3, RAP1GAP2, OXGR1, DIO2, MTMR9LP, NOX1, TKTL1, CCDC27, MYOZ1, ORC1, RCOR2, IL11, FOXB1, TCF21, TRARG1, RDH12, NKPD1, NUF2, WFDC3, PXDN, C2CD6, TNNT2, ULBP2, STUM, CDH18, VCAM1, NDOR1, TLL2, FBXO10, RAB9B, PCBP3, PACC1, TEDC2, FAR2P1, TCP10L, MPZ, TREML1, MYH16, MMEL1, SOX7, REEP2, OLAH, FRMD5, TRIM17, TINCR, LHX6, FOXH1, UBE2QL1, UHRF1, TAT, MYH15, PIEZO2, SOX11, TRPC6, WNT10A, WNT16, SEPTIN3, SH2D6, INSYN2A, TTYH2, NAA11, FRG1BP, NUTM2B, ALOX12, FGFR4, JAKMIP2, PEX5L, SERPIND1, FFAR4, P2RY2, TNNI2, WNK3, CD5, SLC9A5, FCER2, TNFSF15, OPRL1, PDZD4, P2RX6, TRIL, MAPK11, TDRD12, TENM2, TUBB1, PCOLCE2, TUBA8, OPRK1, MMP21, MPPED2, FKBP9P1, PDPN, MMAA, MYH7B, P2RY8, RHBDL1, CCDC184, CDAN1, CCN6, CNGA2, INCA1, INHBA, UCP3, TONSL, OR2A1-AS1, PHYHIPL, NOS1, EMX2, PCOLCE, INAFM2, VWA5B1, IHH, MROH3P, TDGF1P3, MTMR11, LDLRAD2, NOX5, NLRP6, INHBC, SHC3, STC1, PTGES3L-AARSD1, CDCA5, RASL11B, MAPK8IP2, TEX14, GBAP1, HEPACAM, NECAB2, SNX32, PTGS1, PAK3, MAB21L2, NPTX1, TNIP3, FOXO3B, NCAM2, SHANK3, GSDMC, TSSK4, SEPTIN12, FOLH1, HEPHL1, MMP2, TRPC3, PATE2, PRAMENP, PAX5, FBN2, NAP1L2, SPAG4, CCNE1, SLCO5A1, PGF, PNPLA1, SEMA6A, TM4SF18, PGBD5, NLGN3, FST, SMTNL2, PRELID3A, TNNT1, MROH8, LEP, MRC2, TMPRSS7, CDH6, NXF3, TRPM2, FGF2, NLRC4, CDH7, MS4A2, NOTCH4, IRX2, FMO1, THSD7A, TMC3, BCRP2, NEDD8-MDP1, MOCS1, MYZAP, PTGDR2, RGL3, PDCD1, PDZK1, IL36RN, NOSTRIN, TEKT5, CCN4, CD101, RAPGEF4, PIF1, CAMKK1, TGM3, MYOM1, FCHO1, PAX3, TDGF1, STX1B, PREX2, SGK2, CCDC141, IL11RA, MYBPHL, SH3BGR, UBASH3A, TSLP, TAGLN, BNC1, MXRA8, IZUMO2, PTGIR, SEMG2, IL23R, SIM2, CNGA3, BMP6, F13A1, USP32P2, SNURF, TRIM55, TM4SF20, PTGIS, GSDMA, DIRAS2, USH1C, FBN1, PAX6, SULT1C4, FOLR2, TWNK, NTRK3, OBSCN, RASAL1, MPP4, PIWIL4, CABP7, IL19, NLGN4Y, MIOX, TGFB1I1, FLG2, BCORL1, CCL22, PLD4, ITIH4, TRIM46, ITGBL1, PRELID2, CYSLTR2, RBBP8NL, WASF1, SCNN1D, PNPLA3, F12, PHACTR3, MTMR8, TACR2, SMOC2, IL1RL1, NFASC, TNNI3K, STPG4, JAKMIP1, IMPG2, ISLR, PADI1, BMP8B, RHCE, NOS3, TESMIN, MUC22, TNFSF8, TNFSF9, FNDC4, FSCN3, ALOX15B, WIF1, STAR, PTHLH, NR5A2, NRIP2, TRIM61, EMCN, SPAAR, MTUS2, OLFML2B, TBXAS1, NPY6R, DDIAS, TSC1, NMNAT2, UMODL1, PRF1, OPLAH, NTRK2, IL15RA, CAMTA1, DEPDC7, DIPK2B, TMC7, MYRF, TMC2, NIM1K, PDCD11, BMS1P17, MOG, CD1C, FAXC, SNTG2, IZUMO1, RCN3, FEZ1, SNORC, IGFL2, CCDC9B, PRDM7, TUBB4A, PLCXD3, THSD1, JAM3, SEMA7A, IL1A, SLC9B2, IGSF11, CA14, CDH9, TSPAN5, TIGIT, SERPINF2, RADIL, PRELP, RGN, OPRD1, CCDC87, MYRIP, NKD1, SCUBE2, OR51B5, SLC24A4, FAM92A1P2, FOXD2, NFAM1, NPNT, FANCG, SORBS1, RECQL4, FANCE, TIAM1, MYH11, TBXA2R, NCF1B, NCAM1, NMRAL2P, NNAT, STXBP5L, IQCF3, NLRP14, NSUN5P2, INSL4, GFAP, PLCL1, IGFBPL1, FBLN2, IGSF5, C1R, P2RX7, TBX21, FLNC, OTULINL, SOX9, FOXN4, OSR1, TK1, DGCR5, CCIN, NOVA1, RFESD, STAG3L1, TSHR, HEMGN, PI4KAP1, TBX19, CD209, TRO, NR1I2, TCF23, VIT, SLIT1, NFE4, DDX43, BMP8A, ENAM, CDK2, PROC, FPGT-TNNI3K, NUDT10, PID1, FSD2, TPK1, RELL2, GDF6, TRPV6, INSYN1, WTAPP1, CCN3, CD27, RHOJ, XKR4, CLCNKB, SGSM1, NUTM2D, MAP3K10, TSPAN9, PIP5KL1, MAP3K15, NRXN3, CCDC38, NETO2, DGKB, SKIDA1, CCL3L1, NDST2, FOXI3, CABLES2, RASIP1, SLITRK2, IQSEC2, SULT1C2, UAP1L1, TPTE2P6, CABP1, XG, RCE1, CLDN15, FRRS1, CCDC183, CYGB, OSCAR, WEE2, TSPAN4, FGF20, LRP4, FDPSP2, CCDC36, NXF2B, STX1A, TLN2, CAND2, P2RX1, IGF2BP3, LDLRAD3, FILIP1L, DEPDC1B, TIGD5, TDRD6, SNHG28, JAM2, OLFML1, MPIG6B, PRC1, CCDC73, ELP4, PGBD1, CA1, GDNF, N4BP3, NPAP1, NCKAP5, RGMA, DIPK1B, CABLES1, RAD54B, VKORC1L1, RBMXL1, TNFRSF13B, RAPGEF3, NDST3, TRIM6, WASF3, TUBA3FP, IL3RA, PROCR, TLDC2, NOS2P3, DDR2, USP6, DDX25, STRA6, PIPOX, FXN, PDGFRL, SERPINE1, FMN2, ZYG11A, MUC7, CD99P1, PKD1P1, NMUR1, WNT2B, OLFML3, PALD1, LIPG, CCNB3, USP35, TCAF2, PHLDB2, OR2A9P, NANOG, PNPLA7, MROH6, VWCE, TGFB3, SLC9C1, TEN1-CDK3, ITPR1, ACE2, DEPDC5, TP73-AS1, RD3, RASA4CP, SIK1, LRP3, P3H2, PHLDB1, PAPLN, CCDC150, TLCD4-RWDD3, SLC9A7P1, NLRP10, FGFBP3, IL17RB, ZWINT, PIMREG, NOP9, NUDT1, CCDC198, TTK, FHIT, SPIN2A, IL22RA1, IGSF9, PAPPA, VENTX, NOD1, F2RL2, CCR6, MXRA5, NPR2, CABP4, ELOVL7, NUGGC, C2orf16, PELI3, VPS33B, PKDREJ, WDFY4, PHF19, RHBG, P3H3, TPRA1, CD28, SOX6, PDLIM3, PLBD2, FDXACB1, LARGE2, ZAP70, PIPSL, TTLL13P, SHCBP1, FASLG, FBXL6, GCOM1, OR52B6, WDR62, HERC2P3, TIGD6, CCDC68, NUFIP1, NEUROD2, MAP7D2, STK31, IFIH1, SCUBE3, TRIM45, FCRL3, LANCL3, TCP11X2, FCGR2C, PLG, FBXL19, WASH7P, ITIH5, SLAMF8, TUNAR, MOBP, CSF1, TENM4, MUC2, TNIK, WASHC1, CA6, IL21R, SDAD1P1, MYOT, TBKBP1, TIAF1, SULT1C2P1, IL12RB2, TCP11, CDC20, TTN, CD177, WDR53, PEAK3, SH3TC1, MRAS, TTC41P, TPX2, CNIH2, QRICH2, C1S, TPP1, IL18BP, BNC2, PYGM, USP27X, BMP7, NOS1AP, IGHMBP2, PHKG1, FOXM1, FBXL16, IL12RB1, PLCH2, CCL2, VAMP1, TNK1, CCNYL2, ODAPH, FSTL4, RDM1P5, NOX4, QPCTL, PKHD1L1, FER1L4, NPIPB6, FGF12, NDUFAF7, RAD51B, TSNARE1, C2, ACVR2B, MMP15, TAF1A, FRS3, CCDC158, CDH17, PRB3, LAT, NPTXR, CDH12, NUMBL, MYOCOS, SHF, TEX22, C5, CCDC7, CCNI2, OAZ3, FOXRED2, NRG2, CD72, WASH8P, TXK, GCSAML, SLCO4A1, MTMR7, DIO1, NR6A1, GDF9, FCGR2B, NECAP1, VWF, FCGR1B, CDCA3, UPP2, SPP1, FBXL22, TRPC1, TIAM2, NBPF10, CCDC136, F8, MOGAT3, RAB39A, RACGAP1, SHE, CCR7, CCNF, CD226, BOP1, FLVCR2, FASTKD1, THAP2, FCHSD1, OTUB2, TEX35, FKBP6, FHDC1, TPRG1, RAD9B, ITGAM, CCDC159, CCN5, TRIM73, OPRM1, FRRS1L, CD93, FANCA, FRG1HP, TRIM66, COL6A1, SLX4, SIRT6, CDC25B, CCNJL, SULF1, TTYH1, VLDLR, RAB6B, TAF4B, GCM1, LEPR, TAF5, WIPF3, RAD52, TRIM72, NKAPL, FERMT1, CDH11, NEURL4, PANK1, WDR97, SCRG1, VIPR1, PHETA1, ZBED3, MMRN2, PGM5, TULP2, NBPF1, CDH8, LNP1, TIMELESS, SKA1, NLE1, WBP2NL, RAB42, SLCO2A1, OSGIN1, TMCO5A, TTLL6, SGO1, TRAF1, TOMM40L, NINJ2, RASGRP4, RAB19, FTH1P3, USHBP1, NOD2, PKD1L3, VAV2, CLCF1, PHLDB3, NEXN, SKA3, TXNRD3, TAFA2, IL18R1, LCAT, GSDME, NTNG2, SOCS7, TYRO3, FRMPD2B, SH2D3C, TIGD7, TRPV1, RAG1, MON1A, ITPRIPL1, TRPM6, TOP3B, RBFA, C4B, NAP1L5, FHOD3, DGAT1, MXI1, CLCN5, MAP3K7CL, TRAM2, TDRD1, TNFRSF11A, STK19, CCDC102B, RCCD1, WWC2, TCP11X1, GCNT4, HLA-DOB, CCDC15, PLCB3, PLCG1, CCDC142, PHOSPHO2, F5, VPS53, LRMDA, VANGL2, TFPT, GDF11, PIDD1, RHEX, MIGA2, SDC3, SLCO2B1, NFKBIL1, IRAK2, EML5, MYL9, TCF19, RELT, FIGNL1, P2RY1, TTF2, CXCL9, LMNB2, NR1I3, BCS1L, VEPH1, CA5BP1, SIX5, SPHK1, HEXIM2, FREM2, WASH2P, OSGIN2, CNIH3, TYW1B, NRP1, SH3D21, PIGZ, VDR, PAX8, CD8A, CCDC22, CLCN6, FES, NCAPH, TAZ, RCC1L, LIG1, CD33, UBE2Q2P1, MYC, PHLPP2, MYO15B, ALG1, TET1, PLCD4, FER1L5, TTC7B, RBM44, SPHK2, FGF23, HEMK1, NLN, TLCD5, WDR4, FLRT2, STAG3L3, FZR1, FRMD4A, IGFL4, LIF, NCAPG2, TESK2, MAPK12, TTC28, FGF7P6, SIRT3, HMBS, CDK1, CCR5, MAP3K9, CD300LF, OLR1, SPAG5, PGAP3, TECPR1, ALPK3, TRAF2, U2AF1L4, STMN3, ITSN1, NBPF15, CDC20B, TBL2, SLX1B, IKBKE, TIGAR, WBP4, CSF1R, GCNT2, UCK2, HLA-L, PARD6G, PTK6, PRDM11, SCNN1G, PALM, FRY, FLT1, PFKM, PDGFA, MAP3K6, NR1H3, PCSK6, TCF7L1, EMC3-AS1, TMTC4, RECQL5, NAIF1, GRWD1, RGPD5, CCDC85C, UBE2E2, MACO1, PDIA5, CD7, FN3KRP, FRAS1, PRICKLE2, PKNOX2, VSNL1, NRDE2, TSEN15, TSFM, WDHD1, UPK3BL1, RBMS3, DERL3, RBM20, CTF1, FOXI2, TPCN2, PLB1, RFX1, CDC7, TUBGCP3, LCK, CCDC175, STARD9, NSG1, TGFB2, BOK, VASH1, CCDC62, CLCN4, CCDC112, TRIM31, NEK8, CYTH3, NOP2, LEF1, CCDC18, CSF2RA, PAOX, IL27RA, PAMR1, IQCM, NEIL3, FGF5, FGF7, SHB, TRNT1, WDR74, CDK5R1, BOC, CCR4, PCSK4, THTPA, XDH, MAB21L3, OR2C3, TELO2, IRF8, BMS1P2, IRS1, TNFRSF25, NINL, CAMKMT, PLA1A, SLC8B1, RAB26, URB2, FNTB, TUBG2, VGLL3, TRMT61A, A1BG, NFKBID, TESPA1, CCSER1, FUT6, PC, FBRSL1, LDOC1, FOXRED1, FANCC, FHL3, PFAS, GRB7, TEPSIN, TIRAP, TLR5, CCNA2, USP32P1, DAB2, PYROXD2, TNS2, ISY1, PIK3R5, RAD51AP1, IL17RE, TIMP3, IPCEF1, SLCO1A2, NGEF, MICB, SYT5, NUDT15, PEX5, QDPR, CD200, SDHAP2, DDTL, NDUFAF6, MYBBP1A, CCHCR1, RHD, WASH3P, TNFRSF9, SH2B1, IGF1, EML6, JDP2, CD84, TRIM47, TUB, STK11IP, IL1R2, RFLNB, NCMAP, CAMK4, MORC2, NPIPB5, NCR3LG1, HERC2P2, LMF1, EML3, LMCD1, CD274, THG1L, FANCD2, TP53AIP1, NFATC1, TTC13, NIPSNAP3B, JAG2, FAS, TJAP1, NICN1, NCAPD3, LARS2, SNAPC4, REXO5, HFE, RGPD1, OGFOD3, FBXO16, ITGB7, CD3EAP, VARS2, FKBP2, MAP4K1, TTC31, TNFRSF10D, FANCM, SNX33, IFNLR1, MTR, PLD2, DDX31, SLC9A9, TF, TRIM65, SLITRK5, TRABD2A, NLRX1, TBX6, CCDC88B, IKZF4, CAMKK2, PAK1IP1, STAT4, NEMP1, FBLN1, CLCN7, FZD5, OTUD3, OSBPL7, TOP2A, M1AP, CCDC9, PLCD3, ING5, TTC27, GFOD1, NOXRED1, FMO4, FANCI, EDA, STX3, TINAGL1, MIEF2, NOTCH2NLA, TAF1C, TARS2, MAP2K6, LARGE1, UBIAD1, TSPAN11, TTC3P1, CCDC28B, MALL, SH3BP5L, DFFB, FDXR, WDR25, TOMM40, PANK4, SPN, LMNTD2, TUT1, PKP1, TRIM7, MXD3, HELQ, PFDN6, CYB561D1, THOP1, NLRP2, PGGHG, HERC2, RAP1GAP, NDRG4, NPHP4, OASL, CFI, TCF7L2, NOTCH3, MVB12A, CDH13, PAGR1, MRGBP, SMAD7, CLCN2, MAP7D3, PEX14, PISD, HEXD, FGF14, THOC3, CCDC134, VWA2, LRPAP1, CABYR, RHBDL2, PRIM1, SMOX, TNK2, MAGOHB, TFAP4, SNX21, MROH1, TIMM21, TMPRSS13, USP13, NCKAP5L, ELOVL6, CCT6P3, GAB3, IPO5P1, NIPAL1, CDK18, PDLIM7, ULBP3, TNS1, NACC2, FOXO4, NEXMIF, INCENP, USP49, TACC3, BCAR1, ALG10, MAP3K20, TNKS1BP1, PICK1, CD99, OXNAD1, LLGL1, C6orf47, NUP210, FOXJ2, VSIG10, LRP8, RFT1, WIZ, MVD, TMCO4, FCGR1A, NOL12, SERAC1, NCLN, FBXL7, IKBKG, NAV3, PLCL2, SMPD1, EMC10, LMAN2L, UROS, TDRKH, CCNB2, MYLK, PLCXD2, NUP85, TANGO6, PLCD1, RFTN1, SNCAIP, OBSL1, SLC9A1, NFRKB, PRDM10, PADI2, PEX26, RBSN, INSIG2, FOXP4, TAB1, MAP2K5, NAT9, NPM2, RHOBTB2, RBM19, ZWILCH, IMPDH1, B4GALT6, PABPC1L, PANK2, MINDY1, SPINDOC, SUFU, TENT4A, RAB11FIP5, ALOX15P1, NEGR1, PTDSS2, FOXL2NB, PHKA1, BCL9, MAP4K2, PRIM2, IGSF3, RBMX2, PCNT, SKIV2L, TBL1X, RIC3, RHOBTB1, SMPD4, GSTCD, FAT2, PIK3C2B, CAMSAP3, CCDC174, DDX51, C5AR2, VPS9D1, PES1, UBQLN4, NDUFA10, VPS16, NOC3L, NIBAN3, PFKFB2, PLCB2, TAF12, MICAL2, FUT4, SPR, OSBP2, RASSF4, MMP14, CCDC144B, NUAK1, TAMM41, TAOK2, MPV17L2, FGD6, HES2, PAK6, NEU3, RAD54L2, FXR2, CCDC162P, ING3, BCDIN3D, TTLL9, GCDH, IL2RB, PANX1, NDUFAF1, PLCB1, VTI1A, NSL1, MAPK7, FOXI1, PDK1, ALG14, LMBR1L, FCGBP, CD4, MIIP, RBM45, NSMCE3, RAD18, QTRT1, CD163, TRPM4, PHF1, WDR76, CCDC88A, IRF3, PAQR7, URB1, FMNL3, ITGB6, IL17RC, MORN1, INF2, RHOU, NATD1, TFAP2A, PIGM, PARP2, HERC3, TYSND1, IPO4, NARS2, NDST1, NOMO2, WHRN, SNTA1, TPCN1, PI4KAP2, IVD, WNK2, DAB2IP, TRIM16L, SNX8, VAV3, MOCOS, IL17RA, TRANK1, PJA1, TPST2, RGP1, MAFG, MOB3B, NUP160, VPS72, FAN1, RBL1, FKTN, PHACTR1, TCAF1, FLRT3, IL10RA, CDC42EP1, TRIOBP, TTI2, NRP2, MYH10, EMG1, TRIT1, TMCC3, MROH9, DEPP1, SH3RF3, SOX5, SLA2, PARN, NSUN4, NAPB, TMUB1, USP36, PALB2, MAGI2, MAD1L1, NUP93, MICAL3, IL20RB, OPA3, NT5DC3, LARP1B, SNX11, CCDC149, ILVBL, CCDC71L, TTL, PRKCA, NECTIN4, NFXL1, IGF2R, CAMTA2, TSC2, TTC23, SEPSECS, THRA, TIFA, IL6R, IRF7, TSPOAP1, CA5A, SNAP47, STIMATE, NOMO3, PRKAB2, REXO1, TSPAN17, PKD2, LATS2, FKRP, NOM1, MYCL, SERF1B, CAPN10, LONRF1, DISC1, VIPAS39, CCS, MICALL2, SNX30, TPRN, LRP6, LNPK, WDR5, STX4, NISCH, GDAP1, SOX13, WTIP, MUS81, LRP1, FCSK, RABEP2, NRSN2, FLAD1, C8orf34, TFAP2C, UTP6, CCR1, TRDMT1, RIC8B, MAFK, STRADA, PRDM5, PAXIP1, PAPOLG, ITPKB, TCEANC, MYO1G, NPIPB4, ALS2CL, NUDCD1, MYO19, MICAL1, TGFBR3, VCAN, NECTIN1, MOB3C, TTC4, CDK11B, C2CD2, PIAS2, SNRPA, TVP23C, EMC1, FBF1, RCSD1, GDPD1, SPRED2, RAPGEF5, TRIP10, TLR6, TK2, PTK7, LCMT2, SPIRE1, MYL6B, DDX10, SCNN1B, TAF3, OSMR, TUBGCP4, LCMT1, VANGL1, NIF3L1, UTP25, TMTC1, TLE2, WDR72, ITFG2, TLR4, PNPLA6, TNS3, JMJD6, SLC9A6, GAA, RBM41, ULK1, PRDM15, THSD4, VPS28, MIB2, GSTA4, ENDOD1, WDR81, DET1, NCDN, WRN, MAF, DIP2C, RBM48, ORC5, TCOF1, PHRF1, TRIM11, DESI1, N4BP2L1, TRAF3IP3, MVB12B, TEP1, PIK3R2, BMPR1B, CCDC137, TLCD2, PGPEP1, TUBD1, FERMT2, STAMBP, SCRIB, RAB4B, FRAT1, WDR12, WDR59, TRPV4, CDK14, NT5E, CD276, TOR1B, FLYWCH1, ELOVL1, TOE1, SH3RF2, TTYH3, RANBP10, PEX6, SOGA1, UHRF1BP1, HEY2, CDADC1, HMBOX1, VAV1, NMNAT1, TAF6L, TTI1, FBXL18, ZBED4, TP53, FERMT3, FOXK1, RCAN1, SMUG1, GPN2, RBP1, IRF5, TAF4, DGKA, CCDC171, BOLA2-SMG1P6, FYN, SGSH, PREP, TFB1M, SEPTIN8, TRMT13, TAP2, STARD5, PCNX2, FPGS, PGAP2, IFIT5, NAALADL2, RASA3, SLIT2, TPRKB, PHF23, STK35, LMF2, UGGT1, MAP2K7, VPS37C, RALGPS1, BACE1, VPS52, PIGG, MIEF1, NOL4L, CD99L2, RBPMS, SMURF1, TRMT5, SLX4IP, TCF3, CCDC97, NACC1, PIGU, PIEZO1, PDZD2, PAN2, SULT1A3, CA8, GAB2, NUDCD3, OSBPL2, WWOX, PARD3B, SOBP, MYO10, NEO1, SCYL3, URM1, TRAPPC5, MPHOSPH9, SMARCA1, ULK2, SLC9A7, CXXC1, TUBG1, CAPG, SMYD4, NCAPH2, PAFAH2, XPO5, RAD9A, INTS13, SIN3B, WDR93, RAB35, PTK2B, IL16, OTULIN, NIPSNAP1, USP45, RARG, PHKA2, SPIRE2, FZD4, NABP2, NLRC3, CANT1, USB1, MORN3, OSGEP, FKBP9, CCNH, LDAH, WASHC2C, TADA2A, WRAP53, RANBP3, MADD, MKNK1, TUBGCP5, SH3BP2, NCS1, UTP20, MTOR, RANGAP1, NFKBIB, C1RL, TTC22, NUP107, SIPA1L2, NME9, PIGX, TBP, TSTD2, FARSB, WDR27, MACROD2, TSEN54, RBM28, JAG1, MICA, TTPAL, FGFR2, STAT5A, PNPO, VWA8, CD40, PELP1, PHF21A, UBE3B, TANC1, TNRC6C, STARD4, SNX15, UTP18, RARA, CCDC120, MON2, USP5, PDP2, NVL, LCORL, RBFOX2, DGCR8, PAK4, MUC5B, NHSL1, UBE2O, MVK, FECH, LMBR1, FTSJ3, TTLL4, SP140L, NOL9, PHC1, FMN1, MYO18A, CDC23, LAMP3, PIP5K1C, USP46, RAB15, NFYC, SHC1, NPHP3, HEXA, DIP2A, THOC5, XRCC1, MYO5A, RAI1, D2HGDH, UIMC1, VCL, STOX2, WWC1, VPS4A, UNC13B, TBRG1, TRIO, SPOUT1, VHL, IGF2BP2, PIGO, BCL9L, RDH13, SENP1, C2CD2L, MAP7D1, TTC7A, BABAM2, OPA1, B9D1, FIG4, VPS33A, NUP214, USP21, NOMO1, RHNO1, CCDC151, HELZ2, NIPAL3, FEM1A, NYNRIN, UXS1, MYLK3, REC8, DDX20, MTPAP, PIK3CD, TSPAN14, PHYHD1, SH3PXD2B, NDE1, TRAPPC9, TCF4, RAB11FIP2, TTC5, TRIM21, PEX16, PIGS, NLRP1, PKD1, USP40, NECTIN2, TRERF1, CD68, MYO1F, SLF2, SDHAP1, CCDC130, ISG20, STT3A, TYK2, FBRS, SUOX, MOV10, UBE2D4, TGFBRAP1, NDUFA9, SH3RF1, FOXK2, NSUN2, ITGB1BP1, NUP188, WDR20, TSPYL4, SGSM2, MTO1, VOPP1, NOP14, TIMM50, FRMD4B, MTMR4, SMARCA4, SH2D3A, MPHOSPH10, WWC3, NOL8, MMAB, SMAD1, RGMB, LANCL2, INTS1, NTAN1, TRAFD1, PATZ1, USP31, MINK1, RABGEF1, PBXIP1, FBXW8, MPI, NOL10, SCYL1, WDR36, TRIM39, TRUB2, SNN, TSR2, LRP5, TFEB, USP6NL, FBXL4, FBH1, RBM34, NAGK, MAPK8IP3, GBA2, NR2F2, IPO13, FER, TRIM41, SMU1, DDX47, TSC22D2, SIPA1L3, PXMP4, CYTH2, SLC9A8, CCNT1, FAT1, PHF2, RAD1, STX6, NDUFV3, TP73, PCNX3, TRAF3IP2, NDRG2, CCDC57, PTGFRN, PIK3C3, ITPR3, URGCP, MAGI3, ORAI2, FOCAD, STRN4, SPOP, RBM33, RAPGEFL1, TENT4B, LIFR, TFCP2, RAPH1, UBA7, PKN1, IFNAR2, PCYT1B, USE1, IPO9, STAP2, DIS3L2, BCL7C, FKBP15, MAGI1, OGFR, PCYT1A, MAPK13, WASHC2A, NPC1, TUBGCP6, WIPF2, TNRC6A, MPV17, RAB37, PIP4K2C, CDC42BPG, RAP2B, TAOK3, DERL1, TFAM, FER1L6, LDLR, UMPS, HERC1, VPS13D, IKBKB, CEP104, DUSP4, DFFA, TMEM189, RASAL2, RNF41, RFX5, RNF216, PAX7, CEP95, ATP8B4, FNBP4, SLC25A37, H6PD, EP400, PER3, ERBB3, SNX29, INTS6, ITPRIPL2, CHD6, CAMK1D		gene expression	up	severe COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_Severe tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	64	70	years	33	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	CAPRIN1, DAZAP2, NCL, PRKAR1A, HSPH1, CAPN2, EIF5, HIPK1, PIGR, PJA2, VAPA, ATP5F1B, PERP, GNAS, EIF4A2, GLUL, SUMO2, HNRNPK, DNAJA4, MYL12A, GNB1, PRDX1, TAX1BP1, NCOA4, PCBP2, B2M, TMBIM6, ARPC2, SNTN, DDX5, HNRNPA2B1, ZNF664, CCDC170, CAST, ATP5F1C, SRP14, HIPK3, YWHAB, DSTN, CALM2, YWHAQ, LDHA, YWHAE, NUCB2, AHNAK, PFDN5, TXNIP, ANXA1, XBP1, ALOX15, RPL23, PLAC8, TLE5, PDLIM1, GABRP, KRT18, HNRNPA1, EPAS1, TMEM123, YBX1, PLEKHF2, RPL11, ACTG1, TPPP3, MYL6, ALCAM, CD74, EIF4G2, PPP1CB, PRDX6, HLA-DRA, ALDH3A1, PNRC1, PFN2, LRP11, CD164, HLA-C, PIFO, MTRNR2L3, IFT57, HLA-B, SOD1, PPIA, EIF1, RPS16, C11orf88, PTMA, ADH1C, FOXA1, RPL37A, SNX3, CCNI, RPL34, SPA17, RPS25, YWHAZ, RPL31, BPIFB1, HSP90AB1, TUBA1A, HINT1, RPL18A, CDC37, NFE2L2, RPL18, AGR2, TXN, PRDX5, RPL5, DAP, TSPAN1, DUSP1, TPT1, SPAG6, CCDC190, ACTB, FTH1, PLCG2, EEF1B2, MYL12B, ZNF207, PABPC1, CALM1, MIPOL1, RPL15, SERP1, EEF2, PPP2CB, RPS14, MORF4L2, HLA-DRB1, RHOA, SH3BGRL, DYNLL1, KRT8, OMG, H3-3A, RPS4X, ANXA2, RPS27A, SERPINB3, FAM216B, RPS15, ZNF91, GPX4, ST13, PCBP1, FTL, FOS, EZR, RPL36A, CETN2, RPL4, ADH7, RPL6, RPS15A, IGFBP7, RPS20, RPL12, ALDH1A1, RPS23, RPS12, BTF3, RPL10A, RPL32, S100A11, RPLP2, HSPA8, LAPTM5, RPL13, UBB, MUC5AC, RPL8, HSP90AA1, RPSA, RPS6, UBC, HLA-DQA1, RPS17, RPL19, RPS2, RPL3, GAPDH, TUBB4B, RPL27, RPLP0, RPL23A, RPL7A, RPLP1, RPS11, RPL30, GSTA1, RPL10, TMEM45A, RPL17, RPL35, RPS3A, RPL26, BLOC1S6, RPL13A, RPL21, RACK1, FAU, RPS8, EEF1A1, IGKC, RPS27, RPS18, C20orf85, RPL41, MTRNR2L10, MTRNR2L4, MTRNR2L8, MTRNR2L1, MTRNR2L6		gene expression	down	severe COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_Severe tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	49	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	DUSP5P1, PRR20C, ELOA3B, ELOA3, PRR20B, IGFN1, PRR20A, INS-IGF2, COL22A1, COL5A3, NPIPA2, ELOA3D, COL11A2, NRXN2, HSD3BP4, COL20A1, MYO18B, HERC2P7, COL2A1, NBPF6, TP53TG3B, MYO7B, MALRD1, DRD5P2, IQSEC3, PAX2, DLGAP2, TP53TG3C, ELFN2, CUX2, MYOCD, GRIN2D, DNM1P50, ITPRID1, LMTK3, GUCY2D, DAZ4, LAMC3, ADGRB1, DAZ1, GRIK4, POM121L8P, DLK1, NPEPPSP1, ALPG, COL13A1, JPH2, IGSF9B, EPHA8, JPH4, DSCAM, DDX11L1, COL6A4P2, CTAGE15, GRIN2B, COL6A5, CHRDL2, NRAP, PDE4DIPP1, DDX11L9, COL4A1, EPHA6, LHFPL4, DISP3, NOVA2, GRIN1, NBPF4, ERG, IGSF22, DDX11L5, C3P1, DAZ3, GLIS1, CTAGE6, DUXAP8, DLG4, INSRR, DAAM2, HERC2P11, DPP6, FUT5, PRKXP1, PRLR, ADGRA1, DUSP27, H3P4, CT45A5, ENPP1, IL31RA, CBARP, CILP2, COL25A1, ALPP, LPA, ALOXE3, COL11A1, FREM1, HRNR, FGF10, CTNND2, ITGB3, CT45A1, LRRC3, PPIEL, LCT, HPSE2, CLVS2, TFAP2B, CNTNAP5, TGIF2-RAB5IF, PDGFRB, CLEC18A, LHX9, PDE2A, LRP1B, NPC1L1, GLI1, FTCD, NRG1, DCHS1, GGT3P, DUSP15, CDHR1, ALPI, CLEC18B, AOX1, GRIN2A, TSBP1, LY6L, PODN, ERICH6B, EMILIN1, POTEG, HGFAC, ALOX12B, DCC, HOXA3, ABLIM2, RFX4, HK3, GGN, FIGN, COL14A1, IQGAP3, NPHS1, CNTNAP4, LYPD1, DPYSL4, ANKLE1, POTEF, CLCN1, TP53TG3, PKD2L1, EPHA5, ZIC4, PIANP, IGDCC4, DEFA1B, PRKCG, DAZ2, COL6A2, LHX1, TMPRSS9, HPCAL4, EN2, CHEK2P2, TLR9, LOXL3, NPHP3-ACAD11, ITGA2B, MYO3A, HTR4, ECEL1, LRFN2, CPNE6, NBR2, PITX2, GUCY2GP, NR2F1, ENPP7P13, HLA-H, CREB3L3, F11, TEX15, LAMB4, GRIK1, PDGFRA, GRID2, LMLN2, GRM8, GUCY2EP, MPL, HECW1, CYP4F22, CPZ, DSG1, PNMA8B, LRRC32, PHYHIP, HKDC1, FRMD1, IGLON5, CORO7-PAM16, ABCC12, GFRA2, MAGED4, PKHD1, ELAVL2, DGKK, CLEC18C, GNAT1, CTNNA3, CPNE4, PIWIL1, IQCA1L, C4A, TGM6, COL5A2, DCDC2C, DDX12P, DDN, COL9A3, IGDCC3, GSX1, ALX4, COMP, LRRC15, ENTHD1, LRP2, CRTAC1, FFAR3, GHRHR, MAMSTR, NOTUM, EIF4E1B, POTEM, CXorf49B, FRG1JP, LVRN, DTNA, THBS4, CDH5, F7, MYO1H, CDC6, H4C12, HAPLN2, CDX2, GRIK3, EDNRB, DDX11L16, ZIM2, C2CD4C, LCN10, DRGX, ICAM5, MAST1, DIRAS1, HS6ST3, MYLK4, GGT2, EGFLAM, GRM1, ERFL, CRYGN, FGF1, CRHR2, NRL, BMPER, DDC, ZIC1, NPAS1, CDH20, GRID2IP, GFRA1, RFX6, RFLNA, FGA, HRH3, CNKSR2, PDGFB, ALG1L9P, GLP1R, HOXB9, ERVV-1, TRPV5, MAGEL2, DSPP, GFPT2, DDX11L2, CYP21A2, HES7, GRM3, TMIE, POU3F2, PI16, BMP10, HTR3D, DRD3, HOXA4, THPO, FIGNL2, HOXD3, CDK3, CD70, CNTNAP3P2, GPIHBP1, LGI4, DPEP3, PIP5K1P1, ENPP7, PKLR, GGT8P, DMRTB1, DYTN, CPS1, HTR5A, MAGED4B, IL13, DMRTC2, PHOX2B, HOXC5, CRHR1, ISM2, NRK, PRLHR, EPHA7, THBS2, ENPEP, FUT7, HOXC11, CILP, EDNRA, POU4F1, PAX4, DLL3, DEFT1P, DSC1, GRM6, LBP, CXADRP2, NPY4R, NR5A1, DEFT1P2, DES, HOXC12, EPHA3, COL7A1, EN1, CTNNA2, CDSN, ITIH2, ELOA2, ASB10, GRIA3, CNTN6, COL4A2, CRB2, ALK, HOXA7, LMBRD1, EPO, CSPG4, GUSBP16, CDHR5, LHX5, CNTN2, DPEP1, TFAP2D, LYPD4, CHKB-CPT1B, CXorf49, CT45A9, GLRA1, COMMD4P1, PAH, MYLK2, PROP1, GSTA7P, DUXAP9, CPLX1, DSG4, GJA3, GRM4, MMP23B, FLT4, G6PC, ACHE, HTR3E, ASB15, USH2A, HDGFL1, DAO, GLDC, GRID1, LGI3, THSD7B, GRIA2, HOXC10, CTAGE4, CDX1, DUOXA2, GIPC3, RFPL2, NPAS4, HOXA5, PPAN-P2RY11, TRIM10, TP53TG3D, LMX1B, CTAGE8, EPHA10, MMD2, PIGY, TMPRSS5, GNAO1, KLRG2, FUT1, LHX8, COL9A1, NAT8L, CHRD, GLP2R, SMAD6, ENTPD8, TPO, HOXD12, DACT1, GRK1, GREM2, CPA5, CPNE9, H4C11, GASK1A, CDIPTOSP, DDX11L10, PAX1, FKBP10, POM121L4P, GZMM, HPD, NR2E3, GREB1, TGM5, HOXA10, HOXB1, TFAP2E, LHFPL3, JCAD, LRFN1, PRKG1, GPER1, GFRA3, ELOVL2, MMP23A, INSC, LIPM, CYP2D7, ITGA7, ITGAD, CROCCP2, F2, FETUB, IGFL1, H1-7, DBH, HOXA11, HOXB6, IMPA1P1, PAK5, CLDND2, CTRB1, HCN1, IL1RL2, PPIAL4D, DMBX1, C7, LPL, CERS1, CPA1, CBX2, NPHS2, TPBGL, APOC4-APOC2, TPD52L3, CSNKA2IP, CDCA2, CPNE7, DSC2, GPC6, GPA33, CTRB2, FSD1, CYP26B1, PITX3, LY6G6F-LY6G6D, DAB1, DUSP26, PATE1, HOXA13, TNFRSF8, EFCAB8, HERC2P4, CYP4F24P, MYO1A, CLEC4GP1, FGD5, ISLR2, ECEL1P2, CNGB3, HCRTR1, GDF7, INO80B-WBP1, IL21, CNTD2, LHCGR, CDCP2, LAMA1, MMP16, DOK7, IL1F10, HEPN1, ISL2, ELOVL3, CYLC2, NPY2R, FZD9, DKKL1, DCD, DUSP13, ITIH1, GUCA1A, CYP27B1, GRB14, LRRC14B, CNTFR, IGF2, EPGN, HFM1, HTRA3, ULBP1, EPB42, MAPK4, NPY5R, HOXC8, CUTALP, GRK6P1, POTEE, ASCL1, DIO3, MAGEA9B, IQCJ, MYLPF, COL15A1, CTAGE1, ERC2, CPN1, CTSLP2, GPC5, TEX19, PKN3, HAND2, IRX1, MAGEA9, LHX6, COMMD4P2, CLCNKA, FRMPD4, HTR7, CTXN3, CLEC5A, MYO3B, CTXN2, DAZL, TRIL, CSDC2, COLEC11, IRX4, CRYAA, GUCY1A2, CSTL1, TOB2P1, H1-8, HR, ALPK2, GLYCAM1, IGSF21, HOXA9, MAMDC4, INKA2, IL17REL, EMX1, CSH2, AMHR2, TMPRSS11F, IGHV3-30, ACVRL1, DCAF8L2, DIPK1C, IL9R, IFNL1, GPBAR1, EGFL7, CRYBA2, KLF17, ADGRA2, IGHV3-33-2, FRG2B, INTS4P2, IFNL2, EGF, COL23A1, DPH3P1, MAGEA4, GRIN3A, NOX3, DOK5, CLEC12B, ACVR1C, CSH1, CYP3A4, HEYL, NLRP13, TMEM95, PI15, LRFN5, LIMS2, POM121L2, PIK3C2G, LGR5, MASP1, DHRS4L1, DLX2, NR1H4, LRIT2, ELAVL3, NRN1L, CMTM1, CT55, EEF1E1-BLOC1S5, CST9, DCSTAMP, NBPF22P, FSTL3, GNAT2, COL18A1, EDN3, CBLN4, POTEH, DNMT3B, HUS1B, COLGALT2, MYO16, HLA-G, HOXD13, PCSK1, TEX48, TNR, ZIC2, MAGEA2B, CRYBA4, CPA2, GLYATL1, DMRTC1, EPS8L3, EPYC, HECW2, CLPS, TMIGD3, LINGO1, MYOD1, CORO6, MMP28, CBLN2, FKBP1AP1, BAAT, IGF2BP1, FGF18, DCAF4L2, CSN1S1, HJV, POU3F3, FGF17, HEPH, LRP5L, HIVEP3, MYOM2, FXYD6-FXYD2, C8B, CLCA1, POU4F2, RFPL3, CBLIF, ITGA10, CHIA, CIB3, HCG22, HIPK4, MARCO, HAPLN3, IRGC, MYOZ2, P4HA3, GRIA4, IL36A, HSF4, CXCL12, DEFB132, HAO2, ELOVL4, CHGA, HPR, H2BC12, CYP2T1P, GMCL2, CDHR2, MYL7, TRH, ERVV-2, IFNL4, E2F1, IFITM10, NDUFA4L2, EPOP, ELAVL4, GPHA2, GOT1L1, INTS4P1, CYP19A1, MYOG, PATE3, ILDR2, PMP22, CLIP3, GJD2, TP53TG5, PRODH2, PIRT, PHOX2A, COL27A1, CPLX2, IGFL3, FREM3, LMAN1L, BIVM-ERCC5, CDH22, LCNL1, GPD1, CLEC14A, FRMPD3, COL8A2, CYP4F62P, CLDN14, CSPG5, FGF21, TEX45, CRYAB, KLKP1, BCRP3, APOH, FRG2C, PODNL1, PPIAL4F, IL10, GLRA4, CYP11B1, H2AB1, FTMT, COL6A4P1, DLX1, CDH4, LAG3, MAGEA11, DNTT, LIN28B, POU6F2, GNG3, C2CD6, ADM2, DCLK3, EMID1, CLDN2, LRRC37A, ZIC5, FGD5P1, HOXB8, TGM1, INPP5J, HS3ST3A1, CIDEA, GLYAT, COL3A1, HHIPL2, ERFE, MATN1, EFCAB5, HRC, CLK2P1, HOXD9, MAPK11, FOXO6, CLPSL1, ITIH3, DMRTC1B, CSMD2, NLRP2B, MAPK8IP1P2, CDH24, FTCDNL1, TRHR, EDN2, HLA-DRB6, PROKR2, CBLN1, FSCN2, DDI1, IL2RA, CPT1C, CDH15, INHA, HOXC4, MXRA8, ADM5, TGFBR3L, PNCK, HAPLN1, CNGB1, MMP19, GHSR, MYOZ1, BMP6, LYZL6, EGR4, MMEL1, LYZL2, HROB, DOCK3, CLDN19, INHBA, TNFSF11, EMILIN3, CUZD1, DBX1, NLRP11, FOXR1, GRIP2, ADGRB2, CLEC4C, INAFM2, HOXA2, GAS2L1P2, CSGALNACT1, TMOD1, MAEL, PIWIL2, PDE3A, C6, ITLN2, CRH, A1CF, GAPDHS, P2RY2, CTAGE10P, CYP21A1P, FRMPD1, PPIAL4E, CYP26C1, CRIP3, CDH10, HGF, GLRA3, IL22, FZD10, P2RY6, CDK15, CLEC9A, JAKMIP3, CLEC11A, PM20D1, DCST1, MMP17, PLXNA4, NANOGP8, CNMD, PMS2P4, GFI1B, ISM1, GRIK5, ELSPBP1, LMO3, IGSF23, CYP8B1, DDX4, ELANE, MAPK8IP2, GGT1, CYP17A1, ITLN1, GRK7, FUT9, CLEC3B, PMS2P5, SERPINC1, COL16A1, GJC2, LBX2, GRIA1, CPLX3, MLNR, GRIN2C, FEZF2, GSC, ITGA8, IL17RD, HPN, CYP1A1, NLGN4Y, DHDH, MAP6D1, CPEB1, FLT3, PROZ, DEFA1, HOXB3, FRG1BP, HCG4, ALX3, TSLP, GNG13, HOXB7, HEATR4, PIF1, INHBE, COL1A2, LZTS1, LAMP5, RFPL4AL1, CDCA5, TEX11, BMP2, PCK1, MYO7A, PMS2P9, DPF1, TFR2, HBZ, MMP13, MAJIN, TSACC, DLX4, PROB1, PCP2, COL4A3, TSSK1B, POMC, COL26A1, ACER1, GREM1, APOC4, MMP26, MLXIPL, KNG1, FGF11, ANXA2P2, CDK5R2, FST, NAPSA, TSGA13, MYO15A, USH1G, HYAL3, DBIL5P, HHATL, CLDN5, CDH16, EFNA3, LALBA, CNTN1, GP1BA, LINGO2, DCT, LYG2, TGM4, DLX3, CSF3, GP5, ELMOD1, LMO1, LRIT3, HEATR9, HPCA, DCLRE1B, POM121L9P, INSYN2A, CIDEC, CAVIN4, HCN3, SUSD5, DLGAP1, NRN1, PNPLA5, CBY2, CPO, MADCAM1, F12, CPA6, IHH, ARTN, DEFB4A, IFNL3, MYOM3, ENO3, HSF2BP, TONSL, MLLT10P1, GJB6, EMCN, FSHR, CRCT1, DLGAP5, ENDOU, HHIP, MMAA, CCL3L1, DLL4, CNR1, GP9, P2RY8, ITGA11, NBPF7, AOC3, EMX2, PCOLCE2, IL11, CNPY1, SUSD2, JAKMIP2, PKD1P1, CLRN1, PI4KAP1, IL34, FZD2, PMF1-BGLAP, NDST4, IRX2, PIEZO2, NRCAM, NRXN1, PPIAL4C, GLI2, IL27, IQCJ-SCHIP1, CYP4F30P, LOXHD1, FZD7, ERICH6, GGTLC3, GJA1, LMOD2, HERC2P3, PITPNM2, CIB4, FJX1, CBY3, DUSP8, NANOS3, IDUA, TSC1, MALT1, DPPA2P3, DLGAP3, EFNA2, DARS2, ISY1-RAB43, FOXP3, CRYBB3, HOXB4, LMOD1, EPHB6, CSRP3, MATN3, IBSP, CCL2, DRD5, COL6A6, EBF2, CHGB, LIN7A, DPF3, G6PC2, MMP21, STPG4, HAVCR1, TNFSF15, EPX, CDH18, TFAMP1, HCN2, ULBP2, HAS1, PDE1B, CLEC4F, CYP2C9, TNFRSF4, PIWIL4, IFIT1B, MAFA, NRROS, PRPH2, CNRIP1, PKDCC, NOS3, IGHV1OR15-3, FUNDC2P2, DCLK2, HIC1, AMY1C, INCA1, GAP43, CCL25, EPHB2, CXADRP3, DSCC1, NODAL, FRZB, COL6A3, PLXND1, CPXM2, LRP3, GSTT2B, ADAD2, GIGYF1, CRISP3, LIAS, CAV3, GZMB, PROK1, HOXD10, ARIH2OS, AOC1, DEFA3, CDH7, FKBP9P1, ALOX12, LRRC24, CXCR2P1, GPR1, CPB1, FXYD2, GHRL, CORO2B, PHYHIPL, GSTM5, DMBT1, APOC2, ABCC13, CYP3A7-CYP3A51P, HCG4B, ART5, CDCA7, HS3ST4, NLGN4X, CBLN3, CYP4F2, PCSK2, BAHCC1, DIPK1B, HIF3A, LYG1, HLX, LYPLA2P2, PJVK, GNB3, MAB21L2, PDCD11, LHB, NPFFR2, CYP2D6, GPR12, UBQLN3, CPED1, DLSTP1, POTEKP, GNRHR, GNLY, DCST2, NOS1, CTXND1, ITPKA, IL11RA, PAX6, CSMD3, GPC2, TEX14, CDH19, NRADDP, DLX6, ADD2, MYOM1, H3C13, PLXNB3, DACH1, PA2G4P4, NOTCH4, GUCY1A1, NRTN, GJD4, IGFL2, DNM3, GALR2, ELP4, GRAPL, CHIT1, LTA, INSM2, APOF, IL12B, C1R, ESAM, DENND2A, CRNN, TEX38, CNGA3, ALOX15B, DIRAS2, GJC3, IL15RA, HIGD1B, IL23R, CLEC2A, COL12A1, PNPLA1, CXXC1P1, THSD7A, CR1L, PTCH2, HRH1, GJA9, LPAR5, DEPDC7, EFHD1, P3H2, EOMES, CRX, CPSF4L, TNFSF9, TGFB1I1, PDE11A, NOX5, PON1, DISP2, C4B, GREB1L, IGF2BP3, TNFSF12-TNFSF13, CRYBB2, SERPIND1, H3-5, TNIP3, CPLX4, CHIAP2, ADIPOQ, GNAI1, DRD4, DOK2, CYP4F35P, TMOD4, IL1RL1, CNTNAP1, PLVAP, AMY1B, TEX44, COL24A1, IGFBPL1, CTSE, TPI1P3, FLG2, DRD1, IL36RN, HIC2, IL4I1, EBI3, POU5F1, IRX6, DLEU7, EPPIN-WFDC6, PDCD1, CLEC1A, EPHA1, DEFB1, ASB16, CSNK1A1P1, F13A1, TSSK2, DPYSL5, CNNM1, CLDN24, HGH1, INSL4, CMA1, DGKQ, TMPRSS6, LRRC31, CRYBG2, HEPHL1, CNBD2, GLYCTK, DBIL5P2, INHBC, HENMT1, KLRG1, CSNK1A1L, NOP9, ASB5, E2F7, CDH6, IGFBP6, FILIP1L, GSTT2, CYP2W1, PRMT8, CTCFL, IQSEC2, NPY6R, MAP2K4P1, PAX3, ABI3BP, TESMIN, LY6G6C, RFESD, POTEJ, DDX25, FRMD5, FGF2, DCAF13P3, BMP8B, IAPP, KLF16, IGSF5, GNG11, AOC2, HASPIN, TOMM20L, EEF1A2, ITIH4, MATK, GGT5, NAT8B, LTC4S, GSS, DPPA2, PRR16, IDO2, GUCY1B2, MANEAL, FGD1, H2BP1, PIK3R6, GZMH, GRAP2, FUT6, NLRC4, NOVA1, MARCHF4, PATE2, PAK3, CYSLTR2, POC1A, SPP1, FRRS1, EGFEM1P, FLNC, HEPACAM, CBS, CLEC19A, PRKD1, IL23A, CHRDL1, HRH4, GLUD1P3, USH1C, GDF6, LHX4, GLRB, CPAMD8, ITGBL1, TNFRSF6B, GK3P, LNX2, CRMP1, CRB1, POU5F1P5, TSSK3, PBK, GLIPR1L1, EMC9, NRGN, INSYN1, PMS2P1, HTR7P1, GSDMC, FER1L4, DMRT1, NPAP1, IGFALS, CNTN5, C2CD4D, TEX12, P3H3, PNPLA7, DCLRE1CP1, CLCNKB, CHODL, CYSRT1, MAS1, NPFF, FKBP6, ITIH6, ISG15, GIMAP1-GIMAP5, TEX52, LHX2, ADAMTSL4, GUSBP3, POC1B-GALNT4, DCLK1, COL9A2, CKMT2, HTR6, PNPLA3, MAP3K10, TRPC1, CDKL4, ZYG11A, BMP1, MXI1, JAKMIP1, DOK6, GRHL3, EFNB2, IGSF9, H2AC20, GSG1L, PDE4C, GRIP1, DIRAS3, ENTPD2, CPXM1, EDDM13, BMP5, GDF9, SERPINF2, LEP, LTB4R, H4C1, CLSTN2, LRCOL1, HESX1, TMPRSS7, PDCD1LG2, HCN4, ITPR1, ENOX1, CTAGE7P, DHRS4, COL5A1, GOSR2, EMBP1, JPH3, CYP2A7, HOXB2, NRXN3, CDR2L, HAL, NRG2, CDPF1, HTR3A, ADAMTSL5, INO80E, EDA2R, ECE2, HJURP, CEP85, GFAP, LRRC29, NDST3, DLC1, ARNT2, PNOC, CTAGE9, ASAH2, COMMD10, ANO1, FUOM, F2RL2, HS3ST2, CYP1B1, CHN1, CDCA3, IL18R1, FFAR4, PROCR, DMP1, CRISP2, LIMS4, SERPINE1, GJD3, ZIM3, POU5F1P4, FGF20, TEX22, FXN, THSD1, NRIP2, IGSF1, LGR6, C4BPA, FEZ1, GNG7, IFIH1, INA, NDST2, CLDN15, CLDN6, CPOX, GUCA1B, NOX1, MMP15, CNDP1, NPBWR1, ENGASE, ERVFRD-1, GLTPD2, DPPA4, PROX2, PKDREJ, IRGM, KLKB1, IL17RB, EEPD1, AZU1, EPHX4, CYP4F29P, POPDC2, IL3RA, ABHD16B, CRELD1, PMS2P7, ENPP6, IL1A, DCAF4L1, ENG, HAP1, DOHH, CNTNAP2, HPDL, TGFB3, IRS4, LEPR, IFI6, IL12RB2, DDX43, FRMPD2B, CYP4F12, DHX37, PRKCQ, ICAM4, NR1I2, DUXB, KLRF1, ZWINT, CTSW, TNFRSF18, CDH9, PID1, P2RY11, KLRC3, DEPDC1B, HERC2P2, DDIAS, FFAR1, CNTN3, NPTXR, LRP4, LPAL2, PP2D1, PARPBP, PCSK4, GIMAP8, KLC3, CYP2A6, NANOG, CCBE1, H2AC7, TMIGD2, HIGD1C, PLG, ANKDD1A, PIP5KL1, NLGN3, DEPDC5, DGKI, CDT1, EME1, ERVMER34-1, COX6B2, INPP5F, CYP27C1, FOXO3B, RELT, CMKLR1, LUZP2, ARG1, NBPF10, LARGE2, PDCL3P4, IL19, NOTO, BIN1, NR1H3, LGSN, JAM3, TP73-AS1, GALR1, DSCAML1, TGM3, IGHMBP2, EPM2A, CLEC10A, CUBN, CLTCL1, DOC2A, ISLR, GLS2, DSG3, FKBP2, CLECL1, CLCA3P, CPVL, FASLG, ALG6, C2, CLTRN, LIPN, EFS, LYSMD1, LHFPL6, NOS1AP, LIPG, PNLDC1, NOTCH2NLA, LIPE, DCX, PMS2P2, PCOLCE, RFX1, PMEL, CBFA2T3, IL21R, GSTM1, DCHS2, C2CD4B, NDUFC2-KCTD14, LNP1, MMP2, GARNL3, DACT2, CC2D2B, LPO, EPHX3, DPP4, NBEAP1, HSF5, LMNTD2, CNN1, CTU2, CXorf58, JAM2, PALD1, C5, BMP8A, GRK5, CCL22, DERL3, DLG2, HRK, CCR7, CDK2, MXD3, CDC45, CTTNBP2, COCH, NOXA1, GP6, TNK1, GJB1, DNMT3A, NDUFAF7, ACE2, TPP1, ERCC5, PIPSL, IL18BP, PON3, CERCAM, CLASRP, JMJD7-PLA2G4B, TRPV6, GLRX2, TNFRSF11A, MACO1, CPT1B, LYPD6, VWF, CYP4A22, CBX8, HEMGN, ASAH2B, CYP3A7, TPK1, CTU1, MAP2, IL12A, LRRC26, DGKG, ARVCF, TMEM92, CRAMP1, COL19A1, CRYBA1, GEMIN8P4, HRG, DAND5, IMPG1, IQCF3, FES, EFCC1, DAGLA, GIMAP1, MYO15B, PDCD2L, CLUL1, DHRS2, HHIPL1, ACMSD, H2AC13, IDI2, COLQ, PMFBP1, NPTX2, HLA-J, CYP11A1, NLRP10, C1S, CLCF1, CAPN8, BAGE2, PKMYT1, LTK, HAAO, LHFPL1, PDE10A, CNTN4, EBF4, PRR11, AZIN2, IGSF11, CLIC3, GMEB2, ELOVL7, LIPC, FRS3, EFL1P1, PRKG2, PROC, CORT, POTEI, LAMA4, FTH1P3, LY6H, ITGAM, CSF1, EDN1, HLA-DOB, LRFN4, H3C14, DDR2, CYP2C8, H3C7, LTB, LANCL3, FGF12, LY6K, DDX11, H3C15, HAS3, CRTC1, H3C4, GRM2, FRG1HP, INSYN2B, POU2F3, EPB41L3, BCS1L, CRLF2, KLLN, GRAMD4, CLEC17A, GPAT3, EPOR, GUCY2F, PPIP5K1, COL6A1, TFPT, MAFK, POMK, ENHO, BCRP2, BMP4, DMC1, USHBP1, ANXA9, FOXRED2, CLCN7, TNFRSF12A, LMNB2, NOS2P3, IMPG2, COL10A1, ACVR2B, NAP1L2, IFFO1, PIPOX, GAS2L3, CREG2, CTC1, EPHA4, DOK1, NR6A1, EPHB3, IL24, CYGB, P2RY12, TPCN2, GSDMA, MARK4, EBF3, IKBKE, PAX5, ACE, PDE1A, POU3F1, CLMP, PRKN, LINGO4, IL12RB1, PAX8, DYNC1I1, ITIH5, TFPI2, LIN28A, LIF, TNFAIP8L3, POFUT2, ABLIM3, KLRC1, EFNA4, ALPK3, GAREM2, E2F2, CDH17, FIGNL1, PDE1C, HEG1, MAP3K7CL, FZD5, EMC3-AS1, IFNK, DRAXIN, PKHD1L1, TPI1P2, PIDD1, IFI27L1, FPGT-TNNI3K, TREML4, TOMM40L, DYRK4, H2BC11, HAPLN4, NDUFAF4P1, EHD2, HS3ST3B1, POP1, HPGDS, CRLF1, DUS3L, PINX1, FSCN3, GRAP, DSEL, BMP7, MAT1A, C7orf31, LYAR, DBNDD1, COL17A1, USP13, MARCHF3, NBPF1, CXCR3, ARPC4-TTLL3, DMPK, DKK3, NAP1L5, MVD, LSP1P4, CSAD, GAS2L1, HEXD, GAS1, ECM2, GNAZ, PRR12, PARP10, LIPT1, CSF1R, GRWD1, E2F6, NBPF15, TMPRSS12, KLRA1P, KLRC4-KLRK1, CLCN5, MAPT, GRB10, PROCA1, BMS1P17, MAP3K15, CPSF1, CROCC2, LONRF1, CMC2, CDH12, HEXIM2, DMGDH, FUT4, PIMREG, HAS2, TNFAIP6, NRDE2, FZR1, SOCS7, ERP27, COPA, PAGR1, PNMA8A, HAUS7, LYSMD4, DNM1P46, LPIN3, INTS9, EIF5AL1, ASB9P1, CHPF2, HGD, JAG2, MMP14, H2AC21, BLACAT1, FRAS1, CSRNP3, CYP2C18, LRRC17, MYC, CRABP2, DLL1, DYNC1H1, GNB1L, THTPA, ESPL1, DGAT1, DENND1C, MAB21L3, TPCN1, EML3, CYTH3, DMWD, LIN37, INF2, PKD1L3, DAPK2, EFR3B, CDH8, TOP3B, TSC2, PROX1, LRCH1, HEMK1, CT75, DGCR5, EML5, GUCY2C, DSE, DPEP2, HYAL1, MAP3K6, PMEPA1, CCR5, NSG1, GINS1, MAB21L1, LOXL2, GHDC, PDGFA, MAMDC2, CLSTN3, PIAS4, NOX4, POTEC, IL22RA1, CREB3L4, CKAP2L, CIT, CDK11A, GJB7, CXCL5, FKBPL, CYP2C19, FREM2, LONRF3, DMRTA1, DBF4B, ITGA5, CYP24A1, ELL, IGF2R, HAVCR2, GRAMD1B, CYP7B1, CTH, EIF2S3B, IER5L, HPSE, IKBKG, BDKRB1, HARBI1, MAFG, IL17RE, CLCN6, LAMA3, CYP1A2, MMP12, LRMDA, DDX31, ABHD5, PIGN, DLK2, HELZ2, TNKS1BP1, DAPK3, HDAC8, CLIP2, CHEK1, IRF3, GRB7, PARP16, CNIH2, ANKHD1-EIF4EBP3, LYPD5, CDH11, GNRH1, CTF1, GIPR, GGACT, CSF2RA, MACROH2A2, DXO, LPCAT4, IFI35, CTSV, HERC2, LOXL4, GJA4, ANLN, H2AC19, GNMT, ITGA1, LCAT, CIDEB, FRMD4A, MAP3K14, IL27RA, CNIH3, NLRP14, IPO5P1, ASB2, LYNX1, LIN7B, LYVE1, PMS2P3, LY96, FDXACB1, PRORSD1P, LINGO3, EPB41, MAPKBP1, IMMP2L, LIN52, GSDME, GPATCH1, AGAP3, CLDN18, ULK1, CC2D1B, LOXL1, DEPDC4, REXO5, ENTR1, MMP25, FRRS1L, FSTL4, PCK2, F5, PALM, COMMD3-BMI1, MATN2, CISD2, CLEC12A, HCFC1R1, MAP7D2, HCAR1, NDUFAF6, HDC, PCNT, CTIF, GFOD1, GPATCH3, PISD, EPS8L1, ELN, DBN1, DCBLD1, TNFAIP8L2, EEF2KMT, EPHB4, PABPC1L, GPR135, GZMA, ALS2CL, NPB, MMD, BCAP29, CREB5, FSD2, DGKB, PDCD6IPP2, LCK, DNA2, CRYM-AS1, ESCO2, FER1L5, PC, SUSD3, HYOU1, GASK1B, GLT1D1, ITSN1, FOXO4, FXYD1, ERO1B, FKBP1B, NAT9, DPP9, DPY19L1P2, CUTC, DYRK3, FKRP, LIME1, HDGFL2, FLRT2, GPLD1, CYP20A1, ISY1, PODXL2, ITGB1BP2, COL1A1, CHEK2, MXRA5, NOP2, GIMAP6, DAB2, CLYBL, DGKD, IGSF3, PKD1, CNTF, DKK1, NLN, CDK1, LTBP4, PIGZ, GDF11, TNK2, HDDC3, CRADD, LARS2, ITGAE, GGH, DIO1, CDK11B, ANO10, HTRA1, LBHD1, MAMLD1, SMAD7, EPHB1, GRK4, HLA-L, DDO, PPM1E, DAGLB, PTCH1, E2F3, CXCL3, BIK, TEX55, RFT1, INCENP, FDXR, H2BC9, TNFRSF25, CYP2E1, LIMS3, PI4KAP2, LAIR1, CPEB2, GLIS2, GLI4, FRY, GNE, GJC1, IGFL4, CTSK, TNFRSF10D, HK2, GPAM, PICK1, PRKAR1B, NANOS1, NRP1, GEMIN5, CXCR5, C5AR2, MAPK8IP3, CXCL9, LRRC37A2, TTC7B, GPC1, ABHD18, CPSF4, IPO4, FZD4, CBLC, LIG1, ERICH2, DDX60, DTNB, LARGE1, NLRP2, TGFB2, IMPDH1, CLNK, PIGC, TMUB1, CLDN22, CLUHP3, DDX51, MAP4K2, NOTCH3, MALL, MAP3K9, LRPAP1, CLDN8, DPY19L2P3, IFNLR1, CIB2, PDE4A, AS3MT, PRKCD, DGCR8, GPAT4, LTB4R2, MMP1, LSMEM2, ERF, JPH1, SMURF1, GJB2, DHRS13, CTPS1, PRKCZ, IL10RA, MAD1L1, LRRC2, ACKR2, MAGOHB, HARS2, DCP1B, DYSF, LRGUK, FER1L6, NPHP4, CYB561D1, BAALC, ILVBL, EFL1, CMTR1, PLXNA1, CIP2A, CLEC4E, D2HGDH, EPSTI1, CXCL6, MAP2K6, ITGB7, ASB1, C2CD2, TET1, PLA1A, CHFR, DCAF15, EFNA5, MAP11, LMAN2L, CPLANE2, ALG8, EMG1, DOCK8-AS1, NDUFA10, CRB3, CEP76, ERCC2, DDX54, GAA, DOK4, COQ3, IRAK2, HP, NSFP1, UROS, TF, PIK3R2, GFER, LLGL1, EFNB1, HELQ, ADAL, CSNK2A1, DHRS4L2, EDIL3, HUNK, MARVELD1, CSMD1, CDKL3, PIEZO1, FPGS, PKP3, NSUN4, TMTC4, ERCC3, PCSK6, INSIG2, DISP1, TNFRSF9, MYL9, IL6R, FLT1, IBA57, EEFSEC, CRISPLD2, MAPK7, CBLB, PNPLA6, GGTA1P, FUT3, NOP16, HES4, PIK3R5, DAB2IP, CPNE5, JDP2, IL15, INMT-MINDY4, HIP1R, BICRA, CC2D1A, CNPPD1, EMC10, DOT1L, PHRF1, EID2B, CDKL2, PDE3B, IP6K3, LMCD1, GUSBP1, H1-3, HPX, CWH43, ENDOD1, CXorf56, MANSC1, POU6F1, HMBOX1, NBEAL2, NARS2, ING5, PROSER3, ITGA9, RFLNB, LTBP1, CROCC, MAN2C1, TOMM40, HS6ST1, CRPPA, IRS1, TLR5, DUOX2, MAN1C1, IRX5, IRF7, FXR2, THRB, DAZAP1, CBWD6, TP53I3, DPY19L1P1, GRTP1, HPS6, LY75-CD302, LRRC20, DHX35, PARP2, IGF1, NR1I3, M1AP, TMPPE, TP53I13, HDAC6, PCGF2, CDK18, PMS2, NBPF11, GPANK1, LRRC14, PPFIBP2, FSBP, HFE, ENDOV, ARL10, ALOX15P1, TPM2, COMTD1, CRIPT, CMPK2, KLHDC3, IFIT5, TEX30, TTF2, PORCN, DHRS12, TPBG, ALG9, PDE4D, EMILIN2, CUL9, CHID1, KMT2B, C3AR1, LAMA2, PPIL2, GPHN, IRF2BP1, DCAF4, FLAD1, H3P6, CDON, LRATD2, TGFBR3, CDK5R1, HECTD3, GPR107, TGIF2, COX19, LY9, MLLT11, UBIAD1, IVD, DVL2, CNNM2, GALT, CLK2, ERMAP, PIGG, CUL7, INPP5K, CFI, LAMB3, EARS2, F8, DRAM1, HLA-DRB5, NSMCE3, APOL2, A1BG, GGCX, EDEM2, MAP2K5, DOCK6, TFAP2A, INTS1, FEN1, CNTD1, GID4, GIMAP7, MVB12A, ARFRP1, MAP2K7, GZF1, USF1, HECTD2, MAPK10, LTBP2, PI4K2B, H2BC8, GAS2, ENO2, CBR3, CPA4, E2F8, GSTCD, ELOVL1, HID1, LMF1, FOXRED1, EDARADD, DPP7, LZTS3, ASAP3, POMT1, TP53AIP1, BACE1, ITPRIPL1, IFIT1, FERMT3, DHRS1, TNFRSF1B, MYLK, HERC5, CYTH2, CLSPN, ANKS6, CAPN9, DACT3, CORO1B, COQ8B, IFI44, PAK6, DGAT2, LRP1, TPM3P9, DISC1, LMBR1L, NLRC5, HES2, PIGM, BDKRB2, PCNX3, ISG20, NOP14, GSDMD, PRPF40B, CRAT, ARL11, CHDH, CDKN2A, LYRM1, GEMIN7, HCK, LBR, GINS4, MAF, RFNG, FOXP4, DPH7, TNFSF13, IKZF4, PKP1, LRP8, CDR2, COX10, PRPF18, CNKSR3, IRF5, ERN1, EPN1, CPNE8, IFNGR1, IL2RB, COQ2, CREBZF, COLGALT1, MYO10, INTS7, G2E3, POFUT1, NBL1, CIART, PARN, LZTR1, CDRT1, FEZF1, ASAP2, PRPH, TOP2A, LYL1, GLIPR1L2, IFITM1, BIRC6, DENND3, ARNTL2, DHX16, TLR4, ERCC6, HYLS1, KLC2, BAG2, COL4A6, PLXNA2, FZD8, LMBR1, CYB561D2, GSTM4, DOCK4, LZTS2, ACER2, FOXQ1, FRMD6, NATD1, JMJD7, HERC6, CTNS, CLASP1, PKD2, LCMT2, LONRF2, LRCH4, DVL3, CDK5RAP1, MLYCD, GNG4, TFAP2C, CSTF2, PROSER1, CDRT4, PRMT7, MAP1S, BMPR1B, BIVM, CNTNAP3, ZKSCAN2, ELOVL6, DCPS, LRP6, CLCN2, GMPR, PLXDC1, HERC3, FZD1, PPAN, EFEMP2, BICDL2, POU5F2, INTS2, ITPKB, PILRA, HIRA, TNIK, IL17RA, ELMO3, CBFB, HDHD3, GNL1, ASB6, PMVK, GGT7, UBA7, ERC1, FIZ1, H4C14, TMTC1, DCUN1D3, DEF6, EEF1AKMT2, GLMP, LMF2, TTI1, NR2C1, MARS1, HIP1, DIP2A, EPDR1, LRRC27, GMPPB, MVB12B, LAMB2, CLIC5, ENC1, COMMD1, DEAF1, IPPK, DPH6, NAPB, NAXD, MX1, ITM2C, CYP2J2, PBXIP1, ZIK1, CLN8, MMP24, LIMCH1, LATS2, LAMA5, DCAF11, TAB1, MYO1G, TIRAP, CROCCP3, DOLK, GPATCH2L, DZIP1L, DMAC2, LARP1B, CDK5RAP3, DTWD1, PMS1, PIGW, SURF4, ITGB6, FKBP14, GRIK2, JARID2, GAS8, TOP3A, GNA12, NRP2, DPP3, SUSD1, PRKCA, CHMP1B2P, CYP4F3, PIK3C2B, CRACD, PCTP, CHERP, HAUS5, MAP7D1, IFRD2, NANP, JMJD4, PATL2, FRMD3, NSL1, LPCAT1, MAN2A2, PIGV, HIRIP3, NLRC3, BMP3, PIGS, MAST3, FRMD8, MACROD1, CMYA5, PMS2CL, CLCN4, COG8, IL1R2, TNRC6C, CHPF, GMNC, EME2, JMJD6, GNPDA1, COL4A5, EDRF1, DMRTA2, DHRS11, ECT2, DMKN, PRR14, MMP10, LCN2, CYP2B7P, DUSP28, TRPV4, GMFG, DIP2C, PCGF3, ARFGAP2, GIMAP5, GLB1L2, PRODH, DHX34, IFI44L, IFIT2, PALB2, GPN3, CYBRD1, CCAR2, PIAS2, CSKMT, FKTN, DDX10, TNIP2, CLN6, ALOX12P2, CXXC1, EFNB3, DOLPP1, HDAC11, NDUFAF1, LPAR6, IFFO2, CRTC3, TFB1M, FECH, HACE1, ENTPD6, EP400, GRN, DENND1A, ANKAR, EPB41L5, MAP3K20, DDX58, LSR, CHMP4A, KLC4, GLDN, ING1, MAB21L4, ITFG2, FLII, TGFA, COMMD5, GRK2, KLF11, PPIH, GANC, GTPBP8, FGF14, H6PD, DHCR7, LAMP3, PNPLA2, DPH1, GPKOW, CBWD3, EMC1, CTSA, IL6ST, EDC3, DTWD2, PNPO, EDC4, DTYMK, DDX20, ITPR3, TLR6, UROD, GPNMB, DEF8, TNRC18, DPY19L1, LY6E, CLN3, HEY2, CBX6, FURIN, LTBP3, COX15, ENTPD4, CWC27, CRACR2B, DUSP5, CBWD2, CNTLN, DDAH2, CHKA, MAGI2, CPEB3, EGLN2, HS2ST1, DTD1, HSCB, BAHD1, LONP1, DUOX1, SURF6, DPAGT1, DIABLO, PODXL, FGD6, EID3, PAK4, ADO, POMGNT1, HDAC10, DTNBP1, DIPK1A, CNTROB, KLF2, PAK1IP1, IL20RB, ALG2, PMPCA, NRBP2, PIP5K1C, FUT11, SUPV3L1, INPP5A, ITGA3, INTS14, PLXNB1, HTT, DPH2, FERMT2, GJB3, ZKSCAN3, DYRK1A, TP53, EEF2K, INPP4A, TRERF1, DHODH, ANKK1, LRIG1, CHKB, PAXIP1, IL17RC, PPIC, HGSNAT, DET1, TP73, PIGO, MADD, DDX55, HS1BP3, MLPH, IP6K1, ITGAV, ARPIN, EIF2B5, IRF9, TFCP2L1, POMT2, PROM2, DDR1, GRIPAP1, ITM2B, MAEA, LCORL, ERAP1, DGLUCY, AP2A2, ELP6, MARK2, CDKAL1, LIFR, MAN1A1, DCUN1D5, LRIF1, DDIT4, RBL1, DERL1, EIF1AD, DHX58, IFIT3, EDA, CNOT10, HUS1, THSD4, CHN2, LRP5, DEK, COQ8A, PARL, GSAP, PNKP, MAPK15, GAS6, DMTN, LAP3, FKBP9, BACE2, DPY19L2, ERP44, DHPS, MMACHC, NOTCH1, CNNM3, MYO19, DHX33, TMUB2, DDX56, FEM1A, IL2RG, DBNL, IL7, GMPR2, PIK3CD, DENND4B, CYREN, INPP5E, H2BC18, DCLRE1A, MLLT3, FKBP15, PCGF1, DDX39A, DHFR2, ITGB2, MARK1, HEATR6, KLHDC4, TRIB2, CDK13, TMPRSS13, DHDDS, HYAL2, ITGB5, ABL1, ELMO2, LRP12, CREB3, EGFR, LGMN, CNIH4, ERLIN1, PRKRIP1, CD40, ANKH, INVS, GPD2, CNP, ZZEF1, DDA1, CDK20, CDK5RAP2, TNFAIP1, DIDO1, HPCAL1, RFX5, HDAC4, CLUH, DVL1, EHHADH, CPTP, ERBB3, MARVELD3, LIPH, APOL1, CYP2B6, PILRB, CPQ, BMPR2, POT1, NSF, ILDR1, EPG5, PRPF3, PRKD2, C2CD2L, B9D1, MAGI3, CYTH1, LGR4, CEP78, FTSJ3, CKAP4, HS3ST1, CUEDC1, TGFBR1, CNOT3, BLCAP, CREM, CNOT6L, CDIPT, CBX4, DIPK2A, CTDP1, ANKDD1B, PASK, C1RL, CYP4X1, COPS7B, PATZ1, ICAM2, LUC7L, SMAD1, CUX1, CWF19L2, LUZP1, LAMC1, IFI27, CSGALNACT2, DTX2, CYBA, HM13, PARP12, PHYHD1, DPYD, EIF2AK3, HDAC5, EPN3, TNRC6A, JMJD8, EIF2B3, MLLT10, EIF4G1, COG4, IFNAR2, CDK4, IKBKB, HLCS, ITGA6, GRK6, FRMD4B, LSP1, DLG5, HEXA, EHMT1, CRNKL1, DIS3L2, GPN2, INO80, TGFBRAP1, GEN1, MAPK13, CHIC2, CNNM4, PCNX2, TMPRSS3, DDX19B, MAN2B1, ERN2, IL16, LMO2, TFAM, NPC1, ELAC2, USB1, PRPF39, ILKAP, BABAM2, P4HA2, PMM2, GPATCH2, EPS8, NLRP1, EPN2, TNFRSF10B, NR1H2, DSTYK, MYO1F, HDAC3, INSR, NPEPL1, HSDL1, NBPF3, IFT140, MARCHF5, CNPY3, ITPKC, MVK, GRPEL1, CHPT1, EPHX2, TMSB10, DUSP16, MYO1C, HIF1AN, MAML1, IFT122, GSTZ1, ENTPD5, TMX3, IPO9, IGF2BP2, C3, GAB2, COG5, DLGAP4, DEDD, TGM2, HLA-A, GLB1, CBFA2T2, MACROD2, HEATR1, GIPC1, GANAB, DCUN1D4, TOM1L2, CLCC1, LIMK2, BAG1, PIM3, DDOST, DAPK1, LAYN, FUT2, CWC25, EIF4E2, NR3C2, HIBCH, IRGQ, H2BC21, HECTD4, DHTKD1, DUOXA1, LIMD1, EIF2B4, GPATCH4, PHTF2, LLGL2, TNFRSF14, DTX3, GAS2L2, LRRC37A3, MYO5A, COASY, ANKZF1, PCLO, PIK3IP1, NPIPA1, IQCC, LPCAT3, MAPK14, LMLN, MLLT6, INTS8, EPS8L2, ECPAS, ITPRIPL2, NRF1, CYP2F1, ICMT, DPM2, IMPACT, PIGR, LTBR, FPGT, DNMT1, FLCN, IRF2BPL, CPNE1, PARP14, CIC, PNPT1, DYNC2H1, GTF2E2, DELE1, IMP4, CLEC16A, MAP3K3, HPS4, HDAC7, DENND11, DCTN5, GUSB, DCTN1, NSUN2, ITGB1BP1, ERI2, COMMD3, TFEB, DEDD2, HERC1, CHD8, AP2A1, ENTPD7, UBN1, LMTK2, LRRC1, DENND2C, CORO7, DYRK1B, GLB1L, CLDN12, CDK10, PDE4DIP, CTNNBL1, MAN2A1, BIN3, GNL2, LCMT1, CRYBG3, TMEM98, CEP89, EHMT2, CTSO, CSNK1G2, LSS, IGF1R, PNKD, MAP2K1, CTTNBP2NL, PLXNA3, PRKCH, PITPNM1, CMTM4, CYFIP1, LMNA, DROSHA, MYNN, INTS3, ANKFY1, INAVA, AP1M1, TET3, GART, DUSP11, EFTUD2, TNFSF10, DHRS3, HSF1, DDX3X, UBAC2, GGA1, CHD6, ALPK1, BDH1, EPM2AIP1, DLG3, HBP1, CTSL, LPIN2, DDX59, CRY2, IFI16, HARS1, DDX52, DIXDC1, MXD4, DENND2B, TOGARAM2, DHX8, TMEM94, DGKZ, TMTC2, TNPO2, BCR, ASCC2, PCYT1A, LRIG3, TNFRSF1A, DOCK1, UIMC1, SUSD6, DDX47, NARF, GARS1, DDX27, FOXP1, CDH26, DENND6B, EDEM3, TNPO3, ABI2, PKN1, PBX2, MAP3K11, LNX1, HK1, IPO8, NOTCH2, FIP1L1, CHD7, PAX7, PRKCE, GNL3, PIK3C3, UBN2, MAP7, NAT1, DUSP4, TRRAP, FER, ADH1C, PATJ, EIF4ENIF1, ICE1, COBL, MAP3K13, MYOF, PIP4K2C, ACLY, PI4KA, ABR		gene expression	up	moderate COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_Moderate tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	49	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	MORF4L1, CHMP3, CLNS1A, SLAIN2, WNK1, CALM2, UBC, YBX3, SUMO2, ZC3H6, ZFP36L1, ZNF664, HLA-DRA, PTP4A2, PTBP3, ATRX, HSPA8, EIF3D, VPS25, EIF2A, VAPA, CNBP, IPO7, C5orf49, CHP1, PELI1, SRP14, YWHAB, UQCRB, PRDX6, SLC25A3, EFHC2, FRK, CFAP221, FAM104B, PNRC1, FAM229B, ATF2, DSTN, CSTB, HNRNPA3, HSP90AB1, EIF4B, ELOC, RAB6A, CETN2, MYL6, ANAPC13, NFE2L2, METAP2, PRDX5, SNX3, UBQLN2, RPL22, TEX26, UCP2, STK17B, STOML3, RNF11, ACTR2, RPS3, CCDC170, CLN5, TEX9, ARHGDIB, EEF2, GNG5, MBNL1, NET1, PDLIM1, HIPK3, PRDX3, RHOA, SEPTIN7, YWHAZ, TRAK2, NPM1, NACA, UBB, ZC2HC1A, NAP1L1, PPP1CB, WDR78, ID2, FBXO15, ANKRD66, HINT3, ACTB, GPX4, SELENOK, TUBA1A, MRPS31, NSA2, TAB2, AKAP14, HNRNPA1, HLA-DPA1, GSTA1, TWF1, GABARAP, HDDC2, SOD2, RPS10, RPL14, CFAP53, FOXA1, TBCA, UQCRQ, PIFO, CALM1, IGFBP7, FAM216B, CYSTM1, ATP5F1E, PPP1CC, PHB2, C11orf88, RPL38, RPS24, RPL27A, CAV2, TMEM182, GSTA2, PCBP2, FAU, PFDN5, C9orf24, C20orf85, SMS, FAM183A, ETFB, ST13, INO80C, SEC14L3, DYNLL1, RPL18, SULT1B1, RPL11, GNB1, H3-3A, ATOX1, RPAP2, IRAK1BP1, ZNF207, ATP9B, MAPK9, FNTA, KPNA5, CRIP1, RPS25, RPL29, PNPLA4, RPL37, SNRPD2, KLF10, C16orf72, RPL9, EIF2S3, SESN3, PPP2CB, FAM221A, SLC25A6, YBX1, EIF3H, EIF1, KRT17, DMAC2L, RPS17, CXCL17, MUC4, HSP90AA1, GNAS, RPS19, NDUFB2, SLC25A43, TOMM7, RAC2, PPIA, NEDD4, ASTN2, ZNF91, GAPDH, FAM228B, S100A11, ERVW-1, CCDC122, EIF3E, KRT5, SPINK9, RPSA, ASB3, RPL24, RPS7, PAIP2, CKB, RPLP2, CCNI, EEF1G, PPEF2, SCGB1A1, HINT1, PLLP, RPL10A, TIGD1, NBPF9, FTL, PCBP1, RPL23, HLA-DPB1, RPL35, TMEM212, EEF1B2, ORC4, EIF3L, RPL28, RPS28, RPS12, STATH, RPS2, RPS23, RPL5, RPS26, RPS20, RPS27A, RPL31, ATP5MG, RPL8, HLA-DQB1, LAPTM5, SPA17, C12orf75, RPS6, WDPCP, RPLP0, RPL3, TRIM69, RPL7A, RPL18A, RPL37A, RPL19, RPS5, TFPI, RPS4X, RPL27, RPL15, RPS14, RPL34, BTF3, ADAM32, RPL7, RPS16, EVI2B, PPIAP46, RPL10, RPL6, TEX101, RPL4, PABPC1, IGHG1, FTH1, EEF1A1, RPL13, TPT1, RPL32, RPS27, RPS15, SH3BGRL, KIAA1328, RPL12, RPS18, ANP32B, RPL30, MS4A1, RPS11, FAM241A, RPL13A, RPL23A, RPS15A, RPL26, RPL17, RPL36A, RACK1, MTRNR2L7, RPS8, RPLP1, HLA-V, RPL21, PLCG2, MIPOL1, RPS3A, TBC1D8B, RPL41, IGHA1, HLA-DQA1, BLOC1S6, MTRNR2L3, CYSLTR1, MORC4, OMG, JCHAIN, TMEM45A, IGKC		gene expression	down	moderate COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_Moderate tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	69	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	IGFN1, ELOA3B, ELOA3, FBN3, OTOG, TP53TG3B, TP53TG3C, INS-IGF2, ITPRID1, OTOGL, C4orf54, FGF7P3, ARPP21, C3P1, DAAM2, CGB8, DAZ1, TP53TG3, CD8B2, IL31RA, CUX2, IGSF22, CDHR1, FREM1, DGKK, ENPP7P13, INSRR, JPH4, HPSE2, GGT2, PDGFRB, GGT3P, PRLR, IGSF9B, ATP4A, LCT, JPH2, CAPN11, DEFA1B, DISP3, CAMK2A, DPP6, HKDC1, TFAP2B, ELOA3D, CADM2, ALOXE3, NXF4, FNDC1, CLCN1, ENPP1, ATP2B2, GRIA3, GCK, FAT3, ATP2B3, TP53TG3D, ERVV-1, ITGA2B, ANO5, NXPE1, CLEC18B, HSPB6, CGB7, ITGB3, ALOX12B, FIGN, IGDCC4, CGB5, MMP23B, ASTN1, DAZ3, AMY2A, ARGFX, THPO, IGLON5, ENPEP, OTOF, CALN1, MMP23A, CDC6, CNKSR2, CDSN, EPHA3, ANTXRL, MRC1, CXorf49B, CLEC18C, WT1, EN2, CLEC18A, BPIFC, CXorf49, GRIA2, NXF5, WSCD1, F11, AOX1, ASPHD1, EXTL1, CACNG7, RFX6, PDGFRA, ABLIM2, CDH20, DAO, TLR9, HSPA12B, ATP8B5P, L1CAM, DAZ2, CCDC92B, ATRNL1, CILP2, ALPG, FRMPD4, MPL, DDC, CECR2, GATA4, ALX4, ASIC2, ITIH2, FRMD1, IGDCC3, TFAP2D, ACP4, GNAT1, CGB3, CDH5, CA11, BMPER, MN1, HSFX2, FIGNL2, CDO1, CD163L1, DDN, MUCL3, BPIFB6, FOXL1, BMP10, FRG2B, CABP5, DES, NSG2, GCKR, GPC6, CILP, CNTFR, HK3, ANO3, ALPI, MPP2, CD70, CDH10, CLDN2, CCER1, HOXA11, LBP, HECW1, HSPB7, DPYSL4, CREB3L3, PITX2, THBS4, UBE2U, TGM5, GNAO1, FIBCD1, AMBP, TGIF2-RAB5IF, GPIHBP1, MUC3A, DPEP3, CNTN2, CGB2, CRHR1, ALPP, OTOA, AMY1A, ACSBG2, HJV, FKBP10, DRD3, CA7, CXCL11, CRHR2, APOC4-APOC2, F7, GPA33, CPA5, TH, ALK, CDX2, F2, CDCP2, GCM2, FLT4, CALCR, GDAP1L1, AMBN, FTCD, EMILIN1, CALHM4, FRMPD3, ASPG, GDF1, C4A, CRISP1, IMPA1P1, C8A, DNMT3L, CUZD1, LDB2, CXADRP2, TGM6, BAIAP2L2, CCDC144NL, SARDH, JCAD, HRH3, ANP32D, APOB, CDHR5, CSH2, DAB1, ANO2, CDIPTOSP, ELK2AP, MPPED1, PDGFB, ANO7, ACR, FRG1JP, GGN, FHL5, ELOVL3, OTOAP1, ITGA7, ENPP7, ITIH1, MMRN1, ITGA10, ITGAD, IFNL1, ACVR1C, ADGRL4, CSH1, CCDC196, C8B, FNDC5, ELOVL2, IL13, CD300LG, DMBX1, EPHA10, MMP8, CCKAR, C2CD4C, APOA5, CABP2, FOXN1, MAST1, KANK4, HSFX1, AMPD1, CAMKV, MPP3, THBS2, CCDC197, CA4, ALG1L9P, ENTHD1, BCRP3, EPB42, FTCDNL1, IGHV3-30, ASGR2, ARSI, ANP32C, GNG13, C9, CCKBR, TNFRSF8, C7, MATN4, HSPA7, OTOP3, GATA5, CXCL12, GOT1L1, TEX51, IL9R, ALPK2, ERVV-2, IGF2BP1, CKM, CCL11, GDF7, ARSH, IGSF21, CNGB3, IGF2, ALDOB, CA10, AMER2, ODF4, ICAM5, AMHR2, CCDC105, MASP1, FREM3, CDCA2, FNDC7, DACT1, INSC, CIDEA, FCRLB, ASIC4, ASNSP1, CDH4, AQP12A, CALHM1, ADRB3, CLDN14, MPO, MEOX1, IFNL2, DOK5, ARSF, MMP27, CDC25C, OTOL1, CALR4P, FSTL3, MUC6, C8G, CYMP, GCGR, BASP1P1, IL1RAPL1, FRMPD1, GP1BA, CD34, GC, EN1, SERPINC1, ITIH3, CLCA1, FGF4, ODF3L2, ASPDH, OTP, IL21, MAPK4, TNR, CSMD2, MPZ, BARHL2, FRG2C, CCDC144CP, ELSPBP1, CNTN1, MOGAT2, CD5L, CCT8L2, FSD1, ATP4B, CSN2, HOXA2, ILDR2, HIVEP3, GRIA4, CPA6, DNTT, FMO9P, DHRS4L1, CLDND2, IL17REL, IL25, MEIKIN, BAAT, AMER3, ITLN2, TAF7L, GPC5, CYLC2, HOXA13, CCL24, DKK2, CCL13, CCER2, IFNL4, TNFSF11, CDK3, IL10, EPO, CLEC12B, LCNL1, EPGN, OTOP1, CRIP3, IGFL1, CDC14C, DNMT3B, ANTXRLP1, HRC, OTOP2, CCDC85A, CDH16, ELOA2, ELOVL4, TGM4, TSLP, ITLN1, IL1RL2, EMX1, ASTL, AQP10, FXYD6-FXYD2, IL1RAPL2, DPEP1, FRG2DP, CGB1, AIFM3, FOXP3, DIO3, INKA2, AEBP1, HIPK4, APOL5, IGSF23, INTS4P1, CLCNKA, AQP12B, CLEC14A, CAMK2B, HLA-G, C2orf27A, FGL1, CPB2, F9, EGF, LCN6, INPP5J, ASMT, MRO, IL3, KNG1, FCN2, CA9, IGKV2D-14, IGSF1, SMAD6, FABP7, EMILIN3, CLDN19, OSTN, CALHM5, ARRDC5, GPD1, IGKV2-14, CGREF1, WSCD2, IL2RA, CHST8, CLEC4C, CCDC185, CSN1S1, CDHR2, TFAP2E, CDK5R2, MAP6D1, IL22, FGF3, ATF7-NPFF, CUTALP, C4B, TGM1, CIB3, EMID1, BMX, L1TD1, FKBP1AP1, INAFM2, GPER1, CCL25, CCDC83, CNGB1, ASXL3, GNAT2, GGT1, CSDC2, CCL21, FRG1BP, CACNG8, KY, ESAM, APOC4, CCDC140, CDCA5, DOC2GP, LCN9, CITED1, DHRS7C, FXYD4, CAMK1G, DDI1, CDC42P3, DGAT2L6, FMOD, FNDC8, CDK15, CHSY3, CARMIL3, DEFA1, ARR3, MRAP, GRIA1, FSCB, IFITM10, AMTN, F10, HECW2, DMBT1, CNTD2, ENDOU, CXorf51A, BMS1P22, CMTM5, IL12B, H1-7, CPB1, HR, FSHR, AOC3, ASIC5, CDH22, CD8B, FRMD5, FOXH1, MMP28, CLEC4F, ACRV1, C4BPA, DPH3P1, MNX1, GCNT7, AGTR1, TP53TG3HP, IL17RD, INHBC, C2CD6, CDH15, IGFL3, IFNL3, DOCK3, DOK7, CCL18, C7orf61, CDC25A, FGG, BSX, CXXC1P1, CCM2L, FRZB, INHA, GZMM, CDH19, ANXA2P2, INHBA, MOGAT1, CD109, FRG2, IGHV1OR15-3, IL1F10, CDH23, CCDC116, EPOP, CLEC1B, A1CF, ALOX12, INO80B-WBP1, FKBP9P1, ITGA11, C1QL2, FOXO6, ACOXL, APOBEC1, CALCA, CXADRP3, ALB, FOXR1, APOH, FST, HSFY2, CXorf51B, ITGA8, FLT3, ENTPD8, DPF3, C6, MATN3, FBXL21P, IL11, TAFA1, FLG, EOMES, ACP7, ADD2, CDH24, INHBE, GBX2, MEOX2, FOXF1, ASZ1, CLEC11A, IL36G, IGFALS, CBY2, JAKMIP3, OTOR, IL17A, DIAPH3, CAGE1, MATN1, BPY2, ALX3, BARX1, AMZ1, DKKL1, CCR8, MMP20, ITIH6, F13B, CLEC2A, CALHM3, HSF4, GNG3, ACVRL1, CIB4, DEFA3, CCDC3, FXYD2, AURKC, IGHVII-22-1, BARHL1, CALY, IL26, HIGD1B, FOXR2, OTC, TNP2, IGHE, AMELX, CLEC2L, KSR2, LDB3, CCDC70, ANP32AP1, UBL4B, CDX1, EMCN, BMP2, MPPED2, CRH, MAPK11, CXCR2P1, ATRIP, CPEB1, CDH18, TNFSF15, CIDEC, CD101, TP53TG5, CSHL1, MMP26, ABI3BP, CCR2, ALAS2, IGFBP1, FRMD7, CRISP3, CYLC1, ENO3, FSCN2, GNAT3, CYTL1, BMS1P21, FBP2, FBN2, MAS1L, GBP7, RCOR2, CCK, IGHV1OR15-1, FRG2KP, IGLJ3, CSGALNACT1, HSFY1, CCL27, EMX2, HIGD2B, FLG2, P2RY6, CALML6, CLEC4G, ELMOD1, GP5, IL34, DACH1, FADS6, MMP21, APOC2, ARSL, CDRT15P1, HIF3A, CLDN5, ADARB2, APOA4, IGLL1, CCDC27, HSPB2-C11orf52, CNGA2, CRNN, ADIG, GPHB5, GPR101, FOXF2, KAAG1, AMPH, EZHIP, ANKS4B, HLA-H, FGF8, DIO2, CCL19, SERPIND1, AZGP1P1, CXorf66, JAKMIP2, TEX52, IGLC6, CDH7, INS, CRYAA, DNAH17, CDAN1, F13A1, GNG11, ACSL6, IGHEP1, CCL8, IHH, GBAP1, IFIT1B, DAOA, IL17C, IL27, FCRL6, FSHB, CXCL10, ACSM1, CDRT15L2, CNPY1, IL13RA2, DPF1, KRTAP5-4, FIGLA, DARS2, IGLC5, C1QL1, DMP1, FMR1NB, CLEC17A, CNR1, CNNM1, DPYSL5, CNBD1, IGHVIII-22-2, CNBD2, P2RY8, MELK, IBSP, AIF1L, DDIAS, IL1RL1, AP1B1P1, INCA1, CNMD, NXF3, IAPP, AIRE, CAMP, JAKMIP1, FCN3, CCDC188, DRD1, CSN1S2AP, IL36RN, GATA3, IL23R, CDH6, FOXS1, GPHA2, CDCA7, FDPSP2, KRTDAP, IL19, FOXO3B, CSMD3, TNFRSF13B, NODAL, CABS1, IGHV3-75, IL31, IGLC7, CAMKK1, DISP2, CLDN6, AGTR2, IGHV3-22, BDNF, DACH2, BMP5, IGKV1D-35, HSFX3, BNC1, GCG, AURKB, CLEC3B, DHDH, HRH1, FGF9, DPEP2NB, CD5, IL36A, AMH, CCL7, MAS1, IL4, IL37, IFNA10, C1QL3, C12orf42, CCL23, IFNA4, IL11RA, IL36B, FGF6, CDH9, BANF2, CCDC184, CCDC182, AMY1C, HSPB2, C9orf92, APOF, IGHV3-30-2, GPR1, INSL4, GBX1, CYSLTR2, FRMD8P1, DOK2, CCN4, DEFA5, FASLG, IL20, HRCT1, ANO8, CCR10, IGFL2, HYAL3, ANO4, CKMT2, TNIP3, IGHV3-33-2, IGHV3-32, FAXC, ERVFRD-1, HIGD1C, IGKV2D-28, ACP5, C7orf33, CLEC10A, FATE1, FGFR4, GP9, TGM3, IGKJ4, C1R, FOXE3, FGF22, EGFEM1P, CARTPT, HSPB3, MAP3K15, FBN1, AMIGO3, ELP4, IGKV1D-37, CCL22, INSYN2A, CRISP2, GNB3, FMO1, WTAPP1, CCL3L1, IGHV3-42, CNGA3, ANXA10, IGKJ3, IGLL3P, ANXA2P3, APOOP5, TNFSF9, IGLC4, ITIH4, CCR9, FOXN4, AIPL1, LCN8, HUS1B, ARNT2, LEP, F2RL2, HJURP, ALOX15B, CNDP1, ADAD2, CCDC150, HRG, ZYG11A, KANK3, JAM2, TGFBR3L, MOCS1, MRC2, IL17F, GZMH, IGKV1-37, CXorf58, BAHCC1, FLNC, CCN6, CNRIP1, TFAMP1, CABP1, FSCN3, CADPS, SERPINE1, CABLES1, JAM3, CGA, ANKS1B, IGHV3-37, MPIG6B, MELTF, IGLV10-54, SERPINF2, CARMIL2, CALCB, APOC3, IFNA5, AOC1, GNLY, CCDC9B, AMY1B, FERD3L, MOG, BMP6, IGHV3-60, GBA3, IGHV3-41, AGT, AOC2, ASIC3, CA14, KYAT1, FABP5P3, CCL1, CD3D, ERVMER34-1, MPP4, C2orf16, IFNA8, IFITM5, ITGBL1, CNN1, CKMT1B, CCDC87, CCDC183, CABP7, CCN3, DOK6, DLC1, CAMK2N2, IGKV1-17, IGHV3-52, IL22RA2, FIBIN, IGHV3-57, BAGE2, ASIP, IGHV3-29, CDRT15, CPAMD8, IGHV3-63, BMS1P17, GGT5, HSF5, BMP8B, CEP295NL, DGKG, IGLV5-37, IGKV3-34, IGKV2-10, C12orf40, BCRP2, TNFRSF4, IGLV3-27, FBLN2, CSF3, ENPP6, FGFBP3, DEFA9P, CLEC19A, ODF3L1, GFAP, FDCSP, ACE2, INSYN1, DEFA6, PLG, IGFBPL1, IGHV3-36, IGHV3-43, CAMTA1, CCDC73, IGKV3D-34, INSM2, ANO1, IGKV1-35, IGKJ5, AOC4P, IMPG1, CRMP1, C1QL4, CLDN17, FJX1, GCOM1, IGHVII-65-1, F12, HSFY1P1, CCBE1, AATK, FILIP1L, GOSR2, DGKI, IFNA1, IGLV8-61, ELOVL7, IGLV4-69, IL12RB2, CDRT15P2, IGSF9, IGF2BP3, IGKV2-18, GNAI1, TGFB3, ASGR1, AFAP1L2, IGLV4-3, IGKV1D-13, BATF3, DMC1, HSP90AB4P, CFTR, IGKJ2, HELT, EPHA1, ACRBP, IL17RB, FRRS1, IGKV2D-10, LANCL3, MRAS, IGSF5, IGLV9-49, IGHV3-71, IFNA7, CLDN34, GDF6, DEFA4, CCDC198, CDX4, ALX1, ASPN, TGFB1I1, CDPF1, AURKAP1, IGHV3-66, C2CD4D, FBXO17, IGKV2D-40, IGFBP6, CLEC1A, TNFSF12-TNFSF13, IGLV3-2, CADM3, IGKV3D-25, IGKV2-29, DACT2, HSPA12A, DHRS2, MMP3, IDO2, DHX37, TNP1, HYAL6P, FBXL19, IGHV3-15, AGPAT4, FBXO10, AQP1, CLCNKB, HLA-DRB6, FKBP6, FAT4, CYCSP52, CNTN3, DPP4, IGLVVI-25-1, IGLVI-70, FBXL16, IL17B, CLDN24, IGLVI-63, CXCR3, FRS3, FMN2, ITPR1, AMELY, IFNA17, CC2D2B, CRELD1, TNFSF18, DLEU7, CDK2, CDC45, CRLF2, ADAMTSL5, IGKV2D-23, PROCR, DQX1, IGLV1-41, IL4I1, ABLIM3, ENOX1, IGHVIII-5-2, IGHVIII-67-3, IGKV3-7, CNTN4, LEPR, EME1, CCDC36, IGKV1-13, IGHVIII-13-1, INA, IGKV2D-26, IGHVII-30-1, CALD1, CARNS1, EFNB2, IGLJ6, IFNA2, BACH2, FHIT, CALR3, IL15RA, IGHV3-23, ITGB1BP2, DLG2, SPP1, LARGE2, IFNA21, CDCA3, DGCR5, CLCA3P, IGHVIII-44, IGLVIV-64, CDKL4, TGIF2LX, CD300LF, GNG7, CCIN, CCDC179, BMP1, ACP3, DDR2, EPHX4, IGHV6-1, ALG1L2, FER1L4, IGLVIV-65, IFITM4P, INPP5F, FNDC4, CA3, IGHV3-35, FOXI3, ITIH5, CD177, H1-6, CHTF18, CCL2, BMP8A, EMBP1, IFNA14, IGSF11, IGKV7-3, IGHV3-49, IGHV3-16, UBE2T, GNG8, MMP2, IGLJ2, CSF2, IGHV3-50, C1S, CA1, CAMK1, HSFX4, DHRS4, FGFBP2, INO80E, LCTL, CDH11, IGHV3-65, BGN, IGKV1-8, IL9, CABLES2, IGHVII-43-1, IGHVII-1-1, IGHV3-62, MOBP, DGKQ, BMP15, C5, CCDC38, CCDC102B, CDH17, IGHVIII-38-1, NXF2B, MEIOC, MAPT, MAP7D2, IGKV3D-7, IGBP1P1, ARIH2OS, VWF, IGLVI-56, IGKV2-30, CSF1, FBLL1, IL1A, IGLVIV-53, FGF7P6, FRG1HP, TNFRSF11A, EFR3B, MUC7, AVP, KALRN, CREG2, IGKV3-31, RELT, CLDN25, IDUA, IGKV1D-16, AGRP, IGLV2-33, IGHV3-38, IL2, IGLV3-12, IGLV3-29, IFIH1, BDKRB1, IGLV3-22, JPH3, TAF5, CCDC141, CLDN15, C7orf31, IGKV3D-31, IGKV1D-17, IL3RA, CDH8, IL12RB1, DNAH14, FSTL4, DNMT3A, IL23A, IFNG, IFNA22P, IGHV3-19, DPEP2, MEIOB, ASPHD2, IGLV3-30, DAND5, IGHV3-20, IGLV3-13, IGHV3-73, IGHVII-49-1, GP2, IL5, IDI2, ARSJ, ANXA9, AZU1, CALB2, IGKV2D-30, IL22RA1, B3GALNT1, CYSRT1, IGHV3-7, IGHVII-28-1, FBXL6, CCL17, C7orf77, IL24, IL18BP, FABP9, DRAXIN, HLA-DOB, HSP90B2P, IGKV2-40, FCRL3, FOXE1, DKK3, FOXM1, IGHVIII-47-1, IFNA13, ANXA13, HYAL4, DHFRP3, IGLV2-5, ITPKA, FRMPD2B, IGHV1-24, CAMK2N1, ACVR2B, BMP7, ABRA, CBX8, C2, AMDHD1, NXNL1, GCSAML, CAND2, IGLV7-46, IGHVII-44-2, IGLV1-50, IGLV3-10, IGHV3-47, ENGASE, IGLV2-28, CCDC7, IL21R, CLCN5, IGHVII-51-2, FHL3, IGHV3-25, IGLV11-55, CDC20, IGKV3-25, GNGT2, IGHV4-28, IFNA16, IGKV2-4, DIO1, IGHVII-78-1, ARG1, IGHV7-56, GCNA, APOM, AZIN2, IGHV4-59, ENG, TNK1, IGLV3-16, CCR7, CKLF-CMTM1, IGHVII-46-1, IGHV3-6, OTOS, IGLV10-67, IGLV3-9, IGHV3-64, IGHVII-53-1, DOHH, HLX, IGHJ2, IGKV1-32, MARK4, IGHV3-21, CCN5, BCORP1, CKMT1A, TNFAIP8L3, CD93, DOC2A, IGKV6-21, IGKV2-23, MARK2P9, DEFA8P, IGLV5-48, IGLV3-26, GCM1, CXCL13, DPP10, ASPRV1, IGKV6D-41, FBXL22, ADARB1, APOC1P1, ADH1A, IGHMBP2, IGHVIV-44-1, AMDHD2, CA6, IGLJ7, CDC7, INSM1, IGHVIII-76-1, IGHV3-72, IGLV3-31, DAGLA, IGKV6D-21, PROC, IGHVII-15-1, IFNW1, FHDC1, IFNE, TNFAIP8L2, IGHV1-18, IGKV2D-18, CKAP2L, CCDC136, CDC25B, DEFA11P, TEX53, TNRC18P1, ITGAM, FIGNL1, IMPG2, ADGRV1, TNNT3, FTH1P3, IGKV2-36, DAPK2, GP6, FDXACB1, IGHV3-76, CCSER1, CARD9, EFS, CCR3, MMP9, IGKV2-26, IGLV3-32, IGLV7-35, ALG6, F5, JMJD7-PLA2G4B, SOCS7, FHOD3, FASTKD1, FGF23, IGLVIV-66-1, IGLV6-57, MAT1A, CALML5, KSR1, IGLVVI-22-1, IGLV2-34, FKBP1B, HEG1, IFI6, MMRN2, CDH12, IGLV5-45, MICOS10-NBL1, AIG1, CPE, CLC, ENTPD2, FLVCR2, EPM2A, IGHV3-13, CGNL1, IGHV7-34-1, IL12A, FGF7, SMAD7, EPHX3, IGLVI-42, IGFL4, IGLVI-20, MAP3K7CL, IFNB1, CADM4, INSYN2B, IGHV4-4, ACSM2A, IGKV1-12, IGKV1-9, GDF9, TNFRSF10A, IGHV5-78, IGKV1D-22, CYGB, IGLVV-58, IGHJ4, EPB41L3, CLEC12A, F8, ALPK3, TNFRSF6B, FLRT2, FOXRED2, EML5, CXorf65, IGHV7-27, IGHV4-55, IL18R1, IGKV1D-12, DNA2, FSD2, GBGT1, IGHV1-67, BATF2, GNAZ, FLT1, ITGA1, IKBKG, EMC9, CDR2L, CD7, CLCF1, GNB1L, IGLV3-17, FNDC9, C2orf66, CD19, BMP4, IGKV5-2, CHURC1-FNTB, CCDC85C, IGLV3-25, EFNB1, C1QA, TNFRSF17, H1-1, LIF, GZMK, IGKV1-22, IGKV2-24, DGKB, CDT1, TNFRSF12A, IGLV4-60, GPLD1, IGHVII-30-21, TMSB4Y, ABTB2, IGHVIII-2-1, TGFB2, ERP27, CCDC192, CNIH2, CLASRP, FRMD4A, IFI27L1, CBY3, IFNK, MATN2, FREM2, IGLVIV-59, CD72, IGKV1D-8, DGAT1, BCS1L, IGLV1-62, DKK4, CCR5, TNFRSF11B, CLDN20, IFFO1, IMMP2L, FRAS1, DRD4, FKBP2, ALDOC, CD40LG, DEFA10P, IGHV3-54, CCDC200, CCDC142, AMOTL1, CLCN4, CDKN3, IKBKE, FADS2, AMER1, IL17D, FPGT-TNNI3K, CDC20B, ANO9, CCL15-CCL14, FOXI2, IGKV2D-36, IGLVV-66, FBRSL1, IGHV1-69, CSF2RA, CSF1R, GCSHP3, CNTF, F2RL3, INSL5, CCDC22, IGHV1-68, IGHV3-74, CDCA8, IGLVVII-41-1, MICB, IGKV2D-24, INMT, ITGA9, FRRS1L, CLDN18, IGHV3-79, GDF11, CADM1, HSPA6, GCNT4, BMF, MATK, GPAM, ITGA5, CXCL5, MRM1, TAFA2, FOXO4, IGKV1D-43, IGKV1D-42, CIART, MYC, IGHV3-53, CREB5, FCRL4, IGKV2D-38, TNFRSF18, ENAM, CNGA1, DERL3, APOL3, ALG3, MAP3K14, CRISPLD2, ELN, IGHV1-17, DAB2, IGKV1D-32, FER1L5, IGHVII-60-1, CEP55, IGLV3-7, FRY, IGLVI-38, IFNA6, IGKV1D-27, CLCN6, ENHO, CGAS, ALG1, IL17RE, TNKS1BP1, GCNT2, AARSD1, CIP2A, IGLJ5, ADH1B, ITSN1, IGHJ2P, FN3K, GGACT, IGLJ4, IGHD3-9, IGHV1-2, CAD, IGHV1-12, IGHVII-62-1, IGLV7-43, CD84, CIDEB, CLDN11, AFAP1L1, HYAL1, CCDC15, IGHVII-26-2, AVEN, CDKL2, DMPK, IGHVIII-67-4, CCDC9, IGHVII-33-1, IGLV3-15, IGF1, ICAM4, IGHJ3, IGKV2-38, ANXA2P1, DMGDH, CYTH3, FKBPL, IGHD5-18, CAMKMT, FMC1-LUC7L2, CCDC18, CIT, IGKV2D-19, CPA4, CLEC3A, CTF1, EPB41, ITGAE, GPM6A, MAP3K9, TF, ANO10, CA5BP1, TLR5, EPOR, CLEC4D, EFNA5, IGHV2-26, CCL3L3, IGHVIII-82, CSMD1, IGHVII-74-1, CCL14, MAP2K6, HSPB9, ACSM2B, FAH, CDK11A, INKA1, IGHJ1P, ITGB7, MAPK12, MND1, IGLV3-4, GATA6, SBSPON, HSPE1-MOB4, TNIK, CCDC103, MEIS3, CD8A, CCR4, LDC1P, BARX2, IGHV8-51-1, TNFRSF10D, F8A2, CREB3L4, IGLV3-6, FBLN7, TGIF2LY, MMP7, GATD3A, IGHJ6, MAP3K6, BMS1P2, KANK2, FOXRED1, CISD2, CNFN, CDC42EP5, EMC3-AS1, CXCL9, IGHV1-45, FAR2P2, CCHCR1, FNTB, TNFRSF25, IGHV7-81, IBA57, UBIAD1, CRLF1, IGHV4-39, FCRLA, IKZF4, IFI35, IGSF3, FHL1, ARPIN-AP3S2, HSPA1L, HPSE, FSBP, JAG2, GNGT1, CALCRL, CNIH3, CFI, FHOD1, CDKL3, CLEC4E, TEX55, ELL, IGKV1-6, CACTIN, CD3EAP, CCDC144B, DHRS12, C2orf50, DISP1, ANLN, ASPM, ARPC4-TTLL3, TNFRSF9, ADAL, CCR6, FNDC10, DDO, EDA, FKBP7, CDK1, LARGE1, CCDC28B, MARVELD1, CDK18, CCDC112, BMS1P4, IL27RA, INSL3, TMTC4, CXCL14, CCDC110, CXCR5, ARSK, BATF, CCDC106, FOXJ2, ASNS, IL2RB, GCDH, TNK2, CRIPT, HPX, LIG1, ITPRIPL1, CAMSAP3, IGKV1-16, SPINK1, MAPKBP1, GNB5, FBXO16, CC2D1B, FOXP4, SARM1, EML3, DGKD, H1-3, DHRS4L2, CCDC88B, IMPDH1, EMC10, CNPY4, IGF2R, EMG1, FBXL7, IFNLR1, C22orf46, CCDC134, F8A3, CIB2, PDGFA, TP53AIP1, CDH2, CD160, CDON, MOB3C, FN3KRP, ADAP2, CASK, ASPA, CCL26, AMIGO1, AP1AR, BAX, MOB3B, CD99P1, ACSBG1, TNFSF8, INSIG2, ICOSLG, FADS1, FAT2, FBLN1, ALG14, CX3CR1, ELOVL6, CHAC2, AEN, ABI3, CD86, CH25H, CLDN22, CLCN7, DRD2, AIM2, CNKSR3, MAP4K2, MAP3K20, ASIC1, MIEF2, IRF3, MAP7D3, CYB561D1, CABYR, HELQ, DPP9, CWH43, IGHGP, ANXA8L1, INCENP, TGIF2, CXorf56, MICAL2, JDP2, IGHV1-3, TFAP2A, HYOU1, CCDC149, CDK5R1, IGLV2-18, ITGB6, CLCN2, TMTC1, CYS1, ADTRP, ALS2CL, IFIT1, BST1, DOCK6, IGLV3-19, MASP2, ENDOD1, IGLV2-11, MEN1, GGNBP1, CDK11B, ANTXR2, IL10RA, FGFR1, DDIT4L, MICALL2, GPHN, MAP3K21, DDTL, GCAT, EFNB3, LRGUK, ING5, WTIP, CD163, CPEB2, CUTC, DHRS1, FXYD6, EMILIN2, INPP5K, FITM1, DOK4, CC2D1A, IGKV1D-33, TIRAP, CD99, AMIGO2, FDXR, TAF4B, FRMD6, CCDC77, INGX, TAB1, CABP4, C5AR2, SARS2, INMT-MINDY4, IGKV1-27, FMNL3, ASMTL, ARSB, FOXL2NB, AIMP2, CD80, FRMD3, IGHV3-11, SMURF1, CMTR1, C2CD4B, TGFBR3, CCDC88A, BACE1, CAMKK2, CMYA5, CWC27, HK2, FASTKD3, F8A1, ADH4, FRAT1, HLA-J, ENDOV, GNG4, A1BG, DGCR8, FMO6P, FDX2, DOK1, FKRP, GGH, CNNM2, CLCA2, CEP41, ARG2, CUL9, DAGLB, IGKV2D-29, DKK1, CNTD1, MRGBP, CCT6P3, GNL1, IGLV5-52, CAPN10, IL6R, ALG9, C9orf85, MEIG1, BAALC, ENO2, GGCX, CAMK4, ASPSCR1, MEIS3P1, DACT3, DGAT2, GMPR, CUL7, ALG8, GCSAM, AASS, ALG10, FKTN, AMOTL2, TNFAIP6, IGLV1-44, CNPPD1, IGKV3D-20, CDIP1, CALML3, CDC42EP1, HLA-L, CDKN2C, HELZ2, JRK, CYBRD1, DAB2IP, EXTL3, FMO4, SCAI, GATB, CLDN8, CXCL6, FLAD1, GPKOW, BDKRB2, IRF5, ABT1, ERO1B, CAMK2G, CD4, APOL2, ASF1B, JPH1, FOXQ1, MASTL, DPH6, HIP1, CPA3, ABAT, FPGS, IER5L, ENTR1, ENPP2, TNFSF12, IFRD2, ACP6, LARP1B, DOLPP1, CIDECP1, MMP24, ANXA8, JMJD7, ELOVL1, TNFSF14, IFIT2, TFB1M, EPN1, MRM3, EYS, IGKV1-39, IGLV1-36, INPP4A, FBF1, EPB41L2, CLASP1, GNA12, RBL1, PIK3R2, DMKN, DHCR7, MROH1, CAMTA2, EXT2, HUS1, JMJD6, CKS1B, CLDN9, CD96, GPNMB, DET1, GBP1P1, IL15, FAS, INTS2, DHRS11, FOXK1, ELP6, CD40, CD3E, DHODH, CXCL3, CDH13, BAK1, HIRA, GDAP1, FGFBP1, IL1R2, DHX16, HIRIP3, MAPK7, TP53, CKLF, TAF4, CEP170P1, CAPG, DHX35, CDRT1, HYLS1, ITPKB, FCN1, CSKMT, DPAGT1, INSL6, BAHD1, MMP25, SMAD1, IGLV3-1, IGHV3-48, GGA3, BAG2, ILVBL, IL20RB, CDK5, JSRP1, HSPG2, JRKL, MAP2K7, INF2, EMC1, FMN1, TNFSF4, DAPK3, HSPA13, ADAR, IGHV2-5, ARRB1, TNF, HID1, IDO1, DOCK4, HRH2, INAFM1, DHRS13, C7orf50, DHFR2, CDKAL1, EML6, IL2RG, MICALL1, BMPR1B, CCL16, CD79B, IL17RA, FGFR2, EPB41L5, AIFM2, INPP5A, GCC1, BARD1, FEN1, GNE, CDK5RAP1, AASDH, AMPD2, ANKS6, CD79A, ING3, IGLV1-47, ACP2, CCDC97, NLRP1, IGKV2-28, CLCA4, IL16, CCDC8, TIMP2, TLR4, FN1, CD6, CCDC121, IFITM1, IRF7, DCAF1, CCL4, IFI44, IL6ST, IGSF8, IGKV1D-39, CDK4, DUSP28, TMPRSS3, CCL3, CCDC51, CDS2, ITPRIP, ELF4, CCDC127, CCR1, HLA-DRB5, ILDR1, IRX3, FGFR1OP, IL7, CD14, SLC25A30, HERC1, CDKL1, CCL5, IFT122, C4orf33, MUL1, SLC25A24, HLA-DOA, CDC73, CCDC34, ATP2C1, CDK19, CBX4, WDR86, INTS3, S100A14, MAP2K3, TMEM129, TNFRSF14, PLOD1, IL20RA, SLC16A3, ING2, ILKAP, TMEM128, SAMD9L, ITPRIPL2, FOXK2, TRIM25, CDC27, PI4KA, CLK3, CD2, CEP85L, TP53RK, TBC1D14, CDCA7L, ZNF318, NCBP3, CEP44		gene expression	up	mild COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_mild tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	69	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	UBQLN2, CFAP54, CSTB, C19orf53, PRDX3, EIF2S2, RAB11A, ZFAND5, HNRNPD, UGT2A1, ZNF721, KLF15, EMB, ASTN2, PSMD8, PJA2, IDH3G, RPL11, IRAK1BP1, ZNF440, DAP, DIAPH2, NDUFA4, ORC6, H2AZ1, SON, RAB6A, SEPHS2, EIF3D, HSPB11, TAGLN2, PTP4A2, SLC25A3, B3GNT5, PPDPF, TRIM2, CAST, ANKUB1, COX4I1, CLDN3, HMGN2, LDHA, TMBIM6, EIF5, HSPE1, SLC25A43, CNN3, NDUFA2, RNF11, BHLHE40, ZMYND10, C4orf36, RSPH1, MYL6, KPNA5, SNX3, TAB2, ZNF487, GRHPR, RAB7A, ZFP36L1, RPAP2, CNBP, SMS, NEDD4, ADH7, SNX5, STATH, TUBB4B, SLTM, ATP5F1C, TAF7, SUMO2, SRRM2, CDC16, ATP9B, UFC1, RPS19, AGR2, PICALM, RPL17-C18orf32, ATP5F1E, NSA2, FAM81B, ARGLU1, IFITM2, CFAP206, CHMP5, NBPF9, HLA-DPA1, DMAC2L, SMIM26, MYL12A, ANAPC13, RPL38, SNTN, CIB1, NFKBIA, RPL27A, LAMTOR5, NCOA4, SLC38A2, TRIB1, C12orf65, SOD1, CD164, SERP1, CCN1, RPL37, EIF2S3, SNRPD2, HNRNPA3, CTSS, PUM2, GADD45B, SSU72, MAPK9, FOS, YWHAB, ZNF664, RPL29, FMO3, TACSTD2, SPATA18, NEK10, NDUFB10, CITED2, SPAG6, CCN2, SMDT1, RPL9, TUBB, ARMC3, CALM2, KRT5, NFATC3, PERP, TFF3, ANXA1, VIM, MORF4L1, EZR, TEX101, YBX3, PTBP3, STK17B, MAP1LC3B, EFCAB1, STOML3, BPIFA1, TSPAN19, EEF2, HIPK1, NDUFS5, NAP1L1, RPS10, PRDX5, MBNL1, SULT1B1, PPP1CC, IGFBP2, RPL18, RP1, NFKBIZ, ALMS1, GABARAP, SERPINB3, GNA13, RHOB, TAX1BP1, ZC2HC1A, CEBPD, EIF3H, GNG12, MORN2, SELENOK, VAPA, SET, SRP14, NTS, CETN2, FAM229B, CLN5, RPS25, WDR38, EIF4G2, LRRIQ1, ACTR3, PTRHD1, ATP6V0C, BPIFB1, PDLIM1, PRDX6, TSPAN1, ACTB, TOMM7, SDCBP, ENPP5, RHOA, PFDN5, KLF6, TEX9, TSG101, YBX1, DUSP1, HSPA8, WDR78, GSTA2, ANXA2, MYL12B, ALDH1A1, GNB1, ATOX1, TMC5, RPLP2, CCDC190, UCP2, ADAM32, TMA7, CCDC65, PHB2, PROM1, CCDC170, NRSN1, HLA-DRA, HLA-DPB1, KRT8, HNRNPA2B1, C16orf72, RESF1, CFAP53, PELI1, MUC5AC, DSTN, TRIM69, MS4A1, ARHGAP5, HIPK3, SLC25A36, IFT57, ID2, HNRNPA1, C9orf24, KLF10, C5orf49, PPP1CB, PCSK5, COMMD6, FAM228B, UQCR11, PIFO, RPS12, SLC25A6, FNTA, BORCS7, FAU, KRT17, YWHAZ, CCDC122, EEF1G, HTN1, MUC16, NUCB2, MIF, EIF3E, RAC2, FAM216B, UBB, PAIP2, TBCA, PCBP2, ORC4, C9orf116, UQCRQ, GNAS, GPX4, RPL37A, PPEF2, RPL24, TFPI, TMEM212, MRPS31, RPS7, RPL23, NDUFB2, GSTA1, GNG5, FAM221A, HSP90AB1, LCP1, C11orf88, UBC, RPS20, NFE2L2, LITAF, TIGD1, ST13, RPS4X, NAMPT, BTG1, RPS17, FOXA1, CALM1, IGHG1, SOD2, ARHGDIB, CRIP1, ASB3, RPL34, RPL8, CXCL8, TWF1, RPL10A, CYSTM1, TUBA1A, FAM183A, RPL35, PPP2CB, RPSA, H3-3A, RPL27, EIF3L, RPL5, CXCL17, KIAA1328, RPS6, DYNLL1, EIF1, S100A11, CCNL1, RPS14, RPS28, ZNF91, FTL, C20orf85, WDPCP, EEF1B2, RPL19, RPLP0, RPL31, RPS2, RPS27, MUC4, PPIA, PNRC1, RPL28, RPS27A, ANP32B, ATP5MG, SPA17, RPL18A, RPL7A, ZNF207, FAM241A, HINT1, TPT1, RPL3, EVI2B, CCNI, RPL6, CKB, GAPDH, HSP90AA1, MTRNR2L7, RPL7, BCL2A1, RPL10, RPL15, PLLP, SH3BGRL, RPL4, RPS11, RPS16, RPS18, IGHA1, C12orf75, EEF1A1, RPS5, PCBP1, RPS26, RPS23, RPL12, BTF3, RPL32, RPS15A, RPS15, HLA-DQB1, RPL26, PABPC1, IGFBP7, LAPTM5, RPLP1, RPL13, RPL30, RPL13A, RACK1, RPL36A, MIPOL1, JCHAIN, TBC1D8B, RPL23A, IGKC, FTH1, RPL17, PLCG2, RPS3A, RPS8, CYSLTR1, RPL21, MTRNR2L3, HLA-DQA1, MORC4, HLA-V, RPL41, BLOC1S6, OMG, TMEM45A, MTRNR2L10		gene expression	down	mild COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Control_mild tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	82	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	IGFN1, TP53TG3C, TP53TG3B, C3P1, ITPRID1, CDHR1, FREM1, DAAM2, IGSF22, PDGFRB, IL31RA, PRLR, INSRR, LCT, IGSF9B, ALX4, ITGB3, ALOXE3, TP53TG3D, ITIH2, TFAP2D, FIGN, TLR9, FRMD1, ALPG, IGDCC3, CNTFR, CDH20, AOX1, ALPI, MPL, THBS4, JCAD, BMPER, TGM6, CDC6, PDGFRA, F2, C8B, LBP, FLT4, INSC, ALPP, DDC, ELOVL2, TNFRSF8, CDH5, CDH10, FRMPD4, CLDN14, F11, FSTL3, FKBP10, C7, PITX2, FIGNL2, GDF7, F7, AMHR2, IGLON5, SERPINC1, CDHR2, ELOVL3, ITIH3, THPO, MASP1, EMILIN1, CD70, CDHR5, CDCP2, CDK3, THBS2, CDCA2, CLCNKA, IGSF21, CCL25, DES, CNGB3, CYLC2, MAPK4, TGM5, FRG2C, EGF, FSD1, DAB1, FRMPD3, CDH4, CXCL12, BAAT, IL1RL2, CDH15, CDH19, ALPK2, CXXC1P1, BMP2, TFAP2E, FRZB, MMP28, TNR, HLA-G, ALG1L9P, ACVR1C, IL34, IGF2BP1, CDH22, ITLN1, CDK15, PDGFB, IGF2, TNFSF11, C6, ITIH1, INHBE, NODAL, TGM4, FREM3, FTCDNL1, IL12B, IGSF1, FRMPD1, BMP10, JAKMIP3, ILDR2, SMAD6, CNGB1, EMILIN3, ACVRL1, TGM1, CDH16, KNG1, FLT3, IFITM10, C4A, FSCN2, IL2RA, CLDN19, BMP1, ITIH6, P2RY6, FRG1JP, CDCA7, IL17RD, FOXP3, A1CF, CDH24, IL11, C2CD6, CDH18, FRMD5, INSYN2A, FRG1BP, ALOX12, JAKMIP2, SERPIND1, TNFSF15, MAPK11, MMP21, FKBP9P1, P2RY8, INCA1, INHBA, EMX2, INAFM2, IHH, INHBC, CDCA5, TNIP3, FOXO3B, MMP2, FST, LEP, CDH6, CDH7, BCRP2, IL36RN, TGM3, IL11RA, TSLP, IL23R, CNGA3, BMP6, F13A1, IL19, TGFB1I1, FLG2, CCL22, ITIH4, ITGBL1, CYSLTR2, F12, IL1RL1, JAKMIP1, IMPG2, BMP8B, TNFSF9, FSCN3, ALOX15B, EMCN, DDIAS, IL15RA, BMS1P17, IGFL2, JAM3, IL1A, IGSF11, CDH9, SERPINF2, INSL4, GFAP, IGFBPL1, IGSF5, C1R, FLNC, DGCR5, BMP8A, CDK2, PROC, FPGT-TNNI3K, FSD2, GDF6, INSYN1, CLCNKB, MAP3K15, DGKB, CCL3L1, CLDN15, FRRS1, CYGB, IGF2BP3, FILIP1L, JAM2, ELP4, IL3RA, PROCR, DDR2, SERPINE1, ZYG11A, TGFB3, ITPR1, ACE2, IL17RB, IL22RA1, IGSF9, F2RL2, ELOVL7, FDXACB1, LARGE2, FASLG, MAP7D2, IFIH1, LANCL3, PLG, ITIH5, CSF1, TNIK, IL21R, IL12RB2, CNIH2, C1S, IL18BP, BMP7, IGHMBP2, IL12RB1, CCL2, TNK1, FSTL4, FER1L4, C2, ACVR2B, FRS3, CDH17, CDH12, C5, FOXRED2, DIO1, GDF9, VWF, CDCA3, SPP1, F8, CCR7, FKBP6, ITGAM, FRRS1L, FRG1HP, LEPR, CDH11, CDH8, FTH1P3, CLCF1, IL18R1, SOCS7, FRMPD2B, ITPRIPL1, C4B, DGAT1, CLCN5, MAP3K7CL, TNFRSF11A, HLA-DOB, F5, GDF11, EML5, RELT, FIGNL1, CXCL9, BCS1L, FREM2, CNIH3, CLCN6, LIG1, MYC, FER1L5, FLRT2, FRMD4A, IGFL4, LIF, CDK1, CCR5, MAP3K9, ALPK3, ITSN1, IKBKE, CSF1R, HLA-L, FRY, FLT1, PDGFA, MAP3K6, EMC3-AS1, TMTC4, FRAS1, DERL3, CTF1, TGFB2, CLCN4, CYTH3, CSF2RA, IL27RA, CDK5R1, TNFRSF25, A1BG, FOXRED1, TIRAP, TLR5, DAB2, IL17RE, TNFRSF9, IGF1, JDP2, IL1R2, EML3, TP53AIP1, JAG2, ITGB7, FKBP2, TNFRSF10D, IFNLR1, TF, IKZF4, CLCN7, ING5, EDA, MAP2K6, LARGE1, UBIAD1, FDXR, HELQ, CYB561D1, CFI, SMAD7, CLCN2, TNK2, ELOVL6, CDK18, FOXO4, INCENP, MAP3K20, TNKS1BP1, IKBKG, EMC10, INSIG2, FOXP4, TAB1, IMPDH1, MAP4K2, IGSF3, C5AR2, IL2RB, MAPK7, IRF3, ITGB6, INF2, TFAP2A, DAB2IP, IL17RA, RBL1, FKTN, IL10RA, EMG1, IL20RB, LARP1B, ILVBL, IGF2R, IL6R, IRF7, FKRP, FLAD1, ITPKB, ALS2CL, TGFBR3, CDK11B, EMC1, TMTC1, TLR4, JMJD6, ENDOD1, DET1, PIK3R2, BMPR1B, ELOVL1, TP53, IRF5, TFB1M, FPGS, MAP2K7, BACE1, SMURF1, IL16, CD40, DGCR8, HELZ2, NLRP1, SMAD1, HERC1, ITPRIPL2		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Common_Positively regulated tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	82	nasopharyngeal epithelial cells		shotgun transcriptome sequencing; DEG	VAPA, GNAS, SUMO2, GNB1, PCBP2, ZNF664, CCDC170, SRP14, HIPK3, YWHAB, DSTN, CALM2, PFDN5, RPL23, PDLIM1, HNRNPA1, YBX1, RPL11, MYL6, PPP1CB, PRDX6, HLA-DRA, PNRC1, PIFO, MTRNR2L3, PPIA, EIF1, RPS16, C11orf88, FOXA1, RPL37A, SNX3, CCNI, RPL34, SPA17, RPS25, YWHAZ, RPL31, HSP90AB1, TUBA1A, HINT1, RPL18A, NFE2L2, RPL18, PRDX5, RPL5, TPT1, ACTB, FTH1, PLCG2, EEF1B2, ZNF207, PABPC1, CALM1, MIPOL1, RPL15, EEF2, PPP2CB, RPS14, RHOA, SH3BGRL, DYNLL1, OMG, H3-3A, RPS4X, RPS27A, FAM216B, RPS15, ZNF91, GPX4, ST13, PCBP1, FTL, RPL36A, CETN2, RPL4, RPL6, RPS15A, IGFBP7, RPS20, RPL12, RPS23, RPS12, BTF3, RPL10A, RPL32, S100A11, RPLP2, HSPA8, LAPTM5, RPL13, UBB, RPL8, HSP90AA1, RPSA, RPS6, UBC, HLA-DQA1, RPS17, RPL19, RPS2, RPL3, GAPDH, RPL27, RPLP0, RPL23A, RPL7A, RPLP1, RPS11, RPL30, GSTA1, RPL10, TMEM45A, RPL17, RPL35, RPS3A, RPL26, BLOC1S6, RPL13A, RPL21, RACK1, FAU, RPS8, EEF1A1, IGKC, RPS27, RPS18, C20orf85, RPL41		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Data 2: Common_Negatively regulated tab	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	69	nasopharyngeal epithelial cells		DEG; single cell transcriptomic analysis of BALF in severe COVID-19 patients (another study)	RPL41, CALM1, RACK1, TMEM45A, EEF1A1, EIF1, CALM2		gene expression	down	mild COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	69	nasopharyngeal epithelial cells		DEG; single cell transcriptomic analysis of BALF in severe COVID-19 patients (another study)	IFI44, INF2, IFIT1, CXCL9, CCL2, TNFSF9, IFI6, OTOG, IFNL1, ACE2, OTOA, C4A, CCL5		gene expression	up	mild COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	49	nasopharyngeal epithelial cells		DEG; single cell transcriptomic analysis of BALF in severe COVID-19 patients (another study)	RPL41, CALM1, RPL21, RACK1, TMEM45A, TUBA1A, SLC25A6, RPS8		gene expression	down	moderate COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Fig 2d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	49	nasopharyngeal epithelial cells		DEG; single cell transcriptomic analysis of BALF in severe COVID-19 patients (another study)	IFI44, INF2, CCL2, TNFSF9, TNFSF11, IFNL1, ACE2, IL10, IFNL4, IFIH1		gene expression	up	moderate COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Fig 2d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	35	nasopharyngeal epithelial cells		DEG; single cell transcriptomic analysis of BALF in severe COVID-19 patients (another study)	RPL41, CALM1, MYL6, RHOA, EEF1A1, RPS27, EZR		gene expression	down	severe COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Fig 2e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Dubai, UAE	3	70	years	35	nasopharyngeal epithelial cells		DEG; single cell transcriptomic analysis of BALF in severe COVID-19 patients (another study)	INF2, IFIH1, CXCL9, IFIT5, ACE2, TGFB2, C4A, C7, C5, CDC6, TNFSF8, CD5		gene expression	up	severe COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33425248	(2020-12-17)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/	Suppl Fig 2e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773686/#s0080title		
	Amani	Simranpreet		Wuxi, China	25	61	years	55	lung; bronchoalveolar lavage fluids (BALF)		MCPcounter; Odds Ratio (OR)	neutrophil; white blood cell; neutrophils:lymphocytes (NLR)		cell type frequency	up	severe COVID-19 patients vs mild & moderate COVID-19 patients 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Table 2; 3rd paragraph under Results section "Characteristics of..."	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/table/T2/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title	-ratio of neutrophils to lymphocytes "Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE 93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	55	lung; bronchoalveolar lavage fluids (BALF)		MCPcounter; Odds Ratio (OR)	monocytes; lymphocytes; monocytes:lymphocytes (MLR)		cell type frequency	down	severe COVID-19 patients vs mild & moderate COVID-19 patients 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Table 2; 3rd paragraph under Results section "Characteristics of..."	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/table/T2/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title	-ratio of neutrophils to lymphocytes "Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE 93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	55	lung; bronchoalveolar lavage fluids (BALF)		MCPcounter; Odds Ratio (OR)	C-reactive protein (CRP), AST, total bilirubin, creatine kinase MB, blood urea nitrogen, serum creatinine, D-dimer, fibrinogen, Thrombin time (TT)		protein/cytokine levels	up	severe COVID-19 patients vs mild & moderate COVID-19 patients 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Table 2; 3rd paragraph under Results section "Characteristics of..."	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/table/T2/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	55	lung; bronchoalveolar lavage fluids (BALF)		MCPcounter; Odds Ratio (OR)	ALT, serum albumin, serum potassium, serum sodium, APTT		protein/cytokine levels	down	severe COVID-19 patients vs mild & moderate COVID-19 patients 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Table 2; 3rd paragraph under Results section "Characteristics of..."	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/table/T2/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	8	peripheral blood		MCPcounter; PCA	C-reactive protein (CRP), fibrinogen (FIB)		protein/cytokine levels	positively associated	higher levels associated with increased COVID-19 severity				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	1st paragraph in Results section "Principal Component Analysis..."; Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F2/ 	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	8	peripheral blood		MCPcounter; PCA	neutrophil; neutrophil:lymphocyte (NLR)		cell type frequency	positively associated	higher levels associated with increased COVID-19 severity				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	1st paragraph in Results section "Principal Component Analysis..."; Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F2/ 	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	8	peripheral blood		MCPcounter; PCA	lymphocyte		cell type frequency	negatively associated	lower levels associated with increased COVID-19 severity				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	1st paragraph in Results section "Principal Component Analysis..."; Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F2/ 	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	6	peripheral blood		MCPcounter; dynamic changes	neutrophils		cell type frequency	up	7-9 days vs 0 days	time since symptom onset	7 to 9	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	2nd paragraph in Results section "Principal Component Analysis..."; Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F2/ 	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	53	peripheral blood		MCPcounter; dynamic changes	neutrophils		cell type frequency	up	severe COVID-19 patients vs mild & moderate COVID-19 patients 	time since symptom onset	7 to 9	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	2nd paragraph in Results section "Principal Component Analysis..."; Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F2/ 	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	55	peripheral blood		MCPcounter; dynamic changes	monocytes; lymphocytes		cell type frequency	down	19-27 days vs 0 days	time since symptom onset	19 to 27	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	2nd paragraph in Results section "Principal Component Analysis..."; Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F2/ 	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China	25	61	years	55	peripheral blood		MCPcounter; dynamic changes	monocytes; lymphocytes		cell type frequency	down	severe COVID-19 patients vs mild & moderate COVID-19 patients 	time since symptom onset	19 to 27	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	2nd paragraph in Results section "Principal Component Analysis..."; Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/#s3title ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F2/ 	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung neutrophils		RNA-seq; MCPcounter	FCGR3B, CEACAM3, PI3, PROK2, CSF3R, FPR1, CLEC7A, SLC26A8, ALPL, CXCR2, DOCK5, SLC25A37, CXCR1, STEAP4, BEST1, REPS2, BTNL8, ARHGAP26, LRG1, SLC12A6, VNN3, CMTM2, IRAK3, KCNJ15, NPL, ORM1, PLXNC1		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung neutrophils		RNA-seq; MCPcounter	KIF13A, PLIN5, TECPR2, LRRC4, TNFRSF10C, NFE4, SKAP2, DGAT2, PHOSPHO1, MEGF9, SLC19A1, DHX34, ABHD5, TLE3, NHSL2, NATD1, PISD, ABTB1, C4A		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF neutrophils		RNA-seq; MCPcounter	FCGR3B, CEACAM3, PI3, PROK2, CSF3R, SLC26A8, ALPL, CXCR2, DOCK5, SLC25A37, CXCR1, STEAP4, BEST1, REPS2, BTNL8, ARHGAP26, VNN3, CMTM2, IRAK3, KCNJ15, NPL, ORM1, PLXNC1, KIF13A, PLIN5, LRRC4, TNFRSF10C, NFE4, NHSL2		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF neutrophils		RNA-seq; MCPcounter	FPR1, CLEC7A, LRG1, SLC12A6, TECPR2, SKAP2, DGAT2, PHOSPHO1, MEGF9, SLC19A1, DHX34, ABHD5, TLE3, NATD1, PISD, ABTB1, C4A		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung T cells		RNA-seq; MCPcounter	FTL3LG, SIRPG, CTLA4, CD6, CD3G, THEMIS, TNFRSF25, CD3D, CD8B, CD5, CD28, PBX4, MAL		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF T cells		RNA-seq; MCPcounter	SIRPG, CTLA4, CD3G, THEMIS, MAL		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF T cells		RNA-seq; MCPcounter	FTL3LG, CD6, TNFRSF25, CD3D, CD8B, CD5, CD28, PBX4		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung monocytic lineage		RNA-seq; MCPcounter	WFDC21P, TFEC, PLA2G7, KYNU, CSF1R		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung monocytic lineage		RNA-seq; MCPcounter	CLIC2, CLEC10, RASSF4, FPR3, ADAP2		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF monocytic lineage		RNA-seq; MCPcounter	WFDC21P, CLIC2, CLEC10, TFEC, PLA2G7, CSF1R, FPR3, ADAP2		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF monocytic lineage		RNA-seq; MCPcounter	KYNU, RASSF4		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung B lineage		RNA-seq; MCPcounter	STAP1, IGLC1, FCRLA, CD79A, FCRL1, RALGPS2		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung B lineage		RNA-seq; MCPcounter	SNX29P1, CD79B, CD22, IGHA1, IGHG1, SNX22, IGLL5, FCRL2, IGLV4-60, FCRL3, DTX1, EBF1, IGLJ3, FCRL5, BANK1, IGKV1-17, IGHD, IGHM		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF B lineage		RNA-seq; MCPcounter	STAP1, IGLC1, CD79A, RALGPS2, IGHA1, IGHG1, IGLL5, IGLV4-60, FCRL3, EBF1, FCRL5, BANK1, IGKV1-17, IGHM		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF B lineage		RNA-seq; MCPcounter	FCRLA, FCRL1, SNX29P1, CD79B, CD22, SNX22, FCRL2, DTX1, IGHD		gene expression	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung		RNA-seq; MCPcounter score	cytotoxic lymphocytes; monocytic lineage; myeloid dendritic cells; neutrophils		cell type frequency	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & GEO database	25	61	years	4	lung		RNA-seq; MCPcounter score	T cells; CD8 T cells; NK cells; B lineage		cell type frequency	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF		RNA-seq; MCPcounter score	cytotoxic lymphocytes; B lineage; monocytic lineage; myeloid dendritic cells; neutrophils		cell type frequency	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China & NCBI SRA database	25	61	years	5	BALF		RNA-seq; MCPcounter score	T cells; CD8 T cells		cell type frequency	down	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F4/	"Mild, moderate, and severe cases were defined by...: (1) epidemiological history, (2) fever or other respiratory symptoms, (3) frequency of typical CT image abnormalities of viral pneumonia, and (4) positive RT-PCR result for SARS-CoV-2 RNA...mild cases...no typical CT image abnormality of viral pneumonia (#3 above)...severe patients also met at least one of the following conditions: (1) shortness of breath, respiratory rate (RR) GTE 30 times/min, (2) oxygen saturation (resting state) LTE  93%, or (3) PaO2/FiO2 LTE 300 mm Hg."	
	Amani	Simranpreet		Wuxi, China; GEO & NCBI SRA databases	25	61	years	9	lung; BALF		DEGs; difference in Spearman's correlations	ERLIN2, C1QC, P2RY13, PTMS, PILRA, HCK, CLEC4E, SPI1, MPV17, TREM1, TPP1, SIGLEC14, RNF149, CTSC, CSF2RB, CLEC4A, CEACAM3, CD74, CD164, TRGC1, TRGC2, TNFSF13B, NAGK, LCP1, IL2RG, GCA, CXCL16, CD37, ALOX5AP, STAP1, SERPINA1, RAC2, OAS1, LGALS9, FPR1, CD53, BCAP31, SAMD9, NCF2, EIF2AK2, SH2BGRL3, S100A8, RAB1B, MX2, CTSZ, C1QB, BCL2A1, OAZ1, CD81, STAG2, SIAE, ADA2, ABCB8, STAT1, SAMD9L, FAM161B, ALG12, PSTPIP2, THBD, LCP2, SLAMF7, PLEC, CXCL10, LMNA, IFIH1, CEACAM1, INO80B, ADGRL1, SAMSN1, RPS2P5, GON4L, GBP1P1, CCDC71L, MC1R, TUFM, ST6GALNAC6, S100P, RIPOR2, ITPRIP, IRF9, HNRNPA1, DEPP1, COX6B1, CCL4L2		gene expression	up	COVID-19 patients vs healthy 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33013872	(2020-08-18)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461898/figure/F5/	"(A) The 15 annotated genes of neutrophils activation were calculated the average expression of every single samples as neutrophils activation score, and the correlation of the score with overlapped 1,363 differently expressed genes both in COVID-19 and Healthy control were analyzed. The selected 84 genes were ranked based on delta-R (R1-R2, R1 from COVID-19 patients, R2 from healthy control)."	
	Amani	Simranpreet		Groups A & B in Martin City, Slovakia	45	94	years	13	blood		flow cytometry; absolute counts	lymphocytes		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group B (severe COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 3.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f3/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen); Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)"	
	Amani	Simranpreet		Groups A & C in Martin City, Slovakia	50	94	years	6	blood		flow cytometry; absolute counts	lymphocytes		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group C (critically ill ICU COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 3.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f3/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups A & D in Martin City, Slovakia	50	94	years	7	blood		flow cytometry; absolute counts	lymphocytes		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group D (deceased COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 3.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f3/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group D: deceased COVID-19 patients	
	Amani, edited post-spot check	Simranpreet		Groups B & C in Martin City, Slovakia	45	94	years	14	blood		flow cytometry; absolute counts	lymphocytes		cell type frequency	up	Group B (severe COVID-19 patients) vs Group D (deceased ICU COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 3.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f3/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Groups A & C in Martin City, Slovakia	50	94	years	6	blood		flow cytometry; absolute counts	lowest lymphocytes (most severe lymphopenia)		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group C (critically ill ICU COVID-19 patients)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 4.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f4/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups A & D in Martin City, Slovakia	50	94	years	7	blood		flow cytometry; absolute counts	lowest lymphocytes (most severe lymphopenia)		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group D (deceased COVID-19 patients)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 4.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f4/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Groups B & C in Martin City, Slovakia	45	89	years	13	blood		flow cytometry; absolute counts	lowest lymphocytes (most severe lymphopenia)		cell type frequency	up	Group B (severe COVID-19 patients) vs Group C (critically ill ICU COVID-19 patients)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 4.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f4/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups B & D in Martin City, Slovakia	45	94	years	14	blood		flow cytometry; absolute counts	lowest lymphocytes (most severe lymphopenia)		cell type frequency	up	Group B (severe COVID-19 patients) vs Group D (deceased COVID-19 patients)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 4.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f4/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups A & B in Martin City, Slovakia	45	94	years	13	blood		flow cytometry; absolute counts	neutrophil:lymphocyte (NLR)		cell type frequency	down	Group A (mild & moderate COVID-19 patients) vs Group B (severe COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f5/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen); Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)"	
	Amani	Simranpreet		Groups A & C in Martin City, Slovakia	50	94	years	6	blood		flow cytometry; absolute counts	neutrophil:lymphocyte (NLR)		cell type frequency	down	Group A (mild & moderate COVID-19 patients) vs Group C (critically ill ICU COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f5/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups A & D in Martin City, Slovakia	50	94	years	7	blood		flow cytometry; absolute counts	neutrophil:lymphocyte (NLR)		cell type frequency	down	Group A (mild & moderate COVID-19 patients) vs Group D (deceased COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f5/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Groups B & C in Martin City, Slovakia	45	89	years	13	blood		flow cytometry; absolute counts	neutrophil:lymphocyte (NLR)		cell type frequency	down	Group B (severe COVID-19 patients) vs Group C (critically ill ICU COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f5/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups B & D in Martin City, Slovakia	45	94	years	14	blood		flow cytometry; absolute counts	neutrophil:lymphocyte (NLR)		cell type frequency	down	Group B (severe COVID-19 patients) vs Group D (deceased COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f5/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Groups A & B in Martin City, Slovakia	45	94	years	13	lymphocytes		flow cytometry; absolute counts	CD3+ cells; CD3+ CD8+ cells		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group B (severe COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 6A & 6C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f6/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen); Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)"	
	Amani	Simranpreet		Groups A & C in Martin City, Slovakia	50	94	years	6	lymphocytes		flow cytometry; absolute counts	CD3+ cells; CD3+ CD8+ cells; CD19+ cells		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group C (critically ill ICU COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 6A & 6C-D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f6/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups A & D in Martin City, Slovakia	50	94	years	7	lymphocytes		flow cytometry; absolute counts	CD3+ cells; CD3+ CD4+ cells; CD3+ CD8+ cells; CD19+ cells		cell type frequency	up	Group A (mild & moderate COVID-19 patients) vs Group D (deceased COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 6	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f6/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Groups B & C in Martin City, Slovakia	45	89	years	13	lymphocytes		flow cytometry; absolute counts	CD3+ cells; CD3+ CD8+ cells; CD19+ cells		cell type frequency	up	Group B (severe COVID-19 patients) vs Group C (critically ill ICU COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 6A & 6C-D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f6/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Groups B & D in Martin City, Slovakia	45	94	years	14	lymphocytes		flow cytometry; absolute counts	CD3+ cells; CD3+ CD8+ cells; CD19+ cells		cell type frequency	up	Group B (severe COVID-19 patients) vs Group D (deceased COVID-19 patients)	time of hospital admission 			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 6A & 6C-D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f6/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Groups B & C in Martin City, Slovakia	45	89	years	13	lymphocytes		flow cytometry; absolute counts	CD3+ cells; CD3+ CD4+ cells		cell type frequency	up	Groups B + C (symptomatic surviving patients): recovery vs admission				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f7/	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Martin City, Slovakia	45	94	years	20	lymphocytes		flow cytometry; absolute counts	PD-1+ CD3+ CD4+ cells; PD-1+ CD3+ CD8+ cells		cell type frequency	up	Group D (non-survivors) vs Groups A + B + C (survivors)	time at hospital admission			SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 8A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f8/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)...Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C: "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Groups B & C in Martin City, Slovakia	45	89	years	13	lymphocytes		flow cytometry; absolute counts	Tim-3+ CD3+ CD4+ cells; Tim-3+ CD3+ CD8+ cells; CD38+ CD3+ CD8+ cells		cell type frequency	down	Groups B + C (symptomatic surviving patients): recovery vs admission				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 9; Fig 10C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f9/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f10/ 	"Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO"	
	Amani	Simranpreet		Martin City, Slovakia	45	94	years	20	lymphocytes		flow cytometry; absolute counts	CD38+ HLA-DR+ CD3+ CD8+ cells		cell type frequency	down	Group D (non-survivors) vs Groups A + B + C (survivors)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 10B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f10/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)...Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C: "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO" Group D: deceased COVID-19 patients	
	Amani	Simranpreet		Martin City, Slovakia	45	94	years	20	lymphocytes		flow cytometry; absolute counts	CD38+ CD3+ CD8+ cells		cell type frequency	up	Group D (non-survivors) vs Groups A + B + C (survivors)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33937096	(2021-04-15)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/	Fig 10A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082075/figure/f10/	"Group A (including asymptomatic patients or patients with mild/moderate symptoms, who were hospitalized for another reason than COVID-19, did not have signs of pneumonia on chest X-ray and did not require supplementation of oxygen)...Group B (including patients with severe symptoms, signs of bilateral pneumonia on chest X-ray and/or SpO2 below 93% on room air, thus requiring supplementation of oxygen)" Group C: "critically ill patients requiring intensive care unit stay and either invasive ventilation or non-invasive ventilation support or HFNO" Group D: deceased COVID-19 patients	
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		spectral flow cytometry; quantification of general immune cell populations	CD45+ T cells		cell type frequency	up	Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		spectral flow cytometry; quantification of general immune cell populations	CD45+ monocytes		cell type frequency	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		spectral flow cytometry; quantification of general immune cell populations	CD45+ B cells		cell type frequency	down	ICU COVID-19 patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's PBMCs	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		spectral flow cytometry; quantification of general immune cell populations	CD45+ conventional dendritic cells (cDC)		cell type frequency	up	ICU COVID-19 patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's PBMCs	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	monocytes		spectral flow cytometry; quantification of general immune cell populations	intermediate monocytes		cell type frequency	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	classical monocytes; alternative monocytes; conventional dendritic cells 1 (cDC1); conventional dendritic cells 2 (cDC2); plasmacytoid dendritic cells (pDC)		spectral flow cytometry; MFI	HLA-DR		protein/cytokine levels	down	ICU COVID-19 Patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's PBMCs	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1H-I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	classical monocytes; intermediate monocytes; plasmacytoid dendritic cells (pDC)		spectral flow cytometry; MFI	HLA-DR		protein/cytokine levels	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1H-I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	plasma		spectral flow cytometry; Human Magnetic Luminex Assay	IL-6, IP-10, MCP-1, IL-10		protein/cytokine levels	up	ICU COVID-19 Patients' Plasma vs Healthy's plasma	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1J (left side of bottom row)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; Human Magnetic Luminex Assay	IL-6, IP-10, MCP-1, IL-10		protein/cytokine levels	up	ICU COVID-19 Patients' Plasma vs Healthy's plasma	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1J (left side of bottom row)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	plasma; Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; Human Magnetic Luminex Assay	IL-6, MCP-1, IL-10		protein/cytokine levels	up	ICU COVID-19 Patients: BALF vs plasma	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1J (left side of bottom row)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	plasma		spectral flow cytometry; ELISA	IFN-alpha; Anti-N IgG; Anti-RBD IgG		antibody response	up	ICU COVID-19 Patients' Plasma vs Healthy's plasma	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 1K (right side of bottom row)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F1/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		spectral flow cytometry; T cell phenotyping	naive (CD45RA+ CD27+ CD28+ CD95-) CD4+ T cells; effector memory Ra+ (TEMRA) (CD45RA- CD27+ CD28+ CCR7-) CD4+ T cells		cell type frequency	down	ICU COVID-19 Patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's PBMCs	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		spectral flow cytometry; T cell phenotyping	CD4+ T regulatory cells (Tregs) (CD25+ CD127-); effector memory-4 (EM4) (CD45RA- CD27- CD28- CCR7-) CD4+ T cells; effector memory-3 (EM3) (CD45RA- CD27- CD28+ CCR7-) CD4+ T cells; effector memory-2 (EM2) (CD45RA- CD27- CD28+ CCR7+) CD4+ T cells; effector memory-1 (EM1) (CD45RA- CD27+ CD28+ CCR7-) CD4+ T cells		cell type frequency	up	ICU COVID-19 Patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's PBMCs	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; T cell phenotyping	effector memory-4 (EM4) (CD45RA- CD27- CD28- CCR7-) CD4+ T cells; effector memory-3 (EM3) (CD45RA- CD27- CD28+ CCR7-) CD4+ T cells; effector memory-2 (EM2) (CD45RA- CD27- CD28+ CCR7+) CD4+ T cells		cell type frequency	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid (BALF)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; T cell phenotyping	naive (CD45RA+ CD27+ CD28+ CD95-) CD4+ T cells; effector memory Ra+ (TEMRA) (CD45RA- CD27+ CD28+ CCR7-) CD4+ T cells; central memory (CM) (CD45RA- CD27+ CD28+ CCR7+) CD4+ T cells; Stem cell-like memory (SCM) (CD45RA+ CD27+ CD28+ CD95+) CD4+ T cells; effector memory-1 (EM1) (CD45RA- CD27+ CD28+ CCR7-) CD4+ T cells		cell type frequency	up	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid (BALF)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		spectral flow cytometry	HLA-DR+ CD38+ effector memory-4 (EM4) (CD45RA- CD27- CD28- CCR7-) CD4+ T cells		cell activation state	up	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		spectral flow cytometry	HLA-DR+ CD38+ central memory (CM) (CD45RA- CD27+ CD28+ CCR7+) CD4+ T cells		cell activation state	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		spectral flow cytometry	HLA-DR+ CD38+ CD8+ T cells		cell activation state	up	ICU COVID-19 Patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's Peripheral Blood Mononuclear Cells (PBMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		spectral flow cytometry	HLA-DR+ CD38+ CD8+ T cells		cell activation state	up	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	activated (HLA-DR+ CD38+) CD4 T cells		spectral flow cytometry; Human Magnetic Luminex Assay	PD-1		protein/cytokine levels	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	activated (HLA-DR+ CD38+) CD8 T cells		spectral flow cytometry; Human Magnetic Luminex Assay	PD-1		protein/cytokine levels	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	plasma; Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; Human Magnetic Luminex Assay	IL-2, Granzyme B, TRAIL		protein/cytokine levels	down	ICU COVID-19 Patients: Plasma vs Bronchoalveolar Lavage Fluid (BALF)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2K-L & 2O	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	plasma; Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; Human Magnetic Luminex Assay	PD-L1		protein/cytokine levels	up	ICU COVID-19 Patients: Plasma vs Bronchoalveolar Lavage Fluid (BALF)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2N	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	plasma		spectral flow cytometry; Human Magnetic Luminex Assay	IL-2, Granzyme B, PD-L1, IL-7		protein/cytokine levels	up	ICU COVID-19 Patients' Plasma vs Healthy's plasma	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2K-N	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	plasma		spectral flow cytometry; Human Magnetic Luminex Assay	TRAIL		protein/cytokine levels	down	ICU COVID-19 Patients' Plasma vs Healthy's plasma	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2O	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; Human Magnetic Luminex Assay	Granzyme B, IL-2, IL-7, PD-L1, TRAIL		protein/cytokine levels	up	ICU COVID-19 Patients' Plasma vs Healthy's plasma	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2K-O	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		spectral flow cytometry; T cell phenotyping	naive (CD45RA+ CD27+ CD28+ CD95-) CD8+ T cells; Stem cell-like memory (SCM) (CD45RA+ CD27+ CD28+ CD95+) CD8+ T cells; central memory (CM) (CD45RA- CD27+ CD28+ CCR7+) CD8+ T cells		cell type frequency	down	ICU COVID-19 Patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's PBMCs	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Males in Amsterdam, The Netherlands	48.7	76.9	years	27	Peripheral Blood Mononuclear Cells (PBMCs)		spectral flow cytometry; T cell phenotyping	effector memory-4 (EM4) (CD45RA- CD27- CD28- CCR7-) CD8+ T cells; effector memory-3 (EM3) (CD45RA- CD27- CD28+ CCR7-) CD8+ T cells; effector memory-1 (EM1) (CD45RA- CD27+ CD28+ CCR7-) CD8+ T cells; effector memory Ra+ (TEMRA) (CD45RA- CD27+ CD28+ CCR7-) CD8+ T cells		cell type frequency	up	ICU COVID-19 Patients' Peripheral Blood Mononuclear Cells (PBMCs) vs Healthy's PBMCs	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; T cell phenotyping	effector memory-4 (EM4) (CD45RA- CD27- CD28- CCR7-) CD8+ T cells; effector memory-2 (EM2) (CD45RA- CD27- CD28+ CCR7+) CD8+ T cells		cell type frequency	down	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid (BALF)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs); Bronchoalveolar Lavage Fluid (BALF)		spectral flow cytometry; T cell phenotyping	naive (CD45RA+ CD27+ CD28+ CD95-) CD8+ T cells; effector memory Ra+ (TEMRA) (CD45RA- CD27+ CD28+ CCR7-) CD8+ T cells; central memory (CM) (CD45RA- CD27+ CD28+ CCR7+) CD8+ T cells; Stem cell-like memory (SCM) (CD45RA+ CD27+ CD28+ CD95+) CD8+ T cells; effector memory-1 (EM1) (CD45RA- CD27+ CD28+ CCR7-) CD8+ T cells		cell type frequency	up	ICU COVID-19 Patients: Peripheral Blood Mononuclear Cells (PBMCs) vs Bronchoalveolar Lavage Fluid (BALF)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F2/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Bronchoalveolar Lavage Fluid (BALF)		manual gating; Spearman correlation	CD4/8 ratio		cell type frequency	positively correlated	correlated with CD4/8 ratio in Peripheral Blood Mononuclear Cells (PBMCs)	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F3/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	CD4 Central Memory (CD45RA- CD27+ CD28+ CCR7+) Peripheral Blood Mononuclear Cells (PBMCs)		manual gating; Spearman correlation	CD4 (CD45RA- CD27+ CD28+ CCR7+) central memory T cells		cell activation state	positively correlated	correlated with alphabeta T cells (percent (%) of total Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs))	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F3/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	CD4 Central Memory (CD45RA- CD27+ CD28+ CCR7+) Peripheral Blood Mononuclear Cells (PBMCs)		manual gating; Spearman correlation	CD4 (CD45RA- CD27+ CD28+ CCR7+) central memory T cells		cell activation state	negatively correlated	correlated with monocyte-like cells (Mo-MQs: Monocyte-like Macrophage) (percent (%) of total Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs))	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F3/		
	Amani: have not curated Fig 3B			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	CD4 T cells Peripheral Blood Mononuclear Cells (PBMCs)		manual gating; Spearman correlation	T regulatory (Tregs) (CD25+ CD127-) cells		cell type frequency	negatively correlated	correlated with DN T cells (Double Negative) (percent (%) of T cells Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs))	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F3/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry; omiq unsupervised clustering	CD4 effector memory-1 (EM1) (CD45RA- CD27+ CD28+ CCR7-) cells		cell activation state	down	COVID-19 Patients' with ICU stay of >14 days vs COVID-19 patients' with ICU stay of =<14 days	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F4/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		flow cytometry; omiq unsupervised clustering	CD4 effector memory-3 (EM3) (CD45RA- CD27- CD28+ CCR7-) cells; CD8 effector memory-4 (EM4) (CD45RA- CD27- CD28- CCR7-) cells; CD8 effector memory Ra+ (TEMRA) (CD45RA- CD27+ CD28+ CCR7-) cells		cell activation state	down	COVID-19 Patients' with ICU stay of >14 days vs COVID-19 patients' with ICU stay of =<14 days	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F4/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs)		flow cytometry; omiq unsupervised clustering	correlated with alphabeta T cells (percent (%) of total Bronchoalveolar Lavage Fluid Mononuclear Cells (BALFMCs))		cell type frequency	down	COVID-19 Patients' with ICU stay of >14 days vs COVID-19 patients' with ICU stay of =<14 days	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F4/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	plasma		flow cytometry; Human Magnetic Luminex Assay	IP-10, IL-10		protein/cytokine levels	down	COVID-19 Patients' with ICU stay of >14 days vs COVID-19 patients' with ICU stay of <14 days	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 4E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F4/		
	Amani			Almost All Male ICU COVID-19 patients in Amsterdam, The Netherlands	53.73	73.51	years	17	Peripheral Blood Mononuclear Cells (PBMCs)		flow cytometry; omiq unsupervised clustering	CD4 effector memory-3 (EM3) (CD45RA- CD27- CD28+ CCR7-) cells; CD8 effector memory-4 (EM4) (CD45RA- CD27- CD28- CCR7-) cells; CD8 effector memory Ra+ (TEMRA) (CD45RA- CD27+ CD28+ CCR7-) cells		cell activation state	up	non-survivors vs survivors	time after ICU admission	1 to 31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33846275	(2021-03-28)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/	Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050882/figure/F5/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	12	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein or IAV PR8	TNF-alpha+ CD4+ T cells		cell type frequency	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	none	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig01/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein or IAV PR8	IL-2+ CD4+ T cells		cell type frequency	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	none	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig01/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	10	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein	IL-2+ CD4+ effector T cells		cell type frequency	up	ex vivo stimulation with 5g/mL vs 0g/mL of SARS-CoV-2 spike protein; ex vivo stimulation with 1g/mL vs 0g/mL of SARS-CoV-2 spike protein	none	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Suppl Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/#DC1		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	12 (SARS-CoV-2 spike protein); 13 (PR8 strain of IAV)	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein or IAV PR8	TNF-alpha+ IL-2+ IFN-gamma+ CD4+ T cell		cell type frequency	up	ex vivo stimulation with SARS-CoV-2 spike protein vs PR8 strain of IAV	none	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig02/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	9	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein or IAV PR8	Ratio of IFN-gamma+ : TNF-alpha+ CD4+ T cells		cell type frequency	up	ex vivo stimulation with SARS-CoV-2 spike protein vs PR8 strain of IAV	none	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig02/		
	Simranpreet	Amani	2021-09-06	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	9	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein	TNF-alpha+ CD4+ effector T cells		cell type frequency	down	central memory T cells vs naive T cells; central memory T cells vs terminally differentiated effector memory T cells; central memory T cells vs effector memory T cells	none	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig02/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	9	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein, SARS-CoV-2 nucleocapsid protein, or IAV PR8	HLA-DR+ 4-1BB+ CD4+ T cell		cell type frequency	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with SARS-CoV-2 nucleocapsid vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	none	none		SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig02/	cell type frequency of subsets of TNF-alpha+/CD4+ T cells determined after ex vivo incubation of SARS-CoV-2 convalescing patient PBMCs with SARS-CoV-2 spike protein	
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein, SARS-CoV-2 nucleocapsid protein, or IAV PR8	IFN-gamma		protein/cytokine levels	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with SARS-CoV-2 nucleocapsid vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein, SARS-CoV-2 nucleocapsid protein, or IAV PR8	TNF-alpha		protein/cytokine levels	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with SARS-CoV-2 nucleocapsid vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein or IAV PR8	IL-2		protein/cytokine levels	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 nucleocapsid protein	IL-2		protein/cytokine levels	down	ex vivo stimulation with SARS-CoV-2 nucleocapsid vs control	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein, SARS-CoV-2 nucleocapsid protein, or IAV PR8	IL-10		protein/cytokine levels	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with SARS-CoV-2 nucleocapsid vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein or IAV PR8	IL-13		protein/cytokine levels	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with PR8 strain of Influenza A virus vs control	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 spike protein or SARS-CoV-2 nucleocapsid protein	IL-6		protein/cytokine levels	up	ex vivo stimulation with SARS-CoV-2 spike protein vs control; ex vivo stimulation with SARS-CoV-2 nucleocapsid vs control	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with SARS-CoV-2 nucleocapsid protein or IAV PR8	IGN-gamma:TNF-alpha ratio; IFN-gamma:IL-10 ratio		protein/cytokine levels	up	ex vivo stimulation with PR8 strain of Influenza A virus vs ex vivo stimulation with SARS-CoV-2 nucleocapsid	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 3G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig03/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry following ex-vivo stimulation with OC43 spike protein from seasonal CoV	IFN-gamma, TNF-alpha, IL-10, IL-6		protein/cytokine levels	up	ex vivo stimulation of SARS-CoV-2-convalescent PBMC with OC43 spike protein from seasonal CoV vs control (unstimulated SARS-CoV-2-convalescent PBMC)	time of stimulation	48	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig04/		
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Serum	BTO_0001239	flow cytometry	anti-SARS-CoV-2 nucleocapsid protein IgG		antibody response	positively correlated	cell type frequency of IL-2+ pTfh				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig05/	ex vivo stimulation of PBMCs from SARS-CoV-2 convalescent patients in response to SARS-CoV-2 nucleocapsid protein	
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Serum	BTO_0001239	flow cytometry	anti-SARS-CoV-2 spike (RBD) protein IgA		antibody response	positively correlated	cell type frequency of IL-2+ pTfh				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 5D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig05/	ex vivo stimulation of PBMCs from SARS-CoV-2 convalescent patients in response to SARS-CoV-2 spike (RBD) protein	
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Serum	BTO_0001239	flow cytometry	anti-SARS-CoV-2 nucleocapsid protein IgG		antibody response	positively correlated	cell type frequency of IL-2+ CD4+ T cells				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 6A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig06/	ex vivo stimulation of PBMCs from SARS-CoV-2 convalescent patients in response to SARS-CoV-2 nucleocapsid protein	
	Simranpreet	Amani	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Serum	BTO_0001239	flow cytometry	anti-SARS-CoV-2 spike (RBD) protein IgA		antibody response	positively correlated	cell type frequency of IL-2+ CD4+ T cells				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig06/	ex vivo stimulation of PBMCs from SARS-CoV-2 convalescent patients in response to SARS-CoV-2 spike (RBD) protein and SARS-CoV-2 nucleocapsid protein	
	Simranpreet	Amani 	2021-06-07	SARS-CoV-2 convalescing patients (27d - 90d after symptom onset)	31	72	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IFN-gamma & granzyme B-coproducing CD4+ T cells		cell type frequency	positively correlated	cell type frequency of IL-2+ pTfh				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33208459	2021-01-01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/	Fig 8C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750861/figure/fig08/	ex vivo stimulation of PBMCs from SARS-CoV-2 convalescent patients using S-master peptides pool	
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	17	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD4+ CD25+ CD127- CD3+ regulatory T cells		cell type frequency	up	COVID severe vs COVID mild	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	18	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD4+ CD25+ CD127- CD3+ regulatory T cells		cell type frequency	up	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	19	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-hi CD45RO-low CD4+ naive T cells		cell type frequency	down	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	18	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-hi CD45RO-low CD4+ naive T cells		cell type frequency	down	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	19	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-low CD45RO-hi CD4+ effector memory T cells		cell type frequency	up	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	18	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-low CD45RO-hi CD4+ effector memory T cells		cell type frequency	up	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	19	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-hi CD45RO-low CD8+ naive T cells		cell type frequency	down	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	18	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-hi CD45RO-low CD8+ naive T cells		cell type frequency	down	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	18	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-low CD45RO-hi CD8+ effector memory T cells		cell type frequency	up	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	17	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD62L-low CD45RO-hi CD8+ effector memory T cells		cell type frequency	up	COVID severe vs COVID mild	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f001/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	24	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ Vdelta2 gammadelta2 T cells		cell type frequency	down	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	22	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ Vdelta2 gammadelta2 T cells		cell type frequency	down	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	64	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	43	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	39	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID mild, acute patients vs healthy controls	time of symptom onset	0-72	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID severe, acute patients vs healthy controls	time of symptom onset	0-72	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	42	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+/MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	12	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+/CD161+/Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	25	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+/MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID convalescent vs healthy controls	time of hospital admission	4-9	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	12	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+/CD161+/Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID acute (mild & severe) vs healthy controls	time of symptom onset	0-72	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	9	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+/CD161+/Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID convalescent vs healthy controls	time of hospital admission	4-9	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IL-12R+/MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell; IL18R+/MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cell		cell type frequency	down	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 2F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f002/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	CD38+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	up	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	59	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	CD69+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	up	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	56	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	HLA-DR+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell; CTLA-4+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	up	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	57	CD3+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cells		flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	PD-1		protein/cytokine levels	up	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	35	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	CD38+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell; CD69+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	up	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	31	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	CD38+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell; CD69+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell; CTLA-4+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	up	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	35	CD3+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cells		flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	PD-1		protein/cytokine levels	up	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	22	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	CD38+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cells; CD69+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT)cells		cell type frequency	down	COVID convalescent vs COVID acute (mild & severe)	time of symptom onset	0-9	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	22	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	CTLA-4+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cells		cell type frequency	down	COVID severe, convalescent patients vs COVID severe, acute patients	time of symptom onset	0-9	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	84	years	8	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	HLA-DR+ CD161+ Valpha7.2+ mucosal-associated invariant T (MAIT) cell		cell type frequency	positively correlated	SAPS II score in convalescent COVID-19 patients	time of hospital admission	4-9	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3E; Text (Results: Section 3.3)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	56	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	IL-17A+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT)cells		cell type frequency	up	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry of ex-vivo expression of surface activation markers on MAIT cells 	TNFalpha+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells; GrzB+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	COVID patients vs healthy controls	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 3F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f003/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	86	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	TNFalpha+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells; GrzB+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	COVID mild vs healthy controls	time of symptom onset	1-56	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	23	84	years	19	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	GrzB+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells; Perforin+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	COVID severe vs healthy controls	time of symptom onset	7-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	25	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	Perforin+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	COVID severe vs COVID mild	time of symptom onset	1-74	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	22	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry & co-culture with E.coli	IFNgamma+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	in-vitro stimulation of COVID-19 patient PBMCs through incubation with paraformaldehyde-fixed E.coli vs unstimulated COVID-19 patient PBMCs (control)	time of incubation	24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f004/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	21	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry & in-vitro stimulation with IL-12 and IL-18	IFNgamma+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	in-vitro stimulation of COVID-19 patient PBMCs through incubation with IL-12 and IL-18 vs unstimulated PBMCs (control)	time of incubation	24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 4B, Fig S4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f004/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	21	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry & in-vitro stimulation with IL-12 and IL-18 & co-culture with E.coli	Perforin+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	down	in-vitro stimulation of COVID-19 patient PBMCs through incubation with IL-12 and IL-18 vs unstimulated patient PBMCs (control)	time of incubation	24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/figure/viruses-13-00241-f004/		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	30	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IFNgamma+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	COVID severe vs COVID mild (response component for both groups measured after in-vitro stimulation of COVID-19 patient PBMCs through incubation with IL-12 and IL-18)	time of incubation	24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	26	84	years	30	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	GrzB+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	COVID severe patient PBMCs after in-vitro stimulation through incubation with IL-12 and IL-18 vs unstimulated COVID severe patient PBMCs	time of incubation	24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-10	Munich, Germany	24	86	years	30	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	GrzB+ MR1 5-OP-RU+ mucosal-associated invariant T (MAIT) cells		cell type frequency	up	COVID severe vs COVID mild (response component for both groups measured after in-vitro stimulation of COVID-19 patient PBMCs through incubation with IL-12 and IL-18)	time of incubation	24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33546489	2021-02-03	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/	Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913667/#		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	absolute lymphocytes		cell type frequency	down	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Results: 1st paragraph	https://www.nature.com/articles/s41467-020-17292-4#Sec2		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	CD4+ T cell		flow cytometry	CD4+ T cells; (CCR7+ CD45RA+ CD28+ CD27+) naive T cells; central memory (CCR7- CD45RA+ CD28+ CD27+-) T cells; effector memory (CCR7- CD45RA- CD28+- CD27+-) T cells		cell type frequency	down	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 1B	https://www.nature.com/articles/s41467-020-17292-4/figures/1	Significant changes are seen in the absolute value of CD4+ T cells, (CCR7+/CD45RA+/CD28+/CD27+) naive T cells, central memory (CCR7-/CD45RA+/CD28+/CD27+-) T cells and effector memory (CCR7-/CD45RA-/CD28+-/CD27+-) T cells	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	CD4+ T cell		flow cytometry	terminal effector (CCR7- CD45RA+ CD28- CD27+-) T cells		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 1B	https://www.nature.com/articles/s41467-020-17292-4/figures/1	Significant changes are seen in the percentage of terminal effector (CCR7-/CD45RA+/CD28-/CD27+-) T cells.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	CD4+ T cell		flow cytometry	activated (HLA-DR+ CD38+) T cells; exhaused/senescent (CD57+ PD1+) T cells; PD1+ T cells; regulatory (CD127- CD25+) T cells		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 1C	https://www.nature.com/articles/s41467-020-17292-4/figures/1	Significant changes are seen in the percentage of activated (HLA-DR+/CD38+) T cells, exhaused/senescent (CD57+/PD1+) T cells, PD1+ T cells and regulatory (CD127-/CD25+) T cells. 	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	CD4+ T cell		flow cytometry	naive T regulatory cells; central memory T regulatory cells; PD1+ effector memory T cells; PD1+ activated (HLA-DR+ CD38+) central memory T cells; CD38+ central memory T cells		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 2C	https://www.nature.com/articles/s41467-020-17292-4/figures/2		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	13	CD4+ T cell		flow cytometry	CCR6+ T cells; CXCR3+ T cells; CCR6+ CD161+ T cells		cell type frequency	down	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 2E	https://www.nature.com/articles/s41467-020-17292-4/figures/2	Significant changes are seen in the percentage of all listed cell types.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	13	CD4+ T cell		flow cytometry	CXCR4+ T cells; CCR4+ T cells		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 2E	https://www.nature.com/articles/s41467-020-17292-4/figures/2	Significant changes are seen in the percentage of all listed cell types.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	CD8+ T cell		flow cytometry	CD8+ T cells; naive (CCR7+ CD45RA+ CD28+ CD27+) T cells; central memory (CCR7- CD45RA+ CD28+ CD27+-) T cells		cell type frequency	down	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 3B	https://www.nature.com/articles/s41467-020-17292-4/figures/3	Significant changes are seen in the absolute value of CD8+ T cells, absolute value and percentage of naive (CCR7+/CD45RA+/CD28+/CD27+) T cells, absolute value and percentage of central memory (CCR7-/CD45RA+/CD28+/CD27+-) T cells.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	CD8+ T cell		flow cytometry	terminal effector (CCR7- CD45RA+ CD28- CD27+-) T cells		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 3B	https://www.nature.com/articles/s41467-020-17292-4/figures/3	Significant changes are seen in the percentage of terminal effector (CCR7-/CD45RA+/CD28-/CD27+-) T cells.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	34	CD8+ T cell		flow cytometry	activated (HLA-DR+ CD38+) T cells; CD57+ PD1+ T cells; CD57+ T cells; PD1+ T cells		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 3C	https://www.nature.com/articles/s41467-020-17292-4/figures/3	Significant changes are seen in the absolute value and percentage of activated (HLA-DR+/CD38+) T cells, percentage of CD57+/PD1+ T cells, percentage of CD57+ T cells, and percentage of PD1+ T cells.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	32	CD8+ T cell		flow cytometry	CD38+ terminal effector T cells; CD38+/CD57+ effector memory T cells; PD1+ activated effector memory T cells; CD57+ effector memory T cell; CD57+ terminal effector T cell		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 4C	https://www.nature.com/articles/s41467-020-17292-4/figures/4		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	32	CD8+ T cell		flow cytometry	central memory T cell; naive T cell		cell type frequency	down	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 4C	https://www.nature.com/articles/s41467-020-17292-4/figures/4		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	13	CD8+ T cell		flow cytometry	CCR4+ T cell; CXCR4+ T cell; GATA3+ T cell		cell type frequency	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 4E	https://www.nature.com/articles/s41467-020-17292-4/figures/4	Significant changes are seen in the percentage of all listed cell types.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	13	CD8+ T cell		flow cytometry	TBET+ T cell; CXCR3+ T cell; CXCR3+/TBET+ T cell; CCR6+ T cell; CD161high T cell; CCR6+/CD161+ T cell		cell type frequency	down	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 4E	https://www.nature.com/articles/s41467-020-17292-4/figures/4	Significant changes are seen in the percentage of all listed cell types.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	38	blood plasma	UBERON:0001969	flow cytometry	Galectin 1; Galectin 3; Galectin 9; CCL2; CCL3; CCL4; CXCL6; CD27; CD40; CD40L; major histocompatibility complex class I chain-related protein A (MICA); IL-1alpha; IL-1beta; IL-4; IL-6; IL-7; IL-8; IL-10; IL-13; glucocorticoid-induced TNFR-related protein (GITR); TNF; IFN-gamma; PD-L1		protein/cytokine levels	up	COVID-19 patients vs healthy controls	time of symptom onset	0-19	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 7	https://www.nature.com/articles/s41467-020-17292-4/figures/7		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	14	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IFN-gamma+ CD4+ T cells; TNF+ CD4+ T cells; IL-17A+ CD4+ T cells; IL-2+ CD4+ T cells; CD107a+ CD4+ T cells		cell type frequency	up	COVID-19 patients PBMCs after stimulation with anti-CD3/CD28 vs healthy control PBMCs after stimulation with anti-CD3/CD28 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 8C	https://www.nature.com/articles/s41467-020-17292-4/figures/8	Significant changes are seen in the percentage of CD4+ T cells producing the given cytokine.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	14	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IL-17A+ CD8+ T cells; IL-2+ CD8+ T cells; CD107a+ CD8+ T cells		cell type frequency	up	COVID-19 patients PBMCs after stimulation with anti-CD3/CD28 vs healthy control PBMCs after stimulation with anti-CD3/CD28 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 8D	https://www.nature.com/articles/s41467-020-17292-4/figures/8	Significant changes are seen in the percentage of CD8+ T cells producing the given cytokine.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	18	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	107+ IFN+ TNF+ CD4+ T cells; TNF+ CD4+ T cells; IL2+ IL17+ CD4+ T cells		cell type frequency	up	COVID-19 patients PBMCs after stimulation with anti-CD3/CD28 vs healthy control PBMCs after stimulation with anti-CD3/CD28 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 9B	https://www.nature.com/articles/s41467-020-17292-4/figures/9	Significant changes are seen in the percentage of CD4+ T cells producing the given cytokine.	
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	10	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	terminally differentiated CD4+ T cells		proliferation index	down	COVID-19 patients PBMCs after stimulation with anti-CD3/CD28 vs healthy control PBMCs after stimulation with anti-CD3/CD28 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 5A	https://www.nature.com/articles/s41467-020-17292-4/figures/5		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	10	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	terminally differentiated CD8+ T cells		proliferation index	down	COVID-19 patients PBMCs after stimulation with anti-CD3/CD28 vs healthy control PBMCs after stimulation with anti-CD3/CD28 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 5B	https://www.nature.com/articles/s41467-020-17292-4/figures/5		
	Simranpreet	Amani	2021-06-13	Modena, Italy	36	49	years	10	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	terminally differentiated CD8+ T cells		% divided	up	COVID-19 patients PBMCs after stimulation with anti-CD3/CD28 vs healthy control PBMCs after stimulation with anti-CD3/CD28 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32632085	2020-07-06	https://www.nature.com/articles/s41467-020-17292-4	Fig 5B	https://www.nature.com/articles/s41467-020-17292-4/figures/5		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	78	years	11	Peripheral Blood Mononuclear Cells	CL:2000001	clinical laboratory data	Neutrophils		cell type frequency	up	COVID-19 patients with severe or critically severe disease (Group A) vs COVID-19 patients with mild or common disease (Group B)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Table 1	https://academic.oup.com/view-large/213500504		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	78	years	11	Serum	BTO_0001239	clinical laboratory data	C-reactive protein		protein/cytokine levels	up	COVID-19 patients with severe or critically severe disease (Group A) vs COVID-19 patients with mild or common disease (Group B)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Table 1	https://academic.oup.com/view-large/213500505		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	78	years	11	Serum	BTO_0001239	clinical laboratory data	Albumin		protein/cytokine levels	down	COVID-19 patients with severe or critically severe disease (Group A) vs COVID-19 patients with mild or common disease (Group B)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Table 1	https://academic.oup.com/view-large/213500506		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	78	years	11	Serum	BTO_0001239	Luminex bead-based milliplex assay	IL-10		protein/cytokine levels	up	samples at 5d from COVID-19 patients with severe or critically severe disease (Group A1) vs samples at 0d from COVID-19 patients with mild or common disease (Group B1)	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 1A	https://academic.oup.com/view-large/figure/213500507/ciaa462_fig1.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	65	years	5	Serum	BTO_0001239	Luminex bead-based milliplex assay	IL-10		protein/cytokine levels	down	samples at 5d from COVID-19 patients with mild or common disease (Group B2) vs samples at 0d from COVID-19 patients with mild or common disease (Group B1)	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 1A	https://academic.oup.com/view-large/figure/213500507/ciaa462_fig1.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	78	years	11	Serum	BTO_0001239	Luminex bead-based milliplex assay	IL-10		protein/cytokine levels	positively correlated	IL-6	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 1B	https://academic.oup.com/view-large/figure/213500507/ciaa462_fig1.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	78	years	11	Serum	BTO_0001239	Luminex bead-based milliplex assay	IL-10		protein/cytokine levels	positively correlated	Leukocytes	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 1C	https://academic.oup.com/view-large/figure/213500507/ciaa462_fig1.jpg	IL-10 levels were positively correlated with absolute leukocyte levels.	
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	78	years	11	Serum	BTO_0001239	Luminex bead-based milliplex assay	IL-10		protein/cytokine levels	positively correlated	Neutrophils	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 1D	https://academic.oup.com/view-large/figure/213500507/ciaa462_fig1.jpg	IL-10 levels were positively correlated with absolute neutrophil levels.	
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	CBL, HSPA8, TNFRSF1B, TNFRSF1A, LCK, PTPN11, PTEN, MAPK8, CEBPB, PTPN6, PIAD1, SOCS3, RPS6, STAT5A, JAK1, TRADD, TRAF3, CFLAR, TNF, PRKAA1, PIAS4, PPIA, LCP2, PIAS2, SOS1, JUNB, PRKCQ, MCL1, NFATC2, IL2RB, UBXN1, PTPRC, CD86, CARM1, JUND, TNFRSF10A, MAP2K7, TNFRSF10B, AHR, SELL, FKBP1A, RPS21, RXRB, PARP2, NAIP 		gene expression	down	samples at 0d from COVID-19 patients with severe or critically severe disease (Group A1)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 2C, Suppl Table S5	https://academic.oup.com/view-large/figure/213500508/ciaa462_fig2.jpg ;  https://academic.oup.com/cid/article/71/16/2052/5822600#supplementary-data		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	65	years	5	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	RPS6, TNF, JUNB, RPS21, TRADD, PIAS2, STAT5A, AHR, IL2RB, JUND, RXRB, TNFRSF1A, NFATC2, PTPRC, FKBP1A, TNFRSF10B, JAK1, PIAS1, MCL1, TNFRSF1B, LCP2, HSPA8, PTEN, PRKAA1, PYCARD, NOD1, UBXN1, CALM3		gene expression	down	samples at 0d from COVID-19 patients with mild or common disease (Group B1)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 2C, Suppl Table S6	https://academic.oup.com/view-large/figure/213500508/ciaa462_fig2.jpg ;  https://academic.oup.com/cid/article/71/16/2052/5822600#supplementary-data		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	PTPRC, LCP2, NFATC2, JAK1, IL2RB, MCL1, PIAS1, RPS6, PTEN, HSPA8, JUNB, TRADD, RPS21, UBXN1		gene expression	down	samples at 0d from COVID-19 patients w/ severe or critically severe disease (Group A1) vs samples from normal controls (Group NC)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 2D	https://academic.oup.com/view-large/figure/213500508/ciaa462_fig2.jpg 		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	65	years	5	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	IL2RB, PIAS1, RPS6, HSPA8, JUNB		gene expression	down	samples at 0d from COVID-19 patients w/ mild or common disease (Group B1) vs samples from normal controls (Group NC)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 2D	https://academic.oup.com/view-large/figure/213500508/ciaa462_fig2.jpg 		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	LTBR, MAPK8, AHR, CALM3, PTPN6, SELL, PARP2, PTPRC, CBL, NFATC3, LCP2, PIAS1, HSPA8, IL2RB, LCK, MCL1, JAK1, JUNB, TNF, PRKCQ, TRADD, RPS6, RPS21, PIAS2, CEBPB, FKBP1A, TGFB1		gene expression	down	samples at 5d (Group A2) vs samples at 0d (Group A1) from COVID-19 patients w/ severe or critically severe disease 	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 3A	https://academic.oup.com/view-large/figure/213500517/ciaa462_fig3.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	65	years	5	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	FOS, SOCS3, STAT5A, PRKCQ, JUNB, JUND, AHR, NFATC3, TNF, SRC, JAK1, ATG13		gene expression	down	samples at 5d (Group B2) vs samples at 0d (Group B1) from COVID-19 patients w/ mild or common disease	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 3A	https://academic.oup.com/view-large/figure/213500517/ciaa462_fig3.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	PTPRC, LCP2, JAK1, IL2RB, MCL1, RPS6, HSPA8, JUNB, TRADD, PIAS1, RPS21		gene expression	down	samples at 0d from COVID-19 patients w/ severe or critically severe disease (Group A1) vs samples from normal controls (Group NC)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4A	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	IL2RB, RPS6, HSPA8, JUNB, PIAS1		gene expression	down	samples at 5d (Group A2) from COVID-19 patients w/ severe or critically severe disease vs normal control (NC)	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4A	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	CBL, PTPN6, LCK, PRKCQ, MAPK8, CEBPB, PARP2		gene expression	down	samples at 0d from COVID-19 patients with severe or critically severe disease (Group A1) vs samples from normal controls (Group NC)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4B	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	PTPN6		gene expression	down	samples at 5d from COVID-19 patients with severe or critically severe disease (Group A2) vs samples from normal controls (Group NC)	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4B	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	MAP2K7, SOS1		gene expression	up	samples at 0d from COVID-19 patients with severe or critically severe disease (Group A1) vs samples from normal control (Group NC)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4C	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	microfluidic qPCR	MAP2K7, SOS1		gene expression	up	samples at 5d from COVID-19 patients with severe or critically severe disease (Group A2) vs samples from normal control (Group NC)	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4C	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	CyTOF mass cytometry	T cells; CD4+ T cells; CD8+ T cells		cell type frequency	down	samples at 0d from COVID-19 patients with severe or critically severe disease (Group A1) vs samples from normal control (Group NC)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4D, last half of Results section "Potential Key Genes..."	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg ; https://academic.oup.com/cid/article/71/16/2052/5822600#213500501 		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	46	78	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	CyTOF mass cytometry	T cells; CD8+ T cells		cell type frequency	down	samples at 5d from COVID-19 patients with severe or critically severe disease (Group A2) vs samples from normal control (Group NC)	time of admission	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4D, last half of Results section "Potential Key Genes..."	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg  ; https://academic.oup.com/cid/article/71/16/2052/5822600#213500502 		
	Simranpreet	Amani	2021-06-22	COVID-19 patients w/ mild/common disease in Beijing, China	29	65	years	5	Peripheral Blood Mononuclear Cells	CL:2000001	CyTOF mass cytometry	T cells; CD8+ T cells		cell type frequency	down	samples at 0d from COVID-19 patients with mild or common disease (Group B1) vs samples from normal controls (Group NC)	time of admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32307550	2020-04-20	https://academic.oup.com/cid/article/71/16/2052/5822600/	Fig 4D, last half of Results section "Potential Key Genes..."	https://academic.oup.com/view-large/figure/213500520/ciaa462_fig4.jpg  ; https://academic.oup.com/cid/article/71/16/2052/5822600#213500503 		
	Simranpreet	Amani		London, UK				70	Serum	BTO_0001239	ELISA	anti-SARS-CoV-2 spike IgG		protein/cytokine levels	down	SARS-CoV-2-RNAemia positive samples vs SARS-CoV-2-RNAemia negative samples from COVID-19 ICU patients	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 2E	https://www.nature.com/articles/s41467-021-23494-1/figures/2		
	Simranpreet	Amani 		London, UK				78	Blood	UBERON:0000178	clinical laboratory data	alanine aminotransferase; bilirubin		protein/cytokine levels	up	SARS-CoV-2-RNAemia positive samples vs SARS-CoV-2-RNAemia negative samples from COVID-19 ICU patients	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Suppl Table 3	https://www.nature.com/articles/s41467-021-23494-1#Sec38 		
	Simranpreet	Amani 		London, UK				78	Serum/Plasma		RT-qPCR	bilirubin		protein/cytokine levels	positively correlated	SARS-CoV-2-RNAemia in COVID-19 ICU patients	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 2C	https://www.nature.com/articles/s41467-021-23494-1/figures/2		
	Simranpreet	Amani 		London, UK				78	Serum/Plasma		RT-qPCR	monocytes		cell type frequency	negatively correlated	SARS-CoV-2-RNAemia in COVID-19 ICU patients	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 2C	https://www.nature.com/articles/s41467-021-23494-1/figures/2		
	Simranpreet	Amani 		London, UK; KCH Cohort				54	Plasma	NCIT:C13356	data-independent acquisition-mass spectrometry (DIA-MS)	ALB; APOA1; APOC1; CLEC3B; GSN; LUM; TF		protein/cytokine levels	down	COVID-19 ICU patients vs. ICU patients with sepsis & non-COVID-19, non-ICU controls	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Suppl Fig 4	https://www.nature.com/articles/s41467-021-23494-1#Sec38 		
	Simranpreet	Amani 		London, UK; KCH Cohort				42	Plasma	NCIT:C13356	data-independent acquisition-mass spectrometry (DIA-MS)	PGLYRP2		protein/cytokine levels	down	COVID-19 ICU patients vs. non-COVID-19, non-ICU controls	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Suppl Fig 4	https://www.nature.com/articles/s41467-021-23494-1#Sec38 		
	Simranpreet	Amani		London, UK; KCH Cohort				54	Plasma	NCIT:C13356	data-independent acquisition-mass spectrometry (DIA-MS)	C1S; C1R; C6; C8A; C9; CFB; CFH; CPN1; CD14; CRP; FGA; FGG; HP; ITIH3; ITIH4; LBP; LRG1; SERPINA3; SERPING1		protein/cytokine levels	up	COVID-19 ICU patients vs. ICU patients with sepsis & non-COVID-19, non-ICU controls	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Suppl Fig 4	https://www.nature.com/articles/s41467-021-23494-1#Sec38 		
	Simranpreet	Amani		GSTT Cohort				62	Serum	BTO_0001239	data-independent acquisition-mass spectrometry (DIA-MS)	complement factor B (CFB); carboxypeptidase N (CPN1); alpha-1-antichymorypsin (SERPINA3)		protein/cytokine levels	negatively predictive	28-day mortality in COVID-19 ICU patients	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 3C	https://www.nature.com/articles/s41467-021-23494-1/figures/3	Significant negative association of the given proteins w/ 28-day mortality in COVID-19 ICU patients was observed prior to correcting for multiple testing. After correction, none of the associations remained significant.	
	Simranpreet	Amani		GSTT Cohort				62	Serum	BTO_0001239	data-independent acquisition-mass spectrometry (DIA-MS)	mannose binding lectin 2 (MBL2)		protein/cytokine levels	positively predictive	28-day mortality in COVID-19 ICU patients	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 3D	https://www.nature.com/articles/s41467-021-23494-1/figures/3		
	Simranpreet	Amani		GSTT Cohort				62	Serum	BTO_0001239	data-independent acquisition-mass spectrometry (DIA-MS)	protein C (PROC); plasminogen (PLG); coagulation factor 7 (F7); vitamin D-binding protein (GC); F13B; FN1		protein/cytokine levels	negatively predictive	28-day mortality in COVID-19 ICU patients	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 3D	https://www.nature.com/articles/s41467-021-23494-1/figures/3		
	Simranpreet	Amani		Boston, Massachusetts				306	Plasma	NCIT:C13356		protein C (PROC); coagulation factor 7 (F7)		protein/cytokine levels	up	COVID-19 survivors vs COVID-19 non-survivors	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 4A; Suppl Table 5	https://www.nature.com/articles/s41467-021-23494-1/figures/4 ; https://www.nature.com/articles/s41467-021-23494-1#Sec38  		
	Simranpreet	Amani		Boston, Massachusetts				306	Plasma	NCIT:C13356		PTX3; IL17C; IL6; IL1RN; CX3CL1; IL1RL1; CCL2; IL15; CXCL8; CCL20; IL4R; IL19; CXCL13; CRLF1; CXCL10; CCL7; CCL19; IL18R1; LBP		protein/cytokine levels	down	COVID-19 survivors vs COVID-19 non-survivors	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 4A; Suppl Table 5	https://www.nature.com/articles/s41467-021-23494-1/figures/4 ; https://www.nature.com/articles/s41467-021-23494-1#Sec38 		
	Simranpreet	Amani		London, UK; KCH Cohort				42	Plasma	NCIT:C13356	ELISA	PTX3		protein/cytokine levels	up	COVID-19 ICU patients vs. non-COVID-19, non-ICU controls	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 4B	https://www.nature.com/articles/s41467-021-23494-1/figures/4		
	Simranpreet	Amani		GSTT Cohort				62	Serum	BTO_0001239	ELISA	PTX3		protein/cytokine levels	up	COVID-19 non-survivors vs COVID-19 survivors	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 4B	https://www.nature.com/articles/s41467-021-23494-1/figures/4		
	Simranpreet	Amani		London, UK; KCH Cohort				42	Plasma	NCIT:C13356	ELISA	RAGE		protein/cytokine levels	up	COVID-19 ICU patients vs. non-COVID-19, non-ICU controls	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 4C	https://www.nature.com/articles/s41467-021-23494-1/figures/4		
	Simranpreet	Amani		London, UK; KCH Cohort				24	Plasma	NCIT:C13356	ELISA	RAGE		protein/cytokine levels	up	COVID-19 ICU patients vs. ICU patients with sepsis	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 4C	https://www.nature.com/articles/s41467-021-23494-1/figures/4		
	Simranpreet	Amani						78	Serum/Plasma		Machine Learning	PTX3		protein/cytokine levels	positively predictive	COVID-19 non-survivors vs COVID-19 survivors	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 5C	https://www.nature.com/articles/s41467-021-23494-1/figures/5		
	Simranpreet	Amani		GSTT Cohort				47	Serum	BTO_0001239	DIA-MS analysis	SERPING1; CTSD; F5; C4A		protein/cytokine levels	up	COVID-19 ICU patients with SARS-CoV-2-RNAemia vs. COVID-19 ICU patients without SARS-CoV-2-RNAemia	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 6A	https://www.nature.com/articles/s41467-021-23494-1/figures/6 		
	Simranpreet	Amani		GSTT Cohort				47	Serum	BTO_0001239	DIA-MS analysis	CDH5; CFHR1; CETP; PRSS3; CD5L		protein/cytokine levels	down	COVID-19 ICU patients with SARS-CoV-2-RNAemia vs. COVID-19 ICU patients without SARS-CoV-2-RNAemia	time of ICU admission	0-24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 6A	https://www.nature.com/articles/s41467-021-23494-1/figures/6 		
	Simranpreet	Amani		GSTT Cohort				47	Serum	BTO_0001239		polymeric immunoglobulin receptor (PIGR)		protein/cytokine levels	up	COVID-19 ICU patients with SARS-CoV-2-RNAemia vs. COVID-19 ICU patients without SARS-CoV-2-RNAemia	time of ICU admission	7 & 14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 6B	https://www.nature.com/articles/s41467-021-23494-1/figures/6 		
	Simranpreet	Amani		GSTT Cohort				47	Plasma	NCIT:C13356		kallikrein (KLKB1)		protein/cytokine levels	up	COVID-19 ICU patients without SARS-CoV-2-RNAemia vs. COVID-19 ICU patients with SARS-CoV-2-RNAemia	time of ICU admission	0,7,14	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Fig 6B	https://www.nature.com/articles/s41467-021-23494-1/figures/6 		
	Simranpreet	Amani		GSTT Cohort				46	Serum	BTO_0001239	ELISA	LGALS3BP		protein/cytokine levels	down	samples collected from COVID-19 ICU patients at week 2 vs. samples collected from COVID-19 ICU patients at baseline	time of ICU admission	0, 2	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Suppl Fig 11A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184784/#		
	Simranpreet	Amani		GSTT Cohort				46	Serum	BTO_0001239	ELISA	LGALS3BP		protein/cytokine levels	down	samples collected from COVID-19 ICU patients at week 2 vs. samples collected from COVID-19 ICU patients at week 1	time of ICU admission	0, 1	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Suppl Fig 11A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184784/#		
	Simranpreet	Amani		GSTT Cohort				61	Serum	BTO_0001239	ELISA	LGALS3BP		protein/cytokine levels	down	COVID-19 ICU patients that died 28 days after ICU admission vs COVID-19 ICU patients that were alive 28 days after ICU admission	time of ICU admission	28	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	34099652	2021-06-07	https://www.nature.com/articles/s41467-021-23494-1/	Suppl Fig 11B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184784/#		
	Simranpreet	Amani	2021-09-09	Singapore	31	55	years	80	Serum	BTO_0001239	clinical laboratory data	C-reactive protein; Lactate dehydrogenase		protein/cytokine levels	up	COVID-19 patients w/ pneumonia but no hypoxia (Group B) vs COVID-19 patients w/ no pneumonia (Group A)	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Table 1	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476		
	Simranpreet	Amani	2021-09-09	Singapore	31	68	years	63	Serum	BTO_0001239	clinical laboratory data	hemoglobin; platelets; lymphocytes		protein/cytokine levels	down	COVID-19 patients w/ pneumonia and hypoxia (Group C) vs COVID-19 patients w/ no pneumonia (Group A)	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Table 1	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476		
	Simranpreet	Amani	2021-09-09	Singapore	31	68	years	63	Serum	BTO_0001239	clinical laboratory data	C-reactive protein; Lactate dehydrogenase; creatinine; alanine aminotransferase		protein/cytokine levels	up	COVID-19 patients w/ pneumonia and hypoxia (Group C) vs COVID-19 patients w/ no pneumonia (Group A)	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Table 1	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476		
	Simranpreet	Amani	2021-07-06	Singapore	31	68	years	63	Serum	BTO_0001239	ELISA	peak anti-SARS-CoV-2 IgM, peak anti-SARS-CoV-2-IgG		antibody response	up	COVID-19 patients with pneumonia and hypoxia (Group C) vs COVID-19 patients with no pneumonia (Group A)	time of enrollment	1-28	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Fig 3B	https://academic.oup.com/view-large/figure/208213631/ciaa1280_fig3.jpg		
	Simranpreet	Amani	2021-07-06	Singapore	31	68	years	104	blood plasma	UBERON:0001969	multiplex microbead-based immunoassay	IL-2, IL-18, IFN-gamma, TNF-alpha, monocyte chemoattractant protein 1 (MCP-1)		protein/cytokine levels	up	COVID-19 patients vs healthy controls	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Fig 4A; 1st paragraph in Results section "Proinflammatory signature..."	https://academic.oup.com/view-large/figure/208213634/ciaa1280_fig4.jpg ; https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476#208213619 		
	Simranpreet	Amani	2021-07-06	Singapore	31	68	years	104	blood plasma	UBERON:0001969	multiplex microbead-based immunoassay	hepatocyte growth factor (HGF), brain-derived neurotropic factor (BDNF), leukemia inhibitory factor (LIF), placenta growth factor-1 (PLGF-1), beta-nerve growth factor (bNGF)		protein/cytokine levels	up	COVID-19 patients vs healthy controls	time of hospital admission	0-25	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Fig 4A; 1st paragraph in Results section "Proinflammatory signature..."	https://academic.oup.com/view-large/figure/208213634/ciaa1280_fig4.jpg ; https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476#208213619  		
	Simranpreet	Amani	2021-07-06	Singapore	31	68	years	53	blood plasma	UBERON:0001969	multiplex microbead-based immunoassay	IL-6, IP-10, interleukin-1 receptor antagonist (IL-1RA), hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGF-A), IL-18, 2 B subunits of platelet-derived growth factor (PDGF-BB), monocyte chemoattractant protein-1 (MCP-1), MIP-1alpha, IL-12p70		protein/cytokine levels	up	COVID-19 patients with pneumonia and hypoxia (Group C) vs COVID-19 patients with no pneumonia (Group A)	time of symptom onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Fig 4C	https://academic.oup.com/view-large/figure/208213634/ciaa1280_fig4.jpg		
	Simranpreet	Amani	2021-07-06	Singapore	35	68	years	47	blood plasma	UBERON:0001969	multiplex microbead-based immunoassay	IL-6, IP-10, interleukin-1 receptor antagonist (IL-1RA), hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGF-A), IL-18, 2 B subunits of platelet-derived growth factor (PDGF-BB), MIP-1alpha, IL-12p70		protein/cytokine levels	up	COVID-19 patients with pneumonia and hypoxia (Group C) vs COVID-19 patients with pneumonia but no hypoxia (Group B)	time of symptom onset		days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32856707	2020-08-28	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1280/5898476/	Fig 4C	https://academic.oup.com/view-large/figure/208213634/ciaa1280_fig4.jpg		
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	21	Whole Blood	UBERON:0000178	clinical laboratory data	white blood cells; neutrophils		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Table 2	https://www.jci.org/articles/view/137244/table/2		
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	21	Whole Blood	UBERON:0000178	clinical laboratory data	lymphocyte		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Table 2	https://www.jci.org/articles/view/137244/table/2		
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	21	Whole Blood	UBERON:0000178	clinical laboratory data	alanine aminotransferase; aspartate aminotransferase; lactate dehydrogenase; high-sensitivity C-reactive protein; ferritin; D-dimer; blood urea nitrogen		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Table 2	https://www.jci.org/articles/view/137244/table/2		
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	21	Whole Blood	UBERON:0000178	clinical laboratory data	albumin		protein/cytokine levels	down	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Table 2	https://www.jci.org/articles/view/137244/table/2		
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	16	Serum	BTO_0001239	chemiluminescence immunoassay	IL-2R; IL-6; IL-10; TNF-alpha		protein/cytokine levels	up	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Fig 2, Suppl Table 1	https://www.jci.org/articles/view/137244/figure/2 ; https://www.jci.org/articles/view/137244/sd/1 		
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	14	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	Total T Lymphocytes; CD4+ T cells; CD8+ T cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Fig 3A-B, Table 3	https://www.jci.org/articles/view/137244/figure/3 ; https://www.jci.org/articles/view/137244/table/3 	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	21	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	Total T Lymphocytes		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Table 3	https://www.jci.org/articles/view/137244/table/3	Significant changes were observed in the frequency (%) of the given cell(s).	
	Simranpreet	Amani	2021-07-07	Wuhan, China	42.8	66	years	21	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	Total B Lymphocytes		cell type frequency	up	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Table 3	https://www.jci.org/articles/view/137244/table/3	Significant changes were observed in the frequency (%) of the given cell(s).	
	Amani		2021-07-07	Wuhan, China	42.8	66	years	21	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD45RA+ Treg cells		cell type frequency	down	severe COVID-19 patients vs moderate COVID-19 patients	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32217835	2020-03-27	https://www.jci.org/articles/view/137244	Table 3	https://www.jci.org/articles/view/137244/table/3	Significant changes were observed in the frequency (%) of the given cell(s) within Treg cells	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	91.6	years	74	Peripheral Blood Mononuclear Cells	CL:2000001	clinical laboratory data	White blood cells		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with no respiratory failure vs bacterial community-acquired pneumonia (CAP) patients with no respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Table 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/table/tbl1	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	57	86.6	years	84	Peripheral Blood Mononuclear Cells	CL:2000001	clinical laboratory data	White blood cells		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with severe respiratory failure vs bacterial community-acquired pneumonia (CAP) patients with severe respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Table 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/table/tbl1	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	91.6	years	74	Peripheral Blood Mononuclear Cells	CL:2000001	clinical laboratory data	Creatinine		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients w/ no respiratory failure vs bacterial community-acquired pneumonia (CAP) patients w/ no respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Table 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/table/tbl1		
	Simranpreet	Amani	2021-07-11	Athens, Greece	57	86.6	years	84	Peripheral Blood Mononuclear Cells	CL:2000001	clinical laboratory data	Creatinine		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients w/ severe respiratory failure vs bacterial community-acquired pneumonia (CAP) patients w/ severe respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Table 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/table/tbl1		
	Simranpreet	Amani	2021-07-11	Athens, Greece	57	86.6	years	84	Peripheral Blood Mononuclear Cells	CL:2000001	clinical laboratory data	Fibrinogen; D-dimers		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with severe respiratory failure vs bacterial community-acquired pneumonia (CAP) patients with severe respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Table 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/table/tbl1		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	91.6	years	66	Peripheral Blood Mononuclear Cells	CL:2000001		mHLA-DR/CD14 monocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs bacterial community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	47	Peripheral Blood Mononuclear Cells	CL:2000001		mHLA-DR/CD14 monocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	33	Peripheral Blood Mononuclear Cells	CL:2000001		mHLA-DR/CD14 monocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	12	CD14-positive monocyte	CL:0001054		HLA-DR		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	26	CD14-positive monocyte	CL:0001054		HLA-DR		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	31	CD14-positive monocyte	CL:0001054		HLA-DR		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	33	CD14-positive monocyte	CL:0001054		HLA-DR		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	47	CD14-positive monocyte	CL:0001054		HLA-DR		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	47	Serum	BTO_0001239		Ferritin		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	33	Serum	BTO_0001239		Ferritin		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	28	Serum	BTO_0001239		Ferritin		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	47	Peripheral Blood Mononuclear Cells	CL:2000001		Neutrophils		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	33	Peripheral Blood Mononuclear Cells	CL:2000001		Monocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	28	Peripheral Blood Mononuclear Cells	CL:2000001		Monocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig1/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	19	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD4+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	19	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD8+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	19	Peripheral Blood Mononuclear Cells	CL:2000001		CD19+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	19	Peripheral Blood Mononuclear Cells	CL:2000001		CD3- CD16+ CD56+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	24	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD4+ CD45+ lymphocytes; CD3+ CD8+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	13	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD4+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	13	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD8+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	13	Peripheral Blood Mononuclear Cells	CL:2000001		CD19+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs healthy volunteers				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	24	Peripheral Blood Mononuclear Cells	CL:2000001		CD3- CD16+ CD56+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	24	Peripheral Blood Mononuclear Cells	CL:2000001		CD19+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	45	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD4+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	45	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD8+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	45	Peripheral Blood Mononuclear Cells	CL:2000001		CD3- CD16+ CD56+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	45	Peripheral Blood Mononuclear Cells	CL:2000001		CD19+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	30	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD4+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	23	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD4+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	23	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD8+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	12	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD8+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	30	Peripheral Blood Mononuclear Cells	CL:2000001		CD3- CD16+ CD56+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	23	Peripheral Blood Mononuclear Cells	CL:2000001		CD3- CD16+ CD56+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	12	Peripheral Blood Mononuclear Cells	CL:2000001		CD3- CD16+ CD56+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	30	Peripheral Blood Mononuclear Cells	CL:2000001		CD19+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs 2009 H1N1 community-acquired pneumonia (CAP) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	12	Peripheral Blood Mononuclear Cells	CL:2000001		CD19+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	57	78.6	years	21	Peripheral Blood Mononuclear Cells	CL:2000001		CD3+ CD4+ CD45+ lymphocytes		cell type frequency	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with severe respiratory failure vs 2009 H1N1 influenza virus community-acquired pneumonia (CAP) patients with severe respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	57	78.6	years	21	Peripheral Blood Mononuclear Cells	CL:2000001		CD3- CD16+ CD56+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with severe respiratory failure vs 2009 H1N1 influenza virus community-acquired pneumonia (CAP) patients with severe respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	57	78.6	years	21	Peripheral Blood Mononuclear Cells	CL:2000001		CD19+ CD45+ lymphocytes		cell type frequency	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with severe respiratory failure vs 2009 H1N1 influenza virus community-acquired pneumonia (CAP) patients with severe respiratory failure				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2J	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	14	Peripheral Blood Mononuclear Cells	CL:2000001	in-vitro stimulation of PBMCs from SARS-Cov-2 patients	IL-17		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 2K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig2/	In-vitro stimulation of PBMCs from SARS-CoV-2 patients using heat-killed Candida albicans.	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	14	Serum	BTO_0001239		IgG1		antibody response	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs bacterial community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAs) 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig3/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	15	Serum	BTO_0001239		IgG2		antibody response	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig3/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	23	Serum	BTO_0001239		IgM		antibody response	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation vs bacterial community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 3E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig3/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	15	Serum	BTO_0001239		IgM		antibody response	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 3E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig3/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	28	Serum	BTO_0001239		IgM		antibody response	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 3E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig3/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	36	Serum	BTO_0001239		IgA		antibody response	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs bacterial community-acquired pneumonia (CAP) patients with immunoparalysis				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 3F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig3/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	15	Serum	BTO_0001239		IgA		antibody response	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 3F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig3/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	14	Peripheral Blood Mononuclear Cells	CL:2000001		IL-1beta		protein/cytokine levels	down	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	8	Peripheral Blood Mononuclear Cells	CL:2000001		IL-1beta		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	47	Serum	BTO_0001239		IL-6		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	28	Serum	BTO_0001239		IL-6		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	33	Serum	BTO_0001239		IL-6		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	47	Serum	BTO_0001239		C-reactive protein		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	28	Serum	BTO_0001239		C-reactive protein		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	33	Serum	BTO_0001239		C-reactive protein		protein/cytokine levels	up	SARS-CoV-2 community-acquired pneumonia (CAP) patients with macrophage-activation syndrome (MAS) vs SARS-CoV-2 community-acquired pneumonia (CAP) patients with intermediate immune activation				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 4L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig4/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	54	Serum	BTO_0001239		IL-6		protein/cytokine levels	negatively correlated	absolute number of mHLA-DR/CD14 monocytes 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	54	Peripheral Blood Mononuclear Cells	CL:2000001		lymphocyte		cell type frequency	positively correlated	absolute number of mHLA-DR/CD14 monocytes 				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	8	Peripheral Blood Mononuclear Cells	CL:2000001	in-vitro incubation	mHLA-DR/CD14 monocytes		cell type frequency	down	in-vitro incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using their plasma + medium vs incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using medium				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	8	CD14-positive monocyte	CL:0001054	in-vitro incubation	HLA-DR		protein/cytokine levels	down	in-vitro incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using their plasma vs in-vitro incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using their plasma + 10 micrograms/mL Tocilizumab				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	8	Peripheral Blood Mononuclear Cells	CL:2000001	in-vitro incubation	mHLA-DR/CD14 monocytes		cell type frequency	up	in-vitro incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using their plasma + medium + 10 micrograms/mL Tocilizumab vs incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using their plasma + medium				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	8	CD14-positive monocyte	CL:0001054	in-vitro incubation	HLA-DR		protein/cytokine levels	up	in-vitro incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using their plasma + 10 micrograms/mL Tocilizumab vs incubation of PBMCs from SARS-CoV-2 community-acquired pneumonia (CAP) patients with immune dysregulation using their plasma				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/		
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	immunomodulatory therapy w/ Tocilizumab	lymphocyte		cell type frequency	up	24h vs before the start of immunomodulatory therapy with Tocilizumab in SARS-CoV-2 patients w/ immune dysregulation	start of immunomodulatory therapy with Tocilizumab	24	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	immunomodulatory therapy w/ Tocilizumab	lymphocyte		cell type frequency	up	72h vs 24h after the start of immunomodulatory therapy with Tocilizumab in SARS-CoV-2 patients w/ immune dysregulation	start of immunomodulatory therapy with Tocilizumab	24, 72	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani	2021-07-11	Athens, Greece	48.9	78.6	years	6	Peripheral Blood Mononuclear Cells	CL:2000001	immunomodulatory therapy w/ Tocilizumab	lymphocyte		cell type frequency	up	72h vs before the start of immunomodulatory therapy with Tocilizumab in SARS-CoV-2 patients w/ immune dysregulation	start of immunomodulatory therapy with Tocilizumab	72	hours	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32320677	2020-04-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/	Fig 5G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841/figure/fig5/	Significant changes were observed in the absolute number of the given cell(s).	
	Simranpreet	Amani			42	91	years	13	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD27high CD38high B cells		cell type frequency	up	severe COVID-19 patients vs healthy controls	time of ICU admission	3-31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33785765	2021-03-30	https://www.nature.com/articles/s41467-021-22210-3	Fig 1A	https://www.nature.com/articles/s41467-021-22210-3/figures/1	Significant changes were observed in the percentage of the given cell(s).	
	Simranpreet	Amani			58	91	years	14	Peripheral Blood Mononuclear Cells	CL:2000001	ELISA; cytometric serology	IgA2+ CD27high CD38high B cells		cell type frequency	up	severe COVID-19 patients with samples more than 7 days after ICU admission (Late) vs severe COVID-19 patients with samples within 7 days after ICU admission (1st week)	time of ICU admission	3-31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33785765	2021-03-30	https://www.nature.com/articles/s41467-021-22210-3	Fig 2B	https://www.nature.com/articles/s41467-021-22210-3/figures/2	Significant changes were observed in the percentage of the given cell(s).	
	Simranpreet	Amani			58	91	years	14	Serum	BTO_0001239	ELISA	IgA2 		protein/cytokine levels	up	severe COVID-19 patients with samples more than 7 days after ICU admission (Late) vs severe COVID-19 patients with samples within 7 days after ICU admission (1st week)	time of ICU admission	3-31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33785765	2021-03-30	https://www.nature.com/articles/s41467-021-22210-3	Fig 2D	https://www.nature.com/articles/s41467-021-22210-3/figures/2 ; https://www.nature.com/articles/s41467-021-22210-3#Sec26 		
	Simranpreet	Amani			42	91	years	14	autopsied lung tissue		MELC	IgA2+ CD27+ CD38+ plasmablasts		cell type frequency	down	severe COVID-19 patients vs healthy controls	time of ICU admission	3-31	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33785765	2021-03-30	https://www.nature.com/articles/s41467-021-22210-3	Fig 6A-B	https://www.nature.com/articles/s41467-021-22210-3/figures/6	Significant changes were observed in the absolute numbers of the given cell(s) per image in 6A.	
	Simranpreet	Amani			22	82	years	39	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	memory CD8+ T cells		cell type frequency	up	hospitalized COVID-19 patients (severe disease) vs non-hospitalized patients (mild disease)	time of symptom onset	2-47	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33478949	2021-01-21	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101257/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101257/figure/F1/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		lymphocytes		cell type frequency	down	severe disease (SD) vs healthy controls (HC)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	30	Whole Blood	UBERON:0000178		lymphocytes		cell type frequency	down	severe disease (SD) vs mild disease (MD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		lymphocytes		cell type frequency	down	mild disease (MD) vs healthy control (HC)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		B cells; NK cells; NK T cells; TCRgammadelta+ cells; Vgamma9- cells; Vgamma9+ cells; CD8+ T cells; CD4+ T cells; regulatory T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0001/		
	Simranpreet	Amani			19	91	years	30	Whole Blood	UBERON:0000178		NK cells; NK T cells; TCRgammadelta+ cells; CD8+ T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0001/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		B cells; regulatory T cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0001/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		effector/effector memory (CD45RA- CD62L-) CD4+ T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		terminally differentiated (CD45RA+ CD62L-) CD4+ T cells		cell type frequency	up	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		effector/effector memory (CD45RA- CD62L-) CD4+ T cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	30	Whole Blood	UBERON:0000178		effector/effector memory (CD45RA- CD62L-) CD4+ T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		terminally differentiated (CD45RA+ CD62L-) CD4+ T cells; central memory (CD45RA- CD62L+) CD4+ T cells		cell type frequency	up	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		CD8+ naive T cells; CD8+ effector/effector memory T cells		cell type frequency	up	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		CD8+ central memory T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		CD8+ terminally differentiated T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/		
	Simranpreet	Amani			19	91	years	30	Whole Blood	UBERON:0000178		CD8+ terminally differentiated T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		CD8+ naive T cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		CD8+ effector/effector memory T cells		cell type frequency	up	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	30	Whole Blood	UBERON:0000178		CD8+ naive T cells		cell type frequency	up	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	30	Whole Blood	UBERON:0000178		CD8+ effector/effector memory T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/bin/mmc1.docx		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		naive-like (CD45RA+ CD62L+) TCRgammadelta T cells		cell type frequency	up	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		naive-like (CD45RA+ CD62L+) TCRgammadelta T cells		cell type frequency	up	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		effector/effector memory-like (CD45RA- CD62L-) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		effector/effector memory-like (CD45RA- CD62L-) TCRgammadelta T cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		central memory-like (CD45RA- CD62L+) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani			19	91	years	75	Whole Blood	UBERON:0000178		terminally differentiated-like (CD45RA+ CD62L-) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani			19	91	years	30	Whole Blood	UBERON:0000178		central memory-like (CD45RA- CD62L+) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani			19	91	years	7	Whole Blood	UBERON:0000178		naive (CD45RA+ CD62L+) CD4+ T cells		cell type frequency	down	convalescing vs COVID-19				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani			19	91	years	7	Whole Blood	UBERON:0000178		effector/effector memory (CD45RA- CD62L-) CD4+ T cells; central memory (CD45RA- CD62L+) CD4+ T cells		cell type frequency	up	convalescing vs COVID-19 in mild disease (MD) & severe disease (SD) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani			19	91	years	7	Whole Blood	UBERON:0000178		CD8+ naive T cells		cell type frequency	down	convalescing vs COVID-19 in mild disease (MD) & severe disease (SD) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani			19	91	years	7	Whole Blood	UBERON:0000178		CD8+ effector/effector memory T cells; CD8+ central memory T cells		cell type frequency	up	convalescing vs COVID-19 in mild disease (MD) & severe disease (SD) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani	2021-06-19	SARS-CoV-2 patients	2	98	years	403	nasopharyngeal epithelial tissue	CL:1001573	DESeq2	ACE2		gene expression	up	SARS-CoV-2 infected males vs SARS-CoV-2 infected females				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33195414	2020-10-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/figure/F4/	54 samples of healthy tissue were also compared for differences in ACE2 expression levels between males and females. No significant difference was observed.	
	Simranpreet	Amani	2021-06-19	Healthy individuals & SARS CoV-2 patients	2	98	years	457	nasopharyngeal epithelial tissue	CL:1001573	DESeq2	ACE2		gene expression	up	SARS-CoV-2 infected patients vs healthy patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33195414	2020-10-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/figure/F4/		
	Simranpreet	Amani	2021-06-19	Females	2	98	years	231	nasopharyngeal epithelial tissue	CL:1001573	DESeq2	ACE2		gene expression	up	SARS-CoV-2 infected females vs healthy females				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33195414	2020-10-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/figure/F4/		
	Simranpreet	Amani	2021-06-19	Males	2	98	years	200	nasopharyngeal epithelial tissue	CL:1001573	DESeq2	ACE2		gene expression	up	SARS-CoV-2 infected males vs healthy males				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33195414	2020-10-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597396/figure/F4/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	74.31	years	125	Peripheral Blood Mononuclear Cells	CL:2000001	Complete blood count	lymphocytes		cell type frequency	up	Age<24 w/ no mechanical ventilation (Group 1) vs Age<24 w/ MIS-C (Group 2); Age<24 w/ no mechanical ventilation (Group 1) vs Adult w/ no mechanical ventilation (Group 3); Age<24 w/ no mechanical ventilation (Group 1) vs Adult w/ mechanical ventilation or death (Group 4)	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 1A, Table 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F1/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/table/T2/ 		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	74.31	years	125	Serum	BTO_0001239	Millipore (instrument/assay used)	C-reactive protein		protein/cytokine levels	down	Age<24 w/ no mechanical ventilation (Group 1) vs Age<24 w/ MIS-C (Group 2); Age<24 w/ no mechanical ventilation (Group 1) vs Adult w/ no mechanical ventilation (Group 3); Age<24 w/ no mechanical ventilation (Group 1) vs Adult w/ mechanical ventilation or death (Group 4)	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 1B, Table 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F1/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/table/T2/ 		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	73.09	years	68	Serum	BTO_0001239	Millipore (instrument/assay used)	D-dimer		protein/cytokine levels	down	Age<24 w/ no mechanical ventilation (Group 1) vs Age<24 w/ MIS-C (Group 2); Age<24 w/ no mechanical ventilation (Group 1) vs Adult w/ mechanical ventilation or death (Group 4)	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 1C, Table 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F1/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/table/T2/ 		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	74.31	years	80	Serum	BTO_0001239	Millipore (instrument/assay used)	D-dimer		protein/cytokine levels	up	Age<24 w/ MIS-C (Group 2) vs Adult w/ no mechanical ventilation (Group 3); Age<24 w/ mechanical ventilation or death (Group 4) vs Adult w/ no mechanical ventilation (Group 3)	time of hospital admission	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 1C, Table 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F1/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/table/T2/ 		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	9.29	74.31	years	101	Serum	BTO_0001239	clinical laboratory data	serum lactate dehydrogenase		protein/cytokine levels	up	Age<24 w/ mechanical ventilation or death (Group 4) vs Age<24 w/ no mechanical ventilation (Group 1); Age<24 w/ mechanical ventilation or death (Group 4) vs Adult w/ no mechanical ventilation (Group 3)	time of hospital admission	0-7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 1D, Table 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F1/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/table/T2/ 		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	73.09	years	69	Serum	BTO_0001239	multiplexed Luminex assay	IL-6, TNF-alpha, IP-10		protein/cytokine levels	down	Age<24 w/ no mechanical ventilation (Group 1) vs Age<24 w/ MIS-C (Group 2); Age<24 w/ no mechanical ventilation (Group 1) vs Adult w/ mechanical ventilation or death (Group 4)	time of hospital admission	0-7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F2/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	44.53	74.31	years	45	Serum	BTO_0001239	multiplexed Luminex assay	IL-6 		protein/cytokine levels	down	Adult w/ no mechanical ventilation (Group 3) vs Age<24 w/ mechanical ventilation or death (Group 4)	time of hospital admission	0-7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F2/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	9.29	74.31	years	44	Serum	BTO_0001239	multiplexed Luminex assay	IL-17A		protein/cytokine levels	up	Age<24 w/ no mechanical ventilation (Group 1) vs Adult w/ no mechanical ventilation (Group 3)	time of hospital admission	0-7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F2/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	74.31	years	56	Serum	BTO_0001239	multiplexed Luminex assay	IL-17A		protein/cytokine levels	up	Age<24 w/ MIS-C (Group 2) vs Adult w/ no mechanical ventilation (Group 3); Age<24 w/ MIS-C (Group 2) vs Age<24 w/ mechanical ventilation or death (Group 4)	time of hospital admission	0-7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F2/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	74.31	years	62	Serum	BTO_0001239	multiplexed Luminex assay	IFN-gamma		protein/cytokine levels	up	Age<24 w/ MIS-C (Group 2) vs Age<24 w/ no mechanical ventilation (Group 1); Age<24 w/ MIS-C (Group 2) vs Adult w/ no mechanical ventilation (Group 3); Age<24 w/ MIS-C (Group 2) vs Age<24 w/ mechanical ventilation or death (Group 4)	time of hospital admission	0-7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F2/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	74.31	years	82	Serum	BTO_0001239	multiplexed Luminex assay	IL-17A, IFN-gamma		protein/cytokine levels	negatively correlated	age	time of hospital admission	0-7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F2/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	52.99	73.09	years	3	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IFN-gamma+ CD4+ T cells		cell type frequency	up	CD4+ T-cells in adults w/ mechanical or death (Group 4) before vs after in-vitro stimulation with spike protein	time of hospital admission	30.4-49.6	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 3A&B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F3/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	44.53	74.31	years	11	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD25+ CD4+ T cells		cell type frequency	up	CD4+ T-cells in adults w/ no mechanical ventilation (Group 3) before vs after in-vitro stimulation with spike protein; CD4+ T-cells in adults w/ mechanical ventilation or death (Group 4) before vs after in-vitro stimulation with spike protein	time of hospital admission	30.4-49.6	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F3/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City	3.87	74.31	years	71	Serum	BTO_0001239	ELISA	anti-SARS-CoV-2 spike protein IgG1:anti-SARS-CoV-2 spike protein IgG3		protein/cytokine levels	up	Age<24 w/ MIS-C (Group 2) vs Age<24 w/ no mechanical ventilation (Group 1); Age<24 w/ MIS-C (Group 2) vs Adult w/ no mechanical ventilation (Group 3); Age<24 w/ MIS-C (Group 2) vs Age<24 w/ mechanical ventilation or death (Group 4)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 4E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F4/		
	Simranpreet	Amani	2021-06-19	Bronx, New York City				32	Serum	BTO_0001239		IFN-gamma		protein/cytokine levels	negatively correlated	neutralization activity of anti-SARS-CoV-2 spike protein IgG				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 5D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F5/	According to the text (Section: Immunoglobulin responses in patients with COVID-19), area under the curve (AUC) of Fig. 5A was used as a measure of neutralization activity of anti-SARS-CoV-2 spike protein IgG.	
	Simranpreet	Amani	2021-06-19	Bronx, New York City				32	Serum	BTO_0001239		IL-17A		protein/cytokine levels	negatively correlated	neutralization activity of anti-SARS-CoV-2 spike protein IgG				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32958614	2020-10-07	https://pubmed.ncbi.nlm.nih.gov/32958614/	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658796/figure/F5/	According to the text (Section: Immunoglobulin responses in patients with COVID-19), area under the curve (AUC) of Fig. 5A was used as a measure of neutralization activity of anti-SARS-CoV-2 spike protein IgG.	
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Serum	BTO_0001239	laboratory data	C-reactive protein		protein/cytokine levels	up	Severe vs Mild 	time of symptom onset	5-20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Table 2	https://academic.oup.com/view-large/211133831		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Whole Blood	UBERON:0000178	laboratory data	Eosinophils; Monocytes		cell type frequency	down	Severe vs Mild 	time of symptom onset	5-20	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Table 2	https://academic.oup.com/view-large/211133831		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		SS-hi CD15+ Granulocytes; SS-hi CD15+ CD16+ Granulocytes; SS-hi CD16+ Granulocytes; PD1+ CD56+ CD3- NK Cells; PD-L1+ CD56+ CD3- NK Cells; CD3+ CD4+ CCR7+ PD1+ T cells		cell type frequency	up	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		CD3- CD56- Lymphocytes; SS-low CRTH2+ Basophils; CD4+ SS-med CD14+ Monocytes; NKG2D+ NKp46+ NK Cells		cell type frequency	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		CD3+ T cells		cell type frequency	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Suppl Fig 2A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/jid/article/222/12/1985/5907982#supplementary-data		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		CD3+ CD4+ T cells		cell type frequency	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Suppl Fig 2B	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/jid/article/222/12/1985/5907982#supplementary-data		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		lineage- CD11c- HLA-DR+ CD123+ pDCs		cell type frequency	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Suppl Fig 2C	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/jid/article/222/12/1985/5907982#supplementary-data		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		CD3+ CD8+ T cells		cell type frequency	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Suppl Fig 2D	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/jid/article/222/12/1985/5907982#supplementary-data		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	SS-hi Granulocyte			CD64		gene expression	up	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	CD3+ CD4+ CCR7+ PD1+ T cell			CCR7		gene expression	up	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	CD3+ CD4+ CD27+ CD45RA+ T cell			CCR7		gene expression	up	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Lineage- CD11c+ HLA-DR+ mDC			CD1c		gene expression	up	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	SS-hi CRTH2+ Eosinophil			CD66b		gene expression	up	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	SS-hi CRTH2+ Eosinophil			CRTH2		gene expression	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Fig 2B	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/view-large/figure/211133835/jiaa591_fig2.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	SS-hi CD15+ Granulocyte			CD16		gene expression	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	SS-low CRTH2+ Basophil			CRTH2		gene expression	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Fig 2B	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/view-large/figure/211133835/jiaa591_fig2.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	SS-low CRTH2+ Basophil			CD11b		gene expression	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Fig 2C	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/view-large/figure/211133835/jiaa591_fig2.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	SS-hi CD15+ Granulocyte			CD11b		gene expression	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Fig 2C	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/view-large/figure/211133835/jiaa591_fig2.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Monocyte	CL:0000576		HLA-DR		gene expression	down	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		Basophils		cell type frequency	down	COVID-19 Patients vs Healthy Blood Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 2A	https://academic.oup.com/view-large/figure/211133835/jiaa591_fig2.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	31	74	years	51	Whole Blood	UBERON:0000178		SS CD15+ Granulocytes		cell type frequency	up	COVID-19 Patients vs Healthy Blood Donors	time of infection	10	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 1A, Fig 2A	https://academic.oup.com/view-large/figure/211133834/jiaa591_fig1.jpg https://academic.oup.com/view-large/figure/211133835/jiaa591_fig2.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Serum	BTO_0001239		lineage- CD11C- HLA-DR+ CD123+ pDCs; CD4+ SS-med CD14+ Monocytes; CD3+ Lymphocytes; NKG2D+ NKp46+ NK Cells; CD3- CD56- Lymphocytes; CD16+ CD56+ CD3- NK Cells; SS-low CRTH2+ Basophils		cell type frequency	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Serum	BTO_0001239		SS-hi CD15+ Granulocytes; SS-low CRTH2- PD-L1+ Basophils; SS-hi CD15+ CD16+ Granulocytes; SS-hi CD16+ Granulocytes; PD-L1+ CD56+ CD3- NK Cells; SS-hi CD16+ Granulocytes		cell type frequency	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Serum	BTO_0001239		PDL1+ NK Cells		cell type frequency	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Suppl Fig 3A	https://academic.oup.com/jid/article/222/12/1985/5907982#supplementary-data		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Monocyte	CL:0000576		HLA-DR		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A, Suppl Fig 3C	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg https://academic.oup.com/jid/article/222/12/1985/5907982#supplementary-data		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	T cell	CL:0000084		PD-1		gene expression	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	"Partners of the Granylocyte Signature" text. Last Paragraph in Results section.	https://academic.oup.com/jid/article/222/12/1985/5907982#211133828		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	SS-hi CRTH2+ Eosinophil			PD-L1		gene expression	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	CD45+ Leukocyte			CD69		gene expression	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Lineage- CD11c+ HLA-DR+ mDC			CD1c		gene expression	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Monocyte	CL:0000576		CD4, CD64		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	SS-hi CRTH2+ Eosinophil			CRTH2		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	SS-hi CD15+ Granulocyte			CD15, CD11b		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	SS-hi CD15+ Granulocyte			CD16		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A, Fig 4A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg https://academic.oup.com/view-large/figure/211133839/jiaa591_fig4.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	NKG2D+ NKp46+ NK Cells			NKp46		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	SS-low CRTH2+ Basophil			CD11b		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 3A	https://academic.oup.com/view-large/figure/211133838/jiaa591_fig3.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Eosinophil	CL:000071		CRTH2		gene expression	down	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 4B	https://academic.oup.com/view-large/figure/211133839/jiaa591_fig4.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Eosinophil	CL:000071		PD-L1		gene expression	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 4C	https://academic.oup.com/view-large/figure/211133839/jiaa591_fig4.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Basophil	CL:0000767		PD-L1		gene expression	up	Severe vs Mild/Moderate				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 4D	https://academic.oup.com/view-large/figure/211133839/jiaa591_fig4.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	SS-hi CD15+ Granulocyte			CD11b		gene expression	negatively correlated	SOFA clinical severity score				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 5A	https://academic.oup.com/view-large/figure/211133841/jiaa591_fig5.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Eosinophil	CL:000071		CRTH2		gene expression	negatively correlated	SOFA clinical severity score				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 5B	https://academic.oup.com/view-large/figure/211133841/jiaa591_fig5.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Basophil	CL:0000767		PD-L1		gene expression	positively correlated	WHO clinical severity score				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 5C	https://academic.oup.com/view-large/figure/211133841/jiaa591_fig5.jpg		
	Simranpreet	Amani	2021-06-19	Marseille, France	49	75	years	26	Eosinophil	CL:000071		PD-L1		gene expression	positively correlated	SOFA clinical severity score				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32941618	2020-09-17	https://academic.oup.com/jid/article/222/12/1985/5907982	Fig 5D	https://academic.oup.com/view-large/figure/211133841/jiaa591_fig5.jpg		
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000000	FACS	CD3- CD56+ NK cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 1A	https://www.nature.com/articles/s41423-020-00557-9/figures/1	Significant changes are seen in the absolute value of CD3-/CD56+ NK cells.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	immature CD56-bright NK cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 1B	https://www.nature.com/articles/s41423-020-00557-9/figures/1	Significant changes are seen in the percentage of immature CD56-bright NK cells.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	immature CD56-bright NK cells		cell type frequency	down	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 1B	https://www.nature.com/articles/s41423-020-00557-9/figures/1	Significant changes are seen in the percentage of immature CD56-bright NK cells.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	mature CD57+ NK cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 1C	https://www.nature.com/articles/s41423-020-00557-9/figures/1	Significant changes are seen in the percentage of immature mature CD57+ NK cells.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	mature CD56-dim CD57+ NK cells		cell type frequency	up	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 1C	https://www.nature.com/articles/s41423-020-00557-9/figures/1	Significant changes are seen in the percentage of mature CD56-dim CD57+ NK cells.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	FCepsilonRly- CD56+ CD57+ NK cells		cell type frequency	up	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 1D	https://www.nature.com/articles/s41423-020-00557-9/figures/1	Significant changes are seen in the percentage of FCepsilonRI- CD56+ CD57+ NK cells.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ NK cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2A	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	TIM-3+ NK cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2B	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	PD1+ NK cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2C	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	NKG2D+ NK cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2D	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	Siglec-7+ NK cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2E	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	DNAM-1+ NK cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2F	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CXCR6+ NK cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2G	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Natural Killer Cell	CL:0000623	FACS	Aiolos		protein/cytokine levels	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 2F	https://www.nature.com/articles/s41423-020-00557-9/figures/2	Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS & in-vitro stimulation w/ SW480	IFNgamma+ NK cells		cell type frequency	down	SW480-stimulated cells from SARS-CoV-2 patients vs SW480-stimulated cells from healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 3A	https://www.nature.com/articles/s41423-020-00557-9/figures/3	IFNg+ NK cells after in-vitro stimulation with SW480 target cell. Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS & in-vitro stimulation w/ K562	IFNgamma+ NK cells		cell type frequency	down	K562-stimulated cells from SARS-CoV-2 patients vs K562-stimulated cells from healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 3B	https://www.nature.com/articles/s41423-020-00557-9/figures/3	IFNg+ NK cells after in-vitro stimulation with K562 target cell. Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS & in-vitro stimulation w/ K562	CD56-bright CD107a+ cells		cell type frequency	down	K562-stimulated cells from SARS-CoV-2 patients vs K562-stimulated cells from healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 3C	https://www.nature.com/articles/s41423-020-00557-9/figures/3	CD56-bright CD107a+ cells after in-vitro stimulation with K562 target cell. Significant changes are seen in the percentage of the given cell.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS & in-vitro stimulation w/ K562	CD56-bright IFNgamma+ cells		cell type frequency	down	K562-stimulated cells from SARS-CoV-2 patients vs K562-stimulated cells from healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 3C	https://www.nature.com/articles/s41423-020-00557-9/figures/3	CD56-bright IFNg+ cells after in-vitro stimulation with K562 target cell. Significant changes are seen in the percentage of the given cell	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001		CD107a+ NK cells; IFNgamma+ NK cells		cell type frequency	negatively correlated	correlated w/ C-reactive protein value in all patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 3D	https://www.nature.com/articles/s41423-020-00557-9/figures/3	C-reactive protein was negatively correlated to the percentage of CD107a+ NK cells, IFNg+ NK cells.	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD3- CD4+ T cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4A	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage and absolute number of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD3- CD8+ T cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4B	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage and absolute number of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD3- CD8+ T cells		cell type frequency	down	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4B	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage and absolute number of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ CD8+ T cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4C	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ CD8+ T cells		cell type frequency	up	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4C	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ CD4+ T cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4D	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	32	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ CD4+ T cells		cell type frequency	up	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4D	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	TIM-3+ CD8+ T cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4E	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	TIM-3+ CD4+ T cells		cell type frequency	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4F	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CXCR6+ CD8+ T cells		cell type frequency	down	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4G	https://www.nature.com/articles/s41423-020-00557-9/figures/4	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19	Pavia, Italy	32	92	years	57	CD8+ alpha-beta T cell	CL:0000625	FACS	Aiolos		protein/cytokine levels	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 4H	https://www.nature.com/articles/s41423-020-00557-9/figures/4		
	Simranpreet	Amani	2021-06-19					7	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD3+ CD8+ T cells		cell type frequency	up	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5A	https://www.nature.com/articles/s41423-020-00557-9/figures/5	Significant changes are seen in the percentage and absolute number of the given cell(s).	
	Simranpreet	Amani	2021-06-19					7	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	TIM-3+ NK cells		cell type frequency	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5B	https://www.nature.com/articles/s41423-020-00557-9/figures/5	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					7	Natural Killer Cell	CL:0000623	FACS	TIM-3		protein/cytokine levels	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5B	https://www.nature.com/articles/s41423-020-00557-9/figures/5		
	Simranpreet	Amani	2021-06-19					7	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	TIM-3+ CD8+ T cells		cell type frequency	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5C	https://www.nature.com/articles/s41423-020-00557-9/figures/5	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					7	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ NK cells		cell type frequency	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5D	https://www.nature.com/articles/s41423-020-00557-9/figures/5		
	Simranpreet	Amani	2021-06-19					7	Natural Killer Cell	CL:0000623	FACS	CD69		protein/cytokine levels	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5D	https://www.nature.com/articles/s41423-020-00557-9/figures/5	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					7	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ CD8+ T cells		cell type frequency	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5E	https://www.nature.com/articles/s41423-020-00557-9/figures/5	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					7	Peripheral Blood Mononuclear Cells	CL:2000001	FACS	CD69+ CD4+ T cells		cell type frequency	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 5F	https://www.nature.com/articles/s41423-020-00557-9/figures/5	Significant changes are seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19		32	92	years	57	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-6		protein/cytokine levels	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6A	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	32	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-6		protein/cytokine levels	up	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6A	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	77	years	17	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-6		protein/cytokine levels	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6A	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	57	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-8		protein/cytokine levels	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6B	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	77	years	17	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-8		protein/cytokine levels	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6B	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	57	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-10		protein/cytokine levels	up	SARS-CoV-2 patients vs healthy donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6C	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	32	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-10		protein/cytokine levels	up	SARS-CoV-2 deceased patients vs SARS-CoV-2 surviving patients	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6C	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	77	years	17	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	IL-10		protein/cytokine levels	down	Convalescing (30-45 days after hospital discharge) vs Acute				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6C	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	32	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	Lactic Dehydrogenase		protein/cytokine levels	positively correlated	serum IL-6 levels in SARS-CoV-2 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6D	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	32	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	C Reactive Protein		protein/cytokine levels	positively correlated	serum IL-6 levels in SARS-CoV-2 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6E	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	32	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	Lactic Dehydrogenase		protein/cytokine levels	positively correlated	serum IL-10 levels in SARS-CoV-2 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6F	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19		32	92	years	32	Serum	BTO_0001239	BD Cytometric Bead Array (CBA)	C Reactive Protein		protein/cytokine levels	positively correlated	serum IL-10 levels in SARS-CoV-2 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 6G	https://www.nature.com/articles/s41423-020-00557-9/figures/6		
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-6+ CD14+ monocytes		cell type frequency	up	Convalescing (30-45 days after hospital discharge) patients vs Healthy Donors	time of hospital discharge	30-45	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 7A	https://www.nature.com/articles/s41423-020-00557-9/figures/7	ex vivo stimulation of freshly isolated monocytes	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-6+ CD14+ monocytes		cell type frequency	up	SARS-CoV-2 patients vs Healthy Donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 7A	https://www.nature.com/articles/s41423-020-00557-9/figures/7	ex vivo stimulation of freshly isolated monocytes	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-8+ CD14+ monocytes		cell type frequency	up	SARS-CoV-2 patients vs Healthy Donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 7B	https://www.nature.com/articles/s41423-020-00557-9/figures/7	ex vivo stimulation of freshly isolated monocytes	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-1beta+ CD14+ monocytes		cell type frequency	up	SARS-CoV-2 patients vs Healthy Donors	time of first examination	1-2	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Fig 7C	https://www.nature.com/articles/s41423-020-00557-9/figures/7	ex vivo stimulation of freshly isolated monocytes	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-6+ classical monocytes		cell type frequency	up	Convalescing (30-45 days after hospital discharge) patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4A	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					20	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-6+ classical monocytes; IL-6+ non-classical monocytes		cell type frequency	up	hospitalized SARS-CoV-2 patients vs Convalescing (30-45 days after hospital discharge) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4A	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-6+ classical monocytes; IL-6+ intermediate monocytes		cell type frequency	up	hospitalized SARS-CoV-2 patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4A	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-6+ non-classical monocytes		cell type frequency	down	Convalescing (30-45 days after hospital discharge) patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4A	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-8+ classical monocytes; IL-8+ non-classical monocytes		cell type frequency	up	hospitalized SARS-CoV-2 patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4B	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					20	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-8+ intermediate monocytes; IL-8+ non-classical monocytes		cell type frequency	up	hospitalized SARS-CoV-2 patients vs Convalescing (30-45 days after hospital discharge) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4B	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-8+ intermediate monocytes; IL-8+ non-classical monocytes		cell type frequency	down	Convalescing (30-45 days after hospital discharge) patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4B	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-1beta+ classical monocytes; IL-1beta+ intermediate monocytes; IL-1beta+ non-classical monocytes		cell type frequency	up	hospitalized SARS-CoV-2 patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4C	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					22	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-1beta+ intermediate monocytes		cell type frequency	up	Convalescing (30-45 days after hospital discharge) patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4C	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani	2021-06-19					20	Peripheral Blood Mononuclear Cells	CL:2000001	ex-vivo stimulation	IL-1beta+ non-classical monocytes		cell type frequency	up	hospitalized SARS-CoV-2 patients vs Convalescing (30-45 days after hospital discharge) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	33060840	2020-10-15	https://www.nature.com/articles/s41423-020-00557-9	Suppl Fig 4C	https://www.nature.com/articles/s41423-020-00557-9#Sec17	ex vivo stimulation of freshly isolated monocytes. Significant changes were seen in the percentage of the given cell(s).	
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	lymphocytes		cell type frequency	down	severe disease (SD) vs healthy controls (HC)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title		
	Simranpreet	Amani		Germany	19	91	years	30	Whole Blood	UBERON:0000178	flow cytometry	lymphocytes		cell type frequency	down	severe disease (SD) vs mild disease (MD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	lymphocytes		cell type frequency	down	mild disease (MD) vs healthy control (HC)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	B cells; NK cells; NK T cells; TCRgammadelta+ cells; Vgamma9- (V9-) cells; Vgamma9+ (V9+) cells; CD8+ T cells; CD4+ T cells; regulatory T (Treg) cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0001/		
	Simranpreet	Amani		Germany	19	91	years	30	Whole Blood	UBERON:0000178	flow cytometry	NK cells; NK T cells; TCRgammadelta+ cells; CD8+ T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0001/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	B cells; regulatory T (Treg) cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0001/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	effector/effector memory (CD45RA- CD62L-) CD4+ (CD4 eff/em) T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	terminally differentiated (CD45RA+ CD62L-) CD4+ (CD4 temra) T cells		cell type frequency	up	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	effector/effector memory (CD45RA- CD62L-) CD4+ (CD4 eff/em) T cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	30	Whole Blood	UBERON:0000178	flow cytometry	effector/effector memory (CD45RA- CD62L-) CD4+ (CD4 eff/em) T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	terminally differentiated (CD45RA+ CD62L-) CD4+ (CD4 temra) T cells; central memory (CD45RA- CD62L+) CD4+ (CD4 cm) T cells		cell type frequency	up	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2A, Suppl Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	CD8+ naive T cells; CD8+ effector/effector memory T cells		cell type frequency	up	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	CD8+ central memory (CD8 cm) T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	CD8+ terminally differentiated (CD8 temra) T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/		
	Simranpreet	Amani		Germany	19	91	years	30	Whole Blood	UBERON:0000178	flow cytometry	CD8+ terminally differentiated (CD8 temra) T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Suppl Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	CD8+ naive T cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	CD8+ effector/effector memory T cells		cell type frequency	up	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	30	Whole Blood	UBERON:0000178	flow cytometry	CD8+ naive T cells		cell type frequency	up	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	30	Whole Blood	UBERON:0000178	flow cytometry	CD8+ effector/effector memory T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 2B, Suppl Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0002/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/#sec0019title 		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	naive-like (CD45RA+ CD62L+) TCRgammadelta (TCRdelta-) T cells		cell type frequency	up	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	naive-like (CD45RA+ CD62L+) TCRgammadelta (TCRdelta-) T cells		cell type frequency	up	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	effector/effector memory-like (CD45RA- CD62L-) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	effector/effector memory-like (CD45RA- CD62L-) TCRgammadelta T cells		cell type frequency	down	mild disease (MD) vs healthy control (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	central memory-like (CD45RA- CD62L+) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3A-B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani		Germany	19	91	years	75	Whole Blood	UBERON:0000178	flow cytometry	terminally differentiated-like (CD45RA+ CD62L-) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs healthy controls (HC)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani		Germany	19	91	years	30	Whole Blood	UBERON:0000178	flow cytometry	central memory-like (CD45RA- CD62L+) TCRgammadelta T cells		cell type frequency	down	severe disease (SD) vs mild disease (MD)	time of symptom onset	2-32	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0003/		
	Simranpreet	Amani		Germany	19	91	years	7	Whole Blood	UBERON:0000178	flow cytometry	naive (CD45RA+ CD62L+) CD4+ T cells		cell type frequency	down	convalescing vs COVID-19				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani		Germany	19	91	years	7	Whole Blood	UBERON:0000178	flow cytometry	effector/effector memory (CD45RA- CD62L-) CD4+ (CD4 eff/em) T cells; central memory (CD45RA- CD62L+) CD4+ (CD4 cm) T cells		cell type frequency	up	convalescing vs COVID-19 in mild disease (MD) & severe disease (SD) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani		Germany	19	91	years	7	Whole Blood	UBERON:0000178	flow cytometry	CD8+ naive T cells		cell type frequency	down	convalescing vs COVID-19 in mild disease (MD) & severe disease (SD) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani		Germany	19	91	years	7	Whole Blood	UBERON:0000178	flow cytometry	CD8+ effector/effector memory (CD8 eff/em) T cells; CD8+ central memory (CD8 cm) T cells		cell type frequency	up	convalescing vs COVID-19 in mild disease (MD) & severe disease (SD) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute & post-infection	32650275	2020-07-07	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338277/figure/fig0004/		
	Simranpreet	Amani			22	81	years	56	Whole Blood	UBERON:0000178		peripheral blood mononuclear cells		cell type frequency	up	COVID-19 Patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Extended Data Fig 1A	https://www.nature.com/articles/s41590-020-00814-z/figures/7		
	Simranpreet	Amani			22	81	years	56	CD45+ cell			CD19+ CD45+ B cell		cell type frequency	up	COVID-19 Patients vs Healthy Donors				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Extended Data Fig 1B	https://www.nature.com/articles/s41590-020-00814-z/figures/7		
	Simranpreet	Amani			34	81	years	10	Peripheral Blood Mononuclear Cells	CL:2000001	high-dimensional FCM	CD138+ antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C); severe COVID-19 (ICU-C) vs healthy donor (HD)	time of symptom onset	7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 1B	https://www.nature.com/articles/s41590-020-00814-z/figures/1		
	Simranpreet	Amani			26	44	years	7	Peripheral Blood Mononuclear Cells	CL:2000001	high-dimensional FCM	CD21-low transitional B cell		cell type frequency	up	outpatient COVID-19 (OUT-C) vs severe COVID-19 (ICU-C); outpatient COVID-19 (OUT-C) vs healthy donor (HD)	time of symptom onset	4	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 1C	https://www.nature.com/articles/s41590-020-00814-z/figures/1		
	Simranpreet	Amani			34	81	years	10	Peripheral Blood Mononuclear Cells	CL:2000001	high-dimensional FCM	DN2 B cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C); severe COVID-19 (ICU-C) vs healthy donor (HD)	time of symptom onset	7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 1D	https://www.nature.com/articles/s41590-020-00814-z/figures/1		
	Simranpreet	Amani			34	81	years	10	Peripheral Blood Mononuclear Cells	CL:2000001	high-dimensional FCM	usM B cells		cell type frequency	down	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C); severe COVID-19 (ICU-C) vs healthy donor (HD)	time of symptom onset	7	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 1F	https://www.nature.com/articles/s41590-020-00814-z/figures/1		
	Simranpreet	Amani			22	61	years	27	CD19+ B cell	CL:0001201	high-dimensional FCM	aN naive B cell		cell type frequency	up	severe COVID-19 (ICU-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years	17	CD19+ B cell	CL:0001201	high-dimensional FCM	aN naive B cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			22	61	years	27	CD19+ B cell	CL:0001201	high-dimensional FCM	DN2 B cell		cell type frequency	up	severe COVID-19 (ICU-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years	17	CD19+ B cell	CL:0001201	high-dimensional FCM	DN2 B cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			34	81	years	4	CD11c+ naive B cell		high-dimensional FCM	T-bet		protein/cytokine levels	up	CD11c+ (aN) naive B cell vs CD11c- (rN) naive B cell in severe COVID-19 (ICU-C) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3E&F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			34	81	years	4	CD11c+ CD21- double negative B cell		high-dimensional FCM	T-bet		protein/cytokine levels	up	CD11c+ CD21- double negative (DN2) B cell vs CD11c- CD21+ double negative (DN1) B cell in severe COVID-19 (ICU-C) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3E&F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			22	61	years	22	CD19+ B cell	CL:0001201	high-dimensional FCM	antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years	17	CD19+ B cell	CL:0001201	high-dimensional FCM	antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			22	61	years	22	CD19+ B cell	CL:0001201	high-dimensional FCM	CD138+ antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years	17	CD19+ B cell	CL:0001201	high-dimensional FCM	CD138+ antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			22	61	years	22	antibody-secreting cell	CL:0000946	high-dimensional FCM	CD138+ antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years	17	antibody-secreting cell	CL:0000946	high-dimensional FCM	CD138+ antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			22	61	years		CD19+ B cell	CL:0001201	high-dimensional FCM	transitional B cell		cell type frequency	up	outpatient COVID-19 (OUT-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3J	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years		CD19+ B cell	CL:0001201	high-dimensional FCM	transitional B cell		cell type frequency	down	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3J	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			22	61	years		CD19+ B cell	CL:0001201	high-dimensional FCM	CD21-low transitional B cell		cell type frequency	up	outpatient COVID-19 (OUT-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years		CD19+ B cell	CL:0001201	high-dimensional FCM	CD21-low transitional B cell		cell type frequency	down	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	44	years		CD21-low transitional B cell		high-dimensional FCM	IgM, CD10, CD24		protein/cytokine levels	up	CD21-low transitional B cell vs CD21-hi transitional B cell in outpatient COVID-19 (OUT-C) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	44	years		CD21-low transitional B cell		high-dimensional FCM	CD21, CXCR5		protein/cytokine levels	down	CD21-low transitional B cell vs CD21-hi transitional B cell in outpatient COVID-19 (OUT-C) patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			22	61	years		CD21-low transitional B cell		high-dimensional FCM	CD138		protein/cytokine levels	up	CD21-low transitional B cell in outpatient COVID-19 (OUT-C) patients vs CD21-low transitional B cell in healthy donors (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 3L	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F3/		
	Simranpreet	Amani			26	81	years		CD19+ B cell	CL:0001201	high-dimensional FCM	DN3 B cell		cell type frequency	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Extended Data Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F8/		
	Simranpreet	Amani			26	81	years	17	DN B cell		high-dimensional FCM	DN1 B cell		cell type frequency	down	CoV-A patient cluster vs CoV-B patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			26	81	years	17	DN B cell		high-dimensional FCM	DN2 B cell		cell type frequency	up	CoV-A patient cluster vs CoV-B patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			22	81	years	26	DN B cell		high-dimensional FCM	DN2:DN1		cell type frequency	up	CoV-A patient cluster vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani						15	DN B cell		high-dimensional FCM	DN2:DN1		cell type frequency	up	SLE patients vs CoV-B patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			26	81	years	17	DN B cell		high-dimensional FCM	DN2:DN1		cell type frequency	up	CoV-A patient cluster vs CoV-B patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			22	81	years	26	CD19+ B cell	CL:0001201	high-dimensional FCM	usM B cells		cell type frequency	down	CoV-A patient cluster vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			26	81	years	17	CD19+ B cell	CL:0001201	high-dimensional FCM	usM B cells		cell type frequency	down	CoV-A patient cluster vs CoV-B patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			34	81	years	9	aN naive B cell		high-dimensional FCM	CXCR5		protein/cytokine levels	down	aN naive B cell vs rN naive B cell in CoV-A patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			34	81	years	9	DN2 B cell		high-dimensional FCM	CXCR5		protein/cytokine levels	down	CD11c+ CD21- double negative (DN2) B cell vs CD11c- CD21+ double negative (DN1) B cell in CoV-A patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			34	81	years	9	aN naive B cell		high-dimensional FCM	CXCR3		protein/cytokine levels	up	aN naive B cell vs rN naive B cell in CoV-A patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani			34	81	years	9	DN2 B cell		high-dimensional FCM	CXCR3		protein/cytokine levels	up	CD11c+ CD21- double negative (DN2) B cell vs CD11c- CD21+ double negative (DN1) B cell in CoV-A patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 4H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F4/		
	Simranpreet	Amani						34	CD19+ B cell	CL:0001201	high-dimensional FCM	antibody-secreting cell		cell type frequency	up	severe COVID-19 (ICU-C) vs African American healthy donor (AA HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Extended Data Fig 3A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F9/		
	Simranpreet	Amani						33	CD19+ B cell	CL:0001201	high-dimensional FCM	uSM B cells		cell type frequency	down	CoV-A patient cluster vs African American healthy donor (AA HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Extended Data Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F9/		
	Simranpreet	Amani						33	DN B cell		high-dimensional FCM	DN2:DN1		cell type frequency	up	CoV-A patient cluster vs African American healthy donor (AA HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Extended Data Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F9/		
	Simranpreet	Amani			22	61	years	61	Serum	BTO_0001239	high-dimensional FCM	9G4-idiotype antibodies		antibody response	up	severe COVID-19 (ICU-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 5H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F5/		
	Simranpreet	Amani			26	81	years	15	Serum	BTO_0001239	high-dimensional FCM	9G4-idiotype antibodies		antibody response	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 5H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F5/		
	Simranpreet	Amani			22	81	years	21	Blood plasma	UBERON:0001969	high-dimensional FCM	CXCL10		protein/cytokine levels	up	CoV-A patient cluster vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			22	81	years	21	Blood plasma	UBERON:0001969	high-dimensional FCM	IL-6		protein/cytokine levels	up	CoV-A patient cluster vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			22	81	years	21	Blood plasma	UBERON:0001969	high-dimensional FCM	C Reactive Protein		protein/cytokine levels	up	CoV-A patient cluster vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			26	81	years	13	Blood plasma	UBERON:0001969	high-dimensional FCM	C Reactive Protein		protein/cytokine levels	up	CoV-A patient cluster vs CoV-B patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			26	81	years	12	Blood plasma	UBERON:0001969	high-dimensional FCM	C Reactive Protein		protein/cytokine levels	positively correlated	CXCL10 plasma levels in COVID-19 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			26	81	years	12	Blood plasma	UBERON:0001969	high-dimensional FCM	C Reactive Protein		protein/cytokine levels	positively correlated	IL-6 plasma levels in COVID-19 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			26	81	years	12	Blood plasma	UBERON:0001969	high-dimensional FCM	C Reactive Protein		protein/cytokine levels	positively correlated	CD11c+ CD21- double negative (DN2) B cell vs Total CD19+/CD27-/CD38-/CD24-/IgD- double negative (DN) B cells in COVID-19 patients				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			22	81	years	23	Serum	BTO_0001239	high-dimensional FCM	anti-RBD of SARS-CoV-2 spike protein IgM; anti-RBD of SARS-CoV-2 spike protein IgG; anti-RBD of SARS-CoV-2 spike protein IgA		antibody response	up	severe COVID-19 (ICU-C) vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			26	81	years	17	Serum	BTO_0001239	high-dimensional FCM	anti-RBD of SARS-CoV-2 spike protein IgM; anti-RBD of SARS-CoV-2 spike protein IgG; anti-RBD of SARS-CoV-2 spike protein IgA		antibody response	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			26	81	years		Serum	BTO_0001239	high-dimensional FCM	anti-RBD of SARS-CoV-2 spike protein IgG; anti-RBD of SARS-CoV-2 spike protein IgA		antibody response	up	severe COVID-19 (ICU-C) vs outpatient COVID-19 (OUT-C)	time of symptom onset	5	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6H, Results (Paragraph: Robust extrafollicular responses correlate with neutralizing antibody titers)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/		
	Simranpreet	Amani			22	81	years	6	Serum	BTO_0001239	high-dimensional FCM	neutralization capacity		antibody response	up	CoV-A patient cluster vs healthy donor (HD)				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6I, Results (Paragraph: Robust extrafollicular responses correlate with neutralizing antibody titers)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/	in-vitro viral neutralization using patient serum	
	Simranpreet	Amani			26	81	years	7	Serum	BTO_0001239	high-dimensional FCM	neutralization capacity		antibody response	up	CoV-A patient cluster vs CoV-B patient cluster				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33028979	2020-10-07	https://www.nature.com/articles/s41590-020-00814-z	Fig 6I, Results (Paragraph: Robust extrafollicular responses correlate with neutralizing antibody titers)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739702/figure/F6/	in-vitro viral neutralization using patient serum	
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	monocyte:lymphocyte ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	monocyte:lymphocyte ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	monocyte:lymphocyte ratio		cell type frequency	up	SARS CoV-2 severe patients vs SARS CoV-2 mild	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	26	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	26	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 mild	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f1/		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 contacts	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 contacts	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 mild	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 asymptomatic	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7- FSC-Ahigh monocytes of CD3- cells; monocyte:NK cell ratio		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 asymptomatic	time of diagnosis	0,1,2,3,4,5,6	weeks	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	47	76	years	77	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3- CD7+ FSC-Alow NK cells of CD3- cells		cell type frequency	down	SARS CoV-2 ICU vs SARS CoV-2 non-ICU				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f2/		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD14+ CD16++ non-classical monocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f3/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD14+ CD16++ non-classical monocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f3/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD14+ CD16++ non-classical monocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f3/		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	HLA-DR		protein/cytokine levels	down	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f3/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	HLA-DR		protein/cytokine levels	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f3/		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ T cells of lymphocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4A, Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ T cells of lymphocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ T cells of lymphocytes		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ T cells of lymphocytes		cell type frequency	down	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ T cells of lymphocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD4+ T cells of CD3+ cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+ T cells of CD3+ cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD4+ T cells of CD3+ cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+ T cells of CD3+ cells		cell type frequency	down	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD4+ HLADR+ T cells of CD4+ T cells; CD8+ HLADR+ T cells of CD8+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4B, Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD4+ HLADR+ T cells of CD4+ T cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4B, Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+ HLADR+ T cells of CD8+ T cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+ HLADR+ T cells of CD8+ T cells		cell type frequency	up	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+ HLADR+ T cells of CD8+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4B, Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD8+ HLADR+ T cells of CD8+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 mild	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4B, Fig S2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31+ CD45RA+ CCR7+ CD4+ T cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4C, Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD4+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4C, Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31+ CD45RA+ CCR7+ CD4+ T cells; CD31+ CD45RA+ CCR7+ CD8+ T cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4C, Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD4+ T cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4C, Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31+ CD45RA+ CCR7+ CD4+ T cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4C, Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD4+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4C, Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31+ CD45RA+ CCR7+ CD4+ T cells; CD31+ CD45RA+ CCR7+ CD8+ T cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4C, Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31+ CD45RA+ CCR7+ CD4+ T cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31+ CD45RA+ CCR7+ CD4+ T cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD4+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD4+ T cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31+ CD45RA+ CCR7+ CD8+ T cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD8+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD8+ T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD31- CD45RA+ CCR7+ CD8+ T cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ CCR7- CD45RA+ CD4+ (TEMRA) T cells		cell type frequency	down	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ CCR7- CD45RA+ CD8+ (TEMRA) T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ CCR7- CD45RA+ CD8+ (TEMRA) T cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ CCR7- CD45RA+ CD8+ (TEMRA) T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD3+ CCR7- CD45RA+ CD8+ (TEMRA) T cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic	time of diagnosis	0	days	SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f4/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	B cells of lymphocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5B, Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD24- CD27++ CD38++ plasmablasts of B cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	B cells of lymphocytes		cell type frequency	up	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5B, Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	B cells of lymphocytes		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5B, Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	memory B cells of B cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	memory B cells of B cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	memory B cells of B cells		cell type frequency	down	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD24- CD27++ CD38++ plasmablasts of B cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5B, Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	CD24- CD27++ CD38++ plasmablasts of B cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5B, Fig S4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM+ cells of CD27+ memory B cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM+ cells of CD27+ memory B cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM- (switched) cells of CD27+ memory B cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5C, Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM+ cells of CD27+ memory B cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5C, Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM- (switched) cells of CD27+ memory B cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5C, Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM+ cells of CD27+ memory B cells		cell type frequency	down	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM+ cells of CD27+ memory B cells		cell type frequency	up	SARS CoV-2 mild vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	34.3	63.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgM- (switched) cells of CD27+ memory B cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig S4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgG+ cells of memory B cells		cell type frequency	down	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5D, Fig S4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgG+ cells of memory B cells		cell type frequency	down	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5D, Fig S4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgG- IgM- cells of memory B cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5D, Fig S4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgG- IgM- cells of memory B cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5D, Fig S4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	flow cytometry	IgG- IgM- cells of memory B cells		cell type frequency	up	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 5D, Fig S4D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f5/ ; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/#s10title 		
	Simranpreet	Amani		Rome, Italy	32	82.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	ELISA	IgA; IgG		antibody response	up	SARS CoV-2 severe vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 6A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f6/		
	Simranpreet	Amani		Rome, Italy	34.3	82.5	years	28	Peripheral Blood Mononuclear Cells	CL:2000001	ELISA	IgA; IgG		antibody response	up	SARS CoV-2 severe vs SARS CoV-2 asymptomatic				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 6A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f6/		
	Simranpreet	Amani		Rome, Italy	48	82.5	years	16	Peripheral Blood Mononuclear Cells	CL:2000001	ELISA	IgA		antibody response	up	SARS CoV-2 severe vs SARS CoV-2 mild				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 6A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f6/		
	Simranpreet	Amani		Rome, Italy	32	63.5	years	36	Peripheral Blood Mononuclear Cells	CL:2000001	ELISA	IgA; IgG; IgM		antibody response	up	SARS CoV-2 mild vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 6A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f6/		
	Simranpreet	Amani		Rome, Italy	32	48.5	years	48	Peripheral Blood Mononuclear Cells	CL:2000001	ELISA	IgA; IgG; IgM		antibody response	up	SARS CoV-2 asymptomatic vs SARS CoV-2 contacts				SARS-CoV-2.	2697049	Occurrence of infectious disease	COVID-19.	acute	33391280	2020-12-16	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/	Fig 6A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772470/figure/f6/		